<SEC-DOCUMENT>0001019056-21-000561.txt : 20211102
<SEC-HEADER>0001019056-21-000561.hdr.sgml : 20211102
<ACCEPTANCE-DATETIME>20211102162116
ACCESSION NUMBER:		0001019056-21-000561
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		75
FILED AS OF DATE:		20211102
DATE AS OF CHANGE:		20211102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260682
		FILM NUMBER:		211371606

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>modular_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:modd="http://modular-medical.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_modd_modular%2Dmedical.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20210401_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" contextRef="AsOf2021-06-30" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" contextRef="AsOf2021-03-31" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-04-01to2021-06-30" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-04-012021-06-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012021-06-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y9M</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P1Y11M8D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P8Y1M2D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2020-03-31" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2020-03-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" id="xdx2ixbrl0588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-03-31" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2021-03-31" id="xdx2ixbrl0613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0718" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0723" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0726" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0729" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0731" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0758" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0775" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0800" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedPlacementFeesMember" id="xdx2ixbrl0891" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedInterestMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-03-31" id="xdx2ixbrl1085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-03-31" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CEOAndInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedWagesAndBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedWagesAndBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedPlacementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedPlacementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on November 2, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: right"><span style="font-size: 10pt"><b>Registration
No. 333- </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_906_edei--DocumentType_c20210401__20210630_zRnHEXj65wh4"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityRegistrantName_c20210401__20210630_zruOrLZ5n4a7"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Exact
    name of registrant as specified in its charter)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20210401__20210630_zB6h57BUInQ9"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>3841</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210401__20210630_zvbo0vzLIW35"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(State
    or other jurisdiction of </i></span><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif"><i>incorporation or organization)</i></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Primary
    Standard Industrial </i></span><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif"><i>Classification Code Number)</i></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(I.R.S.
    Employer </i></span><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif"><i>Identification Number)</i></span></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20210401__20210630_z9991QtU0zT9"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressAddressLine1">16772 W. Bernardo Drive</ix:nonNumeric></span> </b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20210401__20210630_z4jWzYWpdi9h"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210401__20210630_zCzoLm6FVDYb"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20210401__20210630_zqSp6yEmUrcc"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--CityAreaCode_c20210401__20210630_zOhK09EQHva3"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:CityAreaCode">(858)</ix:nonNumeric></span> <span id="xdx_90D_edei--LocalPhoneNumber_c20210401__20210630_z0eBto6nXJ8"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>(Address,
including zip code, and telephone number, including</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>area code,
of registrant&#8217;s principal executive offices)</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Ellen O&#8217;Connor
Vos</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Chief Executive
Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>16772 W. Bernardo
Drive </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>San Diego,
California 92127</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>(858) 800-3500</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>(Name,
address, including zip code, and telephone</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>number, including
area code, of agent for service)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>With copies
to:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Joseph
        Lucosky, Esq.</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Lawrence
        Metelitsa, Esq.</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Lucosky
        Brookman LLP</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>101
        Wood Avenue South</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Woodbridge,
        NJ 08830</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(732)
        395-4400</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Ivan
        K. Blumenthal</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Mintz,
        Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</b><br />
        <b>666 Third Avenue </b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>New
        York,&#160;NY&#160;10017</b><br />
        <b>(212) 692-6750</b></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
    soon as practicable after the effective date of this registration statement</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Approximate
    date of commencement of proposed sale to the public)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box. <span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>



<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 0pt"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->



<!-- Field: Page; Sequence: 1 -->

    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer <span style="font-family: Wingdings">o</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer &#160;<span style="font-family: Wingdings">o</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityFilerCategory_c20210401__20210630_zKmtrBBWv03c"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> &#160;<span style="font-family: Wingdings">x</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company <span style="font-family: Wingdings"><span id="xdx_909_edei--EntitySmallBusiness_c20210401__20210630_z7lpy0Hg2bV5"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">x</ix:nonNumeric></span></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth
    company <span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20210401__20210630_zO1MFXzjFH99"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityExTransitionPeriod_c20210401__20210630_z16R7dVWE0Vc"><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">o</ix:nonNumeric></span></span></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 0; margin-bottom: 0"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt; text-transform: uppercase"><b>Calculation
of Registration Fee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">Title
    of Each Class of Securities to be Registered</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Proposed
    Maximum</b><br />
    <b>Aggregate Offering</b><br />
    <b>Price<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Amount
    of </b><br />
    <b>Registration Fee<sup>(3)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; padding-bottom: 1pt"><span style="font-size: 10pt">Common Stock, $0.001 par value
    per share<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 8%"><span style="font-size: 10pt">34,500,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 8%">3,198.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>





<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes the public
    offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any. Estimated solely
    for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933,
    as amended.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to Rule
    416 of the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares
    of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Calculated pursuant
    to Rule 457(o) based on an estimate of the proposed maximum aggregate initial public offering price.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on
such date as the Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>
<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 0pt"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->
<!-- Field: Page; Sequence: 2 -->

    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><b></b></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red; text-indent: 0"><span style="font-size: 10pt">The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell
nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0"><span style="font-size: 10pt"><b>SUBJECT
TO COMPLETION, DATED NOVEMBER 2, 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red; text-indent: 0"><span style="font-size: 10pt"><b>PRELIMINARY PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>&#160;</b></span><img src="modular001.jpg" alt="(LOGO)" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Shares
of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are offering
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock, par value $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is presently traded on the over-the-counter market and quoted on the OTCQB market under the symbol &#8220;MODD.&#8221; On &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2021, the last reported sale price of our common stock was $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. We have applied to list our common stock on the Nasdaq
Capital Market under the symbol &#8220;MODD.&#8221; No assurance can be given that our application will be approved or that the trading
prices of our common stock on the OTCQB market will be indicative of the prices of our common stock if our common stock were traded
on the Nasdaq Capital Market. If our listing application is not approved by the Nasdaq Stock Market, we will not be able to consummate
the offering and will terminate this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All
share and per-share information, as well as all financial information, contained in this prospectus has been adjusted to give
effect to the one-for-____ (l-for-__) reverse stock split (the &#8220;Reverse Stock Split&#8221;), which was implemented
on_________, 2021 and effective at the commencement of trading of our common stock on&#9;__________, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are an &#8220;emerging
growth company&#8221; under applicable Securities and Exchange Commission rules and will be subject to reduced public company
reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Per
    share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><span style="font-size: 10pt">Public
    offering price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Underwriting
    discounts and commissions<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Proceeds to us (before
    expenses)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
underwriters will receive compensation in addition to the underwriting discount. See &#8220;Underwriting&#8221; beginning on page
77.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The underwriters have the option to purchase up to an additional ________ shares of our common stock from
us at the public offering price, less the underwriting discounts and commissions, within 30 days after the date of this prospectus
to cover over-allotments, if any.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Investing
in our common stock involves a high degree of risk. See &#8220;Risk Factors,&#8221; beginning on page 13.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The underwriters
expect to deliver the shares of common stock to investors on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>,
</b>2021.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>Sole
Book-Running Manager</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 18pt"><b>Oppenheimer&#160;&amp;&#160;Co.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The date of this
prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2021</span></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>TABLE OF CONTENTS
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%"><a href="#modulara001"><span style="font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right; vertical-align: bottom">1</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara002"><span style="font-size: 10pt">THE OFFERING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span>10</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara003"><span style="font-size: 10pt">SUMMARY FINANCIAL DATA</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;11</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara004"><span style="font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;13</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara005"><span style="font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara006"><span style="font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;32</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara007"><span style="font-size: 10pt">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;33</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara008"><span style="font-size: 10pt">DIVIDEND POLICY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;33</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara009"><span style="font-size: 10pt">CAPITALIZATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;33</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara010"><span style="font-size: 10pt">DILUTION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara011"><span style="font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara012"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara013"><span style="font-size: 10pt">MANAGEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;62</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara014"><span style="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;74</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara016"><span style="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">75</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara017"><span style="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span>76</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara018"><span style="font-size: 10pt">UNDERWRITING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;78</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara019"><span style="font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;84</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara020"><span style="font-size: 10pt">EXPERTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;84</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara021"><span style="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;84</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara022"><span style="font-size: 10pt">INDEX TO FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">F-1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara023"><span style="font-size: 10pt">PART II INFORMATION NOT REQUIRED IN PROSPECTUS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">II-1</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>We have not
authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in
any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only
under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current
only as of its date.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For investors
outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States.
Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any
restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United
States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Market and Other Industry Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Unless
otherwise indicated, market data and certain industry forecasts used throughout this prospectus were obtained from various sources,
including internal surveys, market research, consultant surveys, publicly available information and industry publications and
surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein
has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed.
We have not independently verified any of the data from third-party sources nor have we ascertained the underlying economic assumptions
relied upon therein. Similarly, internal surveys, industry forecasts and market research, which we believe to be reliable based
upon our management&#8217;s knowledge of the industry, have not been independently verified. The future performance of the industry
and markets in which we operate and intend to operate is necessarily subject to a high degree of uncertainty and risk due to a
variety of factors, including those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding
Forward-looking Statements&#8221; and elsewhere in this prospectus. These and other factors could cause results to differ materially
from those expressed in these publications and reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We expect
to effect a reverse stock split of our Common Stock at a ratio of up to l-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;. No fractional shares will be issued in connection
with the reverse stock split and all such fractional interests will be rounded up to the nearest whole number of shares of common
stock. The conversion or exercise prices of our issued and outstanding convertible securities, stock options and warrants will
be adjusted accordingly. Following the effectiveness of the reverse stock split, all information presented in this prospectus
other than in our consolidated financial statements and the notes thereto will be adjusted to give effect to such reverse stock
split.</span></p>





<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<div style="border: black 1px solid; padding: 6pt; width: 98%">


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><span style="font-size: 10pt"><span id="modulara001"></span>PROSPECTUS
SUMMARY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>This summary
highlights selected information contained elsewhere in this prospectus and does not contain all the information that you should
consider before making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus,
including the information set forth under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; sections of this prospectus and our consolidated financial statements
and the accompanying notes included in this prospectus. Except as otherwise indicated herein or as the context otherwise requires,
references in this prospectus to &#8220;Modular Medical,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
and &#8220;our&#8221; refer to Modular Medical, Inc. and its wholly-owned subsidiary, Quasuras, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular
Medical is a development stage medical device company focused on the design, development, and commercialization of an
innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the
creation of a novel two-part patch pump, our MODD1 product, or MODD1, the Company seeks to fundamentally alter the
trade-offs between cost and complexity and access to the higher standards of care that presently available insulin pumps
provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and
day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated &#8220;super
users&#8221; and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly
growing, especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Differentiatio</i>n
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that
there are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people
who require insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe that by tailoring our insulin
pump to address such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader
market acceptance, an insulin pump must be easier to learn to use, less time consuming to operate, more intuitive to both patients
and physicians, and meet the standards for coverage by insurance providers so that co-payments required from patients are affordable
and the hurdles to insurance coverage are significantly reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Among
the more prominent issues are:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Complexity</i>:
        Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such
        pumps were designed for &#8220;super users,&#8221;<b>&#160;</b>who have high levels of motivation and technical competence.
        The complexity of pumps proves daunting to less technically inclined users.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; padding-right: -34.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cumbersome</i>:
    We believe that a majority of existing pumps are bulky and difficult to manage, in many cases requiring additional equipment
    to introduce a catheter to the patient&#8217;s body and up to 48 inches of tubing, which must be replaced frequently, to connect
    the catheter to a pump. This requires users to carry spare parts and other equipment adding to the difficulty of using the
    pump.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: -34.7pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: -34.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost</i>:
    Costs associated with insulin pump therapy are high and can be prohibitive, especially for those on fixed or limited incomes.
    These costs vary by pump, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible
    daily co-payments on consumables, can easily place current pumps out of reach for patients. This makes insurance providers
    hesitant to pay for them, leading to limited or absent reimbursement/coverage and high hurdles for patients to gain access.</span></td></tr>
</table>
</div>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our team has
substantial knowledge of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing
insulin pumps to market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method
of pumping insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both
basal (steady flow) and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration
path to multi-chamber/multi-liquid pumps, potentially offering an exciting array of new therapies to patients with diabetes and
other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is
to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just
care for the super users, but &#8220;diabetes care for the rest of us.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MODD1 is
a high-precision, first-line pump that we believe represents the best choice for new pump patients because it is easy to afford,
easy to learn, easy to use, and has a revolutionary design and technology that enable precision with low-cost manufacture and
high reproducibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Key features
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two
                                         parts - one reusable, one disposable - snap together to form the working system</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">One
                                         button interface, easy to learn and use</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">90-day
                                         reusable, 3-day disposable cartridges</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Removable
                                         at any time from an adhesive bracket</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
                                         external controller required, no charging, no battery replacement</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Slim
                                         profile, lighter weight</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-size: 10pt; background-color: white">A
proprietary survey of American healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives)
performed for us by industry leading survey firm ISA has demonstrated that a majority of payors are willing to grant equivalent or
preferential coverage for a product with this feature set at launch in exchange for about a 20% discount. These costs are built
into all of our models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Diabetes is typically classified
as either type 1, or T1D, or type 2, or T2D:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">T1D
is an auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently diagnosed
during childhood or adolescence. Individuals with T1D require daily insulin therapy to survive.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">T2D represents over 90% of all
                                                                                                                             individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either properly utilize insulin or
                                                                                                                             produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in diet and
                                                                                                                             exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their
                                                                                                                             diabetes advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and
                                                                                                                             ultimately to intensified mealtime rapid-acting insulin therapy.&#160;&#160;This represents an important portion of the
                                                                                                                             diabetes market with an estimated 1.6 million T2D intensively treated with insulin currently in the United States, this number
                                                                                                                             being
                                                                                                                             expected to grow to 2.2 million by in 2030.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt; background-color: white">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function
and health. In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition
known as hyperglycemia, and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications,
including blindness, kidney disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular
disease, and death. Hypoglycemia can lead to confusion or loss of consciousness, often requiring a visit to the emergency room
or, in certain cases, result in seizures, coma, and/or death.</span></p>
</div>
<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All people with
T1D, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18%
of people with T2D in the United States, or 4.7 million people, require insulin (basal (steady supply) alone represents 3.1 million
and basal plus mealtime represent 1.6 million) to manage their diabetes. In this prospectus, we refer to people with T1D and people
with T2D who require mealtime insulin as &#8220;insulin-requiring people with diabetes.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Currently, there
are two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into
the body through syringes or insulin pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump
to deliver mealtime insulin boluses (single doses) to help with glucose absorption after carbohydrate consumption and a continuous
subcutaneous insulin infusion, or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages
over MDI therapy, primarily an improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin
A1c (HbA1c) measure and more recently Time in Range (TIR) where a continuous glucose measuring device is used to calculate this
test. Among other medical benefits, it has been demonstrated that insulin pump use can decrease glucose variability, reduce the
number of hypoglycemia, decrease the daily doses of insulin and reduce the fear of hypoglycemia<sup></sup>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notwithstanding
these advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well
as high and often prohibitive costs for both the patient and insurance provider has resulted not only in dissatisfaction among
many existing pump users (fewer than half purchase a new pump after the warranty expires per Seagrove Partners estimate), but
also has severely limited the adoption rate of insulin pumps by a large segment of the MDI diabetes population, who we refer to
in this prospectus as &#8220;Almost Pumpers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We define Almost
Pumpers as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past experiences,
pump shortcomings, cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps, continue
to receive their daily insulin through MDI therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Our initial
focus for our insulin pump is the almost pumper segment population located in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><img src="modular002.jpg" alt="(Graphic)" style="float: right; margin-left: 30pt" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our
research, along with marketplace data, estimates that 32% of Americans with T1D use insulin pump therapy and 28% of Americans
with T1D (44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the
American Diabetes Association guidelines of glucose control if their objections to the currently available suite of products
can be overcome. They do not want to closely manage their glucose levels and incur  the associated time and effort involved.
They are the Almost Pumpers. We have developed what we believe to be the most technologically advanced delivery system,
overcome the objections and provided motivation for this market. We believe that there are four addressable hurdles to
adoption:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Usability:
                                         the device needs to be easy to learn and to operate; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Affordability:
                                         we will focus on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance
                                         journey&#8221; to the clinician and patient; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accessibility
                                         and Education: we will seek to engage patients to sample this new technology by supplying
                                         clinicians with free samples and simple training to allow people to see first-hand the
                                         typical barriers to adoption that have been overcome; and </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Service
                                         and Support: where we will answer their questions and concerns during this diabetes experience.
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We believe
this conversion process, engaging people to try and thereby receive the benefits of our technology will substantially increase
adoption of insulin pumps among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease
that appears throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care.
We intend to create an insulin pump that appeals to all Almost Pumpers.</span></p>
</div>
<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Our
Insulin Pump </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Instead
of building complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology
and the user in mind. Using proprietary and patented methods of insulin measurement, we were able to eschew the complex mechanisms
used today and instead build a product using only parts from high volume consumer electronics manufacturing lines, breaking the
cost vs. functionality curve that has existed in the insulin pump space and representing the first truly modern insulin pump design.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
pre-production models of our low-cost insulin pump are now undergoing the testing required to submit to the Food and Drug Administration,
or FDA, for clearance to market them in the United States. We expect to submit our product to the FDA in March 2022 through a
 premarket notification (or 510(k)) process (see the section titled <i>Government Regulation </i>below for a discussion of the
FDA submission process and requirements). After submission, we expect to receive two rounds of comments from the FDA, and we believe
it will take approximately six months to obtain clearance from the FDA. After we obtain clearance from the FDA, we can commence
our commercialization process, as discussed in the section titled <span style="background-color: white"><i>Commercialization Strategy:
Overcoming the Insurance Hurdles </i>below.<b> </b></span>We continue to devote substantial time and resources to better understand
the needs and preferences of Almost Pumpers and the specific patent/provider/payor requirements to motivate change from MDI patients.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 has several
distinguishing features:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0"><img src="modular003.jpg" alt="(Graphic)" /></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">1 &#8211; The
pump has a simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating
cam to motivate the insulin into the patient along with low power Bluetooth (LPBT) and near field communication (NFC) chips to
allow the patient to communicate with their smart phone, tablet, or other mobile computing platform, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2 &#8211; The
pump snaps together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power
source and a simple coin cell that allows it to run through the 80-hour life of the cartridge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">3 &#8211; There
is a set (not shown) that contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle
used to transfer insulin to the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">4 &#8211; MODD1
comes with a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching
to the body that has features for holding the pump to the patient; overwraps to hold the product to patient; and a velcro strap
with a base plate suitable for wrapping around the arm or leg of the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The system will
deliver a small continuous rate, called a basal, that will provide approximately 50% of the total daily dose required and the
user will use the on-pump button to administer boluses, typically before and after meals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The objective
is to make the product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand
the pump market, drive adoption and ultimately better clinical outcomes.</span></p>
</div>
<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Technological
Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The adoption
of new ultra-high volume technologies will result in far easier manufacturing scale up as parts sourcing and assembly processes
are far easier. The MODD1 was designed from the beginning for mass manufacturing processes and fully automated production assembly
lines. This advantage is compounded by the high availability and already optimized cost reduction in its components. This has
resulted in a cost of goods, estimated on our competitors&#8217; announced margins and sales, 70%<sup></sup> lower than our
closest patch pump competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
adoption of modern, miniaturized technologies has led to numerous other advantages as well. The MODD1 pump is smaller in
overall volume than Insulet&#8217;s popular Omnipod product and has a lower profile to the skin. Despite this, it holds a
full 3mL (300 units) of insulin in line with full sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir
in the Omnipod. We believe that this volume advantage over other patch pumps will be significant as 24%<span style="color: #002060"> </span>of
type 1 and over 50% of the rapidly growing type 2 market require more than 2 milliliters of insulin every 3 days (the
expected wear time of patch pumps).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In addition,
our new and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a healthy
pancreas) delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering
micro-boluses every 15 minutes for Omnipod and five minutes for industry leader Medtronic. We plan to demonstrate the impact of
our system on glycemic control in a future clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The technology
allows the patient to simply add insulin and operate. The battery is included in each cartridge and the device is operated without
a controller. Nothing requires charging. MODD1 has been made push button simple to appeal to a wider audience of users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">This
new technology has also made the MODD1 lighter than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams
(vs. 26g) empty and 23 grams (vs. 28g) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18% respectively.
Also, unlike existing patch pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires.
This avoids loss of insulin in a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable
dissatisfaction with on other patch pumps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">This
technology is also uniquely suited to dual (or more) chamber pumps. We believe that such pumps will be integral to the
realization of high time in range artificial pancreas solutions that require no human intervention, the next step forward
from the cumbersome and awkward solutions today that require the user to announce meals, count and input carbs, and adjust
delivery for exercise and sleep. The advantages of cost and miniaturization are multiplied in a multi-chamber setup and we
expect to be able to reach price points, ease of use, and form factor unlike anything seen in the industry thus far. We
believe that a prefilled, multi-hormone peel and stick-patch pump able to function in a fully autonomous closed loop system
with CGM&#8217;s represents the next generation of diabetes care. We believe that we have demonstrated our technology and are
securing the intellectual property on our approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe
this technology, especially in dual chamber, will open up numerous applications outside of diabetes where medication compliance
of complex therapy regimes is difficult, addressing such spaces as weight loss and fertility, and simplifying complex delivery
of multi-drug cocktails, especially those with diverse and challenging dosing schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">Our
goal is to establish MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and
Type 2) and the newly motivated CGM users. <span style="background-color: white">&#160;We seek to grow the market by providing
first-line insulin pump therapy that is well suited to meet the needs of both diabetes patients requiring insulin and their clinicians.
</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt; background-color: white">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">According
                                         to Insulet published costs of goods, MODD1 is approximately 70% less expensive to manufacture
                                         than Omnipod. This low cost allows us to spend more on patients and sampling. This will
                                         save money for payers. We can offer the pump with no upfront cost to patients. Benefits
                                         of MODD1 include:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">20%
                                         discount vs. Insulet (PODD) will drive preferred status</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Designed
                                         to use pharmacy benefits manager (PBM) codes as a disposable</span></td></tr></table>

                                         </div>
<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<div style="border: black 1px solid; padding: 6pt; width: 98%">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No
                                         new code needed to be reimbursed at launch</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Saves
                                         provider an estimated $1062/patient/year vs. Omnipod</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">MODD1
                                         will be sampled and given to patients by the doctor or diabetes nurse educator at the
                                         time of the patient visit. When a patient is motivated to make change, our starter kit
                                         will make it easy for the clinician to initiate the new therapy that same day. We seek
                                         to eliminate the currently challenging &#8220;insurance journey&#8221; and product acquisition
                                         timeline and significantly reduce training time for the busy clinician, all major hurdles
                                         to pump adoption. We intend to add telehealth support to help the patient throughout
                                         adoption and use and to facilitate greater collaboration between patients and their physicians.
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Europe
represents another large potential market for MODD1. Sixty million people in Europe live with diabetes and one in four dollars
of global diabetes spending occurs in Europe. ($156 billion is spent annually on diabetes healthcare costs in the EU). At present,
cost containment is restricting pump uptake across Europe. Current pump usage across the EU reaches 30% in a few markets but remains
below 10% in many. Single payor healthcare systems across the EU traditionally attempt to contain costs in the short term and
seek low price technologies with moderate medical benefits. MODD1 will offer a rebalance of this risk/reward strategy in that
payors will incur only minor incremental short-term costs with the benefit of longer-term cost savings associated with reliable
pump use. We intend to employ a partnership strategy across the EU following in-house managed regulatory and pricing activities
in the major markets (e.g., UK) and more cost receptive markets (e.g., Nordics). We are targeting European and United Kingdom
approval towards early 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our
success depends in part on our ability to obtain patents and trademarks, maintain trade secrets and know-how protection, enforce
our proprietary rights against infringers, and operate without infringing on the proprietary rights of third parties. Because
of the length of time and expense associated with developing new products and bringing them through the regulatory approval process,
the health care industry places considerable emphasis on obtaining patent protection and maintaining trade secret protection for
new technologies, products, processes, know-how, and methods.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As
of October 20, 2021, we had one issued U.S., utility patent, five published U.S. utility patents, two pending&#160;foreign patent
applications, and two pending international Patent Cooperation Treaty (PCT) patent applications covering various aspects of our
technology, including&#160;our proprietary fluid movement technology.&#160; There can be no assurance that our pending patent
applications will result in the issuance of patents, that patents issued to or licensed by us will not be challenged or circumvented
by competitors, or that these patents will be found to be valid or sufficiently broad to protect our technology or provide us
with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify"><span style="font-size: 10pt">Investing
in our common stock involves substantial risk. You should carefully consider all of the information in this prospectus before
investing in our common stock, including the risks related to this offering and our common stock, our business and industry, our
intellectual property, our financial results, and our need for financing, each as described under the section titled &#8220;Risk
Factors&#8221; and elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Risks
in investing in our common stock include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Even
                                         if we are able to obtain all regulatory approvals and have completed all other steps
                                         needed to be taken to commercialize our insulin pump, if we or any contract manufacturers
                                         we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing
                                         and distribution of our product could be interrupted, and our product sales and operating
                                         results could suffer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 59.25pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         will need to outsource and rely on third parties for various aspects relating to the
                                         development, manufacture, sales and marketing of our insulin pump as well as in connection
                                         with assisting us in the preparation and filing of our FDA submission, and our future
                                         success will be dependent on the timeliness and effectiveness of the efforts of these
                                         third parties.</span></td></tr></table>
</div>
<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         are a developmental-stage medical device company and have a history of significant operating
                                         losses; we expect to continue to incur operating losses for the foreseeable future, and
                                         we may never achieve or maintain profitability.</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.25pt"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         may not receive the necessary regulatory clearance or approvals for our insulin pump,
                                         and failure to timely obtain necessary clearances and/or approvals could harm our then
                                         operations, including our ability to commercialize our product</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
                                         marketing authorization in the United States will not obviate the need to obtain marketing
                                         authorization in other jurisdictions We must obtain approval from foreign regulatory
                                         authorities before we can market and sell any of our products in countries outside the
                                         United States. We will incur additional costs in seeking such approvals, may experience
                                         delays in obtaining such approvals and cannot be certain that such approvals will be
                                         granted.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Although
our product does not presently require clinical trials to apply to the FDA for clearance, and even if a clinical trial is conducted,
the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise
not be sufficient for us to obtain approval of our product.<b><i>.</i></b></span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">We require additional capital
to fund our growth, operations, and obligations, and our growth may be limited. We believe the proceeds of this offering will
provide us with the capital required to obtain FDA approval of and to commercialize our insulin pump.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Any outbreak or worsening
of an outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on
our business operations, financial condition and results of operations.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Our competitors may develop
products that are more effective, safer and less expensive than ours.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
currently trade on the OTCQB and there is a limited market for our securities, which may make it more difficult to dispose of
our securities. When we list on Nasdaq, we may fail to sustain trading on Nasdaq, which could make it more difficult for investors
to sell their shares.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Sales of a significant number
of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price
of our common stock.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">We have limited internal
research and development personnel, making us dependent on consulting relationships<b><i>.</i></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete<b><i>.</i></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to identify,
negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies, and we will
be dependent on our corporate partners if we do<b><i>.</i></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>Listing
on the Nasdaq Capital Market&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our common stock is currently quoted on the OTCQB Market. In connection with this offering, we have applied
to list our common stock on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;MODD.&#8221; If our listing
application is approved, we expect to list our common stock on Nasdaq upon consummation of the offering, at which point our common
stock will cease to be traded on the OTCQB Market. No assurance can be given that our listing application will be approved. This
offering will occur only if Nasdaq approves the listing of our common stock. Nasdaq listing requirements include, among other things,
a stock price threshold. As a result, prior to, or immediately following, the effective date of this offering, but prior to the
closing of this offering, we will need to take the necessary steps to meet Nasdaq listing requirements. If Nasdaq does not approve
the listing of our common stock, we will not proceed with this offering. There can be no assurance that our common stock will be
listed on the Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"><span style="font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"><span style="font-size: 10pt">We are
an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS
Act. We will remain an emerging growth company until the earlier of (1) _____, 202_, (2) the last day of the fiscal year in which
we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be
a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the
Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the
last business day of the second fiscal quarter of such fiscal year or (4) the date on which we have issued more than $1.0 billion
in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified
reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable
to public companies. As an emerging growth company, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">present
only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related
management&#8217;s discussion and analysis of financial condition and results of operations in this prospectus;</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify"></p>
</div>
<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">avail
ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our
internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 49.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.25pt">provide
reduced disclosure about our executive compensation arrangements; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 49.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">not
require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements. </td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify; text-indent: 0"><span style="font-size: 10pt">In
addition, under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period,
and, as a result we will adopt new or revised accounting standards on relevant dates on which adoption of such standards is required
for other public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 auto; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Exchange Act and have elected to take advantage
of certain of the scaled disclosure available to smaller reporting companies.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Corporate Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our
principal executive offices are located at 16772 W. Bernardo Drive, San Diego, CA 92127 and our telephone number is (858) 800-3500.
We maintain a website at <span style="text-decoration: underline">www.modular-medical.com</span> to which we regularly post copies of our press releases, as well as additional
information about us. Our filings with the Securities and Exchange Commission, or SEC, will be available free of charge through
the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained
on, or accessible through, our website does not constitute a part of this prospectus or our other filings with the SEC, and you
should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in
deciding whether to purchase shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">All
brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other
parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship
with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<p style="border-bottom: black 0pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>Officer Stock Purchases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">On October
28, 2021, we entered into purchase agreements with Ellen O&#8217;Connor (Lynn) Vos, our Chief Executive Officer, and Paul DiPerna,
Chairman of our board of directors and our President, Chief Financial Officer and Treasurer, providing for the sale and issuance
by us of 92,592 shares of our common stock, par value $0.001 per share at the closing market price on October 28, 2021 of $2.70
per share. We received proceeds of approximately $250,000 from the sale of the shares, comprising $150,000 from Ms. Vos and $100,000
from Mr. DiPerna.</span></p>
</div>
<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Credit Facility
and Security Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">On October 28,
2021, we issued a secured promissory note (Note) to Manchester Explorer, L.P., (Manchester) that provides us with a $3,000,000
revolving credit facility with all amounts being drawn down by us thereunder being due and payable, subject to acceleration in
the event of a default, on March 15, 2022 (Maturity Date). Interest at the rate of 12% is payable on each drawn down without regard
to the draw down date or the date when interest is paid. As of the date of this prospectus, there have been no borrowings under
the Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The
principal amount of the Note and interest due thereon is payable to Manchester no later than the earlier of (i) the Maturity Date
and (ii) the date on which we have received proceeds in excess of $12,000,000 from a transaction or series of related transactions
occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of our equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font-size: 10pt">Provided
that not Event of Default (as such term is defined in the Note) has occurred, on any date prior to the Maturity Date, upon no
less than three days written notice by us specifying the draw amount, Manchester will advance the draw amount to us. No draw amount
can be in an amount less than $100,000 or exceed an amount equal to US$3,000,000 <span style="text-decoration: underline">minus</span> the aggregate principal amount outstanding
under the Note at the time of such draw request.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: justify"><span style="font-size: 10pt">If
an Event of Default occurs and is continuing, Manchester may declare all of the Note, including any interest and other amounts
due, to be due and payable immediately. As security for our obligations under the Note, on October , 2021, we entered into a Security
Agreement with Manchester under which granted Manchester a continuing and unconditional first priority security interest in and
to any and all of our property, of any kind or description, tangible or intangible, wheresoever located and whether now existing
or hereafter arising or acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0pt; text-align: justify"><i>Reverse Stock Split</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0pt; text-align: justify">On September 30, 2021, we received
a written consent in lieu of a meeting by the holders of approximately 67% of the voting power of the Common Stock authorizing
a reverse stock split of the Company&#8217;s issued and outstanding Common Stock with a ratio within a range of 1-for-2 to 1-for-4
(the &#8220;Reverse Stock Split Ratio&#8221;), with the exact Reverse Stock Split Ratio to be determined by our Board of Directors
(the &#8220;Board&#8221;) in its discretion. The final Reverse Stock Split Ratio within the range will be determined solely by
our Board prior to March 31, 2022, without further action or approval of our stockholders.</p>

</div>
<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara002"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock offered by us:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 63%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
        (or approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares if the underwriters
        exercise their option to purchase additional shares in full).</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Common stock to
    be outstanding </span><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif">after this offering:</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>&#160;shares
    (or approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares if the underwriters exercise
    their option to purchase additional shares in full).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Option
    to purchase additional shares:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    underwriters have an option within 30 days of the date of this prospectus to purchase up to an additional $_______ of shares
    of our common stock for the purpose of covering over-allotments.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Use
    of proceeds:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We estimate
        that the net proceeds from this offering will be approximately $___________(or approximately $________ if the underwriters
        exercise their over-allotment option in full), after deducting underwriting discounts and commissions and the estimated
        offering expenses payable by us.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to use the net
        proceeds of this offering for general corporate purposes, including working capital, to develop our sales and marketing
        infrastructure, to fund additional research and development activities, to develop our manufacturing and production capabilities
        and make related capital expenditures and to repay our bridge loan. See &#8220;Use of Proceeds&#8221; for additional information.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Risk
    factors:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Investing
    in our common stock involves substantial risk. You should read the &#8220;Risk Factors&#8221; section beginning on page 13
    and other information included in this prospectus for a discussion of factors to consider carefully before deciding to invest
    in our securities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Proposed
    Nasdaq Trading Symbol:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    common stock is quoted on the OTCQB of the OTC Markets Group, Inc. (the &#8220;OTCQB&#8221;), under the symbol &#8220;MODD,&#8221;
    and, to date, has traded on a limited basis. As of _______, 2021, the last reported sale price of our common stock on the
    OTCQB Market was $___________. We have applied to list our common stock on The Nasdaq Stock Market (the &#8220;Nasdaq&#8221;)
    under the symbol &#8220;MODD.&#8221; If Nasdaq does not approve the listing of our common stock, we will not proceed with this offering. There
can be no assurance that our common stock will be listed on the Nasdaq.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Except
as otherwise indicated herein, all information in this prospectus assumes the underwriters <span style="text-decoration: underline">do not </span>exercise their option
to purchase an additional $_______________ of shares of our common stock to cover over-allotments, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 18,982,562 shares of our common stock outstanding
as of September 30, 2021, and excludes, as of such date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,579,764
    shares of our common stock issuable upon conversion of our convertible promissory notes and accrued interest, assuming such
    convertible promissory notes were outstanding for their full one-year term and converted at a price of $2.87 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,303,348
    shares of our common stock issuable upon exercise of warrants issued to our convertible promissory note holders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4,792,949 <span style="background-color: white">shares
    of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
    $2.39 per share; and</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3,207,051
    shares of our common stock reserved for issuance pursuant to future awards under our 2017 Equity Incentive Plan, or the 2017
    Plan.</span></td></tr>
</table>
</div>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">









<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara003"></span>SUMMARY
FINANCIAL DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
following tables summarize our financial data for the periods presented and should be read together with the sections of this
prospectus titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations,&#8221; and our financial statements and related notes thereto appearing elsewhere in this prospectus. The
following summary statements of operations data for the three months ended June 30, 2021 and June 30, 2020 and the years ended
March 31, 2021 and March 31, 2020 have been derived from our financial statements and footnotes included elsewhere in this prospectus.
Our historical results are not necessarily indicative of our future results or of the results we expect in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,083,303</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,034,152</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,253,412</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,313,870</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,336,715</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,348,022</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,336,715</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,348,022</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,749</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(39,791</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,376,376</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,319,273</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,377,976</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,320,873</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.40</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.30</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,634,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,864,769</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended<br /> June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,788,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">970,815</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,585,456</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">903,397</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,373,587</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,874,212</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,373,587</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,874,212</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(508,877</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Loss on debt extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,321,450</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,835,091</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,874,157</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,954,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,334,482</td><td style="text-align: left">&#160;</td></tr>
</table>

</div>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<div style="border: black 1px solid; padding: 6pt; width: 98%">





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt 0 0"><span style="font-size: 10pt">The following summary
balance sheet data as of June 30, 2021 is presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">on an actual basis;
    and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">on
    an as adjusted basis to (i) give effect to our sale of $30,000,000 of shares of common stock in this offering at the assumed
    offering price of $________per share, which is the last reported sale price of our common stock on the OTCQB Market on ______,
    2021, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
summary as adjusted balance sheet is for informational purposes only and does not purport to indicate balance sheet information
as of any future date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">June
    30, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Actual</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">As<br />
    Adjusted<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: italic 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">(Unaudited)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Balance Sheet data:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Cash and
    cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">3,380,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Total assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,042,313</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Total liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,623,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Accumulated deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(20,782,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Total stockholders&#8217;
    equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(1,581,488</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>









<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The as adjusted information
        discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of
        this offering determined at pricing.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p></td></tr>
</table>
</div>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.25pt; text-align: center; text-indent: 0.5in"></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara004"></span>RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the following
risks, as well as general economic and business risks, and all of the other information contained in this registration statement.
Any of the following risks could harm our business, operating results and financial condition and cause the trading price of our
common stock to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you
should also refer to the other information contained in this prospectus, including our financial statements and the related notes
thereto.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><i>Risks Related To Our Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We are
a developmental stage medical device company and have a history of significant operating losses; we expect to continue to incur
operating losses, and we may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a development-stage enterprise,
we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating
losses in each year due to costs incurred in connection with research and development activities and general and administrative
expenses associated with our operations. For the years ended March 31, 2021 and 2020, we incurred net losses of approximately
$7.4 million and $5.3 million, respectively. At March 31, 2021, we had an accumulated deficit of approximately $15.9 million.
For the three months ended June 30, 2021, we incurred a net loss of approximately $4.8 million. At June 30, 2021, we had an accumulated
deficit of approximately $20.8 million. As a result, we have limited capital resources and require the funds from this offering
to continue our business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We expect to
incur losses for the foreseeable future, as we continue the development of, and seek regulatory clearance and approvals for, our
insulin pump. As our prototype insulin pump is currently our only product candidate, if it fails to gain regulatory approval and
market acceptance, we will not be able to generate any revenue or explore other opportunities to enhance shareholder value, such
as through a sale. If we fail to generate revenue and eventually become profitable, or if we are unable to fund our continuing
losses, our shareholders could lose all or a substantial part of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We might
not be able to continue as a going concern which would likely cause our stockholders to lose most or all of their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify"><span style="font-size: 10pt">Our
audited financial statements for the year ended March 31, 2021 were prepared under the assumption that we would continue as a
going concern. However, our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph
in its report on our financial statements for the year ended March 31, 2021, indicating that, without additional sources of funding,
our cash at March 31, 2021 is not sufficient for us to operate as a going concern for a period of at least one year from the date
that the financial statements included in this prospectus are issued. Management&#8217;s plans concerning these matters, including
our need to raise additional capital, are described in Management&#8217;s Discussion and Analysis of Financial Conditions and
Results of Operations included in this prospectus and in Note 1 to our audited consolidated financial statements included in this
prospectus. However, we cannot assure you that our plans will be successful. In light of the foregoing, there is substantial doubt
about our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose
most or all of their investment in us.</span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><i>We have no revenues and substantial
indebtedness, which could adversely affect our business and financial position and, among other things, our ability to raise additional
capital and our ability to satisfy our financial obligations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because we are
a development stage company, we have not and do not anticipate generating any revenues for the foreseeable future. As a result,
we are dependent upon our ability to raise capital through sales of our debt and equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection
with our private placement completed in May 2021, we issued $6,560,000 aggregate principal amount of our 12% unsecured convertible
promissory notes, hereinafter referred to as the 2021 Notes, with each 2021 Note due 12 months from the issuance date. As a result,
we have substantial outstanding debt, which could adversely affect our business and financial position, and, among other things,
our ability to raise additional capital and our ability to satisfy our financial obligations, including interest and principal
payments on the 2021 Notes. The impact of the indebtedness may include, but may not be limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">limit
    our ability to borrow additional funds for working capital, capital expenditures, acquisitions, or other general business
    purposes;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">require
    us to use a substantial portion of any future cash flow from operations and/or capital raised to make debt service payments
    instead of other business purposes, thereby reducing the amount of any future cash flow and/or capital raised available for
    future working capital, capital expenditures, acquisitions, or other general business purposes;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">limit
    our flexibility to plan for, or react to, changes in our business and industry;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">place
    us at a competitive disadvantage compared with our less-leveraged competitors;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increase
    our vulnerability to the impact of adverse economic, competitive, and industry conditions; and </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increase
    our cost of borrowing. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><i>The
full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain
and could have a material and adverse effect on our business, financial condition, operating results and cash flows.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019, or COVID-19, was declared a pandemic by the World Health Organization and a national
emergency by the U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The extent of the impact on our operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by&#160;&#160;U.S.
and foreign&#160;government agencies to prevent disease spread, all of which are uncertain, out of our control and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify"><span style="font-size: 10pt">We
have been complying with county and state orders and, until May 2021, had implemented a teleworking policy for our employees and
contractors and significantly minimized the number of employees who visit our office. However, a facility closure, work slowdowns
or temporary stoppage at one of our manufacturing suppliers could occur, which could have a longer-term impact and could delay
our prototype production and ability to conduct business.&#160;&#160;</span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If our
workforce is unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility
closures, travel restrictions or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively
impacted. We may be unable to develop our product candidate, and our costs may increase as a result of the COVID-19 outbreak.
The impacts could worsen if there is an extended duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected
regions after they have begun to experience improvement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We rely
on other companies to provide components and to perform services for us. An extended period of supply chain disruption caused
by the response to COVID-19 could impact our ability to produce our initial product quantities and, if we are not able to implement
alternatives or other mitigations, product deliveries would be adversely impacted and negatively impact our business, financial
condition, operating results and cash flows. Limitations on government operations can also impact regulatory approvals that are
necessary for us to operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The continued
spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional
capital in a private placement that commenced in February 2021, however, we will need to raise additional capital to support our
operations in the future. We may be unable to access the capital markets, and additional capital may only be available to us on
terms that could be significantly detrimental to our existing stockholders and to our business.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We will
need substantial additional funding to complete subsequent phases of our insulin pump product candidate and to operate our business
and such funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The discovery,
development, and commercialization of new medical devices, such as our insulin pump, entails significant costs. While we believe
that we have generally completed the engineering and mechanical aspects of our insulin pump prototype, we still must modify, refine
and finalize our insulin pump to, among other things, meet the general needs and preferences of the almost pumper marketplace
and the guidelines of third-party payors. To enable us to accomplish these and other related items and continue to operate our
business, we will need to raise substantial additional capital and/or enter into strategic partnerships or joint ventures to enable
us to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">fund
    clinical studies and seek regulatory approvals;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">build
    or access manufacturing and commercialization capabilities;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">develop,
    test, and, if approved, market our product candidate;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">acquire
    or license additional internal systems and other infrastructure; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">hire
    and support additional management, engineering and scientific personnel.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Until we can
generate a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance
our cash needs primarily through public or private equity offerings, debt financings or through the establishment of possible
strategic alliances. This offering is being conducted to obtain such funding, although there can be no guarantee that we will
successfully raise all the funding we require in this offering.&#160;&#160; Depending on the amount of funding we receive in this
offering, as well as other factors, we may in the future seek additional capital from public or private offerings of our capital
stock&#160;or&#160;borrow&#160;additional amounts under new credit lines or from other sources. If we issue equity or debt securities
to raise additional funds, our existing stockholders may experience dilution, we may incur significant financing costs, and the
new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. In addition,
if we raise additional funds through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements
or other similar arrangements, it may be necessary to relinquish valuable rights to our potential future products or proprietary
technologies or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We cannot be
certain that additional funding will be available on acceptable terms, or at all. If we are not able to secure additional equity
funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical studies, development
programs or future commercialization initiatives. In addition, any additional equity funding that we do obtain will dilute the
ownership held by our existing equity holders. The amount of this dilution may be substantially increased if the trading price
of our common stock is lower at the time of any financing. Regardless, the economic dilution to shareholders will be significant
if our stock price does not increase significantly, or if the effective price of any sale is below the price paid by a particular
shareholder. Any debt financing that we obtain in the future could involve substantial restrictions on activities and creditors
could seek a pledge of some or all of our assets. We have not identified potential sources for such financing that we will require,
and we do not have commitments from any third parties to provide any future debt financing. If we fail to obtain funding as needed,
we may be forced to cease or scale back operations, and our results, financial condition and stock price would be adversely affected.</span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><i>We have a limited operating
history and historical financial information upon which you may evaluate our performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">You should consider,
among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us,
are in their early stages of development. We may not successfully address these risks and uncertainties or successfully complete
our studies and/or implement our existing and new products. If we fail to do so, it could materially harm our business and impair
the value of our common stock. Unanticipated problems, expenses and delays are frequently encountered in establishing a new business,
conducting research, and developing new products. These include, but are not limited to, inadequate funding, failure to obtain
regulatory approval, unforeseen research issues, lack of consumer acceptance, competition, sluggish product development, and inadequate
sales and marketing. The failure by us to meet any of these conditions would have a materially adverse effect upon us and may
force us to reduce or curtail operations. No assurance can be given that we can or will ever operate profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
not be able to meet our future capital needs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To date, we
have no revenue and we have limited cash liquidity and capital resources. We will need additional capital in the near future.
Any equity financings will result in dilution and may contain other terms that are not favorable to our then-existing stockholders.
We currently have debt financing, and any additional sources of debt financing that we may obtain in the future may result in
a high interest expense. Any financing, if available, may be on unfavorable terms. If adequate funds are not obtained, we will
be required to reduce or curtail operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>The amount
of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial
condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than
we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our future funding
requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    testing costs for our insulin pump product candidate and other development activities conducted by us directly, and our ability
    to successfully conclude the studies and activities and achieve favorable results;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to attract future strategic partners to pay for or share costs related to our product development efforts;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    costs and timing of seeking and obtaining regulatory clearance and approvals for our product candidate;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    costs of filing, prosecuting, maintaining and enforcing any patents and other intellectual property rights that we may have
    and defending against potential claims of infringement;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decisions
    to hire additional scientific, engineering or administrative personnel or consultants;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to manage administrative and other costs of our operations; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    presence or absence of adverse developments in our research program.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these
factors cause our funding needs to be greater than expected, our operations, financial condition, ability to continue operations
and stock price may be adversely affected.</span></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our future
cash requirements may differ significantly from our current estimates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our cash requirements
may differ significantly from our estimates from time to time, depending on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">the costs and
    results of our clinical studies regarding our insulin pump product candidate;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">the time and costs
    involved in obtaining regulatory clearance and approvals;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">whether we are
    able to obtain funding under future licensing agreements, strategic partnerships, or other collaborative relationships, if
    any;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24px"></td><td style="width: 24px; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
costs of compliance with laws, regulations, or judicial decisions applicable to us; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24px"></td><td style="width: 24px; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
costs of general and administrative infrastructure required to manage our business and protect corporate assets and shareholder
interests.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to
raise additional funds on a timely basis, we will need to scale back our business plans, which would adversely affect our business,
financial condition, and stock price, and we may even be forced to discontinue our operations and liquidate our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The diabetes
treatment market is subject to rapid technological change and product innovation. Our insulin pump is based on our proprietary
technology, but a number of companies, medical researchers and existing pharmaceutical companies are pursuing new delivery devices,
delivery technologies, sensing technologies, procedures, drugs and other therapeutics for the monitoring, treatment and/or prevention
of insulin-dependent diabetes. Any technological breakthroughs in diabetes monitoring, treatment or prevention could render our
insulin pump obsolete, which, since our insulin pump is our only product candidate, would have a material adverse effect on our
business, financial condition and results of operations and could result in shareholders losing their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Any failure
to attract and retain skilled directors, executives, employees and consultants could impair our product development and commercialization
activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our business
depends on the skills, performance, and dedication of our directors, executive officers and key engineering, scientific and technical
advisors. Many of our current engineering or scientific advisors are independent contractors and are either self-employed or employed
by other organizations. As a result, they may have conflicts of interest or other commitments, such as consulting or advisory
contracts with other organizations, which may affect their ability to provide services to us in a timely manner. We will need
to recruit additional directors, executive management employees, and advisers, particularly engineering, scientific and technical
personnel, which will require additional financial resources. In addition, there is currently intense competition for skilled
directors, executives and employees with relevant engineering, scientific and technical expertise, and this competition is likely
to continue. If we are unable to attract and retain persons with sufficient engineering, scientific, technical and managerial
experience, we may be forced to limit or delay our product development activities or may experience difficulties in successfully
conducting our business, which would adversely affect our operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We have
limited internal research and development personnel, making us dependent on consulting relationships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We consider
research and development to be an important part of the process of designing, developing, obtaining regulatory required approvals
and the eventual commercialization of our insulin pump. We continue to incur increased research and development expenditures,
which are attributable to effort and expenses incurred in designing and developing our innovative insulin pump. We expect to continue
to incur substantial costs related to research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We currently
have a limited number of research and development personnel, and rely and expect for the foreseeable future to continue to rely,
on consultants, who are not our employees, to perform significant functions for us. As a result, we are and expect to continue
for the foreseeable future to be dependent on such third parties. Such third parties may be able to terminate their contractual
relationships with us quickly and with little, if any, notice. Although we believe there is a relatively large and readily accessible
network of third parties that we can draw from to replace any of our third-party consultants, no assurances can be given that
we would be able to quickly and seamlessly find and hire suitable replacements. Any material interruption or delay in our research
and development activities performed by our consultants could impair our ability to meet any deadlines and materially impair our
then product design and development, regulatory approval and/or commercialization activities which could have a material adverse
effect on our business, financial condition and stock price. In addition, if we do not appropriately manage our relationships
with our consultants, we may not be able to efficiently manage the development, testing, regulatory approval and eventual commercialization
of our insulin pump, which also could have a material and adverse effect on our business, financial condition and stock price.</span></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We will
need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing
of our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future
success will be dependent on the timeliness and effectiveness of the efforts of these third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dependent
on consultants for important aspects of our product development strategy. We do not have the required financial resources and
personnel to carry out independently the development of our product candidate, and do not have the capability or resources to
manufacture, market or sell our current product candidate. As a result, we contract with and rely on third parties for important
functions, including in connection with the development and finalization of our insulin pump, the preparation and filing of our
FDA submission and eventual manufacturing and commercialization of our product candidate. We have recently entered into several
agreements with third parties for such services. If problems develop in our relationships with third parties, or if such parties
fail to perform as expected, it could lead to delays or lack of progress in obtaining FDA clearance, significant cost increases,
changes in our strategies, and even failure of our product initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and
technologies, and we will be dependent on our corporate partners if we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may seek
to enter into a strategic alliance with a diabetes related service providing company for the further development and approval
of our insulin pump product candidate. At this time, we have not entered into any such strategic alliance. Strategic alliances,
if entered into, could potentially provide us with additional funds, expertise, access, and other resources in exchange for exclusive
or non-exclusive licenses or other rights to the product that we are currently developing or a product we may explore in the future.
We cannot give any assurance that we will be able to enter into strategic relationships with a diabetes related service providing
company or others in the near future or at all. In addition, we cannot assure you that any agreements that we do reach will achieve
our goals or be on terms that prove to be economically beneficial to us. When we do enter into strategic or contractual relationships,
we become dependent on the successful performance of our partners or counter-parties. If they fail to perform as expected, such
failure could adversely affect our financial condition, lead to increases in our capital needs, or hinder or delay our development
efforts. See &#8220;Our Business &#8211;Employees&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Before we can
market a new medical device, such as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food,
Drug, and Cosmetic Act, or the FDCA. In the 510(k) clearance process, before a device may be marketed, the FDA must determine
that such proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which
includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May
28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to a premarket approval (PMA) and later
down-classified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same
intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different
technological characteristics and not raise different questions of safety or effectiveness than the predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Certain future
modifications made to our product candidate, which we currently expect to be cleared through 510(k), may require a new 510(k)
clearance. The 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually
takes from three to 12 months, but can last longer. Despite the time, effort and cost, a device may not be approved or cleared
by the FDA. Any delay or failure to obtain necessary regulatory authorizations could harm our business, including our ability
to commercialize our product candidate and our shareholders could lose their entire investment. Furthermore, even if we are granted
the required regulatory authorizations, such authorizations may be subject to significant limitations on the indicated uses for
the device, which may limit the market for our product candidate.</span></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the FDA requires
us to go through a lengthier, more rigorous examination for our product candidate than we had expected, product introductions
or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA can
delay, limit or deny clearance or approval for our insulin pump medical device for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    inability to demonstrate to the satisfaction of the FDA that our product candidate is substantially equivalent to the proposed
    predicate device;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    disagreement of the FDA with the design or implementation of our performance testing protocols or the interpretation of data
    from our performance testing;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    data from performance testing may be insufficient to support a determination of substantial equivalence or that our device
    meets required special controls or applicable performance standards;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    inability to demonstrate that the benefits of our pump outweigh the risks;</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    manufacturing process or facilities we intend to use may not meet applicable requirements; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    potential for approval policies or regulations of the FDA to change significantly in a manner rendering our data or regulatory
    filings insufficient for clearance or approval.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition,
the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other
actions, which may prevent or delay approval or clearance of our product candidate or impact our ability to modify our product
candidate after clearance on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that
could delay our ability to obtain clearance for our pump, increase the costs of compliance or restrict our ability to maintain
our current approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a general
rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among
other things, on the evaluation of data supporting the safety and performance of the products during normal conditions of use.
Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of
its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Obtaining
marketing authorization in the United States will not obviate the need to obtain marketing authorization in other jurisdictions
We must obtain approval from foreign regulatory authorities before we can market and sell any of our products in countries outside
the United States. We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals
and cannot be certain that such approvals will be granted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The development,
manufacture, and marketing of our products outside the United States is subject to government regulation. In most foreign countries,
we must complete rigorous pre-clinical testing and extensive human clinical trials that demonstrate the safety and efficacy of
a product in order to apply for regulatory approval to market the product. If foreign regulatory authorities grant regulatory
approval of a product, the approval may be limited to specific indications or limited with respect to its distribution. Expanded
or additional indications for approved devices may not be approved, which could limit our potential revenues. Foreign regulatory
authorities may refuse to grant any approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient
to support regulatory approval for our products, foreign regulatory authorities may not ultimately grant approval for commercial
sale in any jurisdiction. If our product candidates are not approved in such jurisdictions, our ability to generate revenues will
be limited and our business will be adversely affected.</span></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our competitors
may develop products that are more effective, safer and less expensive than ours.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Existing insulin
pumps are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance
and often require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance
plans, forcing some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any
pumps and places pumps out of reach for many patients whom cannot afford such out of pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are engaged
in the diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products that
are quite effective at addressing the effects of diabetes, and we expect that new developments by other companies and academic
institutions in the areas of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved
clinical indication, our product will be competing with existing and future products related to treatments for diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our competitors
may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">develop
    product candidates and market products that increase the levels of safety or efficacy that our product candidates will need
    to show in order to obtain regulatory approval;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">develop
    product candidates and market products that are less expensive or more effective than ours;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">commercialize
    competing products before we can launch any products we are working to develop;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">hold
    or obtain proprietary rights that could prevent us from commercializing our products; or</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">introduce
    therapies or market medical products that render our potential product candidates obsolete.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We expect to
compete against large medical device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation and
smaller companies that are collaborating with larger medical device companies, new companies, academic institutions, government
agencies and other public and private research organizations. These competitors, in nearly all cases, produce similar products
relative to the treatment of diabetes that have substantially greater financial resources than we do. Our competitors also have
significantly greater experience in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    medical device and other product candidates;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">undertaking
    testing and clinical studies;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">building
    relationships with key customers and opinion-leading physicians;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">obtaining
    and maintaining FDA and other regulatory approvals;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">formulating
    and manufacturing medical devices;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">launching,
    marketing and selling medical devices; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">providing
    management oversight for all of the above-listed operational functions.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to
achieve superiority over other existing or newly developed products, we may be unable to obtain regulatory approval. If our competitors&#8217;
market medical devices that are less expensive, safer or more effective than our insulin pump, or that gain or maintain greater
market acceptance, we may not be able to compete effectively. See &#8220;Business &#8211; Competition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We expect
to rely on third-party manufacturers and will be dependent on their quality and effectiveness.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Our insulin
pump requires precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including
failure to detect or control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could
result in patient injury or death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product
testing or delivery, cost overruns, product recalls or withdrawals and other problems that could seriously hurt our business.
Contract medical device manufacturers often encounter difficulties involving production yields, quality control and quality assurance
and shortages of qualified personnel. These manufacturers are subject to stringent regulatory requirements, including the FDA&#8217;s
current good-manufacturing-practices regulations. If our contract manufacturers fail to maintain ongoing compliance at any time,
the production of our product could be interrupted, resulting in delays or discontinuance of our clinical studies, additional
costs and loss of potential revenues.</span></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
not be able to successfully scale-up manufacturing of our product in sufficient quality and quantity, which would delay or prevent
us from developing our product and commercializing our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In order to
conduct larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted,
we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for
our product in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities.
If we are unable to successfully scale up the manufacture of our product in sufficient quality and quantity, the development and
testing of our product and regulatory approval or commercial launch may be delayed, which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
be subject to potential product liability and other claims that could materially impact our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The development
and sale of our insulin pump exposes us to the risk of significant damages from product liability and other claims, and the use
of our product in clinical studies may result in adverse effects. We cannot predict all the possible harms or adverse effects
that may result. We maintain a modest amount of product liability insurance to provide some protection from claims. Nonetheless,
we may not have sufficient resources to pay for any liabilities resulting from a personal injury or other claim, even if it is
partially covered by insurance. In addition to the possibility of direct claims, we may be required to indemnify third parties
against damages and other liabilities arising out of our development, commercialization and other business activities, which would
increase our liability exposure. If third parties that have agreed to indemnify us fail to do so, we may be held responsible for
those damages and other liabilities as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">New laws, regulations
and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the health care system
in the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations in medical
devices, testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject the pricing
of medical devices to government control. In addition, third-party payors in the U.S. are increasingly attempting to contain health
care costs by limiting both coverage and the level of reimbursement of new products. Consequently, significant uncertainty exists
as to the reimbursement status of newly approved health care products. Significant changes in the health care system in the U.S.
or elsewhere, including changes resulting from adverse trends in third-party reimbursement programs, could have a material adverse
effect on our projected future operating results and our ability to raise capital, commercialize products, and remain in business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We are
subject to extensive regulation by the U.S. Food and Drug Administration, which could restrict the sales and marketing of our
insulin pump and could cause us to incur significant costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our insulin
pump is subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution
and shipping. Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States,
it must be cleared or approved by FDA through the applicable premarket review process (510(k), PMA, or de novo classification),
unless an exemption applies. If we receive 510(k) clearance for our insulin pump, we may be required to obtain new 510(k) clearances
for significant post-market modifications to the pump. Each premarket submission and review process can be expensive and lengthy,
and entail significant user fees, unless exempt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Medical devices
may be marketed only for the indications for which they are approved or cleared. Further, 510(k) clearances can be revoked if
safety or effectiveness problems develop once the device is on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The current
regulatory requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply
with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA,
which may include any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">customer
    notification, or orders for repair, replacement or refunds;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">voluntary
    or mandatory recall or seizure of our current or future products;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">administrative
    detention by the FDA of medical devices believed to be adulterated or misbranded;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">imposing
    operating restrictions, suspension or shutdown of production;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">refusing
    our requests for 510(k) clearance, PMA or <i>de novo</i> classification of any new products, new intended uses or modifications
    to our insulin pump;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">rescinding
    510(k) clearance that has already been granted; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">criminal
    prosecution.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The occurrence
of any of these events would have a material adverse effect on our business, financial condition and results of operations and
could result in shareholders losing their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"><b><i>Although
our system does not presently require clinical trials to apply to the FDA for clearance and even if a clinical trial is completed,
the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise
not be sufficient for us to obtain approval of our product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Clinical
trials are almost always required to support a PMA application and may also be required to support 510(k)
submissions although at this time ours does not require a PMA. If the device presents a &#8220;significant risk&#8221; to
human health as defined by the FDA, the FDA requires the study sponsor to submit an investigational device exemption
(&#8220;IDE&#8221;) &#160;application and obtain IDE approval prior to commencing human clinical trials. The IDE must be
supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in
humans and that the testing protocol is scientifically sound. &#160;An IDE will automatically become effective 30 days after
receipt by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and may
not begin until the sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s
concerns. The FDA may also notify the sponsor that the study is approved as proposed. If the FDA determines that there are
deficiencies or other concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to
proceed under a conditional approval. Furthermore, the agency may withdraw approval of an IDE under certain circumstances.
Clinical trials for a significant risk device may begin once an IDE is approved by the FDA and the appropriate Institutional
Review Board (&#8220;IRB&#8221;) at each clinical trial site. If the product is deemed a &#8220;non-significant risk&#8221;
device, IDE approval from the FDA would not be required, but the clinical trial would need to meet other requirements
including IRB approval. Our clinical trials must be conducted in accordance with FDA regulations and
federal and state regulations concerning human subject protection, including informed consent and healthcare privacy. A
clinical trial may be suspended by the FDA or at a specific site by the relevant IRB at any time for various reasons,
including a determination that the risks to the trial participants outweigh the benefits of participation in the clinical trial.
Even if a clinical trial is completed, the results of our clinical testing may not demonstrate the safety and efficacy of the
device or may be equivocal or otherwise not be sufficient for us to obtain approval of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our success
depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product candidate
and research technologies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have applied
to the U.S. Patent and Trademark Office for patents on our proprietary fluid movement technology and the configuration of our
insulin pump. There is no assurance that these patents will be issued, and no assurance that they will prevent other companies
from competing with us. We will continue to attempt to patent our innovations as appropriate to help ensure a sustainable competitive
advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to evolving
legal standards relating to the patentability, validity and enforceability of patents covering health care product inventions,
our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent
applications is uncertain and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged
regarding the breadth of claims allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any
pending or future patent applications owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims
of these patents will be held valid or enforceable by a court of law, will provide us with any significant protection against
competing products, or will afford us a commercial advantage over competitive products. If, at some point in the future, one or
more products resulting from our product candidates is approved for sale by the FDA and we do not have adequate intellectual property
protection for those products, competitors could duplicate them for approval and sale in the United States without repeating the
extensive testing required of us to obtain FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>If we
are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable
outcome would have a significant adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Our ability
to commercialize our product depends on our ability to use, manufacture and sell our product without infringing the patents or
other proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third
parties exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with
our insulin pump candidate could infringe.</span></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a third party
claims that our actions infringe on its patents or other proprietary rights, we could face a number of issues that could seriously
harm our competitive position, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">infringement
    and other intellectual property claims that, even if meritless, can be costly and time-consuming, delay the regulatory approval
    process and divert management&#8217;s attention from our core business operations;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">substantial
    damages for infringement, including consequential damages for lost of profits or market share, if a court determines that
    our products or technologies infringe on a third party&#8217;s patent or other proprietary rights;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    court prohibiting us from selling or licensing our products or technologies unless the holder licenses the patent or other
    proprietary rights to us, which it is not required to do; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">even
    if a license is available from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or
    other proprietary rights.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these
events occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>If we
are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition
to patented technology, we rely on our unpatented technology, trade secrets and know-how. We generally seek to protect this information
by confidentiality, non-disclosure and assignment of invention agreements with our officers, employees, contractors and&#160;other
service providers and&#160;with parties with which we do business. These agreements may be breached, which breach may result in
the misappropriation of such information, and we may not have adequate remedies for any such breach. We cannot be certain that
the steps we have taken will prevent unauthorized use or reverse engineering of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Moreover, our
trade secrets may be disclosed to or otherwise become known or be independently developed by competitors. To the extent that our
officers, employees, contractors, other service providers, or other third parties with whom we do business use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If,
for any of the above reasons, our intellectual property is disclosed or misappropriated, it would harm our ability to protect
our rights and have a material adverse effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The degree of
future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to gain and maintain a competitive advantage. The following examples
are illustrative:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">others
    may be able to make devices that are similar to our insulin pump but that are not covered by the claims of the patents that
    we own;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    or any collaborators might not have been the first to make the inventions covered by the issued patents or pending patent
    applications that we own;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    might not have been the first to file patent applications covering certain of our inventions;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our
    intellectual property rights;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">it
    is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">issued
    patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result
    of legal challenges;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from
    patent infringement claims for certain research and development activities, as well as in countries where we do not have patent
    rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial
    markets; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may not develop additional proprietary technologies that are patentable.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Healthcare
reform laws could adversely affect our product and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the
United States, there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March
2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act (ACA), was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both
governmental and private insurers. Among other ways in which it may affect our business, the ACA implemented payment system reforms,
including a national pilot program on payment bundling to encourage hospitals, physicians, and other providers to improve the
coordination, quality, and efficiency of certain healthcare services through bundled payment models and expanded the eligibility
criteria for Medicaid programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Since
its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021,
the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality
of the&#160;ACA. Prior to the Supreme Court&#8217;s decision, President&#160;Biden&#160;issued an executive order to initiate
a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance
coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider
their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access
to health insurance coverage through Medicaid or the&#160;ACA. It is unclear how other healthcare reform measures of the&#160;Biden&#160;administration
or other efforts, if any, to challenge, repeal, or replace the ACA will impact the ACA or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">In addition,
other legislative changes have been proposed and adopted since the ACA was enacted. On August&#160;2, 2011, the Budget Control
Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective
on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the
exception of a temporary suspension implemented under various COVID-19 relief legislation from May&#160;1, 2020 through the end
of 2021, unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was
signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Further, the
Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage
gap in most Medicare drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the manufacturer discount under the
Medicare Part D coverage gap discount program to 70%. It is unclear how the ACA and its implementation, as well as efforts to
repeal or replace, or invalidate, the ACA, or portions thereof, will affect our insulin pump or our business. Additional legislative
changes, regulatory changes, and judicial challenges related to the ACA remain possible. It is possible that the ACA, as currently
enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have
an adverse effect on our industry generally and on our ability to commercialize our insulin pump and achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Even if
we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing
and distribution of our product could be interrupted, and our product sales and operating results could suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">A material
step in the process of the commercialization of our product will involve selecting a manufacturer or manufacturers for our pump.
We and any future contract manufacturers of our insulin pump will be required to comply with the FDA&#8217;s quality system regulations,
which impose a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control,
quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces its quality system
regulations through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing facilities owned
by us or any contract manufacturer will pass any quality system inspection. In the event that our or any contract manufacturer&#8217;s
facilities fails a quality system inspection, the manufacturing or distribution of our product could be interrupted and our operations
disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system inspection could force
a suspension or shutdown of any packaging and labeling operations or then manufacturing operations of any contract manufacturers,
or a recall of our insulin pump. If any of these events were to occur, we at such time would not be able to provide our customers
with the quantity of insulin pumps that they require on a timely basis, our reputation could be harmed and we could lose any customers
we then have, any or all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may come
to believe that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized
use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result
in meritorious counterclaims against us and would distract management&#8217;s attention. Also, in an infringement or misappropriation
proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties
may be able to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court
may refuse to stop the other party from using the technology at issue on the grounds that the other party&#8217;s activities are
not covered by our patents. See &#8220;Business &#8211; Patents,&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
become involved in disputes with our present or future contract partners over intellectual property ownership or other matters,
which would have a significant effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Inventions discovered
in the course of performance of contracts with third parties or contractors may become jointly owned by such third party contractors
and us, in some cases, and the exclusive property of one of us, in other cases. Under some circumstances, it may be difficult
to determine who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership or use
of those inventions or jointly developed improvements thereto. Other disputes may also arise relating to the performance or alleged
breach of our agreements with third parties. Any disputes could be costly and time-consuming, and an unfavorable outcome could
have a significant adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Even assuming
we obtain FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our pump
if we commence manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations
pertaining to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning
the safety or efficacy of the device. A government-mandated recall could occur if the FDA finds that there is a reasonable probability
that our device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of
manufacturing defects, labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall
would divert management&#8217;s attention and financial resources and harm our reputation with customers. A recall involving our
insulin pump would be particularly harmful to our business, financial condition and results of operations because it is currently
our only product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Any disruption
and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets,
and thus adversely affect our business and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Negative
economic conditions and issues with regard to the financial markets, could have a negative impact on our ability to access the
capital markets, and thus have a negative impact on our then operations and liquidity. A general shortage of liquidity and credit
combined with the substantial losses in worldwide equity markets could lead to an extended worldwide recession in the future.
If such occurred, we would face significant challenges if conditions in the capital markets did not improve. Our ability to access
the capital markets under such circumstances could be severely restricted at a time when we need to access such markets, which
could have a negative impact on our business plans. Even if we are able to raise capital under such circumstances, it may not
be at a price or on terms that are favorable to us. We cannot predict the occurrence of future disruptions or how long such negative
conditions might continue.</span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Because
our current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are approved for and are otherwise able to commercialize our insulin pump, but are unable to obtain
adequate reimbursement or insurance coverage for such product from third-party payors, we will be unable to generate significant
revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because our
current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain.
In the United States, patients using insulin pumps are generally reimbursed for all or part of the product cost by Medicare or
other third-party payors. Any future commercial success of our insulin pump will be substantially dependent on whether third-party
coverage and reimbursement is available for future customers. Medicare, Medicaid, health maintenance organizations and other third-party
payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new
medical devices, and, as a result, they may not cover or provide adequate reimbursement for our insulin pump, assuming we are
able to fully develop and obtain all regulatory approval to market it in the United States. &#160;In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device
products and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services
can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and
can, without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products
to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.
Reimbursement systems in international markets vary significantly by country and by region within some countries, and reimbursement
approvals must be obtained on a country-by-country basis. In many international markets, a product must be approved for reimbursement
before it can be approved for sale in that country. Further, many international markets have government-managed healthcare systems
that control reimbursement for new devices and procedures. Accordingly, unless government and
other third-party payors provide coverage and reimbursement for our insulin pump, patients may not use it, which would cause investors
to lose their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We are
subject to the oversight of the SEC and other regulatory agencies. Investigations by those agencies could divert management&#8217;s
focus and could have a material adverse effect on our reputation and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are subject
to the regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face legal
or administrative proceedings by these agencies. We are unable to predict the effect of any investigations on our business, financial
condition or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could
have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We are
a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to
smaller reporting companies, our common stock may be less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a &#8220;smaller
reporting company,&#8221; and are subject to lesser disclosure obligations in our SEC filings compared to other issuers. Specifically,
&#8220;smaller reporting companies&#8221; are able to provide simplified executive compensation disclosures in their filings,
are exempt from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting
firms provide an attestation report on the effectiveness of internal control over financial reporting and have certain other decreased
disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited
financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting
company&#8221; may make it harder for investors to analyze our operating results and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our shares
of common stock are quoted on the OTCQB Market, and the trading market for our common stock is limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our shares of
common stock are traded on the OTCQB Market. There is currently a limited trading market for our common stock, and, prior to 2021,
there had been no active trading market for our common stock. While we believe an active trading market for our common stock is
developing, there can be no assurance that an active trading market for our common stock will develop, or, even if one develops,
will be sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We do
not expect any cash dividends to be paid on our shares of common stock for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never
declared or paid a cash dividend and we do not anticipate declaring or paying dividends on our common stock for the foreseeable
future. We expect to use future financing proceeds and earnings, if any, to fund operating expenses. Consequently, shareholders&#8217;
only opportunity to achieve a return on their investment is if the price of our stock appreciates and they sell their shares at
a profit. We cannot assure shareholders of a positive return on their investment when they sell their shares or that shareholders
will not lose the entire amount of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>If the
beneficial ownership of our common stock continues to be highly concentrated, it may prevent our shareholders from influencing
significant corporate decisions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">As of
October 20, 2021, our executive officers, directors and certain persons who may be deemed affiliates beneficially owned substantially
in excess of 50% of our issued and outstanding common stock. As a result, such persons may exercise substantial influence over
the outcome of corporate actions requiring shareholder approval including, without limitation, the election of directors, certain
mergers, consolidations and sales of all or substantially all of our assets or any other significant corporate transactions. Such
persons may also vote against a change of control, even if such a change of control would benefit our other shareholders.</span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b><i>Sale
of our common stock by shareholders could encourage short sales by third parties, which could contribute to the further decline
of our stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt">The significant
downward pressure on the price of our common stock that would be caused by the sale of material amounts of our common stock could
encourage short sales by third parties. Such an event could place further downward pressure on the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">We are an
&#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). For as long
as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that
are applicable to other public companies that are not emerging growth companies, including not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding
nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.
We could be an emerging growth company for up to five years following the year in which we complete this offering, although circumstances
could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (i) the last day of
the fiscal year (a) following the fifth anniversary of the completion of the first sale of shares covered by this prospectus,
(b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated
filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior
September 30<sup>th</sup>, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the
prior three-year period.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b><i>Our
common stock may be classified as &#8220;penny stock&#8221; and trading of our shares may be restricted by the SEC&#8217;s penny
stock regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Our common
stock is currently traded on the OTCQB Venture Market. Rules 15g-1 through 15g-9 promulgated under the Exchange Act impose sales
practice and disclosure requirements on certain brokers-dealers who engage in transactions involving a &#8220;penny stock.&#8221;
The SEC has adopted regulations which generally define &#8220;penny stock&#8221; to be any equity security that has a market price
of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. If we do not obtain
or retain a listing on Nasdaq and if the price of our Common Stock is less than $5.00, our common shares may be covered by the
penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established
customers and &#8220;accredited investors.&#8221; The penny stock rules require a broker-dealer, prior to a transaction in a penny
stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC, which
provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must
provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s
account. In addition, the penny stock rules require that, prior to a transaction in a penny stock that is not otherwise exempt,
the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and
receive the purchaser&#8217;s written agreement to the transaction. These disclosure requirements may have the effect of reducing
the level of trading activity in the secondary market for stock that is subject to these penny stock rules. Consequently, these
penny stock rules may affect the ability of broker-dealers to trade our common stock. We believe that the penny stock rules may
discourage investor interest in and limit the marketability and reduce the level of trading activity of our common shares. The
market price of our common stock may suffer as a result.</span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b><i>Future
sales of our securities could adversely affect the market price of our common stock and our future capital-raising activities
could involve the issuance of equity securities, which would dilute your investment and could result in a decline in the trading
price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt">We may sell
securities in the public or private equity markets at prices per share below the current market price of our common stock, even
if we do not have an immediate need for additional capital at that time. Sales of substantial amounts of shares of our common
stock, or the perception that such sales could occur, could adversely affect the prevailing market price of our shares and our
ability to raise capital. We may issue additional shares of common stock in future financing transactions or as incentive compensation
for our executive management and other key personnel, consultants and advisors. Issuing any equity securities would be dilutive
to the equity interests represented by our then-outstanding shares of common stock. Moreover, sales of substantial amounts of
shares in the public market, or the perception that such sales could occur, may adversely affect the prevailing market price of
our common stock and make it more difficult for us to raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our
certificate of incorporation allows for our board of directors to create new series of preferred stock without further approval
by our shareholders, which could adversely affect the rights of the holders of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Our board
of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Currently, our board
of directors has the authority to designate and issue up to 5,000,000 shares of our preferred stock without further shareholder
approval. In the future, our board of directors could authorize the issuance of one or more series of preferred stock that would
grant to holders, among other rights, the preferred right to our assets upon liquidation, the right to receive dividend payments
before dividends are distributed to the holders of common stock and the right to the redemption of our preferred shares acquired
by such persons, together with a premium, prior to the redemption of our common stock. In addition, our board of directors could
authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible
into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing
shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>We
have not held regular annual meetings of shareholders in the past, and if we are required by the Nevada District Court to hold
an annual meeting pursuant to Nevada Revised Statutes &#167;78.345(1), it could result in the unanticipated expenditure of funds,
time and other Company resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Section 2.01
of our Amended Bylaws provides that an annual meeting of shareholders shall be held each year on a date and at a time designated
by our board of directors. Section 78.345(1) of the Nevada Revised Statutes provides that, if there is a failure to hold the annual
meeting for a period of 18 months after the last election of directors, shareholders owning at least 15% of the voting power of
the outstanding common stock may apply to the Nevada district court to order the election of directors. We have not held regular
annual meetings of shareholders in the past because approximately 75% of our voting stock is owned by our largest shareholders,
thereby making it easy to obtain written consent in lieu of a meeting when necessary. Moreover, handling matters by written consent
allows us to save on financial and administrative resources required to prepare for and hold such annual meetings. To our knowledge,
no shareholder or director has requested our management to hold such an annual meeting and no shareholder or director has applied
to the Nevada district court seeking an order directing us to hold such an annual meeting of shareholders. However, if one or
more shareholders or directors were to apply to the Nevada district court seeking such an order, and if the Nevada district court
were to order an annual meeting before we were prepared to hold one, the preparation for an annual meeting of shareholders and
the meeting itself could result in the unanticipated expenditure of funds, time, and other resources of ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-size: 10pt"><b><i>If
we fail to establish and maintain an effective system of internal controls, we may not be able to report our financial results
accurately or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation
and adversely affect the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Effective
internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable
financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control
environment existed, and our business and reputation with investors may be harmed. If we are unable to maintain effective internal
controls, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations
as a public company, including the requirements of the&#160;Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition,
we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by
the requirements of the SEC or the&#160;Sarbanes-Oxley Act. Failure to comply with the&#160;Sarbanes-Oxley Act, when and as applicable,
could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain
or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in identification
of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in
material misstatements in our financial statements.</span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Furthermore,
Section 404 of the Sarbanes-Oxley Act and related regulations require our management to evaluate the effectiveness of our internal
control over financial reporting as of the end of each fiscal year. Based on its evaluation, our management concluded that our
internal controls over financial reporting were effective as of March 31, 2021. We cannot provide assurance that, in the future,
a material weakness or significant deficiency will not exist or otherwise be discovered. If that were to happen, it could harm
our operating results and cause shareholders to lose confidence in our reported financial information. Any such loss of confidence
would have a negative effect on the trading price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt"><b><i>Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of common stock
without shareholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Pursuant
to our amended and restated articles of incorporation, our board of directors has the power, without obtaining shareholder approval,
to effectuate recapitalizations of us through forward or reverse splits of our outstanding common stock. As a result of such provision,
our board of directors can implement recapitalizations of us by effectuating a forward or reverse stock split of our outstanding
common stock, which would increase or decrease each of our shareholder&#8217;s number of shares owned, and our shareholders will
have no right to approve or disapprove any such action even if such actions have a material adverse effect on them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Risks Related to This Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>We may
be unable to list our stock on a national exchange, such as the Nasdaq Capital Market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There has been
a limited public market for our common stock. It is our intention to qualify for the trading of our common stock on a national
exchange, and we have applied to list our common stock on Nasdaq concurrently with the closing of the offering. However, we may
not meet or maintain certain qualifying requirements for Nasdaq. If we are unable to meet these requirements, we may be limited
to trading conducted on the OTCQB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>There can be no assurance that we will be able to
comply with the continued listing standards of the Nasdaq Capital Market, a failure of which could result in a de-listing of our
common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Nasdaq Capital Market requires
that the trading price of its listed stocks remain above one dollar in order for the stock to remain listed. If a listed stock
trades below one dollar for more than 30 consecutive trading days, then it is subject to delisting from the Nasdaq Capital Market.
In addition, to maintain a listing on the Nasdaq Capital Market, we must satisfy minimum financial and other continued listing
requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders&#8217;
equity, and certain corporate governance requirements. If we are unable to satisfy these requirements or standards, we could be
subject to delisting, which would have a negative effect on the price of our common stock and would impair your ability to sell
or purchase our common stock when you wish to do so. In the event of a delisting, we would expect to take actions to restore our
compliance with the listing requirements, but we can provide no assurance that any such action taken by us would allow our common
stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock
from dropping below the minimum bid price requirement, or prevent future non-compliance with the listing requirements.<span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Since
we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have not
allocated the net proceeds from this offering for any specific purpose, except as generally set forth under &#8220;Use of Proceeds.&#8221;
As set forth therein, our management will have significant flexibility in applying the net proceeds of this offering. You will
be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used in ways you would agree with or ways which
are likely to increase the value of your investment. Because of the number and variability of factors that will determine our
use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. It is
possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for our company or your
investment. The failure of our management to use such funds effectively could have a material adverse effect on our business,
financial condition, operating results and cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>There
is a limited market for our securities, which may make it more difficult to dispose of our securities and we may fail to sustain
trading on Nasdaq, which could make it more difficult for investors to sell their shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is quoted on OTCQB, under the symbol &#8220;MODD,&#8221; and, to date, has traded on a limited basis. We have applied to list
our common stock on Nasdaq under the symbol &#8220;MODD.&#8221; In the event our common stock begins trading on the Nasdaq, there
can be no assurance that trading of our common stock on such market will be sustained. In the event that our common stock is not
listed on Nasdaq or if we do not sustain such listing, our common stock could be quoted only on the OTC Markets. Under such circumstances,
you may find it significantly more difficult to trade, or to obtain accurate quotations for our common stock and our common stock
may become substantially less attractive to certain purchasers, such as financial institutions, hedge funds, and other similar
investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">A more
active market for our common stock may never develop, and we are under no obligation to seek out a more active market for our
common stock.</span></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>If you
purchase our securities in this offering, you may incur immediate and substantial dilution in the book value of your shares. You
will experience further dilution if we issue additional equity or equity-linked securities in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The public offering
price per share of our common stock may be substantially higher than the net tangible book value per share of our common stock
immediately prior to the offering. After giving effect to the sale of $30,000,000 of shares of our common stock in this offering,
at the assumed public offering price of $________ per share, which is the last reported sale price of our common stock on the
OTCQB Market on ________, 2021, and after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us, purchasers of our common stock in this offering will incur immediate dilution of $_______ per share in
the net tangible book value of the common stock they acquire. For a further description of the dilution that investors in this
offering may experience, see &#8220;Dilution.&#8221; &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.95pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we issue
additional shares of common stock (including pursuant to the exercise of outstanding stock options or warrants), or securities
convertible into or exchangeable or exercisable for shares of common stock, our stockholders, including investors who purchase
shares of common stock in this offering, will experience additional dilution, and any such issuances may result in downward pressure
on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities in any other
offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors
purchasing shares or other securities in the future could have rights superior to existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could
depress the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Sales of a substantial
number of shares of our common stock in the public markets could depress the market price of our common stock and impair our ability
to raise capital through the sale of additional equity securities. We, our directors and our executive officers have agreed not
to sell, dispose of or hedge any common stock or securities convertible into or exchangeable for shares of common stock during
the period from the date of this prospectus continuing through and including the date 90&#160;days after the date of this prospectus,
subject to certain exceptions. The underwriters may, in their discretion, release the restrictions on any such shares at any time
without notice. See &#8220;Underwriting.&#8221; We cannot predict the effect that future sales of our common stock would have
on the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>If the
price of our common stock fluctuates significantly, your investment could lose value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is currently quoted on the OTCQB, under the symbol &#8220;MODD,&#8221; and, to date, has traded on a limited basis. We have applied
to list our common stock on Nasdaq under the symbol &#8220;MODD.&#8221; We cannot assure you that an active public market will
continue for our common stock. If an active public market for our common stock does not continue, the trading price and liquidity
of our common stock will be materially and adversely affected. If there is a thin trading market or &#8220;float&#8221; for our
stock, the market price for our common stock may fluctuate significantly more than the stock market as a whole. Without a large
float, our common stock would be less liquid than the stock of companies with broader public ownership and, as a result, the trading
prices of our common stock may be more volatile. In addition, in the absence of an active public trading market, investors may
be unable to liquidate their investment in us. Furthermore, the stock market is subject to significant price and volume fluctuations,
and the price of our common stock could fluctuate widely in response to several factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    quarterly or annual operating results;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in our earnings estimates or the failure to accurately forecast and appropriately plan our expenses;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">failure
    to achieve our growth expectations;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">failure
    to attract customers and retain them;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    effect of increased or variable competition on our business;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">additions
    or departures of key or qualified personnel;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">failure
    to adequately protect our intellectual property;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">costs
    associated with defending claims, including intellectual property infringement claims and related judgments or settlements;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in governmental or other regulations affecting our business;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    compliance with governmental or other regulations affecting our business; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in global or regional industry, general market, or economic conditions.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The stock
market has experienced extreme price and volume fluctuations in recent years that have significantly affected the quoted prices
of the securities of many companies, including companies in our industry. The changes may not be possible to predict and often
appear to occur without regard to specific operating performance. The price of our common stock could fluctuate based upon factors
that have little or nothing to do with our company and these fluctuations could materially reduce our stock price.</span></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara005"></span>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus
includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer
to as the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange
Act, that relate to future events or to our future operations or financial performance. Any forward-looking statement involves
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied
by such forward-looking statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Words such as,
but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;targets,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221;
&#8220;continue,&#8221; &#8220;scheduled&#8221; and similar expressions or phrases, or the negative of those expressions or phrases,
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this registration statement,
we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown
risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience
or achievements to differ materially from those expressed or implied by any forward-looking statement. Actual results, level of
activity, performance, experience or achievements may differ materially from those expressed or implied by any forward-looking
statement as a result of various important factors, including our critical accounting policies and risks and uncertainties relating,
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         strategies, prospects, plans, expectations, forecasts or objectives;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to achieve a marketable product (i.e., our insulin pump) and the costs and timing
                                         thereof;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">acceptance
                                         of our product by our target market and our ability to compete in such market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to raise additional financing when needed and the terms and timing thereof;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to expand, protect and maintain our intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         future operations, financial position, revenues, costs, expenses, uses of cash, capital
                                         requirements, our need for additional financing or the period for which our existing
                                         cash resources will be sufficient to meet our operating requirements;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         analysis of the target market for our insulin pump;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         impact of COVID-19 and other adverse public health developments on our operations and
                                         our industry :</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to obtain all regulatory approvals and clearances relating to our insulin pump
                                         including those of the United States Food and Drug Administration, or FDA;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">regulatory
                                         developments in the United States and other countries;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         timing and costs of our obtaining all regulatory approvals and clearances identified
                                         immediately above;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         compliance with all applicable laws, rules and regulations, including those of the Securities
                                         and Exchange Commission, or SEC, and the FDA;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         plans to list our common stock on the Nasdaq and whether an active trading market for
                                         our common stock will develop;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to compete in the diabetes marketplace with larger and more substantial medical
                                         device companies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">general
                                         economic, business, political and social conditions;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         reliance on and our ability to retain (and if necessary, timely recruit and replace)
                                         our officers, directors and key employees and their ability to timely and competently
                                         perform at levels expected of them;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to generate significant revenues and achieve profitability;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to manage the growth of our business;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         commercialization, marketing and manufacturing capabilities and strategies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
ability to expand, protect and maintain our intellectual property position;</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    success of competing third-party products;</span></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to fully remediate our identified internal control material weaknesses;</span></td></tr></table>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to meet the initial or continuing listing requirement of the Nasdaq Capital Market;</span></td></tr></table>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to comply with regulatory requirements relating to our business, and the costs
                                         of compliance with those requirements, including those on data privacy and security;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         specific risk factors discussed under the heading &#8220;Risk Factors&#8221; set forth
                                         in this prospectus; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">various
                                         other matters, many of which are beyond our control.</span></td></tr></table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara006"></span>USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We estimate
that our net proceeds from this offering will be approximately $___________ after deducting underwriting discounts and commissions
and estimated offering expenses payable by us. If the option to purchase additional shares is exercised in full, we estimate that
our net proceeds will be approximately $______________.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of September
30, 2021, we had cash and cash equivalents of approximately $0.7 million. We currently expect that to use the net proceeds from
this offering, together with our existing cash and cash equivalents, primarily for the following purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Approximately
$_____ (_____% of net proceeds) for repayment of the promissory note held by Manchester Explorer, LP;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Approximately
$_______ (_____% of net proceeds) for research and development for new products and improvements to our initial pump product including,
but not limited to, hiring of key personnel, and costs for continued research activities;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Approximately
$_______ (_____% of net proceeds) to develop our sales and marketing capabilities and organization, including but not limited
to adding additional staff, public relations and advertising;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Approximately
$ ______ (_____% of net proceeds) to develop our manufacturing and production capability; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
remainder (_____% of net proceeds) for working capital, capital expenditures and other general corporate purposes<span style="background-color: white">.</span></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that
our existing cash and cash equivalents, along with the net proceeds from this offering, together with interest on cash balances,
will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. The
amount and timing of our actual expenditures and actual use of the net proceeds of the offering will depend upon numerous factors,
including the timing of our submission to the FDA for 510(k) clearance of our product, which is necessary to commence commercialization,
the timing and results of our product launch, including all commercialization activities, the progress of our continuing product
research and development activities, our ability to establish our outsourced manufacturing operations, and our ability to add
the required staff to execute our business plan, any collaborations that we may enter into with third parties, and any unforeseen
delays or cash needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our expected
use of the net proceeds from this offering represents our current intentions based upon our present plans and business conditions.
As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on
our judgment regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue
these certain of these activities if the net proceeds from this offering and the other sources of cash are less than, or do not
last as long as, expected. We have no current understandings, agreements or commitments for any material acquisitions or licenses
of any products, businesses or technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pending their
use, we plan to invest the net proceeds from this offering in high-quality, short-term interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara007"></span>MARKET FOR
COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Market Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock trades on the OTCQB
tier of OTC Markets Group, Inc. under the trading symbol &#8220;MODD&#8221; on a very limited basis. We have applied to list our
common stock on Nasdaq under the symbol &#8220;MODD.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of October
22, 2021, there were approximately 70 registered holders of record of our common stock and the last reported sale price of our
common stock on the OTCQB on October 22, 2021, was $2.95 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Any OTCQB quotations
of our common stock reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent
actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara008"></span>DIVIDEND POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We have
never declared nor paid any cash dividends on our capital stock. We do not intend to pay cash dividends on our common stock for
the foreseeable future, and currently intend to retain any future earnings to fund our operations and the development and growth
of our business. Any future determination to declare and pay dividends will be made at the discretion of our board of directors
and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital
requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant.
Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara009"></span>CAPITALIZATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth our cash and cash equivalents and capitalization as of June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">an actual basis (giving effect on a retroactive basis, to a 1-for ____ reverse stock split which was consummated on ______, 2021).</span></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">on
    a pro-forma basis to give effect to (i) our sale of $30,000,000 of shares of common stock in this offering at the
    assumed public offering price of $________ per share, which is the last reported sale price of our common stock on the OTCQB
    Market on ________, 2021, after deducting estimated underwriting discounts and commissions and estimated offering expenses
    payable by us, and (ii) the conversion of $6,610,560 principal amount of convertible notes and accrued interest thereon
    and 2,303,348 common stock purchase warrants (assuming interest calculated through).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The as adjusted
information below is illustrative only and our capitalization following the closing of this offering will be adjusted based on
the actual public offering price and other terms of this offering determined at pricing. You should read this information together
with our financial statements and the related notes thereto included elsewhere in this prospectus and the information set forth
under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included
elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">As
    of June 30, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Actual</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Pro
    Forma</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Cash&#160;&#160;and
    cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">3,380,968</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">6,610,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Stockholders&#8217; equity:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Preferred stock, par
    value $0.001; 5,000,000 shares authorized and undesignated, actual, pro forma; no shares issued and outstanding, actual or
    pro forma</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font-size: 10pt">Common stock, $0.001
    par value, 50,000,000 shares authorized; 18,971,656 shares issued and outstanding, actual;&#160;&#160;_______ shares issued
    and outstanding, pro forma</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">18,972</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font-size: 10pt">Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">19,181,641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt"><span style="font-size: 10pt">Accumulated deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(20,782,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total stockholders&#8217;
    equity (deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(1,581,488</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt"><span style="font-size: 10pt">Total capitalization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,029,062</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each $1.00 increase
(decrease) in the assumed public offering price of $_____ per share would increase (decrease) the as adjusted amount of cash and
cash equivalents, additional paid-in capital, total stockholders&#8217; equity (deficit) and total capitalization by approximately
$_________ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We may also increase or decrease the number of shares we are offering. Each increase (decrease) of&#160;100,000 shares in the
number of shares we are offering would increase (decrease) the as adjusted amount of cash and cash equivalents, additional paid-in
capital, total stockholders&#8217; equity and total capitalization by approximately $_______ million, assuming that the assumed
public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on
the actual public offering price and other terms of this offering determined at pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The number of
shares of our common stock to be outstanding after this offering is based on 18,982,562 shares of our common stock outstanding
as of September 30, 2021, and excludes, as of such date:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,579,764
    shares of our common stock issuable upon conversion of the convertible promissory notes and accrued interest, assuming such
    convertible promissory notes were outstanding for their full one-year term and converted at a price of $2.87 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,303,348
    shares of our common stock issuable upon exercise of warrants issued to our convertible promissory note holders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4,792,949 <span style="background-color: white">shares
    of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
    $2.39 per share; and</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3,207,051
    shares of our common stock reserved for issuance pursuant to future awards under our 2017 Equity Incentive Plan, or the 2017
    Plan.</span></td></tr>
</table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara010"></span>DILUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If you invest
in our common stock, your interest will be diluted immediately to the extent of the difference between the offering price per
share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after giving effect
to this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of June 30,
2021, our historical net tangible book value was $(3,822,597) or $(0.20) per share of common stock. Historical net tangible book
value per share represents the amount of our total tangible assets less total liabilities, divided by 18,971,656, the number of
shares of common stock outstanding on June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">After giving
effect to the sale of $30,000,000 of shares of our common stock in this offering at the assumed offering price of $________ per
share, which is the last reported sale price of our common stock on the OTCQB Market on ________, 2021, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us, and (ii) our net tangible book value as
of June 30, 2021 would have been $__________ or $________ per share. This amount represents an immediate increase in net tangible
book value of $____________per share to our existing stockholders. Investors purchasing our common stock in this offering will
have paid $_________ more than the as adjusted net tangible book value per share after this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table illustrates this dilution on a per share basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%"><span style="font-size: 10pt">Assumed offering price per
    share</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Historical net tangible book value per
    share as of June 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(0.20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Increase in net tangible
    book value per share attributable to new investors</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Net tangible book value
    per share after the offering</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Dilution per share to
    new investors</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each $1.00 increase
(decrease) in the assumed public offering price of $______ per share would increase (decrease) our net tangible book value after
this offering by approximately $_______ per share, and increase (decrease) the dilution per share to new investors by approximately
$_______ per share, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us, and assuming no exercise of the underwrites&#8217; over-allotment option in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the underwriters
exercise their over-allotment option in full in this offering, the as adjusted net tangible book value after the offering would
be $________ per share, the increase in as adjusted net tangible book value per share to existing stockholders would be $_______
per share and the dilution per share to new investors&#160;would be $____ per share, in each case assuming a public offering price
of $______ per share, which is the last reported sale price of our common stock on the OTCQB Market on _________, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The number of
shares of our common stock to be outstanding after this offering is based on 18,982,562 shares of our common stock outstanding
as of September 30, 2021, and excludes, as of such date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,579,764
    shares of our common stock issuable upon conversion of our convertible promissory notes and accrued interest, assuming such
    convertible promissory notes were outstanding for their full one-year term and converted at a price of $2.87 per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2,303,348
    shares of our common stock issuable upon exercise of warrants issued to our convertible promissory note holders;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4,792,949 <span style="background-color: white">shares
    of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
    $2.39 per share; and</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3,207,051
    shares of our common stock reserved for issuance pursuant to future awards under our 2017 Equity Incentive Plan, or the 2017
    Plan.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the shares
described above that are reserved for issuance to the holders of our convertible promissory notes and related warrants and under
our 2017 Plan are issued, or we otherwise issue additional shares of common stock in the future, there could be further dilution
to investors participating in this offering. In addition, we anticipate needing to raise additional capital before generating
positive cash flows and we may choose to raise additional capital because of market conditions or strategic considerations, even
if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through
the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</span></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara011"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>You should
read the following discussion and analysis in conjunction with our unaudited condensed consolidated financial statements and the
notes to those financial statements for the three months ended June 30, 2021 and June 30, 2020 and consolidated financial statements
and notes to those financial statements for the years ended March 31, 2021 and March 31, 2020 included elsewhere in this prospectus.
This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See
&#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results may differ materially from those contained
in or implied by any forward-looking statements. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Company
Overview</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a development-stage
medical device company focused on the design, development and eventual commercialization of an innovative insulin pump to address
shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin dependent people
with diabetes. We have developed a hardware technology allowing people with insulin-dependent diabetes to receive their daily
insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount of insulin to be in the blood at
all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address when the blood glucose level becomes
excessively high. By addressing the substantial time and effort required by them to effectively treat their condition, we believe
we can address the less technically savvy, less motivated part of the market, which we believe is underserved.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We&#160;continue
to develop our insulin pump product and are working on the required testing and documentation for our submission to the&#160;U.S.&#160;Food&#160;and&#160;Drug&#160;Administration,&#160;or&#160;FDA,&#160;to
obtain&#160;clearance to bring the product to market. We have therefore not generated any revenues from product sales. Our net
losses were $4.8 million for the three months ended June 30, 2021 and $7.4 million and $5.3 million for the years ended March
31, 2021 and 2020, respectively. As of June 30, 2021, we had a negative working capital of approximately $2.0 million and an accumulated
deficit of $20.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Historically,
we have financed our operations principally through private placements of our common stock and convertible promissory notes. Based
on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one
year from the date that the financial statements included in this prospectus are issued exists. Our ability to continue as a going
concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future
operations. If we are unable to secure additional capital, we will be required to curtail our research and development initiatives
and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the June 30, 2021 condensed
consolidated financial statements and under &#8220;&#8211; Liquidity and Capital Resources&#8221; below.</span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Impacts of
COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial
performance will depend on future developments, including, without limitation, the duration and spread of the pandemic and related
actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control,
and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In March 2020,
Santa Diego County in California, where we are based, and the state of California issued &#8220;shelter-in-place&#8221; orders
(the Orders). We complied with the Orders and minimized business activities at our San Diego facility from March 2020 until May
2021. During that time, we implemented a teleworking policy for our employees and contractors to reduce on-site activity at our
facility. In May 2021, our employees and certain contractors returned to work in our office. We have and continue to experience
longer lead times for certain components used to manufacture initial quantities of our products for our submission to the FDA,
which is expected to occur in the quarter ending December 31, 2021. We remain diligent in continuing to identify and manage risks
to our business given the changing uncertainties related to COVID-19. While we believe that our operations personnel are currently
in a position to build an adequate supply of products for our FDA submission, we recognize that unpredictable events could create
difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could delay our submission
to the FDA and negatively impact our business, results of operations, financial condition and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The continued
spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional
capital in a private placement of convertible promissory notes (see discussion below under &#8220;&#8211; Liquidity and
Capital Resources&#8221;). However, we need to raise additional capital to support our operations in the future. We may be unable
to access the capital markets or additional capital may only be available to us on terms that could be significantly detrimental
to our existing stockholders and holders of the convertible promissory notes and to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For additional
information on risks that could impact our future results, please refer to the &#8220;Risk Factors&#8221; section of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Critical
Accounting Policies and Estimates&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The discussion
and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires
us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing
basis, we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances.
Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our
significant accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements for the
year ended March 31, 2021, which is included within this prospectus. As of June 30, 2021, there have been no material changes
to our significant accounting policies and estimates.</span></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Results
of Operations for the Three Months Ended June 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020&#160;to&#160;2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: justify">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,788,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">970,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">817,316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">84.2</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research
and development expenses include personnel, overhead and other costs associated with the development of our insulin pump product.
We expense research and development costs as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Research and
development, or R&amp;D, expenses increased for the three months ended June 30, 2021 compared with the same period of 2020, primarily
due to increased engineering and operations personnel and consulting costs. Our full-time R&amp;D employee headcount increased
to 22 at June 30, 2021 from 10 at June 30, 2020.&#160;R&amp;D expenses included stock-based compensation expenses of $138,286
and $103,725 for the quarters ended June 30, 2021 and June 30, 2020, respectively.&#160;We expect research and development expenses
to increase for the remainder of fiscal 2021, as we continue to advance the development of our pump product and develop a low-volume
manufacturing process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>General and
Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020&#160;to&#160;2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: justify">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,585,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">903,397</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">682,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">75.5</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expenses consist primarily of personnel and related overhead costs for marketing, finance, human resources and
general management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses, or G&amp;A, increased for the three months ended June 30, 2021 compared with the same period of 2020,
primarily as a result of increased personnel and consulting costs, stock-based compensation expenses and professional services
fees. Our full-time G&amp;A headcount increased to four at June 30, 2021 from three at June 30, 2020. G&amp;A expenses included
stock-based compensation expenses of $517,635 and $240,991 for quarters ending June 30, 2021 and June 30, 2020, respectively.&#160;We
expect G&amp;A expenses to remain flat for the remainder of fiscal 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Results
of Operations for the Years Ended March 31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
discussion should be read in conjunction with our audited consolidated financial statements and related notes for the years ended
March 31, 2021 and March 31, 2020 included elsewhere in this Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021&#160;to&#160;2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: justify">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,083,303</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,034,152</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,049,151</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">34.6</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research
and development expenses include personnel, overhead and other costs associated with the development of our insulin pump product.
We expense research and development costs as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Research and
development, or R&amp;D, expenses increased in fiscal 2021 compared with fiscal 2020 primarily due to increased engineering and
operations personnel and consulting costs. Our R&amp;D employee headcount increased to 17 at March 31, 2021, from 10 at March
31, 2020.&#160;R&amp;D expenses included stock-based compensation expenses of $390,045 and $422,625 for fiscal 2021 and fiscal
2020, respectively.&#160;We expect R&amp;D expenses to continue to increase in fiscal 2022, as we continue to advance the development
of our pump product and develop a low-volume manufacturing process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>General and
Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021&#160;to&#160;2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: justify">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,253,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,313,870</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">939,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">40.6</td><td style="width: 1%; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expenses consist primarily of personnel and related overhead costs for marketing, finance, human resources and
general management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expenses, or G&amp;A, increased in fiscal 2021 compared with fiscal 2020 primarily as a result of increased personnel
and consulting costs, stock-based compensation expenses and professional services fees related to our financing activities. Our
full-time G&amp;A headcount increased to four at March 31, 2021 from two at March 31, 2020. G&amp;A expenses included stock-based
compensation expenses of $837,533 and $378,619 for fiscal 2021 and fiscal 2020, respectively. We expect G&amp;A expenses to continue
to increase in fiscal 2022, as we commence the commercialization of our product and increase headcount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>Interest
Income</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021&#160;to&#160;2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: justify">Interest income</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">130</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">28,749</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(28,619</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(99.5</td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Interest income
consisted of interest earned on our cash deposits. The decrease in interest income for fiscal 2021 compared with fiscal 2020 was
primarily attributable to lower average cash balances during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Interest expense
represents interest on our 2021 Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Liquidity
and Capital Resources</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have
incurred operating losses and negative cash flows in each year due to costs incurred in connection with R&amp;D activities and
G&amp;A expenses associated with our operations. For the three months ended June 30, 2021, we incurred a net loss of approximately
$4.4 million. For the years ended March 31, 2021 and 2020, we incurred net losses of approximately $7.4 million and $5.3 million,
respectively. At June 30, 2021, we had a cash balance of approximately $3.4 million and an accumulated deficit of approximately
$20.8 million. When considered with our current operating plan and the requirement to repay all of the Notes by May 2022, these
conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from August
16, 2021. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that
may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our
ability to raise additional capital through the sale of equity or debt securities to support our future operations, and we are
currently seeking such additional financing. As discussed in Note 3 to our condensed consolidated financial statements for the
quarter ended June 30, 2021, we obtained forgiveness of the $368,000 principal balance and interest on the PPP Note we received
from Silicon Valley Bank in April 2020 under the U.S. Small Business Administration Paycheck Protection Program. As discussed
in Note 4 to our condensed consolidated financial statements for the quarter ended June 30, 2021, in May 2021, we completed a
private placement of $6,610,500 aggregate principal amount of our convertible promissory notes (the &#8220;Notes&#8221;). The
Notes are unsecured obligations of ours with each Note having a stated maturity date of 12 months from its issue date (the &#8220;Issue
Date&#8221;). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if we fail to pay any amounts
when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by law. Each Note may
be prepaid at our option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day, the &#8220;Trigger
Date&#8221;), subject to a 110% prepayment penalty on all principal and accrued interest then outstanding. No Notes may be prepaid
in whole or in part after the Trigger Date.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our operating
needs include the planned costs to repay the Notes, if the Notes are not converted in connection with a future equity financing,
and operate our business, including amounts required to fund research and development activities, including clinical studies,
working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend
on many factors, including our ability to successfully commercialize our product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
our product offerings. If we are unable to secure additional capital, we will be required to curtail our research and development
initiatives and take additional measures to reduce costs in order to conserve our cash.</span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For the three
months ended June 30, 2021, we used $2,204,621 in operating activities, which primarily resulted from our net loss of $4,835,091,
increased for a non-cash gain on the PPP Note extinguishment of $368,780 and net changes in operating lease assets and liabilities
of $11,474, as adjusted for changes to operating assets and liabilities of $403,174, a loss on debt extinguishment of $1,321,450
stock-based compensation expenses of $655,920, $266,910 for issuances of shares of common stock in exchange for services, depreciation
and amortization expenses of $24,649, interest expense of $338,619 for amortization of debt discount, and other immaterial adjustments.
For the three months ended June 30, 2020, we used $1,507,548 in operating activities, which primarily resulted from our net loss
of $1,874,157 and changes to operating assets and liabilities of $104,129, as adjusted for stock-based compensation expenses of
$344,716, depreciation and amortization expenses of $24,986, net changes in lease assets and liabilities of $101,611 and other
immaterial adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For the three
months ended June 30, 2021, cash used in investing activities of $20,076 was for the purchase of property and equipment. For the
three months ended June 30, 2020, cash used in investing activities of $12,934 was for the purchase of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash provided
by financing activities of $4,137,200 for the three months ended June 30, 2021 was attributable to net proceeds from the issuance
of our Notes. Cash provided by financing activities of $1,539,588 for the three months ended June 30, 2020 was attributable to
proceeds of $1,170,808 from sales of our common stock in a private placement initiated in March 2020 and $368,780 from the PPP
Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Recently Adopted
Accounting Pronouncements are detailed in Note 1 in the Notes to the Condensed Consolidated Financial Statements for the quarter
ended June 30, 2021 included within this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">From inception
to June 30, 2021 we had no off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a smaller
reporting company as defined by Rule 229.10(f)(1) and are not required to provide information under this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our consolidated
financial statements are prepared in conformity with GAAP. Note&#160;1 to the consolidated financial statements describes the
significant accounting policies and methods used in the preparation of our consolidated financial statements. We have identified
the accounting policies below&#160;as some of the more critical to our business and the understanding of our results of operations.
These policies may involve estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses.
Although we believe our judgments and estimates are appropriate, actual future results may differ from our estimates, and if different
assumptions or conditions were to prevail, the results could be materially different from our reported results.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Use of estimates</i>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to accruals, stock-based
compensation and income taxes. Actual results could materially differ from those estimates.</span></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>Stock-based compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We recognize
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite
service period, usually the vesting period, based on the grant-date fair value. We estimate the value of stock options on the
date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date
of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex
and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility over the term
of the awards, and projected stock option exercise behaviors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Income taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We determine
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of our assets and
liabilities using tax rates in effect for the year in which we expect the differences to affect taxable income. A valuation allowance
is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that
our federal and state net deferred tax assets will not be fully realized, and we have recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We account for
uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income Taxes</i>. When
tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while
others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately
sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based
on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other
positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit
that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the
benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for
unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that
would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified
as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated statements
of income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We adopted Accounting
Standards Update (ASU) No. 2016-02,&#160;<i>Leases&#160;</i>(ASC 842),<i>&#160;</i>and related ASUs, which provide supplementary
guidance and clarifications on April 1, 2019. We elected the practical expedient approach and did not reassess whether any contracts
that existed prior to adoption have or contain&#160;leases or the classification of our existing leases<i>.</i>&#160;Under ASC
842, all significant lease arrangements are generally recognized at lease commencement. Operating lease right-of-use (ROU) assets
and lease liabilities are recognized at the commencement date. A ROU asset and corresponding lease liability is not recorded for
leases with an initial term of 12 months or less (short-term leases), and we recognize lease expense for these leases as incurred
over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">ROU assets represent
our right to use an underlying asset during the reasonably certain lease terms, and lease liabilities represent our obligation
to make lease payments arising from the lease. Our lease terms may include options to extend or terminate the lease when it is
reasonably certain that we will exercise that option. Operating lease ROU assets and liabilities are recognized at the lease commencement
date based on the present value of lease payments over the lease term. We use our incremental borrowing rate, based on the information
available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes
any lease payments related to initial direct cost and prepayments and excludes lease incentives. Lease expense is recognized on
a straight-line basis over the lease term.</span></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara012"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>&#160;</b></span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical
is a development stage medical device company focused on the design, development, and commercialization of an innovative insulin
pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part
patch pump, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards
of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond
the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The product seeks to serve both the
type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Differentiation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that
there are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people
who require insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe, that by tailoring our
insulin pump to address such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve
broader market acceptance, an insulin pump must be easier to learn to use, be less time consuming to operate, more intuitive to
both patients and physicians, and meet the standards for coverage by insurance providers so that co-payments required from patients
are affordable and the hurdles to insurance coverage are significantly reduced.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Among
the more prominent issues are:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Complexity</i>:
    Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps
    were designed for &#8220;super users,&#8221;&#160;who have high levels of motivation and technical competence. The complexity
    of pumps proves daunting to less technically inclined users.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: -34.7pt; text-align: justify"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cumbersome</i>:
    We believe that a majority of existing pumps are bulky and difficult to manage, in many cases requiring additional equipment
    to introduce a catheter to the patient&#8217;s body and up to 48 inches of tubing, which must be replaced frequently, to connect
    the catheter to a pump. This requires users to carry spare parts and other equipment adding to the difficulty of using the
    pump.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><i>Cost</i>: Costs associated with insulin pump therapy are high and can be prohibitive, especially for those on fixed or limited incomes. These costs vary by pump, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible daily co-payments on consumables, can easily place current pumps out of reach for patients. This makes insurance providers hesitant to pay for them, leading to limited or absent reimbursement/coverage and high hurdles for patients to gain access.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><i>Outdated style</i>:&#160;Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar progress. We believe that consumers will be more receptive of products designed with the user experience in mind and that many have low tolerance for complex, difficult procedures for use and maintenance of products.</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="text-align: justify"><i>Pump mechanism limitations</i>:&#160;Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our team has
substantial knowledge of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing
insulin pumps to market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method
of pumping insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both
basal (steady flow) and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration
path to multi-chamber/multi-liquid pumps, potentially offering an exciting array of new therapies to patients with diabetes and
other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is
to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just
care for the super users, but &#8220;diabetes care for the rest of us.&#8221; We believe there is a substantial opportunity to
penetrate the type 2 MDI marketplace, whether through this new insulin pump or further simplification of pumps for the type 2
marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MODD1 is
a high-precision, first-line pump that we believe represents the best choice for new pump patients because it is easy to afford,
easy to learn, easy to use, and has a revolutionary design and technology that enable precision with low-cost manufacture and
high reproducibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Key features
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two
                                         parts - one reusable, one disposable - snap together to form the working system;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">One
                                         button interface, easy to learn and use;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">90-day
                                         reusable, 3-day disposable;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Removable
                                         at any time from an adhesive bracket;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
                                         external controller required, no charging, no battery replacement; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Slim
                                         profile, lighter weight.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">A
proprietary survey of American healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives)
performed for us by industry leading survey firm ISA has demonstrated that payors are willing to grant equivalent or preferential
coverage for a product with this feature set at launch in exchange for 10-20% rebates. These costs are built into all of our models.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Diabetes is typically classified
as either type 1 or type 2:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">T1D
        is an auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently
        diagnosed during childhood or adolescence. Individuals with T1D require daily insulin therapy to survive.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">T2D
    represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either
    properly utilize insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition
    with improvements in diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1
    (GLP-1)     drugs. However, as their diabetes advances, patients often progress to requiring insulin therapies such as
    once-daily long-acting     insulin and ultimately to intensified mealtime rapid-acting insulin therapy.&#160;&#160;This
    represents an important portion     of the diabetes market with an estimated 1.6 million T2D intensively treated with insulin
    currently in the United States, this number     being expected to grow to 2.2 million in 2030<sup></sup>.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function
and health. In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition
known as hyperglycemia, and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications,
including blindness, kidney disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular
disease, and death. Hypoglycemia can lead to confusion or loss of consciousness, often requiring a visit to the emergency room
or, in certain cases, result in seizures, coma, and/or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All people with
T1D, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18%
of people with T2D in the United States, or 4.7 million people, require insulin (basal alone represent 3.1 million and basal plus
mealtime represent 1.6 million) to manage their diabetes. In this prospectus, we refer to people with T1D and people with T2D
who require mealtime insulin as &#8220;insulin-requiring people with diabetes.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Currently, there
are two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into
the body through syringes or insulin pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump
to deliver mealtime insulin boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous
insulin infusion, or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over
MDI therapy, primarily an improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin
A1c (HbA1c) measure and more recently Time in Range (TIR) where a continuous glucose measuring device is used to calculate this
test. Among other medical benefits, it has been demonstrated that insulin pump use can decrease glucose variability, reduce the
number of hypoglycemia, decrease the daily doses of insulin and reduce the fear of hypoglycemia.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notwithstanding
these advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well
as high and often prohibitive costs for both the patient and insurance provider has resulted not only in dissatisfaction among
many existing pump users (fewer than half purchase a new pump after the warranty expires per Seagrove Partners estimate), but
also has severely limited the adoption rate of insulin pumps by a large segment of the MDI diabetes population, who we refer to
in this prospectus as &#8220;Almost Pumpers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We define Almost
Pumpers as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past experiences,
pump shortcomings, cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps, continue
to receive their daily insulin through MDI therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Our initial
focus for our insulin pump is the almost pumper segment population located in the United States.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><img src="modular002.jpg" alt="(Graphic)" style="float: right; margin-left: 30pt" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research, along with marketplace data, estimates that 32% of Americans with T1D use insulin pump therapy and 28% of Americans
with T1D (44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes Association
guidelines of glucose control if their objections to the currently available suite of products can be overcome. They do not want
to closely manage their glucose levels and incur  the associated time and effort involved. They are the Almost Pumpers. We have developed what we believe
to be the most technologically advanced delivery system  overcome the objections and provided motivation for this market. We
believe that there are four addressable hurdles to adoption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Usability:
                                         the device needs to be easy to learn and to operate; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Affordability:
                                         we will focus on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance
                                         journey&#8221; to the clinician and patient; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accessibility
                                         and Education: we will seek to engage patients to sample this new technology by supplying
                                         clinicians with free samples and simple training to allow people to see first-hand the
                                         typical barriers to adoption that have been overcome; and </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Service
                                         and Support: where we will answer their questions and concerns during this diabetes experience.
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We believe
this conversion process, engaging people to try and thereby receive the benefits of our technology will substantially increase
adoption of insulin pumps among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease
that appears throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care.
We intend to create an insulin pump that appeals to all Almost Pumpers.</span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The International
Diabetes Federation, or IDF, estimates that, in 2019, approximately 460 million people were living with diabetes worldwide and,
that by 2045, this number will increase to approximately 700 million people</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">An estimated
34 million people in the United States live with diabetes. Within this group, T1D accounts for approximately 1.8 million people
(7% of total) with the remainder being T2D. All people with T1D require daily insulin. However, of the approximately 25.5 million
people with T2D, about 1.6 million of them require intensive insulin treatments to manage their diabetes. This represents a large
and growing market with the effects of diabetes accounting for roughly 25% of all healthcare dollars spent annually in the United
States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-top: 0"><span style="font-size: 10pt">According
to the National Diabetes HCP Survey conducted by Seagrove Partners, approximately 25% of the 1.6 million highly insulin intensive
T2D have considered going &#8220;on pump.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insulin pumps
have been shown to provide a higher level of care for insulin dependent people with diabetes and result in better glycemic control,
fewer comorbidities, fewer trips to the emergency room, and higher overall quality of life. They also result in lower overall
costs to the healthcare system, reducing typical expense per patient year from $27,195 to $16,992.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; margin-top: 0"><span style="font-size: 10pt">Despite
these benefits, only 1 in 3 (32%) of the 1.8 million Americans with T1D and very few of the 1.6 million T2D intensively treated
with insulin currently use an insulin pump with only a slow increase of insulin pump use. The remaining 68% of T1D&#8217;s and
virtually all of the T2D&#8217;s rely on multiple daily injections (MDI) for glucose control. Decades of advances in technology
advances have left these non-pumpers at a significant disadvantage from a control perspective vs their &#8220;pumping&#8221; counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have identified
a large segment of the market that we refer to as &#8220;Almost Pumpers.&#8221; Almost Pumpers are those insulin-requiring people
with diabetes (T1D and T2D) who feel that they would adopt the pump if it were less expensive, less time consuming, less technically
intimidating, and if there was no separate controller. They represent approximately 30% of the T1D market correlating to a $1.9
billion growth opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insulin pumps
on the market today require a substantial amount of time to manage the therapy, have high out of pocket costs that place these
technologies out of reach for a large part of the population, and are feature-heavy with complex systems that have hampered adoption
and intimidated many users. The most commonly used insulin pumps today require extensive training and hours of daily management.
The average pump user must go through 42 steps of setup and refill process every 72 hours to &#8220;stay on track&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="modular004.jpg" alt="(Graphic)" style="float: left; margin-right: 30pt" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The
current reluctance to adopt the insulin pump has had serious consequences on the healthcare system. In the United States, people
living with T1D have struggled to attain glycemic targets. A 2019 analysis of the large T1D Exchange clinical registry found that
only 21% of U</span>.S. adults with T1D achieved the ADA A1c goal (&lt;7.0%). Further, according to a study published in&#160;JAMA
Internal Medicine, researchers found no significant improvements in diabetes care between 2005 and 2016, with persistent gaps
in care related to socioeconomic status.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The recent
introduction and rapid adoption of Abbott Labs Freestyle Libre has made Continuous Glucose Monitoring (CGM) easier and more affordable,
expanding the product category, and doubling its size. Now for the first time, there is an easy, less painful&#8212;no more finger
sticks-- way for patients to have the data they need to understand more about their glucose levels and their insulin requirements.
Access to such data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made
them more comfortable with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control
and better overall care. We believe that the insulin pump market is ready for a similar transition as that experienced in the
CGM space. MODD1 pump represents a new and better offering to assist and induce a wide variety of patients to make the transition
and bridge the void to superior control by becoming a &#8220;pumper&#8221;.</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We believe
the present pump marketplace is approximately a $1.9 billion market, comprising 32% of T1D pumpers and a small group of T2D pumpers.
Seagrove Partners estimates that 28% of T1D patients, or approximately 448,000 individuals, and 25% of T2D patients, or approximately
400,000 individuals, would adopt technology that was easier to use, access and pay for. Assuming revenue of $4,086 per patient,
per year, we believe the total addressable market approximates $3.4 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt">&#160;<img src="modular004a.jpg" alt="(Bar Chart)" /></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dedicated
to helping all people with diabetes gain access to high quality care. We aim to help people with diabetes &#8211; especially Almost
Pumpers and the historically underserved communities &#8211; gain access to insulin pump technology by making it affordable and
easy to use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Diabetes
care is at an inflection point</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe
that the insulin pump market stands at a crossroads as a confluence of events makes the timing for a new product introduction
ideal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">2020
was a very difficult year in diabetes. Between COVID-19 and a loss of glycemic control during quarantines and isolation, deaths
from diabetes rose by 17% in 2020 versus the prior year. This was sharpest among the young who saw deaths rise 29% in the 25-44
year old demographic. This has created a pain point and a desire to find new and better solutions and has raised awareness among
patients, caregivers, payors, and policy makers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">COVID-19
also encouraged (and required) trial and adoption of telehealth models and a great many people have found them to their liking
with a high proportion of patients and of health care providers (HCPs) that want to continue to use these technologies<sup>4</sup>.
We expect much of this shift and newfound comfort with distance care models to persist and believes that this can provide a patient
acquisition and engagement model for insulin pumps and diabetes care, especially for pumps optimized for free trial and easy learning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">At the
same time, reimbursement for patch pumps has been increasingly moving to a pharmacy benefits manager (PBM) model simplifying reimbursement
which will further aid in a &#8220;frictionless launch.&#8221; This represents a fundamental shift in the insulin pump market,
making onboarding rapid and simplifying a previously complex and time consuming &#8220;insurance journey.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The continuous
glucose monitoring (CGM) space (wearable devices that monitor blood glucose levels) has been experiencing explosive growth largely
driven by a new product introduction from Abbott Labs called the &#8220;libre.&#8221; This product was a more affordable, easier
to use version of the popular Dexcom CGM. Not only is it now a larger (by revenues) product than Dexcom, but it accomplished this
without seeming to slow Dexcom&#8217;s growth but rather by growing a new category with a new type of user.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">These
users are increasingly interested in adopting technology and wearables to manage their diabetes. We believe they are a natural
market for a new type of pump if it can meet their needs and address their objections and that the conjunction of the above trends
represents a unique opportunity in the insulin pump market&#8217;s history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Diabetes
technology companies understand that we are at a turning point with new markets (T2D, T1D that are currently not using technologies).
This can be seen with increased discussion around this topic during recent [national] diabetes conferences, but also an increase
in marketing promotion. For example, Dexcom purchased a $5.5 million 30-second spot during the 2021 Super Bowl.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">All these
recent changes support the high proportion of T1D and T2D intensively treated with insulin that are considered as Almost Pumpers,
number that may grow in the next years and that may be more reachable with adequate marketing strategies.</span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Our
Insulin Pump </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Instead
of building complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology
and the user in mind. Using proprietary and patented methods of insulin measurement, we were able to eschew complex mechanisms
and instead built a product using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality
curve that has existed in the insulin pump space and representing the first truly modern insulin pump design. This is a new kind
of product for a new kind of patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pre-production
models of our low-cost insulin pump are now undergoing the testing required to submit to the FDA for clearance to market them
in the United States. We continue to devote, substantial time and resources to better understand the needs and preferences of
Almost Pumpers and the specific patent/provider/payor requirements to motivate change from MDI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 has several
distinguishing features:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><img src="modular003.jpg" alt="(Graphic)" />&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">1 &#8211; The
pump has a simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating
cam to motivate the insulin into the patient along with a low power Bluetooth (LPBT) and near field communication (NFC) chips
to allow the patient to communicate with their smart phone, tablet, or other mobile computing platform, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2 &#8211; The
pump snaps together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power
source and a simple coin cell that allows it to run through the 80-hour life of the cartridge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">3 &#8211; There
is a set (not shown) that contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle
used to transfer insulin to the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">4 &#8211; MODD1
comes with a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching
to the body that has features for holding the pump to the patient; overwraps to hold the product to patient; and a velcro strap
with a base plate suitable for wrapping around the arm or leg of the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The system will
deliver a small continuous rate called a basal that will provide approximately 50% of the total daily dose required and the user
will use the on-pump button to administer boluses, typically before and after meals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The objective
is to make the product simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump
market, drive adoption and ultimately better clinical outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Technological
Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption
of new ultra-high volume technologies will result in far easier manufacturing scale up as parts sourcing, assembly processes are
far easier. The MODD1 was designed from the beginning for mass manufacturing processes and &#8220;lights out&#8221; or near lights
out production assembly lines. This advantage is compounded by the high availability and already optimized cost reduction in its
components. This has resulted in a cost of goods, estimated on the competitors&#8217; announced margins and sales, 70% lower than
our closest patch pump competitor.</span></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The adoption
of modern, miniaturized technologies has led to numerous other advantages as well. The MODD1 pump is smaller in overall volume
than Insulet&#8217;s popular Omnipod product and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units)
of insulin in line with full sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe
that this volume advantage over other patch pumps will be significant as 24% of type 1 and over 50% of the rapidly growing type
2 market require more than 2mL of insulin every three days (the expected wear time of patch pumps).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In addition,
our new and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a healthy
pancreas) delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering
micro-boluses every 15 minutes for Omnipod and 5 minutes for industry leader Medtronic. We plan to demonstrate the impact of our
system on glycemic control in a future clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The technology
allows the patient to simply add insulin and operate. The battery is included in each cartridge and the device is operated without
a controller. Nothing needs charging. MODD1 has been made push button simple to appeal to a wider audience of users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">This
new technology has also made the MODD1 lighter than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams
(vs. 26g) empty and 23 grams (vs. 28g) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18% respectively.
Also, unlike existing patch pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires.
This avoids loss of insulin in a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable
dissatisfaction with on other patch pumps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">This
technology is also uniquely suited to dual (or more) chamber pumps. We believe that such pumps will be integral to
the realization of high time in range artificial pancreas solutions that require no human intervention, the next step
forward from the cumbersome and awkward solutions today that require the user to announce meals, count and input carbs, and
adjust delivery for exercise and sleep. The advantages of cost and miniaturization are multiplied in a multi-chamber setup
and we expect to be able to reach price points, ease of use, and form factor unlike anything seen in the industry thus far.
We believe that a prefilled, multi-hormone peel and stick patch pump able to function in a fully autonomous closed loop
system with CGM&#8217;s represents the next generation of diabetes care. We believe that we have demonstrated our technology
and are securing intellectual property protection on our approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe
this technology, especially in dual chamber, will open up numerous applications outside of diabetes where medication compliance
of complex therapy regimes is difficult addressing such spaces as weight loss, fertility, and simplifying complex delivery of
multi-drug cocktails, especially those with diverse and challenging dosing schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Our
Solution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Our proposed
pump is being designed and developed to address the aforementioned shortcomings of the existing pump market and to appeal to:
(i) the substantial group of &#8220;Almost-Pumpers&#8221; who are currently interested in using an insulin pump, but have not
done so because of the complexity, cost or cumbersome nature of existing products, and (ii) people who are using one of the currently
available insulin pumps but are dissatisfied with such products. We believe that, owing to our new proprietary technology, our
proposed insulin pump will be the simplest and least expensive product on the market and the easiest for providers to prescribe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current
pump prototype of our proposed pump has been built to test what we believe to be our novel approach to insulin pumps. By providing
a pump that we believe will establish industry standards in terms of technology, simplicity to understand, ease of use and price,
we believe our proposed pump will offer the vast majority of benefits afforded by more expensive and complex pumps but remain
accessible to a substantially greater percentage of diabetes sufferers requiring daily insulin therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe people
generally will not use technology that intimidates them and physicians are hesitant to prescribe such technology. We believe mass
market products, such as is intended for our proposed pump, must be &#8220;user friendly&#8221; and affordable. We believe this
approach is fundamentally different from that applied to the existing pump market today where most pumps are continuously adding
complex features and are &#8220;user friendly&#8221; to only the most technically astute.</span></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current
goal is to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter,
commercialize the finished product. Our long-term goal is to become a leading provider of insulin pump therapy by focusing on
both consumer and clinical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To achieve our
above stated immediate and current goals, we intend to pursue the following business strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><i>Use of innovative proprietary
    technology.&#160;</i></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based upon the
substantial experience of Paul DiPerna, our President, Chief Financial Officer, Treasurer and Chairman of our Board of Directors,
in engineering design and innovative technology in the medical device industry and, in particular, with insulin pumps, we have
generated proprietary technology that has been incorporated into our proposed insulin pump. Generally, this technology is involved
in the delivery of insulin to the user at the appropriate and necessary times. We believe this technology will greatly assist
us in creating a simpler, user-friendly pump. We believe the proposed design, engineering and technology being incorporated into
our proposed pump will make it substantially simpler and more affordable than those currently available. These features, together
with the safety and reliability of our proposed pump, are designed to create the next generation of insulin pumps that will feature
important and well-differentiated attributes compared to those currently available and make it available to consumers across mostly
all socioeconomic groups in the United States and around the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><i>Keep costs low during
    our design and development process.&#160;</i></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to
ensure that we have sufficient funds to design, develop, and obtain all required regulatory approvals for our proposed insulin
pump without having to sacrifice quality and efficiency, we intend to maintain a tight budget and limit expenditures where possible.
We believe this will be possible because of the extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry
and more specifically in the insulin pump device market, but also his experience in designing and developing insulin pumps and
other medical devices and his ability to manage a small, focused development team. We currently expect that various other expenses,
such as product scale up, and sales and marketing costs, will not be incurred until such time as development work is completed
and regulatory approvals obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><i>Employ experienced engineers
    selected, supervised, and led by Mr. DiPerna, a highly experienced and respected engineer and executive in the insulin pump
    industry.&#160;</i></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to
ensure our proposed insulin pump is &#8220;state of the art,&#8221; functional, and efficient, as well as to conserve funds, substantially
all of our employees will initially be hand-picked engineers under the leadership of Mr. DiPerna. We believe that there is a strong
pool of engineers with significant applicable experience and knowledge who we will be able to initially employ on a contract and/or
outsource basis to help us design and develop our proposed insulin pump. We believe by hiring such persons on an out-source basis,
we will save substantial resources and by having Mr. DiPerna lead and focus the team on technological and mechanical aspects of
our proposed insulin pump, we believe our team will be well guided, focused, cost efficient, and able to efficiently design and
develop our product that we believe can eventually be a competitive and popular choice for people with insulin requiring diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">Our
goal is to establish MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and
Type 2) and the newly motivated CGM users. <span style="background-color: white">&#160;We seek to grow the market by providing
first-line insulin pump therapy that is well suited to meet the needs of both diabetes patients requiring insulin and their clinicians.
</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt; background-color: white">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">MODD1
                                         is approximately 70% less expensive to manufacture than Omnipod. This low cost allows
                                         us to spend more on patients and sampling. This will save money for payers. We can offer
                                         the pump with no upfront cost to patients. Benefits of MODD1 include:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">20%
                                         discount vs Insulet (PODD) will drive preferred status;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Designed
                                         to use PBM codes as a disposable;</span></td></tr></table>
<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No
                                         new code needed to be reimbursed at launch; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Saves
                                         provider an estimated $1062/patient/year vs Omnipod.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
                                         MODD1 will be sampled and given to patients by the doctor or diabetes nurse educator
                                         at the time of the patient visit. When a patient is motivated to make change, our starter
                                         kit will make it easy for the clinician to initiate the new therapy that same day. We
                                         seek to eliminate the currently challenging &#8220;insurance journey&#8221; and product
                                         acquisition timeline and significantly reduce training time for the busy clinician, all
                                         major hurdles to pump adoption. We intend to add telehealth support to help the patient
                                         throughout adoption and use and to facilitate greater collaboration between patients
                                         and their physicians. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Europe represents
another large potential market for MODD1. 60 million people in Europe live with diabetes and 1 in 4 dollars of global diabetes
spending occurs in Europe. ($156 billion is spent annually in diabetes healthcare costs in the EU). At present, cost containment
is restricting pump uptake across Europe. Current pump usage across the EU reaches 30% in a few markets but remains below 10%
in many. Single payor healthcare systems across the EU traditionally attempt to contain costs in the short term and seek low price
technologies with moderate medical benefits. MODD1 will offer a rebalance of this risk/reward strategy in that payors will incur
only minor incremental short-term costs with the benefit of longer -term cost savings associated with reliable pump use. We intend
to employ a partnership strategy across the EU following in-house managed regulatory and pricing activities in the major markets
(e.g., UK) and more cost receptive markets (e.g., Nordics). We are targeting European and United Kingdom approval towards early
2023. Our initial target market for our insulin pump is the Almost Pumper population located in the United States followed quickly
by an effort to obtain CE mark approval for distribution throughout Europe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt; background-color: white"><b>Marketing
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt; background-color: white"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt; background-color: white">MODD1
tackles the most significant barriers to pump use&#8212;access and affordability&#8212;and makes it easier for clinicians, caregivers
and individuals to manage diabetes care. Our commercialization plan will drive adoption and is designed to expand the market and
is intended to do the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: #222222"><b>Maximize
                                         adoption</b> <b>with a comprehensive&#160;frictionless launch program. </b>We will seek
                                         to decrease the level of reimbursement effort and cost to encourage HCPs to offer our
                                         pumps and encourage patient trials. Our product reduces the technical hurdles to widen
                                         appeal, new starts and increase adherence. We will encourage MDI patients who want or
                                         need more control to make the switch to the pump earlier in their treatment&#8212;ideally
                                         right at diagnosis. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Leverage
                                         technology to support sales and new patient acquisition</b>. We intend to set up tech
                                         enabled sales teams backed with a full omnichannel program to drive awareness and trial
                                         with HCPs and patients. We will focus on educating providers that our product is simple
                                         to teach and easy to support making it an ideal front line offering.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Facilitate
                                         patient trials. To facilitate patient trials, we intend to:</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in; background-color: white; color: #222222">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Provide a free pump and 30
days of cartridges, insurance&#160;verification, co-pay coupons and telehealth support to patients thereby reducing outlay of
time and money</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Partner with connected care
companies to provide superb support of patients from trial through the first year</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">We
believe that MODD1 will be the only insulin pump that patients can take home immediately from the doctor&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Leverage
                                         MODD1 300-unit chamber to increase adoption with Type 2 patients</b>. MODD1 has a major
                                         advantage over existing patch pumps in that the chamber carries enough insulin to meet
                                         the high doses many Type 2 patients need. We intend to promote this advantage and capture
                                         a significant share of the existing Type 2 pump users as well as new starts. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Work
                                         with key organizations and policy makers to pave the way for greater access</b> <b>to
                                         pumps. </b>We will<b> </b>promote MODD1 technology among the underserved, who are typically
                                         low users of health technology. We will identify individuals, patient organizations,
                                         professional societies, and policy and DEI organizations that are critically important
                                         to the adoption of new technologies in the diabetes space and build relationships with
                                         these influential stakeholders. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Initiate
                                         a clinical study program (with key diabetes centers</b>) to provide additional clinical
                                         support for MODD1 in special patient types and clinical setting. After obtaining 510(k)
                                         clearance, we intend to conduct a soft launch and clinical research program in major
                                         markets to pave the way for the full launch in late 2022. We will work with our advisors
                                         and key diabetes associations to educate the community about the MODD1. In addition,
                                         we will conduct clinical studies to develop competitive claims and market expansion.
                                         </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Work
                                         with major health plans to establish MODD1 as the first line pump for Type 2</b> <b>patients</b>.
                                         We believe MODD1 will be payor preferred for both type 1 and type 2 patients. It was
                                         designed to attain preferential reimbursement and avoid the coverage pitfalls many other
                                         pumps have experienced. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Payors want a simple product
that is less expensive. We will launch with a discount program for payers of 20% payers less than Omnipod to drive uptake.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Designed to use existing
PBM codes as a disposable</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; color: #222222; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No
                                         new code: Reimbursed at launch</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Tie-in with
the massive movement to telehealth. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2020 saw personal
telehealth go from beta test to mainstream. Customers and providers have become comfortable with it. There are only 4,000 patient-facing
endocrinologists in the United States. The treatment of diabetes will be significantly enhanced with telehealth to drive more
volume and clinical enhancements through their practices. Telemedicine is a force multiplier for a small group of doctors to better
serve a large market. MODD1 was designed to be affordable enough for free sampling and trial, and simple enough for self-guided
user training. We believe that by combining telehealth support with MODD1, we will decrease the burden of diabetes care and improve
the lives of people with diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Soft Launch/Pre
Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to
initiate a &#8220;soft launch&#8221; following FDA clearance of the MODD1 device. Our plan is to select a group of clinicians
who are well trained, experienced and have the support infrastructure to take on initial patients and monitor them carefully to
provide clinical feedback on our performance to further refine our product and support infrastructure prior to full commercial
launch. Many of these clinicians will have been those who assisted in the development of the MODD1 offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">We intend to continue to modify, refine and finalize our system to best meet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">o</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
general needs and preferences of our almost pumper target market based upon our knowledge of the diabetes industry and information
available and/or obtained by us from Almost Pumpers and their caregivers; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">o</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
general guidelines of third-party payors, private and public insurance companies, preferred provider organizations and other managed
care providers with particular focus on the guidelines established by the Center for Medicare and Medicaid Services, or CMS which
administrates the United States Medicare program, or Medicare. To assist us in making such modifications and refinements, we have
retained independent consultants to focus on ensuring that our product satisfies the existing coverage and reimbursement criteria
of such third-party payors.</span></td>
</tr></table>



<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Manufacturing
requires the production of pumps, cartridges, and baseplates as well as assembly with sets. In connection therewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         plan to build an automation machine for implementation in Southern California, close
                                         to the design engineers, that will be capable of assembling the cassettes at a rate sufficient
                                         to supply 50,000 patients in a single shift (500,000 per month). This equipment will
                                         require nine months to design and build and three months to verify and validate into
                                         our manufacturing process. </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
                                         packaging equipment and boxing will start as manual operations while the automation is
                                         refined. This equipment will be purchased and implemented as the second phase of automation
                                         of the cassette.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
                                         sets will be purchased through third party suppliers with expertise in the product to
                                         time and cost-effectively introduce the product and focus on our core expertise.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pumps will
be built and tested in our San Diego facility while we build volume and expertise. When the production methodology has matured
and the volumes have risen, we will consider a transition to outside and offshore manufacturing as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>FDA
Clearance</b></span> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt">The FDA requires us to meet all applicable regulations for insulin pumps, a subcategory of infusion pumps, which are generally considered Class 2 devices. The design of the MODD1 pump has been completed, units have been built and testing is underway to verify that the design meets all FDA requirements. Appropriate design control and standard operating procedures have been implemented to allow us, when testing is completed, to submit for clearance under the premarket notification (or 510(k)) process. To achieve this, we will continue to work closely with our regulatory consultants to complete, finalize and file our submission to the FDA for 510(k) clearance and all other documentation necessary to obtain marketing authorization of our insulin pump.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have engaged the FDA in two pre-submission conferences to ensure that we understand and meet the FDA&#8217;s requirements, expectations
and standards with regard to clearance of our product. At these meetings, our team, including our FDA regulatory consultant, received
FDA comments and guidance regarding our proposed submission during the pre-market notification period for 510(k) clearance (including
any suggested modifications to the device description, indications for use or summary of supporting data contained in the notification);</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
                                         are currently preparing and ensuring that our premarket notification, which will be part
                                         of our FDA submission in order to demonstrate that our insulin pump is &#160;substantially equivalent to an insulin pump previously cleared by the FDA and legally marketed to the
public and generally safe
                                         and effective for its intended use. We are also preparing our submission to the FDA,
                                         which will include the relevant results of our performance and human factor tests (relating
                                         to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility)
                                         demonstrating the accuracy and usability of our insulin pump, which we believe will
                                         satisfy the mandates of the FDCA and any applicable performance standards. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Commercialization
Steps</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">While we have
substantially completed the general engineering and mechanical aspects of our insulin pump prototype, prior to commercializing,
we still must successfully complete a number of material steps including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Continue
    to modify, refine and finalize our prototype so that it meets:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    general needs and preferences of our almost-pumper target market based upon our knowledge of the diabetes industry and information
    available and/or obtained by us from Almost Pumpers and their caregivers; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    general guidelines of third-party payors, private and public insurance companies, preferred provider organizations and other
    managed care providers with particular focus on the guidelines established by the Center for Medicare and Medicaid Services,
    or CMS which administrates the United States Medicare program, or Medicare. To assist us in making such modifications and
    refinements, we have retained independent consultants to focus on ensuring that our product satisfies the existing coverage
    and reimbursement criteria of such third-party payors.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Refine
    our manufacturing process during the submission process to identify and select a manufacturer of our insulin pump through
    a competitive bidding process, as we prepare for our product introduction;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Take
    such actions, if any, as may be required by the FDA as a condition to granting approval and providing 510(k) clearance for
    our insulin pump; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Hire
    and retain appropriate sales and marketing personnel to develop, implement and launch a promotional campaign for our insulin
    pump substantially focused on our target market.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As with any
medical device attempting to enter and successfully compete with existing products in an established and competitive marketplace,
we will face significant hurdles to accomplish the above steps to commercialization including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
    FDA 510(k) clearance to market and sell our insulin pump to the public;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
    any other FDA-required authorizations with regard to our product, as required by the FDCA;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Educating
    endocrinologists, physician&#8217;s assistants, nurse practitioners and nurse educators, who typically prescribe pump usage,
    and certified diabetes educators and dieticians, who provide education and guidance to diabetes patients, as to what we believe
    to be the superior qualities of our product;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Demonstrating
    to select general practitioners, who have historically been skeptical of the heightened support inherent in insulin pumps,
    our product&#8217;s ease of use and convenience;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Ensuring
    that our final product does, in fact, meet the needs of Almost-Pumpers;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Overcoming
    the historic obstacles and reluctance of Almost-Pumpers to using insulin pumps to treat their diabetes; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Ensuring
    that third party payors agree to cover all or a substantial portion of the purchase price and recurring costs of the use of
    our insulin pump.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Looking Forward</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Going forward,
we expect to continue to evolve the MODD1 pumps and their capabilities and functionality both in response to patient needs and
as part of our current platform roadmap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
                                         MODD1+, we will seek to add phone-based control and ACE and AID capability to allow integration
                                         with popular continuous glucose monitors. This will expand our available market to include
                                         many existing pumpers. The new model has the same modular design and low-cost components
                                         as MODD1 and provides a much desired breakthrough for patients &#8211; two-factor command
                                         authentication that allows the wearer to use his/her own cell phone as the controller.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; color: #222222"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; color: #222222"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Additionally, adds AID control
    functionality via an &#8220;ACE&#8221; Designation</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Any approved algorithm controller can drive
    insulin delivery in &#8220;auto&#8221; mode</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">CGM integration allows the controller to
    potentially adjust basal insulin rate for meals and exercise with an approved algorithm.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white; color: #222222"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">With MOD2, we will seek to
    move to a full featured multi chamber pump optimized for high time in range fully autonomous close loop insulin delivery utilizing
    the form factor and cost advantages of its pumping designs to create an affordable, easy to use drug delivery system to realize
    the aspiration of true &#8220;artificial pancreas&#8221; systems. We envision moving to a drug prefill model such that cartridges
    can be filled with therapeutics and shipped cold chain to patients, further simplifying the use process.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="modular005.jpg" alt="(Graphic)" /></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; background-color: white"><span style="font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Our
operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our
research and development partners do business. The laws and regulations governing our business and interpretations of those laws
and regulations and are subject to frequent change. Our ability to operate profitably will depend in part upon our ability, and
that of our research and development partners and affiliates, to operate in compliance with applicable laws and regulations. The
laws and regulations relating to medical products and healthcare services that apply to our business and that of our partners
and affiliates continue to evolve, and we must, therefore, devote significant resources to monitoring developments in legislation,
enforcement, and regulation in such areas. As the applicable laws and regulations change, we are likely to make conforming modifications
in our business processes from time to time. We cannot provide assurance that a review of our business by courts or regulatory
authorities will not result in determinations that could adversely affect our operations or that the regulatory environment will
not change in a way that restricts our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><span style="font-size: 10pt"><b><i>FDA
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
the United States, medical devices are strictly regulated by the FDA. Under the FDCA, a medical device is defined as &#8220;an
instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including
a component, part or accessory which is, among other things: intended for use in the diagnosis of disease or other conditions,
or in the cure, mitigation, treatment, or prevention of disease, in man or other animals; or intended to affect the structure
or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical
action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of
any of its primary intended purposes.&#8221; This definition provides a clear distinction between a medical device and other FDA
regulated products such as drugs. If the primary intended use of a medical product is achieved through chemical action or by being
metabolized by the body, the product is usually a drug or biologic. If not, it is generally a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">We
are currently developing a insulin pump delivery system, which is regulated by the FDA as a medical device under the FDCA, as
implemented and enforced by the FDA.&#160;The FDA regulates the development, testing, manufacturing, labeling, packaging, storage,
installation, servicing, advertising, promotion, marketing, distribution, import, export, and market surveillance of our medical
devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><span style="font-size: 10pt"><i>Device
Premarket Regulatory Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Before
being introduced into the U.S.&#160;market, each medical device must obtain marketing clearance or approval from the FDA through
the premarket notification (or 510(k)) process, the <i>de novo</i> classification process, or the premarket approval, or PMA,
process, unless they are determined to be Class&#160;I devices or to otherwise qualify for an exemption from one of these available
forms of premarket review and authorization by the FDA.&#160;Under the FDCA, medical devices are classified into one of three
classes&#160;&#8212;&#160;Class&#160;I, Class&#160;II or Class&#160;III&#160;&#8212;&#160;depending on the degree of risk associated
with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification
of a device is important because the class to which a device is assigned determines, among other things, the necessity and type
of FDA review required prior to marketing the device. Class&#160;I devices are those for which reasonable assurance of safety
and effectiveness can be maintained through adherence to general controls which include compliance with the applicable portions
of the FDA&#8217;s Quality System Regulation, or the QSR, as well as regulations requiring facility registration and product listing,
reporting of adverse medical events, and appropriate, truthful and non-misleading&#160;labeling, advertising, and promotional
materials. The Class&#160;I designation also applies to devices for which there is insufficient information to determine that
general controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device or to establish
special controls to provide such assurance, but that are not life-supporting&#160;or life-sustaining&#160;or for a use which is
of substantial importance in preventing impairment of human health, and that do not present a potential, unreasonable risk of
illness or injury.</span></p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Class&#160;II
devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness
and there is sufficient information to establish &#8220;special controls.&#8221; These special controls can include performance
standards, post-market&#160;surveillance requirements, patient registries and FDA guidance documents describing device-specific&#160;special
controls. While most Class&#160;I devices are exempt from the premarket notification requirement, most Class&#160;II devices require
a premarket notification prior to commercialization in the United&#160;States; however, the FDA has the authority to exempt Class&#160;II
devices from the premarket notification requirement under certain circumstances. As a result, manufacturers of most Class&#160;II
devices must submit premarket notifications to the FDA under Section&#160;510(k)&#160;of the FDCA (21 U.S.C. &#167; 360(k)) in
order to obtain the necessary clearance to market or commercially distribute such devices. To obtain 510(k)&#160;clearance, manufacturers
must submit to the FDA adequate information demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to
a &#8220;predicate device&#8221; that is already on the market. A predicate device is a legally marketed device that is not subject
to PMA, meaning, (i)&#160;a device that was legally marketed prior to May&#160;28, 1976 (&#8220;pre-amendments device&#8221;)
and for which a PMA is not required, (ii)&#160;a device that has been reclassified from Class&#160;III to Class&#160;II or&#160;I
or (iii)&#160;a device that was found substantially equivalent through the 510(k)&#160;process. If the FDA agrees that the device
is substantially equivalent to the predicate device identified by the applicant in a premarket notification submission, the agency
will grant 510(k)&#160;clearance for the new device, permitting the applicant to commercialize the device. Premarket notifications
are subject to user fees, unless a specific exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
there is no adequate predicate to which a manufacturer can compare its proposed device, the proposed device is automatically classified
as a Class&#160;III device. In such cases, a device manufacturer must then fulfill the more rigorous PMA requirements or can request
a risk-based&#160;classification determination for its device in accordance with the de novo classification process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Devices
that are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable
risk of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent
to a predicate device and for which safety and effectiveness cannot be assured solely by the general controls and special controls
are placed in Class&#160;III.&#160;Such devices generally require FDA approval through the PMA process, unless the device is a
pre-amendments device not yet subject to a regulation requiring premarket approval. The PMA process is more demanding than the
510(k)&#160;process. For a PMA, the manufacturer must demonstrate through extensive data, including data from preclinical studies
and one or more clinical trials, that the device is safe and effective for its proposed indication. The PMA must also contain
a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing,
and proposed labeling. Following receipt of a PMA submission, the FDA determines whether the application is sufficiently complete
to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days under the FDCA to complete
its review and determine whether the proposed device can be approved for commercialization, although in practice, PMA reviews
often take significantly longer, and it can take up to several&#160;years for the FDA to issue a final decision. Before approving
a PMA, the FDA generally also performs an on-site&#160;inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">The
<i>de novo</i> classification process allows a manufacturer whose novel device is automatically classified into Class&#160;III
to request down-classification&#160;of its device to Class&#160;I or Class&#160;II, on the basis that the device presents low
or moderate risk, as an alternative to following the typical Class&#160;III device pathway requiring the submission and approval
of a PMA application. Under the Food and Drug Administration Safety and Innovation Act&#160;of&#160;2012, the FDA is required
to classify a device within 120&#160;days following receipt of the <i>de novo</i> classification request from an applicant; however,
the most recent FDA premarket review goals state that in fiscal year 2021, FDA will attempt to issue a decision within 150&#160;days
of receipt on 65% of all <i>de novo </i>classification requests received during the year and on 70% of <i>de novo</i> requests
received during fiscal year 2022. If the manufacturer seeks reclassification into Class&#160;II, the classification request must
include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness
of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate device that
would be appropriate for a 510(k)&#160;notification or determines that the device is not low to moderate risk or that general
controls would be inadequate to control the risks and special controls cannot be developed.</span></p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Clinical
trials are almost always required to support PMAs and are sometimes required to support 510(k)&#160;and de novo
classification submissions. All clinical investigations of devices to determine safety and effectiveness must be conducted in
accordance with the FDA&#8217;s investigational device exemption, or IDE, regulations that govern investigational device
labeling, prohibit promotion of investigational devices, and specify recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; as defined by the FDA,
the agency requires the study sponsor to submit an IDE application to the FDA, which must become effective prior to
commencing human clinical trials. The IDE will automatically become effective 30&#160;days after receipt by the FDA, unless
the FDA denies the application or notifies the sponsor that the investigation is on hold and may not begin until the sponsor
provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines
that there are deficiencies or other concerns with an IDE that require modification of the study, the FDA may permit a
clinical trial to proceed under a conditional approval. &#160;The FDA may also notify the sponsor that the study is approved
as proposed or approved with specific requested modification. Furthermore, the agency may withdraw approval of an IDE under
certain circumstances. In addition, the study must be approved by, and conducted under the oversight of, an institutional
review board, or IRB, for each clinical site. If the device presents a non-significant&#160;risk to the patient according to
criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial after obtaining
approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with
abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and record-keeping&#160;requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><span style="font-size: 10pt"><i>Post-Marketing
Restrictions and Enforcement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">After
a device is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">submitting and updating establishment
registration and device listings with the FDA;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">compliance with the QSR,
which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance
of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">unannounced routine or for-cause&#160;device
facility inspections by the FDA, which may include our suppliers&#8217; facilities; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">labeling regulations, which
prohibit the promotion of products for uncleared or unapproved (or &#8220;off-label&#8221;) uses and impose other restrictions
relating to promotional activities;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">corrections and removal reporting
regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to reduce a risk to
health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">post-market&#160;surveillance
regulations, which apply to certain Class&#160;II or&#160;III devices when necessary to protect the public health or to provide
additional safety and effectiveness data for the device.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
addition, under the FDA medical device reporting, or MDR, regulations, medical device manufacturers are required to report to
the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a
way that would likely cause or contribute to death or serious injury if the malfunction of the device or a similar device of such
manufacturer were to recur. The decision to file an MDR involves a judgment by the manufacturer. If the FDA disagrees with the
manufacturer&#8217;s determination, the FDA can take enforcement action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">The
MDR requirements also extend to health care facilities that use medical devices in providing care to patients,
or &#8220;device user facilities,&#8221; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic
facilities, or outpatient treatment facilities, but not physician offices. A device user facility must report any device-related&#160;death
to both the FDA and the device manufacturer, or any device-related&#160;serious injury to the manufacturer (or, if the manufacturer
is unknown, to the FDA) within 10&#160;days of the event. Device user facilities are not required to report device malfunctions
that would likely cause or contribute to death or serious injury if the malfunction were to recur but may voluntarily report such
malfunctions through MedWatch, the FDA&#8217;s Safety Information and Adverse Event Reporting Program.</span></p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
FDA also has the authority to require the recall of commercialized medical device products in the event of material deficiencies
or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable
probability that the device would cause serious adverse health consequences or death. Manufacturers may, under their own initiative,
recall a product if any distributed devices fail to meet established specifications, are otherwise misbranded or adulterated under
the FDCA, or if any other material deficiency is found. The FDA requires that certain classifications of recalls be reported to
the FDA within ten working&#160;days after the recall is initiated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of
the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">warning letters, fines, injunctions
or civil penalties;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recalls, detentions or seizures
of products;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">operating restrictions;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delays in the introduction
of products into the market;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">total or partial suspension
of production;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delay or refusal of the FDA
or other regulators to grant 510(k)&#160;clearance, PMA approvals, or other marketing authorization to new products;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawals of marketing
authorizations; or</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">in the most serious cases,
criminal prosecution.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">To
ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic,
pre-scheduled&#160;and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt"><b><i>Federal
Trade Commission Regulatory Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0; background-color: white"><span style="font-size: 10pt">Our
advertising for our products and services is subject to federal truth-in-advertising&#160;laws enforced by the Federal Trade Commission,
or the FTC, as well as comparable state consumer protection laws. Under the Federal Trade Commission Act, or FTC Act, the FTC
is empowered, among other things, to (a)&#160;prevent unfair methods of competition and unfair or deceptive acts or practices
in or affecting commerce; (b)&#160;seek monetary redress and other relief for conduct injurious to consumers; and (c)&#160;gather
and compile information and conduct investigations relating to the organization, business, practices, and management of entities
engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the
FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions
affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><span style="font-size: 10pt"><b><i>Healthcare
Law and Regulation</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.45pt; text-align: justify">&#160;</p>

<p style="margin: 0"><i>United States</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
our MODD1 product or our other future product candidates are approved in the United&#160;States, we will have to comply with
various U.S.&#160;federal and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback&#160;laws
and physician self-referral&#160;laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal
and civil sanctions, including, in some instances, exclusion from participation in federal and state healthcare programs, including
Medicare and Medicaid. These laws include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback&#160;Statute
prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order
or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program
such as Medicare and Medicaid;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal False Claims
Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly
presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a
false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td>
</tr></table>
<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Health Insurance
Portability and Accountability Act&#160;of&#160;1996, or HIPAA, imposes criminal and civil liability for executing a scheme to
defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations,
including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable
health information;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal false statements
statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal transparency
requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved&#160;drugs, devices, biologics and
medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services
information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician&#160;health
care practitioners and physician ownership and investment interests; and</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt; background-color: white; color: #222222"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">analogous state and foreign
laws and regulations, such as state anti-kickback&#160;and false claims laws, may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by nongovernmental third-party&#160;payors, including private insurers.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Some
state laws require pharmaceutical or medical device companies to comply with the relevant industry&#8217;s voluntary compliance
guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and device
manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; background-color: white"><span style="font-size: 10pt">State
and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each
other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. We also may be subject to,
or may in the future become subject to, U.S.&#160;federal and state, and foreign laws and regulations imposing obligations on
how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations
could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair
our efforts to maintain and expand our customer base and thereby decrease our future revenues.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The European
Union approves the use of medical devices in a very different way. They have similar regulations and requirements to adhere to,
however a Notified Body, in the form of a private company, will represent their interests and is required to have sufficient expertise
to review all applications and the company&#8217;s internal processes to ensure the safety of the product for which approval is
being requested. We are in the process of identifying a Notified Body to represent us, and we will follow our FDA submission process
with regard to preparing the materials and processes required to meet the regulations and gain clearance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 7.4pt 0 8.45pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>European
Union</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt"><span style="text-decoration: underline">EEA</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0"><span style="font-size: 10pt">In the European
Economic Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or EEA,
manufacturers of medical devices need to comply with the Essential Requirements laid out in Annex&#160;I to the EU Medical Devices
Directive (Council Directive 93/42/EEC) or with the General Safety and Performance Requirements (GSPR) of the new EU Medical Devices
Regulation (EU 2017/745). Compliance with these requirements is a prerequisite to be able to affix the CE mark to medical devices,
without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements and the GSPR
and obtain the right to affix the CE Mark, manufacturers of medical devices must undergo a conformity assessment procedure, which
varies according to the type of medical device and its classification. Except for low-risk medical devices (Class&#160;I with
no measuring function and which are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a
self-assessment of the conformity of its products with the Essential Requirements and the GSPR, a conformity assessment procedure
requires the intervention of a Notified Body, which is an organization designated by a competent authority of an EEA country to
conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit and examine
the Technical File and the quality system for the manufacture, design and final inspection of the devices. The Notified Body issues
a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the
medical device and its manufacturer and their conformity with the Essential Requirements and GSPR. This Certificate entitles the
manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.
As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements and
GSPR must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products
during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance
during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when
weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device
are supported by suitable evidence.</span></p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">All manufacturers
placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system,
incidents must be reported to the relevant authorities of the member states of the EEA, and manufacturers are required to take
Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated
with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration
in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which,
directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious
deterioration in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of
the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users
of the device through Field Safety Notices. Where appropriate, our products commercialized in Europe are CE marked and classified
as either Class I or Class II.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">In 2017, the European
Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives,
which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e.,
without the need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate
current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other
things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical
devices and in vitro diagnostic devices and ensure a high level of safety and health while supporting innovation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">The Medical Device
Regulation was meant to become applicable three years after publication (in May 2020). However, in April 2020, to allow EEA national
authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic,
the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Device Regulation
by one year. The Medical Device Regulation became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to
the EU Medical Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service
until May 26, 2025. The Medical Devices Regulation, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 26.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt"><span style="font-size: 10pt">strengthens
                                         the rules on placing devices on the market and reinforces surveillance once they are
                                         available;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 26.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt"><span style="font-size: 10pt">establishes
                                         explicit provisions on manufacturers' responsibilities for the follow-up of the quality,
                                         performance and safety of devices placed on the market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 26.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt"><span style="font-size: 10pt">improves
                                         the traceability of medical devices throughout the supply chain to the end-user or patient
                                         through a unique identification number;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 26.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt"><span style="font-size: 10pt">sets
                                         up a central database to provide patients, healthcare professionals and the public with
                                         comprehensive information on products available in the EU; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 26.45pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 7.4pt"><span style="font-size: 10pt">strengthens
                                         rules for the assessment of certain high-risk devices, such as implants, which may have
                                         to undergo an additional check by experts before they are placed on the market.</span></td></tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of October
20, 2021, we had 17 employees all of whom are located in the United States, consisting of 15 in research and development and manufacturing
operations and two in general and administrative functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Today, in the
United States, only three companies are commercializing insulin pumps to T1D patients and insulin treated T2D patients:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Medtronic
                                         - that commercializes the durable Minimed 770G also offering older durable pumps still
                                         used (670G, 630G etc). In 2020, they held approximately 51% of the US insulin pump market.<sup></sup></span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Tandem
                                         - that commercializes the durable t:slim X2 pump (with or without algorithms - Basal-IQ
                                         and Control-IQ). In 2020, they held approximately 28% of the US insulin pump market.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Insulet
                                         - that commercializes the disposable Omnipod patch pump with about 19% of the US market
                                         in 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Older insulin pumps are also still being used by a minority of patients previously provided by Roche or Animas though these pumps are
not commercialized any longer. To a lesser extent the pumps described below are also used in small numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 50%"><img src="modular006.jpg" alt="(Graphic)" />&#160;</td>
    <td style="width: 50%; text-align: right">&#160;<img src="modular007.jpg" alt="(Graphic)" /></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">These three
insulin pump offerings are vying for the attention of the most motivated and well insured in hope of converting them
away from their reliance on multi day insulin injections. The t:slim X2 and Minimed 770G each have a ~$5,000 list price that
is covered through Durable Medical Equipment (DME) reimbursement; daily consumables and insulin are also required to complete
these offerings. These products have controllers integrated into the pump, making them cumbersome and bulky, along with long
(&gt;20 inch) tubing between the pump and the cannular site. The Omnipod is the third offering, a patch pump that attaches to
your body for 72 hours and uses a separate controller to manage the insulin delivery process. Insurance coverage can be
provided via DME but also via Pharmacy Benefit (PB). The Omnipod patch pump is more expensive per day and less accurate than
other insulin pumps. Around 32% of people living with T1D are currently using insulin pumps, the vast majority are using one
of these three offerings, a statistic that has not changed significantly over the last 5+ years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><img src="modular008.jpg" alt="(Graphic)" />&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All of these
pump products require extensive training to initiate, two to four hours per day to use and manage on an ongoing basis. This level
of sophistication and effort along with the cost and awkwardness of these products contribute to the limited uptake.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Although there
are purely mechanical pumps available to patients with a small percentage of T2D patients are using the Zealand V-Go patch pump,
a fixed basal rate and a button to deliver small boluses. This pump is simple to use though gives little performance decision
to the user (no possibility to change the basal rate, no possibility to stop bolus doses, small reservoir, pump that needs to
be changed every day, etc.). The last available patch pump is provided by Cequr, called Simplicity, a bolus only delivery option
without basal delivery that is yet to be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the near
term future, Medtronic intends to launch a new version of their insulin pump, the Minimed 780G, already available in some European
countries with an advanced algorithm, but no obvious change in hardware. Tandem is currently developing a patch pump called t:sport,
coupled with an algorithm with potential launch expected in summer 2022. The t:sport should have a small 2mL reservoir and would
be controlled by a separate unit as is the current Omnipod. Insulet should launch in the coming quarters the Omnipod 5, a similar
patch pump to their offering today that includes an algorithm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Approximately
71% <sup> </sup>of the people who rely upon MDI choose to not administer a shot outside of their house, which creates a poorly
controlled group. MOD is designed to focus upon a segment of these people and mobilize them via a simple, easy to use, affordable
product.</span></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="modular009.jpg" alt="(Graphic)" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our success
depends in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary
rights against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of
time and expense associated with developing new products and bringing them through the regulatory approval process, the health
care industry places considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies,
products, processes, know-how, and methods.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of October
21, 2021, we had one issued U.S. utility patents, five published U.S. utility patents, two pending&#160;foreign patent applications,
and two pending international PCT patent applications covering various aspects of our technology, including&#160;our proprietary
fluid movement technology.&#160; There can be no assurance that the pending patent applications will result in the issuance of
patents, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these patents
will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our annual reports
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant
to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available
free of charge on our website at <span style="background-color: white">www.modular-medical.com.</span>as soon as it is reasonably
practicable after they are filed or furnished with the SEC. Our Code of Business Conduct and the charters for the Audit Committee
and Compensation Committee are also available on our website. The Code of Business Conduct and charters are also available in
print to any shareholder upon request without charge. Requests for such documents should be directed to James Sullivan, at Modular
Medical, Inc., 16772 W. Bernardo Drive, San Diego CA 92127. Our Internet website and the information contained on it or connected
to it are not part of, or incorporated by, reference into this prospectus. Our filings with the SEC are also available on the
SEC&#8217;s website at&#160;http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Corporate
History and Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We were formed
as a corporation under the laws of the State of Nevada in October 1998 under the name Bear Lake Recreation Inc. We had no material
business operations from 2002 until July 2017, when we acquired Quasuras, Inc., a Delaware corporation, in the Acquisition (as
defined below). Prior to the Acquisition, and, since at least 2002, we were a shell company, as defined in Rule 12b-2 promulgated
under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</span></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>The Control
Block Acquisition.</i></b><i>&#160;</i>On April 26, 2017, pursuant to a Common Stock Purchase Agreement, dated as of April 5,
2017, by and among Manchester Explorer, LP, a Delaware limited partnership, we and certain persons named therein, Manchester Explorer,
LP purchased from us 2,900,000 shares of our common stock representing in excess of a majority of our then issued and outstanding
common stock, for a purchase price of $375,000 (the &#8220;Control Block Acquisition&#8221;), resulting in a change in control
of the Company. In connection with the Control Block Acquisition, James E. Besser was appointed president and a director and Morgan
C. Frank was appointed the chief executive officer, chief financial officer, secretary, treasurer and a director of ours and immediately
following such appointments, our then officers and directors resigned. Mr. Besser is the managing member of and Mr. Frank is the
portfolio manager and a consultant to Manchester Management Company, LLC, a Delaware limited liability company also referred to
herein as MMC. MMC is the general partner of Manchester Explorer, LP and Jeb Partners, L.P. (Jeb Partners, and together with Manchester
Explorer, LP, collectively, the Purchasing Funds).</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>The Acquisition.&#160;</i></b>On
July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement, by and among us, Paul M. DiPerna, the sole officer,
director and a controlling stockholder of Quasuras, Messrs. Besser and Frank (Messrs. Besser, Frank and DiPerna, collectively,
the &#8220;3 Quasuras Shareholders&#8221;), and Quasuras, Inc. (the &#8220;Share Exchange Agreement&#8221;), we acquired all of
the issued and outstanding shares of Quasuras, Inc. owned by the 3 Quasuras Shareholders, resulting in Quasuras, Inc. becoming
our wholly-owned subsidiary (the &#8220;Acquisition&#8221;). Simultaneously with the closing of the Acquisition, Manchester Explorer,
LP cancelled the 2,900,000 shares of our common stock purchased in the Control Block Acquisition, Mr. Besser resigned as our president
and a director and Mr. Frank resigned as our chief executive officer, chief financial officer, secretary, and treasurer, but remained
a director, and Mr. DiPerna was appointed our chairman of the board of directors, chief executive officer, chief financial officer,
secretary and treasurer. Mr. DiPerna served as our chief executive officer until August 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Quasuras, Inc.,
a Delaware corporation, is our only subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In January 2020,
we executed a lease for a corporate facility located at 16772 W. Bernardo Drive, San Diego, CA 92127 <span style="background-color: white">and
paid a $100,000 security deposit.</span>&#160;The 39-month lease term commenced April 1, 2020, and provides for an initial monthly
rent of approximately $12,400<span style="background-color: white">&#160;with annual rent increases of approximately 3%.&#160;</span>In
addition to the minimum lease payments, we are responsible for property taxes, insurance and certain other operating costs. We
believe that our existing facility is adequate to meet our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a Nevada
corporation. Our corporate headquarters and operating facilities are located at 16772 W. Bernardo Drive, San Diego, CA 92127 Our
telephone number is (858) 800-3500. We maintain a website at http:/<span style="background-color: white"> </span>www.modular-medical.com<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="modulara013"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth information on our executive officers and directors as of September 30, 2021. The term for each of our
directors is generally three years or until their successors are duly elected and qualified. We do not have any promoters or control
persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="border-bottom: Black 1pt solid; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Paul DiPerna</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Financial Officer, President, Secretary,
    Treasurer and Director (Chairman of the Board of Directors)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Ellen O&#8217; Connor Vos</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Liam Burns(1)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">William J. Febbo(2)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">52</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Morgan C. Frank(2)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Carmen Volkart(1)(2)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">60</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Member
of Audit Committee</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Member of &#160;Compensation
Committee</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>Family Relationships</b></span> <span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">There
are no family relationships between our officers and members of our Board of Directors.</span> <span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The principal
occupations and positions for at least the past five years of our directors are described below. There are no family relationships
among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Paul DiPerna.&#160;</i>Mr.
DiPerna has been our chairman, chief financial officer, president, and treasurer since we acquired Quasuras, Inc. in July 2017.
He also served as our chief executive officer from July 2017 until August 2021. In 2015, he founded Quasuras, Inc., an early-stage
medical device company developing an insulin pump product, and, until its acquisition by us, he served as its chief executive
officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products
and accumulate technical talent. Our current pump product was one of such proposed products and was spun-out to Quasuras in 2015.
From 2012 to 2015, he served as a co-inventor at a private company with property rights in a medical device used for blood borne
infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care,
Inc. (&#8220;Tandem&#8221;) and held various positions, including as director, chief executive officer and chief technology officer
and was primarily responsible for the design concept and development of Tandem&#8217;s initial insulin pump. Prior to that, he
held executive and management positions at Baxter Healthcare Corporation (&#8220;Baxter&#8221;) where he was tasked with identifying
synergistic opportunities in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in
the diabetes industry and led attempts by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design
engineering positions in the automated test equipment and blood separation sciences industries. Mr. DiPerna holds a number of
patents and patents pending and is a member of the American Diabetes Association. Mr. DiPerna received a Masters in Engineering
Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Lowell. We believe that Mr.
DiPerna is qualified to serve as the chairman of our board of directors due to his extensive knowledge and experience in the medical
device industry generally, and, in particular, with regard to insulin pumps and the diabetes industry, as well as his management
and leadership experience from holding director and senior executive positions in other public and private companies and leading
project development teams of medical device companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Ellen O&#8217;
Connor Vos. &#160;</i>Ms. Vos was appointed to our board of directors on May 18, 2021 and has served as our chief executive officer
since August 2021. Ms. Vos has served as a member of VosHealth LLC since November 2020. Prior to that, she served as the president
and chief executive officer of the Muscular Dystrophy Association from October 2017 to November 2020. Previously, Ms. Vos had
been chief executive officer of ghg | greyhealth group from 1996 to 2017, and she has been a champion of using digital capabilities
to improve the public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a publicly-traded digital health company,
and the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college students, and was a founding
board member of MMRF, a pioneering cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred University. We believe
that Ms.&#160;Vos is qualified to serve on our board of directors because of her executive experience and extensive executive
skills in digital marketing, commercialization and communications in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><i>Liam
Burns</i>. Mr. Burns was appointed to our board of directors in January 2019. Since that time, he has also been the Chief Executive
Officer of Endo-TAGSS, LLC, a privately-held company developing a novel surgical access system for treatment of gastrointestinal
diseases. From December 2017 to December 2018, Mr. Burns was the Chief Executive Officer of CuraSeal Inc., a privately-held regenerative
medical company. From January 2014 to March 2018, he was the Vice President, Global Sales and Marketing for Dextera Surgical Inc.,
which marketed the world&#8217;s smallest surgical stapler. Dextera Surgical Inc. filed for bankruptcy protection on December
11, 2017 and was subsequently sold to B. Braun Aesculap in 2018. From January 2013 to September 2016, Mr. Burns was the managing
member and majority interest holder in Bensi Flemington LLC, which operated a restaurant in Flemington, New Jersey. Bensi Flemington
LLC filed for bankruptcy protection on August 11, 2015. Prior to that, Mr. Burns held a variety of commercial leadership roles
at Ethicon and various early stage medical device companies. Mr. Burns received a B.A. in Economics from the College of the Holy
Cross and an Executive MBA from the Weatherhead School of Management at Case Western Reserve University. We believe that Mr. Burns
is qualified to serve as a member of our board of directors due to his extensive experience and background in developing and launching
new medical technologies, commercial strategy, marketing and branding, as well as his experience in metabolic health.</span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>William J.
Febbo.</i><b>&#160;</b>Mr. Febbo was appointed to our board of directors in January 2020. He is currently the Chief Executive
Officer and a director of OptimizeRx Corporation, a digital health company focused on bringing life sciences support to patients
and providers, having joined us in 2016. Mr. Febbo founded Plexuus, LLC, a payment processing business for medical professionals
in September 2015 and remained its Chairman from September 2015to December 2020. From April 2007 to September 2015, he served
as Chief Operating Officer of Merriman Holdings, Inc., an investment banking firm, where he assisted with capital raises in the
technology, biotechnology, clean technology, consumer and resources industries. Mr. Febbo was a co-founder of, and from September
2013 to September 2015 served as Chief Executive Officer of, Digital Capital Network, Inc. a transaction platform for institutional
and accredited investors. He was a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel,
LLC, a provider of market intelligence and communications for the pharmaceutical, biomedical, and medical device industries. Since
2017, Mr. Febbo has been a faculty member of the Massachusetts Institute of Technology&#8217;s linQ program, which is a collaborative
initiative focused on increasing the potential of innovative research to benefit society and the economy. Since 2004, he has been
a board member of the United Nations Association of Greater Boston, a resource for the citizens of Greater Boston on the broad
agenda of critical global issues addressed by the United Nations and its agencies.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On January 29,
2018, the Financial Industry Regulatory Authority (FINRA) accepted a Letter of Acceptance, Waiver and Consent (the Consent) submitted
by Mr. Febbo. Without admitting or denying the findings, Mr. Febbo consented to the sanctions and to the entry of findings that
he permitted Merriman Capital, Inc. to conduct a securities business while below its net capital requirement. From August 2012
to October 2015, he was the Financial and Operations Principal (FinOp) for a registered broker-dealer, Merriman Capital, Inc.
(Merriman). During certain months, while Mr. Febbo was FinOp, FINRA found that certain of Merriman&#8217;s net capital filings
with FINRA were inaccurate because of the method by which Merriman calculated net capital and that, when corrected, it was retroactively
determined that Merriman had operated below its minimum net capital requirements. Mr. Febbo, as FinOp, signed certain of these
reports and was thus held responsible. Based on the Consent, in settlement, Mr. Febbo, who was then no longer registered with
any broker-dealer, accepted a fine of $5,000, a 10-business day suspension from acting as FinOp for any FINRA member and required
to requalify by examination for the Series 27 license before again acting in a FinOp capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that
Mr. Febbo is qualified to serve on our board of directors because of his wealth of experience in building and managing health
services and financial businesses. Mr. Febbo brings more than 20 years of experience in building and managing health services
and financial businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><i>Morgan
C. Frank.&#160;</i>Mr. Frank was appointed to our board of directors in April 2017. Mr. Frank has worked with Manchester Explorer,
LP since May 2002, and, prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy
and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin
outs. Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San
Francisco based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing
in primary research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment
at Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science
from Brown University. We believe that Mr. Frank is qualified to serve as member of our board of directors due to his extensive
prior experience conducting financial analysis of public companies (certain of which were in the development stage), including
such public companies&#8217; management teams, products, including products in the development stage, the potential markets for
such products and other factors that could affect the likelihood and timing of success and market penetration of such entities&#8217;
products as well as his capital raising activities. We believe this provides us with valuable insights into the financial markets
and investment criteria of institutional and other investors as well as capital raising activities.</span></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Carmen Volkart.&#160;</i>Ms.
Volkart<b>&#160;</b>was appointed to our board of directors in December 2019. She has served as chief financial officer of Natureworks
LLC, an advanced materials company offering a portfolio of renewably-sourced polymers, since October 2018. From October 2012 to
July 2018, Ms. Volkart served as chief financial officer and, for a portion of that time, as senior vice president of commercialization
for NxThera, Inc., a medical device company pioneering the application of convective radiofrequency thermotherapy to treat endurological
conditions. She served as global chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial
officer, corporate secretary, compliance officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, Ms. Volkart
held various executive and financial positions at American Medical, Inc., Medtronic, Inc. and Honeywell, Inc. She holds a B.S.
in accounting from the University of North Dakota and an MBA with a concentration in strategic management from the University
of Minnesota. We believe that Ms. Volkart is qualified to serve on our board of directors because of her substantial financial
and public-company experience, as she has served as chief financial officer at multiple medical device and other companies.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Involvement
in Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Except as described
above with regard to Messrs. Burns and Febbo, to our knowledge, none of our executive officers or our directors has, during the
last ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">had
    any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or
    business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or
    within two years prior to that time;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">been
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction
    or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement
    in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
    or to be associated with persons engaged in any such activity;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">been
    found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to
    have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">been
    the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
    reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an
    alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial
    institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement
    or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or
    any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">been
    the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
    organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of
    the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority
    over its members or persons associated with a member.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To our knowledge,
there are no material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially of
more than 5% of any class of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security
holder is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Arrangements
for Appointment of Directors and Officers&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Pursuant
to the Reorganization and Share Exchange Agreement, hereinafter referred to as the Share Agreement, dated as of July 24, 2017,
by and among us, Quasuras, Inc., Mr. DiPerna and the other stockholders of Quasuras, Inc., until July 24, 2022, our board of directors
shall consist of no more than five and no less than two directors of which (i) Manchester Explorer, LP has the right to appoint
two directors, pursuant to which Manchester Explorer, LP appointed Mr. Frank and Ms. Volkart and (ii) Mr. DiPerna, in addition
to being our chairman of the board, has the right to appoint two additional directors, pursuant to which he appointed Messrs.
Burns and Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester Explorer, LP&#8217;s and Mr. DiPerna&#8217;s
rights to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors
until July 2022; provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr.
DiPerna shall remain as chairman of our board of directors for an additional period of three years. Following such amendment,
our board of directors increased the size of the board to six members and, on May 18, 2021, appointed Ms. Vos as a director to
our board. On August 11, 2021 Mr. DiPerna resigned as our chief executive officer, and Ms. Vos was appointed as chief executive
officer.</span></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>The DiPerna
Employment and Related Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We entered into
an employment agreement dated August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna is employed by us as our president
for an initial two-year term with automatic one-year renewals. Pursuant to such agreement, we agreed to pay Mr. DiPerna: i) an
annual salary of $200,000 in cash, ii) $100,000 per year in fully-vested stock options granted monthly at an exercise price determined
by our board of directors in its sole discretion and iii) an annual bonus of $300,000, payable at the discretion of our board
of directors, either in shares or in cash. If the board chooses to pay the bonus in shares, such shares will be valued at a price
determined by our board of directors. Pursuant to such employment agreement (i) if (a) we terminate Mr. DiPerna&#8217;s employment
without cause or he resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000, and (b) we terminate Mr. DiPerna&#8217;s
employment for cause, we are not obligated to make any severance payment and Mr. DiPerna will receive only his base compensation
through the last day of his employment, (ii) upon Mr. DiPerna&#8217;s death or disability, he will receive his base compensation
through the last day of his employment and will remain eligible for all applicable benefits relative to death or disability pursuant
to any plans that we have in place at such time, and (iii) upon a change of control (as defined in the employment agreement),
Mr. DiPerna will be paid a lump sum of $100,000 within sixty days of the time at which such change of control takes place.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In May
2020, we amended our employment agreement with Mr. DiPerna to provide that in the event of a change in control:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">within
    60 days of the date the change in control occurs, Mr. DiPerna shall be paid by us or our successor in interest a lump sum
    cash payment equal to 12 months of Mr. DiPerna&#8217;s then annual Base Compensation (as defined in the employment agreement);
    and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">immediately
    prior to such change of control, any unvested stock options or other unvested securities of ours issued to Mr. DiPerna shall
    automatically accelerate and immediately become fully vested and exercisable.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In June 2020,
our board of directors approved an amendment to the employment agreement to provide that Mr. DiPerna&#8217;s base salary would
be paid entirely in cash commencing July 1, 2020. The payment of the additional cash component of Mr. DiPerna&#8217;s annual base
salary ($8,333.33 per month) was initially deferred (the &#8220;Deferred Salary&#8221;) and accrue for Mr. DiPerna&#8217;s benefit
until we have received $5,000,000 of cumulative gross proceeds of financing, at which time the Deferred Salary shall be paid to
Mr. DiPerna and the salary deferrals will cease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 15,
2021, our board of directors authorized a $50,000 bonus for Mr. DiPerna for fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a change
of control occurred on March 31, 2021, under his employment agreement, Mr. DiPerna would be entitled to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">payment
    of a lump sum of $300,000 within 60 days of the time at which such change of control takes place; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">accelerated
    vesting of 183,333 shares of common stock under an unvested stock option. The value of the shares subject to accelerated vesting
    is calculated as the intrinsic value per share multiplied by the number of shares that would become fully vested upon a change
    of control. The intrinsic value per share would be calculated as the excess of the closing price of the common stock of $5.25
    on the OTCQB Venture Market on March 31, 2021 over the exercise price of the option. As of March 31, 2021, the intrinsic value
    was approximately $550,000.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection
with our acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with
Quasuras and Mr. DiPerna, pursuant to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or
indirectly by him related to our business. Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services
to be performed for us, pursuant to a royalty agreement, certain fees based upon future sales, if any, of our potential product
subject to a maximum $10,000,000 cap on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>The Vos Employment
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On August 11,
2021, we entered into a two-year employment agreement (the &#8220;Agreement&#8221;) with Ms. Vos for her service as our chief
executive officer, and the Agreement renews for one-year terms, unless either party provides the other with 90-day prior written
notice of termination. The Agreement provides that Ms. Vos will be entitled to total base compensation of $300,000 annually, as
follows: a cash salary of $250,000 per year (the &#8220;Cash Salary&#8221;), plus deferred salary of $50,000 per year (the &#8220;Deferred
Salary&#8221; and, together with the Cash Salary, the &#8220;Base Compensation&#8221;). The Deferred Salary accrues monthly, is
fully vested and nonforfeitable, and is payable in full in cash upon the earliest of: (i) the last day of Ms. Vos&#8217; employment
with us or (ii) a &#8220;change of control,&#8221; as defined and determined in accordance with the Agreement. Notwithstanding
the foregoing, upon occurrence of a change of control, or the registration of our common stock on a national or international
stock exchange, Ms. Vos&#8217; Cash Salary shall be increased to at least $300,000 and no portion thereof shall be deferred. Ms.
Vos will also be eligible to receive an annual performance bonus of $300,000, upon achievement of certain agreed upon goals, as
determined by Ms. Vos and the Board, and will be reimbursed by us for up to $30,000 per year for travel and temporary living expenses
in San Diego County, California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to
the Agreement, we granted Ms. Vos an option to purchase 1,087,354 shares (&#8220;Option Shares&#8221;) of our common stock (the
&#8220;Option&#8221;), at an exercise price of $4.06 per share, the closing price of our common stock on the OTCQB Market on August
10, 2021. Twenty percent of the Option Shares vest after six months with the remaining Option Shares vesting in equal monthly
amounts over the next 42 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Except for a
termination for &#8220;cause,&#8221; in the event of Ms. Vos&#8217; termination by us without cause or Ms. Vos&#8217; termination
for &#8220;good reason&#8221; within six months before or 12 months after a change of control, Ms. Vos shall be entitled to a
lump sum cash severance payment equal to: (i) two times Ms. Vos&#8217; then-current Base Compensation, (ii) any Base Compensation
and bonus earned but not already paid; (iii) reimbursement for 12 months for the continuation of healthcare insurance coverage;
and (iv) accelerated vesting of all unvested Option Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to
the Agreement, Ms. Vos is subject to certain restrictions relating to Company confidential information, employees, customers and
suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Communications
with our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Stockholders
who desire to communicate with the board of directors, or a specific director, may do so by sending the communication addressed
to either the board of directors or any director, c/o&#160;Modular Medical, Inc., 16772 West Bernardo Drive, San Diego, California
92127. These communications will be delivered to the board of directors, or any individual director, as specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Board
Leadership Structure and Role in Risk Oversight</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to our small
size and early stage, we have not adopted a formal policy on whether the chairman and chief executive officer positions should
be separate or combined. Since August 11, 2021, Mr. DiPerna has been serving as our chairman, and Ms. Vos has been serving as
our chief executive officer. Our board of directors has oversight responsibility for our risk management processes. Our board
of directors receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate,
regarding our assessment of risks. Our board of directors will focus on the most significant risks facing us and our general risk
management strategy, and also ensure that risks undertaken by us are consistent with our appetite for risk. While our board of
directors oversees our risk management processes, management is responsible for day-to-day risk management processes. We believe
this division of responsibilities is the most effective approach for addressing the risks facing us and that the leadership structure
of our board of directors supports this approach.</span></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have established
an Audit Committee and a Compensation Committee, and intend to establish a Nominating and Governance Committee, effective upon
completion of this offering. Each Committee&#8217;s members and functions are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Audit
Committee</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Our board
of directors established the audit committee for the purpose of overseeing the accounting and financial reporting processes and
audits of our financial statements. The Audit Committee also is charged with reviewing any internal control violations under our
whistleblower policy. The responsibilities of our audit committee are described in the Audit Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Carmen Volkart
and Liam Burns are the current members of the Audit Committee. Ms. Volkart serves as the chairperson and has been designated by
the board of directors as the &#8220;audit committee financial expert,&#8221; as defined by Item&#160;407(d)(5) of Regulation&#160;S-K
under the Securities Act of 1933, as amended, and the Exchange Act. That status does not impose duties, liabilities or obligations
that are greater than the duties, liabilities or obligations otherwise imposed on her as a member of the audit committee and the
board of directors, however. Our board of directors has determined that she is an independent director, as determined in accordance
with Rule&#160;10A-3 of the Exchange Act. Each of our Audit Committee members will satisfy the &#8220;independence&#8221; requirements
of the NASDAQ listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. Ms. Volkart is independent,
while Mr. Burns is not independent. Prior to effectiveness of this registration statement of which this prospectus forms a part,
we plan to appoint two new independent directors to the Audit Committee, and Mr. Burns will resign from the Audit Committee upon
such appointments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Compensation
Committee</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our board of
directors established the compensation committee for the purpose of&#160;reviewing, recommending and approving our compensation
policies and benefits, including the compensation of all of our executive officers and directors.&#160;<span style="background-color: white">William
Febbo, Morgan Frank and Carmen Volkart are the current members of the compensation committee, and Mr. Febbo serves as the chairperson.
</span>Mr. Febbo and Ms. Volkart are currently independent, and, prior to effectiveness of this registration statement of which
this prospectus forms a part, Mr. Frank will resign from the Compensation Committee. After Mr. Frank resigns from the Compensation
Committee, all of our Compensation Committee members will satisfy the &#8220;independence&#8221; requirements of the Nasdaq listing
rules and meet the independence standards under Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">Our
compensation committee is responsible for reviewing, recommending and approving our compensation policies and benefits, including
the compensation of all of our executive officers and directors, and it also has the principal responsibility for the administration
of our equity incentive plan. The responsibilities of our compensation committee are more fully described in the Compensation
Committee Charter adopted by our board of directors, a current copy of which can be found on the investors section of our website,&#160;www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i>.&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have not
historically had a nominating committee. We intend to establish a Nominating and Governance Committee effective upon completion
of this offering. Prior to May 2021, Manchester Explorer, LP and Mr. DiPerna had the right to appoint directors to our board of
directors. Instead of having such a committee, Messrs. DiPerna and Frank would identify and evaluate qualified individuals to
become nominees for director and board committee members.&#160;Commencing in May 2021, Manchester Explorer, LP and Mr. DiPerna
removed their respective rights to appoint directors, and our board of directors assumed responsibility to appoint new directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">A majority
of our Nominating and Governance Committee members will satisfy the &#8220;independence&#8221; requirements of the Nasdaq listing
rules and meet the independence standards under Rule 10A-3 under the Exchange Act. The Nominating and Governance Committee will
consider persons recommended by stockholders for inclusion as nominees for election to our board of directors if the information
required by our bylaws is submitted in writing in a timely manner addressed and delivered to our secretary at the address of our
executive offices. The Nominating and Governance Committee will identify and evaluate nominees for our board of directors, including
nominees recommended by stockholders, based on numerous factors it considers appropriate, some of which may include strength of
character, mature judgment, career specialization, relevant technical skills, diversity, and the extent to which the nominee would
fill a present need on our board of directors.<b>&#160;</b><span style="background-color: white">The responsibilities of our Nominating
and Governance committee are more fully described in the Nominating and Governance Committee Charter adopted by our board of directors,
a current copy of which can be found on the investors section of our website,&#160;www.modular-medical.com.</span></span></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><span style="background-color: white"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Code of Business
Conduct and Ethics for Employees, Executive Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to
adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and
members of our board of directors. The Code of Conduct will be available on our website at <span style="background-color: white">www.modular-medical.com.
</span>The Audit Committee will be responsible for overseeing the Code of Conduct and our board of directors must approve any
waivers of the Code of Conduct for employees, executive officers and members of our board of directors. In addition, we intend
to post on our website all disclosures that are required by law concerning any amendments to, or waivers from, any provision of
the Code of Conduct. All of our directors, executive officers and employees will be required to certify in writing their understanding
of and intent to comply with the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Board
Diversity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We seek diversity
in experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our board of directors.
We believe directors should have various qualifications, including individual character and integrity; business experience; leadership
ability; strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and
legal matters; communications and interpersonal skills; and the ability and willingness to devote time to our company. We also
believe the skill sets, backgrounds, and qualifications of our directors, taken as a whole, should provide a significant mix of
diversity in personal and professional experience, background, viewpoints, perspectives, knowledge, and abilities. Nominees are
not to be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability, or any other
basis proscribed by law. The assessment of prospective directors is made in the context of the perceived needs of our board of
directors from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All of our directors
have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We
believe that all of our directors are individuals of high character and integrity, are able to work well with others, and have
committed to devote sufficient time to the business and affairs of our company. In addition to these attributes, the description
of each director&#8217;s background set forth above indicates the specific qualifications, skills, perspectives, and experience
necessary to conclude that each individual should continue to serve as a director of ours.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Executive
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>SUMMARY COMPENSATION
TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth compensation information for the years ended March 31, 2021 and March 31, 2020 for each of our named executive
officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Name and Principal<br /> Position</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Salary<br /> ($)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Stock<br /> Awards<br /> ($)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Option<br /> Awards<br /> ($)(1)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Non-Equity<br /> Incentive<br /> Plan<br /> Compensation<br /> ($)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">All<br /> Other<br /> Compensation<br /> ($)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total<br /> ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 30%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Paul DiPerna, CEO, CFO, Secretary,</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: center">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">50,000</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">275,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Treasurer and Director(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,000</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,064,200</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Stephen Daly, Chief Commercial Officer(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,073</td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>







<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Award
amounts reflect the aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC &#160;Topic
718. The assumptions used to calculate the aggregate grant date fair value of option awards are set forth in the notes to the
consolidated financial statements included in item 8 of this Report. These amounts do not reflect actual compensation earned or
to be earned by our named executive officers.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
DiPerna&#8217;s annual salary base was increased from $180,000 to $300,000 in August 2018, under the terms of an employment &#160;agreement
between us and Mr. DiPerna. From August 2018 until June 30, 2020, Mr. DiPerna&#8217;s $300,000 annual salary was paid $200,000
in cash and $100,000 in fully-vested stock options granted monthly. In June 2020, our board of directors amended the salary payment
composition effective July 1, 2020, such that the $100,000 component of Mr. DiPerna&#8217;s salary would be deferred until we
have achieved $5,000,000 in financing proceeds from a subsequent financing. On August 11, 2021, Mr. DiPerna resigned as our chief
executive officer and continues to serve as Chairman of our board of directors and as our President, Chief Financial Officer and
Secretary.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Earned
as a bonus of which $22,000 was paid on April 30, 2021, and the remainder will be paid in four quarterly installments commencing
on July 15, 2021.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Earned
as a bonus, and is being paid in quarterly installments over the 24-month period that commenced on March 31, 2020.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Daly became our Chief
Commercial Officer in March 2020 at an annual base salary of $250,000. In February 2021, Mr. Daly converted to part time and his
annual base salary was reduced to $125,000. Mr. Daly resigned as our Chief Commercial Officer effective September 24, 2021. We
and Mr. Daly intend to enter into a consulting arrangement pursuant to which Mr. Daly would provide transitional services to us
on a part-time, interim basis.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The following
table shows certain information regarding outstanding equity awards held by our named executive officers as of March 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Number
    of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Exercisable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Number
    of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Unexercisable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Option<br />
    Exercise<br /> Price($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Option<br />
    Expiration<br /> Date(1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><span style="font-size: 10pt">Paul DiPerna</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">3,465</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">3.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6/1/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3,504</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5/1/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3,507</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">3.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">4/1/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,979</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3/2/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,235</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2/1/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,181</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1/1/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12/1/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,431</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">11/1/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,161</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10/1/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,986</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,998</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(9)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">8/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,979</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(10)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">7/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,948</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(11)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,028</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(12)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,869</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(13)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">4/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(14)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,921</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(15)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,808</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(16)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1/15/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,324</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(17)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12/28/2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,324</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(18)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">11/14/2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">18,013</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(19)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10/14/2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">18,013</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(20)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">09/14/2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">18,013</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(21)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">08/14/2028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">116,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(22)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">183,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">11/25/2029</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Stephen Daly</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">66,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-size: 10pt">(23)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">133,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3/3/2030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    standard option term is ten years, but all of the options expire automatically unless exercised within 90&#160;days after
    the cessation of service as an employee, director or consultant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on June 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on May 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on April 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on March 2, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on February 1,2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on January 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on December 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on November 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(10)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on October 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on September 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on August 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(13)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on July 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on June 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on May 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
</table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on April 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on March 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(18)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on February 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on January 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on December 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on November 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on October 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on September 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
</table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on August 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    option was granted on November 25, 2019, and the shares subject to this option vest monthly over three years commencing January
    1, 2020, subject to continued service as an employee, director or consultant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(26)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">This
    option was granted on March 3, 2020, and the&#160;</span><span style="font: 10pt Times New Roman, Times, Serif">shares subject
    to this option vest&#160;<span style="background-color: white">as to 1/3rd of the shares the annual anniversary of the grant
    date and as to 1/36th of the shares subject to the option on each monthly anniversary thereafter,&#160;</span>subject to continued
    service as an employee, director or consultant<span style="background-color: white">.</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have entered
into our standard form of employment, confidential information and invention assignment agreement with each of our named executive
officers. We also have entered into agreements to indemnify our directors and certain executive officers, in addition to the indemnification
provided for in our certificate of incorporation and bylaws. These agreements, among other things, provide for indemnification
of our directors and certain executive officers for many expenses, including attorneys&#8217; fees, judgments, fines and settlement
amounts incurred by any such person in any action or proceeding, including any action by or in the right of us, arising out of
such person&#8217;s services as a director or executive officer of ours, any subsidiary of ours or any other company or enterprise
to which such person provided services at our request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the compensation we paid to our non-employee directors for the year ended March 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Fee</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Restricted</p>
                                                                         <p style="margin-top: 0; margin-bottom: 0">Stock</p></td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Option</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Compensation</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">All Other</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Name</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)(1)(2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Compensation</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 35%; text-align: justify">Liam Burns</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">William Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: justify">Morgan Frank(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Award amounts reflect the
aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC Topic 718. The assumptions
used to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated financial
statements included in Item 8 of this Annual Report on Form 10-K. These amounts do not reflect actual compensation earned or to
be earned by our directors.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As of March&#160;31, 2021,
our non-employee directors each held outstanding options to purchase the following number of shares of our common stock: Liam
Burns, 197,062; William Febbo, 200,000; Morgan Frank, 150,000; Carmen Volkart, 150,000.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Frank was granted an option to purchase 150,000 shares of our common stock in May 2020.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0 24.5pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2021, our board of directors had authorized an annual cash retainer fee of $10,000, payable in quarterly installments,
for our non-employee directors, with the exception of Mr. Frank, as compensation for their service. Effective April 1, 2021, our
board of directors approved our outside (non-employee) director compensation plan (the Director Plan). Pursuant to the Director
Plan, outside directors will be paid the following annual retainers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$30,000
    for service as a member of the board of directors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$5,000
    for service as chair of the audit committee; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$5,000
    for service as chair of the compensation committee.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The retainers
will be paid in quarterly installments in either cash or in shares of our common stock, as directed by each director based on
an annual election. In addition, under the Director Plan, each director will also receive an annual service equity award of $100,000
paid in quarterly installments in either options to purchase shares our common stock or shares of our common stock, as directed
by each director based on an annual election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition,
upon appointment to our board of directors, we award our non-employee directors a stock option grant under our Amended 2017 Equity
Incentive Plan, hereinafter referred to as the 2017 Plan, ranging from 50,000 to 200,000 shares of our common stock. These options
vest annually over three years from the date of appointment to our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection
with her May 2021 appointment and service as a non-employee director, Ms. Vos has entered into our standard form of indemnification
agreement. We also awarded Ms. Vos an initial option to purchase 50,000 shares of our common stock vesting over three years, with
one-third of the shares subject to the option vesting on each one-year anniversary of the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
following table shows the number of securities to be issued upon exercise or vesting of outstanding equity awards under the 2017
Plan as of March 31,&#160;2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Plan Category</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of <br /> securities to be<br />
 issued upon exercise<br />
 or vesting of <br /> outstanding <br />
equity awards <br /> (a)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted-<br /> average <br /> exercise price <br /> of outstanding <br /> options <br /> (b)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of securities <br /> remaining available<br />
 for future issuance under <br /> equity compensation plans<br />
 (excluding &#160;securities<br />
 reflected in column(a)) <br /> (c)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%; text-align: justify; padding-left: 8.65pt; text-indent: -8.65pt">Equity compensation plans not approved by security holders</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">3,591,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">408,245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"></p>









<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="modulara014"></span>CERTAIN RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Related Party
Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In March 2021,
we paid Liam Burns, a member of our board of directors, $5,585 in settlement of a liability outstanding at March 31, 2020 for
consulting services rendered during fiscal 2020. Mr. Burns provided no consulting services to us during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">In February
2021, Paul DiPerna and Manchester Explorer, LP, which is represented by Morgan C. Frank, purchased $100,000 and $1,000,000, respectively,
aggregate principal amount of our promissory notes. Effective April 30, 2021, Paul DiPerna and Manchester Explorer, LP entered
into Revocation Agreements with us pursuant to which their collective $1,100,000 aggregate principal amount of notes and accrued
interest of $50,091 were replaced with new notes. <span style="background-color: white">At June 30, 2021, </span>Paul DiPerna
and Manchester Explorer, LP, <span style="background-color: white"> held notes in an aggregate principal amount of $102,663 and
$1,026,630, respectively, with $2,059 and $20,589 of interest payable thereon.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Stephen
Daly became our Chief Commercial Officer in March 2020 at an annual base salary of $250,000. In February 2021, Mr. Daly converted
to part time and his annual base salary was reduced to $125,000. Mr. Daly resigned as our Chief Commercial Officer effective September
24, 2021. We and Mr. Daly intend to enter into a consulting arrangement pursuant to which Mr. Daly would provide transitional
services to us on a part-time, interim basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
William Febbo, a member of our board of directors, purchased $200,000 aggregate principal amount of notes. <span style="background-color: white">At
June 30, 2021, approximately $4,000 of interest was payable by us thereon.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">See
&#8220;Management&#8221; above for other related party transactions involving our executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Board has
undertaken a review of the independence of our directors and considered whether any director has a material relationship with
us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this
review, our Board has determined that William Febbo and Carmen Volkart are &#8220;independent directors&#8221; as defined under
the rules of Nasdaq.</span></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>SECURITY OWNERSHIP
OF CERTAIN</b><br />
<b><span id="modulara016"></span>BENEFICIAL OWNERS AND MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">The
following table sets forth certain information as of September 30, 2021 concerning the ownership of our common stock by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    shareholder known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock (currently
    our only class of voting securities);</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    of our directors;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    of our executive officers; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">all
    directors and executive officers as a group.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Beneficial ownership
is determined in accordance with Rule 13d-3 of the Exchange Act, and includes all shares over which the beneficial owner exercises
voting or investment power. Shares that are issuable upon the exercise of options, warrants and other rights to acquire common
stock that are presently exercisable or exercisable within 60 days of September 30, 2021 are reflected in a separate column in
the table below. These shares are taken into account in the calculation of the total number of shares beneficially owned by a
particular holder and the total number of shares outstanding for the purpose of calculating percentage ownership of the particular
holder. We have relied on information supplied by our officers, directors and certain stockholders and on information contained
in filings with the SEC. Except as otherwise indicated, and subject to community property laws where applicable, we believe, based
on information provided by these persons, that the persons named in the table have sole voting and investment power with respect
to all shares of common stock shown as beneficially owned by them. The percentage of beneficial ownership is based on 18,982,562
shares of common stock outstanding as of September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Unless otherwise
stated, the business address of each of our directors and executive officers listed in the table is 16772 West Bernardo Drive,
San Diego, California 92127.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Name and principal position</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares<br /> Beneficially Owned<br /> (Excluding<br /> Outstanding<br /> Options)(1)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br /> Shares Issuable<br /> on Exercise of<br /> Outstanding<br /> Options(2)</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent of<br /> Class</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%; text-align: left">James Besser</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">6,558,906</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">34.55</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">JEB Partners, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,558,906</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.55</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Manchester Explorer, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,558,906</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.55</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Manchester Management LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,558,906</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.55</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Paul DiPerna</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,523,430</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40.70</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Ellen O&#8217;Connor Vos</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,007</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liam Burns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">William J. Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Morgan C. Frank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,558,906</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.78</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Carmen Volkart</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,788</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">87,880</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; padding-bottom: 1pt"><span style="font-size: 10pt">*</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">All current directors and executive officers as a group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,104,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.44</td><td style="text-align: left">%</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>







<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Represents
less than 1%</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Excludes
shares subject to outstanding options to acquire common stock that are exercisable within 60 days of September 30, 2021.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Represents
the number of shares subject to outstanding options to acquire common stock that are exercisable within 60 days of September 30,
2021.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
(i) 269,719 shares directly held by Mr. Besser, of which: (a) 180,830 shares were received in exchange for Mr. Besser&#8217;s
shares as a result of our acquisition of Quasuras and (b) 88,889 shares purchased in the 2018 Placement; (ii) 5,051,409 held by
Manchester Explorer, L.P.&#160;&#160;of which: (a) 4,545,455 shares were purchased in a private placement in 2017 (the &#8220;2017
Placement&#8221;), (b) 471,111 shares were purchased in the 2018 Placement, and (c) 34,483 were purchased in the 2020 Placement;
(iii) 1,056,948 shares held by JEB Partners, L.P. of which (a) 757,576 shares were purchased in the 2017 Placement, (b) 160,000
shares were purchased in the 2018 Placement and (c) 139,372 shares were purchased in the 2020 Placement; and (iv) 180,830 shares
held by Mr. Frank, which shares were received in our acquisition of Quasuras in exchange for Mr. Frank&#8217;s shares of Quasuras.
Mr. Besser, as the managing member, and Mr. Frank, as the portfolio manager and consultant of Manchester Management, LLC, the
general partner of Manchester Explorer, L.P.&#160;&#160;and JEB Partners, L. P. have shared voting and dispositive power over
shares held by Manchester Explorer, L.P. and JEB Partners, L. P. The address for Manchester Explorer, L.P and Mr. Besser is c/o
MMC, 2 Calle Candina, No. 1701, San Juan, Puerto Rico 00907.</span></td>
</tr></table>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 17.3pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 6,000,000 shares
directly held by the Paul DiPerna Irrevocable Trust, (ii) 1,000,000 shares directly held by Mr. DiPerna&#8217;s adult daughters,
Kelsie DiPerna and Alaria DiPerna, which shares Mr. DiPerna has sole voting power over; (iii) 523,430 shares directly held by
the Paul DiPerna Trust, of which 303,030 shares were purchased in the 2017 Placement, and (iv) 278,015 shares issuable upon exercise
of stock options granted to Mr. DiPerna under the 2017 Plan. The 6,000,000 shares held by the Paul DiPerna Irrevocable Trust,
1,000,000 shares held by Mr. DiPerna&#8217;s adult daughters and 220,440 shares held by the Paul DiPerna Trust were issued in
2017 to Mr. DiPerna in the Acquisition and transferred to such persons in December 2020 by Mr. DiPerna. Mr. DiPerna is the chairman
of our board of directors, and also serves as our president, chief financial officer, and treasurer. Mr. DiPerna is the trustee
of both the Paul DiPerna Irrevocable Trust and the Paul DiPerna Trust.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara017"></span>DESCRIPTION
OF CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">We are
authorized to issue up to 50,000,000 shares of common stock, par value $0.001 per share and up to 5,000,000 shares of preferred
stock, par value $0.001 per share. As of September 30, 2021, we had 18,982,562 common shares issued and outstanding and no shares
of preferred stock issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to our
second amended and restated articles of incorporation, and our bylaws, as amended, each of which is incorporated herein by reference
and are exhibits to the registration statement of which this prospectus forms a part. We encourage you to read our articles of
incorporation, our bylaws and the applicable provisions of the Nevada Revised Statutes (the &#8220;NRS&#8221;) for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Each holder
of our common stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments.
The holders of our common stock are entitled to one vote for each share or record on all matters to be voted on by our shareholders.
There is no cumulative voting with respect to the election of our directors or any other matter. Therefore, under our charter
documents, the holders of more than 50% of the shares voted for the election of those directors can elect all of the directors.
Our board of directors currently are elected as a single class. Our board of directors may from time to time declare dividends
on our outstanding shares. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled
to share ratably in all assets remaining available for distribution to them after payment of our liabilities and after provision
has been made for each class of stock, if any, having any preference in relation to our common stock. Holders of shares of our
common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to
our common stock.</span></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Our articles
of incorporation provide that our board of directors has the right in its discretion to issue preferred stock without approval
of our shareholders and to set the series, classes, rights, privileges and preferences of our preferred stock or any classes,
or series thereof without approval. In the event of a hostile takeover, the board of directors could potentially use this preferred
stock to preserve control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt"><b><i>Outstanding
Common Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April and
May 2021, we issued warrants to purchase 2,303,348 shares of our common stock to the purchasers of our convertible promissory
notes. The warrants have an initial exercise price of $8.00 per share and may be exercised for a period of five years from the
Trigger Date, which is defined as the 270<sup>th</sup> calendar day following the issue date of each note. If, prior to the Trigger
Date, we (i) complete a Qualified Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder&#8217;s
Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall be cancelled. A Qualified Capital Raise is
defined as an offering of our common stock or other securities in excess of $12,000,000 of gross proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt"><b><i>Outstanding
Common Stock Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of September
30, 2021, we had 4,792,949 outstanding options to purchase shares of our common stock at weighted average exercise price of $2.39
per share. In addition, at September 30, 2021, we had 3,207,051 shares available for future issuance under our 2017 Equity Incentive
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt"><b><i>Transfer
Agent and Registrar</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The transfer
agent and registrar for our common stock is Colonial Stock Transfer Company, Inc., 66 Exchange Place, 1<sup>st</sup> Floor, Salt
Lake City, UT 84111. Its telephone number is 801-355-5740.</span></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara018"></span>UNDERWRITING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We entered into
an underwriting agreement with the underwriters named below on , 2021. Oppenheimer &amp; Co. Inc. is acting as the representative
of the underwriters. The underwriting agreement provides for the purchase of a specific number of shares of common stock by each
of the underwriters. The underwriters&#8217; obligations are several, which means that each underwriter is required to purchase
a specified number of shares of common stock, but is not responsible for the commitment of any other underwriter to purchase shares
of common stock. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase
the number of shares of common stock set forth opposite its name below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Underwriter</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br />
 Shares of <br />
Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: justify">Oppenheimer &amp; Co. Inc.</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The underwriters
have agreed to purchase all of the shares of common stock offered by this prospectus (other than those covered by the over-allotment
option described below), if any are purchased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The shares of
common stock offered hereby are expected to be ready for delivery on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2021 against payment in immediately available funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The underwriters
are offering the shares of common stock subject to various conditions and may reject all or part of any order. The representative
of the underwriters has advised us that the underwriters propose to offer the shares of common stock to the public at the public
offering price set forth on the cover page of this prospectus and to dealers at a price less a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;per
share of common stock to brokers and dealers. After the shares of common stock are released for sale to the public, the representative
of the underwriters may change the offering price, the concession, and other selling terms at various times.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have granted
an option to the underwriters, exercisable for up to 30 days after the date of this prospectus, to purchase up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares
of common stock at the public offering price from us to cover over-allotments, if any, less underwriting discounts and commissions.
If the underwriters exercise all or part of this option, they will purchase shares of our common stock covered by the option at
the public offering price that appears on the cover page of this prospectus, less applicable underwriting discounts and commissions.
If this option is exercised in full, the total price to the public will be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, and the total proceeds to us, before expenses, will be $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.
If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting
agreement, to purchase a number of additional shares proportionate to that underwriter&#8217;s amount reflected in the above table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us, before
expenses. <span style="background-color: white">Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217;
option to purchase up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares
from us</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Per
    Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Total
    Without <br />
    Exercise of<br />
    Over-Allotment<br />
    Option</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Total
    With Full<br />
    Exercise of<br />
    Over-Allotment <br />
    Option</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left"><span style="font-size: 10pt">Initial public
    offering price</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Underwriting discounts
    and commissions payable by us (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Proceeds to us, before
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We estimate
that our total expenses of the offering, excluding the estimated underwriting discounts and commissions, will be approximately
$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;which includes the fees and expenses for which we have agreed to reimburse the underwriters, provided that any such fees and
expenses in excess of an aggregate of $150,000 will be subject to our prior written approval (which shall not be unreasonably
withheld).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have agreed
to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection
with this offering, we, our directors, executive officers, and certain stockholders have agreed not to offer, issue, sell, contract
to sell, encumber, grant any option for the sale of or otherwise dispose of any of our common stock or securities convertible
into or exchangeable for, or that represent the right to receive, shares of common stock, for a period of 90 days following the
closing of the offering of the shares. This means that, subject to certain exceptions, for a period of 90 days following the date
of this prospectus, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior
written consent of Oppenheimer &amp; Co. Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subject to certain
conditions, we granted Oppenheimer &amp; Co., Inc., for a period of twelve months after the date of the closing of this offering,
a right of first refusal to act as lead bookrunning underwriter, lead initial purchaser, lead placement agent or lead selling
agent, as the case may be in connection with any financing for the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is presently quoted on the OTCQB marketplace under the symbol &#8220;MODD&#8221;. We have applied to have our common stock listed
on The Nasdaq Capital Market under the symbol &#8220;MODD.&#8221; No assurance can be given that our application will be approved.
Trading quotes of securities on an over-the-counter marketplace may not be indicative of the market price of those securities
on a national securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Rules of the
SEC may limit the ability of the underwriters to bid for or purchase shares of common stock before the distribution of the shares
of common stock is completed. However, the underwriters may engage in the following activities in accordance with the rules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stabilizing
    transactions &#8211; The representative may make bids or purchases for the purpose of pegging, fixing or maintaining
    the price of the shares of common stock, so long as stabilizing bids do not exceed a specified maximum.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Over-allotments
        and syndicate covering transactions &#8211; The underwriters may sell more shares of common stock in connection
        with the offering than the number of shares of common stock that they have committed to purchase. This over-allotment
        creates a short position for the underwriters. This short sales position may involve either &#8220;covered&#8221; short
        sales or &#8220;naked&#8221; short sales. Covered short sales are short sales made in an amount not greater than the underwriters&#8217;
        over-allotment option to purchase shares of common stock in the offering described above. The underwriters may close out
        any covered short position either by exercising its over-allotment option or by purchasing shares of common stock in the
        open market. To determine how they will close the covered short position, the underwriters will consider, among other
        things, the price of the shares of common stock available for purchase in the open market, as compared to the price at
        which they may purchase shares of common stock through the over-allotment option. Naked short sales are short sales in
        excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares of
        common stock in the open market. A naked short position is more likely to be created if the underwriters are concerned
        that, in the open market after pricing, there may be downward pressure on the price of the shares of common stock that
        could adversely affect investors who purchase shares of common stock in the offering.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Penalty
    bids &#8211; If the representative purchases shares of common stock in the open market in a stabilizing transaction
    or syndicate covering transaction, it may reclaim a selling concession from the underwriters and selling group members who
    sold those shares of common stock as part of the offering.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Passive
    market making &#8211; Market makers in the shares of common stock who are underwriters or prospective underwriters
    may make bids for or purchases of shares of common stock, subject to limitations, until the time, if ever, at which a stabilizing
    bid is made.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Similar to other
purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales or to stabilize the market price of
the shares of common stock may have the effect of raising or maintaining the market price of the shares of common stock or preventing
or mitigating a decline in the market price of the shares of common stock. As a result, the price of the shares of common stock
may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an
effect on the price of the shares of common stock if it discourages resales of the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the
price of the shares of common stock. These transactions may occur on the Nasdaq Capital Market or otherwise. If such transactions
are commenced, they may be discontinued without notice at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Electronic
Delivery of Preliminary Prospectus</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">A prospectus
in electronic format may be delivered to potential investors by one or more of the underwriters participating in the offering.
The prospectus in electronic format will be identical to the paper version of such prospectus. Other than the prospectus in electronic
format, the information on any underwriter&#8217;s website and any information contained in any other website maintained by an
underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part.</span></p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Notice to
Non-U.S. Investors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Belgium</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The offering
is exclusively conducted under applicable private placement exemptions and therefore it has not been and will not be notified
to, and this document or any other offering material relating to the shares of common stock has not been and will not be approved
by, the Belgian Banking, Finance and Insurance Commission (&#8220;<i>Commission bancaire, financi&#232;re et des assurances/Commissie
voor het Bank, Financie en Assurantiewezen</i>&#8221;). Any representation to the contrary is unlawful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each underwriter
has undertaken not to offer sell, resell, transfer or deliver directly or indirectly, any shares of common stock, or to take any
steps relating/ancillary thereto, and not to distribute or publish this document or any other material relating to the shares
of common stock or to the offering in a manner which would be construed as: (a) a public offering under the Belgian Royal Decree
of 7 July 1999 on the public character of financial transactions; or (b) an offering of securities to the public under Directive
2003/71/EC which triggers an obligation to publish a prospectus in Belgium. Any action contrary to these restrictions will cause
the recipient and the company to be in violation of the Belgian securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Canada</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This document
constitutes an &#8220;exempt offering document&#8221; as defined in and for the purposes of applicable Canadian securities laws.
No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer
and sale of the securities described herein, or the Securities. No securities commission or similar regulatory authority in Canada
has reviewed or in any way passed upon this document or on the merits of the Securities and any representation to the contrary
is an offence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Canadian investors
are advised that this document has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts
(&#8220;NI 33-105&#8221;). Pursuant to section 3A.3 of NI 33-105, this document is exempt from the requirement to provide investors
with certain conflicts of interest disclosure pertaining to &#8220;connected issuer&#8221; and/or &#8220;related issuer&#8221;
relationships as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Resale Restrictions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The offer and
sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement to prepare
and file a prospectus under applicable Canadian securities laws. Any resale of Securities acquired by a Canadian investor in the
offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction,
and which may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus
requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus
requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain
circumstances apply to resales of the securities outside of Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Representations
of Purchasers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each Canadian
investor who purchases the securities will be deemed to have represented to the issuer and to each dealer from whom a purchase
confirmation is received, as applicable, that the investor (i) is purchasing as principal, or is deemed to be purchasing as principal
in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)
is an &#8220;accredited investor&#8221; as such term is defined in section 1.1 of National Instrument 45-106 <i>Prospectus Exemptions</i>,
or NI-45-106 or, in Ontario, as such term is defined in section 73.3(1) of the <i>Securities Act</i> (Ontario); and (iii) is a
&#8220;permitted client&#8221; as such term is defined in section 1.1 of National Instrument 31-103 <i>Registration Requirements,
Exemptions and Ongoing Registrant Obligations</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Taxation
and Eligibility for Investment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Any discussion
of taxation and related matters contained in this document does not purport to be a comprehensive description of all of the tax
considerations that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not
address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident,
or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment
by such investor under relevant Canadian federal and provincial legislation and regulations.</span></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Rights of
Action for Damages or Rescission</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Securities legislation
in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum, including
where the distribution involves an &#8220;eligible foreign security&#8221; as such term is defined in Ontario Securities Commission
Rule 45-501 <i>Ontario Prospectus and Registration Exemptions</i> and in Multilateral Instrument 45-107 <i>Listing Representation
and Statutory Rights of Action Disclosure Exemptions</i>, as applicable, with a remedy for damages or rescission, or both, in
addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes
an offering memorandum, and any amendment thereto, contains a &#8220;misrepresentation&#8221; as defined under applicable Canadian
securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be,
by the purchaser within the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian
securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available
at law to the investor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Language
of Documents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon receipt
of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating
in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice)
be drawn up in the English language only. <i>Par la r&#233;ception de ce document, chaque investisseur canadien confirme par
les pr&#233;sentes qu&#8217;il a express&#233;ment exig&#233; que tous les documents faisant foi ou se rapportant de quelque
mani&#232;re que ce soit &#224; la vente des valeurs mobili&#232;res d&#233;crites aux pr&#233;sentes (incluant, pour
plus de certitude, toute confirmation d&#8217;achat ou tout avis) soient r&#233;dig&#233;s en anglais seulement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>France</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Neither this
prospectus nor any other offering material relating to the shares of common stock has been submitted to the clearance procedures
of the Autorit&#233; des march&#233;s financiers in France. The shares of common stock have not been offered or sold and will
not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material
relating to the shares of common stock has been or will be: (a) released, issued, distributed or caused to be released, issued
or distributed to the public in France; or (b) used in connection with any offer for subscription or sale of the shares of common
stock to the public in France. Such offers, sales and distributions will be made in France only: (i) to qualified investors (investisseurs
qualifi&#233;s) and/or to a restricted circle of investors (cercle restreint d&#8217;investisseurs), in each case investing
for their own account, all as defined in and in accordance with Articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1
and D.764-1 of the French Code mon&#233;taire et financier; (ii) to investment services providers authorised to engage in portfolio
management on behalf of third parties; or (iii) in a transaction that, in accordance with article L.411-2-II-1&#176;-or-2&#176;-or
3&#176; of the French Code mon&#233;taire et financier and article 211-2 of the General Regulations (R&#232;glement G&#233;n&#233;ral)
of the Autorit&#233; des march&#233;s financiers, does not constitute a public offer (appel public &#224; l&#8217;&#233;pargne).
Such shares of common stock may be resold only in compliance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3
of the French Code mon&#233;taire et financier.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus
does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with
or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed
only at, and any offer of the shares of common stock is directed only at, investors listed in the first addendum to the Israeli
Securities Law, or the Addendum, consisting primarily of joint investment in trust funds, provident funds, insurance companies,
banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities
with equity in excess of NIS 50 million and &#8220;qualified individuals&#8221;, each as defined in the Addendum (as it may be
amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or,
where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors
will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same
and agree to it.</span></p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Italy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The offering
of the shares of common stock offered hereby in Italy has not been registered with the <i>Commissione Nazionale per la Societ&#224;
e la Borsa</i>, or CONSOB, pursuant to Italian securities legislation and, accordingly, the shares of common stock offered hereby
cannot be offered, sold or delivered in the Republic of Italy, or Italy, nor may any copy of this prospectus or any other document
relating to the shares of common stock offered hereby be distributed in Italy other than to professional investors (<i>operatori
qualificati</i>) as defined in Article 31, second paragraph, of CONSOB Regulation No. 11522 of 1 July, 1998 as subsequently amended.
Any offer, sale or delivery of the shares of common stock offered hereby or distribution of copies of this prospectus or any other
document relating to the shares of common stock offered hereby in Italy must be made:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">by
    an investment firm, bank or intermediary permitted to conduct such activities in Italy in accordance with Legislative Decree
    No. 58 of 24 February 1998 and Legislative Decree No. 385 of 1 September 1993, or the Banking Act;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">in
    compliance with Article 129 of the Banking Act and the implementing guidelines of the Bank of Italy; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">in
    compliance with any other applicable laws and regulations and other possible requirements or limitations which may be imposed
    by Italian authorities.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Sweden</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus
has not been nor will it be registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly,
this prospectus may not be made available, nor may the shares of common stock offered hereunder be marketed and offered for sale
in Sweden, other than under circumstances which are deemed not to require a prospectus under the Financial Instruments Trading
Act (1991: 980).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Switzerland</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The shares of
common stock offered pursuant to this prospectus will not be offered, directly or indirectly, to the public in Switzerland and
this prospectus does not constitute a public offering prospectus as that term is understood pursuant to art. 652a or art. 1156
of the Swiss Federal Code of Obligations. The company has not applied for a listing of the shares of common stock being offered
pursuant to this prospectus on the SWX Swiss Exchange or on any other regulated securities market, and consequently, the information
presented in this prospectus does not necessarily comply with the information standards set out in the relevant listing rules.
The shares of common stock being offered pursuant to this prospectus have not been registered with the Swiss Federal Banking Commission
as foreign investment funds, and the investor protection afforded to acquirers of investment fund certificates does not extend
to acquirers of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Investors are
advised to contact their legal, financial or tax advisers to obtain an independent assessment of the financial and tax consequences
of an investment in shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>European
Economic Area and the United Kingdom</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In relation
to each Member State of the European Economic Area and the United Kingdom, each referred to as a Relevant State, no shares of
common stock have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication
of a prospectus in relation to the shares of common stock which has been approved by the competent authority in that Relevant
State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State,
all in accordance with the Prospectus Regulation), except that offers of shares of common stock may be made to the public in that
Relevant State at any time under the following exemptions under the Prospectus Regulation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">to
    any legal entity which is a qualified investor as defined under the Prospectus Regulation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">to
    fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject
    to obtaining the prior consent of the underwriters for any such offer; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">in
    any other circumstances falling within Article 1(4) of the Prospectus Regulation,</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">provided that
no such offer of shares of common stock shall require us or any of underwriters to publish a prospectus pursuant to Article 3
of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each person
in a Relevant State who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented,
acknowledged and agreed to and with us and the underwriters that it is a qualified investor within the meaning of the Prospectus
Regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the case
of any shares of common stock being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common
stock acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired
with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their
offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has
been obtained to each such proposed offer or resale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We, the underwriters
and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 5pt 5pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>For
    the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares of common stock
    in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer
    and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares
    of common stock, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 5pt 5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>References
    to the Prospectus Regulation includes, in relation to the United Kingdom, the Prospectus Regulation as it forms part of UK
    domestic law by virtue of the European Union (Withdrawal) Act 2018.</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The above selling
restriction is in addition to any other selling restrictions set out below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>United
Kingdom</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This document
is for distribution only to persons who (i) have professional experience in matters relating to investments and who qualify as
investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 (as amended, the Financial Promotion Order), (ii) are persons falling within Article 49(2)(a) to (d), or high net worth
companies, unincorporated associations etc., of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are
persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial
Services and Markets Act 2000, as amended, or FSMA,) in connection with the issue or sale of any securities may otherwise lawfully
be communicated or caused to be communicated (all such persons together being referred to as &#8220;relevant persons&#8221;).
This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons.
Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged
in only with relevant persons.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara019"></span>LEGAL MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
validity of the shares of common stock offered by this prospectus has been passed upon for us by Lucosky Bookman LLP, Woodbridge,
New Jersey. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York, is acting as counsel for the underwriters
in connection with this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara020"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
consolidated balance sheets of Modular Medical, Inc. as of March 31, 2021 and March 31, 2020, and the related consolidated statements
of operations, changes in stockholders&#8217; equity (deficit) and cash flows for the years then ended have been audited by Farber
Hass Harley LLP, an independent registered public accounting firm, as stated in their report which is incorporated herein. Such
consolidated financial statements have been incorporated herein in reliance on the report of such firm given upon their authority
as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara021"></span>WHERE YOU
CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1, including exhibits and schedules, under the Securities Act that
registers the shares of our common stock to be sold in this offering. This prospectus does not contain all of the information
contained in the registration statement and the exhibits and schedules filed as part of the registration statement. For further
information with respect to us and our common stock, we refer you to the registration statement and the exhibits and schedules
filed as part of the registration statement. Statements contained in this prospectus as to the contents of any contract or any
other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement,
we refer you to the copies of the contract or document that has been filed. Each statement in this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">You
may read and copy all materials that we file with the SEC, including the registration statement and its exhibits and schedules,
on the website maintained by the SEC at www.sec.gov. Information contained on any website referenced in this prospectus does not
and will not constitute a part of this prospectus or the registration statement on Form S-1 of which this prospectus is a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">In
addition, upon the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act
and we will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements
and other information will be available for inspection and copying at the public reference room and the website of the SEC referred
to above. We also maintain a website at <span style="background-color: white"><span style="text-decoration: underline">www.modular-medical.com</span></span>, at which
you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished
to, the SEC. The information contained in, or that can be accessed through, our website is not a part of, and is not incorporated
into, this prospectus. Additionally, you may request a copy of any of our filings with the SEC at no cost, by writing or telephoning
us at the following address:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Attn.: CFO</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">16772 W. Bernardo
Drive</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">San Diego, California
92127</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">(858) 800-3500</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">You
should rely only on the information contained in this prospectus or to which we have referred you. We have not and the underwriters
have not authorized any person to provide you with different information or to make any representation not contained in this prospectus.</span></p>








<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara022"></span>INDEX TO FINANCIAL
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 34.6pt"><span style="font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">Page&#160;&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Three months
    ended June 30, 2021 and June 30, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb001"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and March 31, 2021 </b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom">F-2<span style="font-size: 10pt"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb002"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2021 and 2020 (Unaudited)</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span>F-3</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb003"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three Months Ended June 30, 2021 and 2020 (Unaudited)</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span><span style="font-size: 10pt">&#160;</span>F-4</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb004"><span style="font: 10pt Times New Roman, Times, Serif"><b>Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2021 and 2020 (Unaudited)</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb005"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Condensed Consolidated Financial Statements (Unaudited)</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Years ended
    March 31, 2021 and March 31, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb006"><span style="font: 10pt Times New Roman, Times, Serif"><b>Report of Independent Registered Public Accounting Firm</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-14</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb007"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Balance Sheets as of March 31, 2021 and March 31, 2020 </b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-16</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb008"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Statements of Operations for the Years Ended March 31, 2021 and March 31, 2020</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-17</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb009"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Years Ended March 31, 2021 and March 31, 2020 </b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-18</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb010"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Statements of Cash Flows for the Years Ended March 31, 2021 and March 31,2020, </b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-19</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-indent: -8.65pt"><a href="#modularb011"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Financial Statements</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-size: 10pt"><span style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span>F-20</span></span></td></tr>
</table>



<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc.</b><br />
<b><span id="modularb001"></span>Condensed Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_z6JBmlYg3Vy9" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210630_z9ictOdiEUo1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2021<br /> (Unaudited)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210331_z3XM5fmkyby9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March
    31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_z0YaJ40rxcz2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsCurrentAbstract_i01B_z0riT7LzlZ67" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzQFf_zfKrtPx3BZag" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Cash and cash equivalents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,380,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PrepaidExpenseCurrent_i02I_maCzQFf_zRli79CI3115" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherAssetsCurrent_i02I_maCzQFf_zcx4ol1RU3L4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,632</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_mtCzQFf_maCzNO4_zQmbBtS6JaZg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,466,430</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,089</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCz2TT_zKWkVSIQ9NMg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCz2TT_z2Vc6Pfxt0wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DepositsAssets_i02I_maCz2TT_zHMdt29IvIoe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsNoncurrent_i02TI_mtCz2TT_maCzNO4_zwyRdGJWCam6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">TOTAL NON-CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575,883</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--Assets_i02TI_mtCzNO4_zVtZJh2vP4u1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,042,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzQGNUs80Iul" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_z5xkNmRVIUId" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzfIc_z2lK1l7m9JV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maLCzfIc_zOtE22lzrFKk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,990</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzfIc_zcMUNJS3nMCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--UnsecuredDebtCurrent_i02I_maLCzfIc_zc6rSVhJIbe7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0073">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maLCzfIc_ztYqeh3uoMb9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,369,440</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_maCzoT4_mtLCzfIc_zdJznKUk2co6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,474,187</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zmiYaZiURo84" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">LONG-TERM LIABILITIES&#8217;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzoT4_zKDGm7SCc0Cg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Long-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzoT4_zyUwuyTATP91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Bonus payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--Liabilities_i02TI_mtCzoT4_maCzEIa_zp3gw33Q4Udd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,623,801</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Commitments&#160;&#160;and Contingencies (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--StockholdersEquityAbstract_i01B_z6QYieAceHLf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_maCzzJ3_z0Vjl4kOQ9qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Preferred Stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210630_zxIfbER2Nk18"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331_zVZJXDsxcPta"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20210630_zVC0nq6wzY08"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20210331_zzLfgG1LWgl9"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210630_zJLklhQvkbba"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210331_zUTdXy2KtlL3"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210331_z3azu64zRzm2"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210630_zv9FSaqNxFfc"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_maCzzJ3_zjiN1BC0Mb83" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 17.3pt; text-indent: -8.65pt">Common Stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_zE1dbtS9Oqih"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210331_zuHZafWNL386"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_z1ESB5zlz4c2"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20210331_zILw5J5SWg58"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20210630_z5GdfffU7hme"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_z3p8HlapdaRc"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,971,656</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20210331_zHqAIqNqFcWf"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20210331_ze8GDVA4lW5a"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,906,148</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2021 and March 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_maCzzJ3_z20xiQGqqY41" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,181,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,652,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_i02NI_di_msCzzJ3_z7iAQpHyZsG2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Common stock issuable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0122">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzzJ3_zzDsxxjyg5K5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,782,101</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_mtCzzJ3_maCzEIa_z3MRUmSXnBzk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">TOTAL STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,581,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtCzEIa_zv6HY9qgWUW" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,042,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these condensed consolidated financial statements.</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc.</b><br />
<b><span id="modularb002"></span>Condensed Consolidated Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zhgvi3xzmU1f" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49F_20210401__20210630_zcgBVrUci1Qi" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49C_20200401__20200630_zpomzoF9WVK9" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended<br /> June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_zFgqdWSQSFw2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzq27_z7nvv2BKgX4i" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,788,131</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">970,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzq27_zFV2o2yyynl7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,585,456</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">903,397</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzq27_msCzLCi_zBVUlkgvMXt1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,373,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,874,212</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingIncomeLoss_i01T_mtCzLCi_maNILzmT9_zjQajHCLjiFg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,373,587</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,212</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_i01_maNILzmT9_zRKvGcjGONaa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--InterestExpense_i01N_di_msNILzmT9_zlEFvP6gHhhh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,877</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNILzmT9_ztPmaWUCK6Yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Loss on debt extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_i01T_mtNILzmT9_zopkuxeJj2p" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--EarningsPerShareAbstract_iB_z4CE9Ho9tFd4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zZxgp8TRuOZj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zFjFE9fW81f9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_zlBAfgq4tHxj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,954,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,334,482</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these condensed consolidated financial statements.</span></p>




<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc.</b><br />
<b><span id="modularb003"></span>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</b><br />
<b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_114_zCinP2VPcbIl" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zgk6M643goll" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zVmFmMYEVgMa" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--CommonStockIssuableMember_zQDru9e5WXh4" style="white-space: nowrap; font-weight: bold; text-align: center">Common</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zU5CwKebfqUd" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BB_z3seLgvNiDL3" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_43B_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zoAi9zdovHl5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcyZ2xX8BpY2" title="Beginning balance, Shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,906,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,652,955</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0175">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_430_c20210401__20210630_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zSm03goBmME" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU3viQLSyyDc" title="Shares issued for services, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20210401__20210630_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zc4PQWuI9dmg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0191">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20210401__20210630_eus-gaap--ShareBasedCompensation_z7OyHDy0XCYi" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z60jRDjVMrT8" title="Stock-based compensation, Shares" style="text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,508</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,914</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43F_c20210401__20210630_eus-gaap--NetIncomeLoss_zsMIi5hbHjWe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_434_c20210401__20210630_eus-gaap--StockholdersEquity_iE_ztQGw0CK0IR7" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbeWpOXlsUNg" title="Ending balance, Shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,971,656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,972</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,181,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,782,101</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,581,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_43B_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zlwfi43KI8lk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuZ2OSAhf6vh" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,870,261</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,870</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,505,592</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20200401__20200630_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zCrgvoXUMTl8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Private placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkdHdvL9Q0Of" title="Private placement of common stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,041,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,118,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20200401__20200630_eus-gaap--ShareBasedCompensation_zjr7pyUXtzyk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20200401__20200630_eus-gaap--NetIncomeLoss_zzdKZZF21Nfa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43B_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zRQEsBvHkDNe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDpwvc8ei8B3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,600,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,892,206</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,443,191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,467,615</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these condensed consolidated financial statements.</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc.</b><br />
<b><span id="modularb004"></span>Condensed Consolidated Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_zpF9igkPahf5" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49E_20210401__20210630_ziHQ8O65vfu6" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_496_20200401__20200630_zRMFIJpcQ336" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended<br /> June 30,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLoss_zESA3KNSBcnh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zM0vP8ZfjEOf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--GainOnPPPNoteForgiveness_i01_zcR39zFkiI18" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Gain on PPP note forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_z4z4UJlAClYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensation_i01_zvM9RyrW9oAd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_i01_zp6vYJprdVrf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i01_zt6hF3brKbD7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">266,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i01N_di_zAJO9TK91zKa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,593</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_ecustom--IncreaseDecreaseInLeaseLiability_i01_zTYlTO1BW7Ue" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Change in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,099</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zPrf8HCh7BD6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_zgYGbKQPE6gg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">575</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zfEJxkF8oRua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_zNGdwWao4U2b" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Other assets and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">451</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,478</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_zcp3tZlsJY9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">117,607</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_maCzEHg_zd0AQgjBa0wf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,204,621</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,507,548</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_ztoadekAWOc2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzmVH_zxjWDTo7Vshb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,076</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,934</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzmVH_maCzEHg_zKOoPY8Pnh42" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,076</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,934</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zQVis6OjtEFf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maNCPBUz69e_zgtBm1io9Xdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,808</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz69e_z8i9g1jo630d" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of convertible notes, net of placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,137,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUz69e_ztslwsAPwc82" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Issuance of PPP note</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCzEHg_mtNCPBUz69e_zobOwtn8Ny9d" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,137,200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,539,588</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCzEHg_zMX1oWRSXD99" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,912,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zaJlu5ia12Bh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zCYFPG1dl5Hd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,380,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_iB_z7lEYWbwk2E1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zjZ3ohQiSDVe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-align: left">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_i02_zEPj5K1yi2Fk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 17.3pt; width: 74%; text-align: left">Fair value of detachable warrants issued with convertible notes</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>



<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>MODULAR MEDICAL,
INC</b><br />
<b><span id="modularb005"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b><br />
<b>(UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_znsMCbFUIpT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 1 &#8211; <span id="xdx_820_zch3DXJAL2Ji">THE COMPANY AND
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:LiquidityPolicyTextBlock"><p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zP0bhh1ad0t3" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_864_z5DYXfoSdPNd">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going Concern</i>, requires
management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.&#160;If
management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going
concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the
plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going
concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include
a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability
to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal
conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s
evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations,
and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#8217;s
plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital,
through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such
additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such
capital will be offered on terms and conditions acceptable to the Company.&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS50JxFyrXhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUd2jEQDs2k8">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year.&#160;Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal&#160;2022&#160;refers
to the fiscal year ending&#160;March&#160;31, 2022). The condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Quasuras, Inc. All significant intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit.&#160;The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC). The information in this report should be read in conjunction with the Company&#8217;s consolidated
financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_zdNMeBvdrMG6" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zNULOOVfYZqf">Use
of Estimates</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBVaERNbaRdg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_863_zqYed8dss7ce">Reportable Segment</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The Company operates in one
business segment and uses one measurement of profitability for its business.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zl1DVRRsI7Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_862_zVYmUBbNPvGh">Research and Development</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5Sl9CpZTL39" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_861_zap7DK35VZr2">General and Administrative</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJ9zWZdhZf4f" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zIOaCa9WuI56">Concentration
of Credit Risk</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&#160;&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84C_ecustom--RisksAndUncertaintiesPolicyTextBlock_zRkpppeZuZsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zOzaeijQf4M4">Risks
and Uncertainties</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQcKX7Pvqo0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zz1LxsPhAfo9">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk3RqqL1ocJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86E_zIKvhxIuoTA8">Property &amp; Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zi3kilqgb5D1" title="::XDX::3">three</span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zRnszKAR0bbd" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zykOpbp9ZKu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86A_zaNJq3OZWuDa">Fair Value of Financial
Instruments</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs to the valuation
methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs to the valuation
methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs to the valuation
methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable, accrued expenses and notes payable approximate
fair value.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfdYFZHKMHQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zcLqvdLJqyx4">Per-Share Amounts</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For
the three months ended June 30, 2021 and 2020, outstanding options to purchase <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_za1mTS6um7Bg"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,751,437</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z7oZc56jjaCa"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,407,587</ix:nonFraction></span> shares of common stock
were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyEVxFlqxohh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zrkQy9CE9Mm4">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRRfC5iABdsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_860_zpXgx0O2bWK3">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30,
2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeacMZKZELzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zl7WyuBQNj6l">Recently
Adopted Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In August 2020, the FASB issued ASU
No. 2020-06, <i>Debt</i>&#160;<i>with Conversion and Other Options</i>&#160;<i>(Subtopic 470-20) and Derivatives and Hedging-Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </i>(ASU
2020-06)<i>.</i>&#160;ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models required
under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no
separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for
equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU
2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective April 1, 2021, and the
impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_807_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zt1Ic83YlFs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 2 &#8211; <span id="xdx_822_zYSTuApIomm7">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
1, 2019, the Company adopted ASU No. 2016-02,&#160;<i>Leases&#160;</i>(ASC 842),<i>&#160;</i>and related ASUs, as amended, using
the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the
&#8220;effective date method&#8221;). In January 2020, the Company executed a lease for a new, larger corporate facility in San
Diego, California&#160;<span style="background-color: white">and paid a $100,000 security deposit.</span>&#160;The <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_z6KyHj6Qz5Mb"><ix:nonNumeric contextRef="AsOf2020-04-02" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">39</ix:nonNumeric></span>-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,400</ix:nonFraction></span><span style="background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_904_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zoQzdrxSonPi" title="Operating Lease Annual Rent Increase Percentage"><ix:nonFraction name="modd:OperatingLeasesAnnualRentIncreasePercentange" contextRef="AsOf2020-04-02" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span>.&#160;</span>In addition to the minimum lease payments, the Company is responsible for
property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility
lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated
the Company&#8217;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized
on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_902_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z0wwJgEA7pe7"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zaCDSyZC1nP2" title="Lease Incentive Received"><ix:nonFraction name="modd:LeaseIncentiveReceived" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z5HZ4L20eB9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B8_zdEpQCkJFzYj">Future minimum
payments under the facility operating lease, as of June 30, 2021, are listed in the table below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:DisclosureLeaseDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeaseDetailsAbstract_zKN0EWmy5i8a" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_zVOlOCGmZcXa" style="white-space: nowrap; font-weight: bold; text-align: center">Operating</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">lease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_z3t0HyaeYl44" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,074</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_zK62Imh2n4Gl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zshoydplaCTl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zSMq2d3uIwD3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="modd:OperatingLeasesImputedInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,038</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zSrCqh8htHu2" style="vertical-align: bottom; background-color: White">
    <td>Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_zDDLLBqGohk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_908_ecustom--CashPaidforLeaseLiabilities_iI_c20210630_zacg8xjxCiNg" title="Cash paid for amounts included in the measurement of lease liabilities"><ix:nonFraction name="modd:CashPaidforLeaseLiabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,085</ix:nonFraction></span>. Rent expense was $<span id="xdx_90F_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_zagodc8eUrO3"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,884</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_zGqzwmCOJlQk"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,885</ix:nonFraction></span> for the three
months ended June 30, 2021 and 2020, respectively.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:PPPNotesPayableTextBlock"><p id="xdx_80A_ecustom--PPPNotesPayableTextBlock_zjuXw9H2hdxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zzrX3ReFL8S9">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zN9wm3m1F9Si" title="Unsecured Loan Received under Paycheck Protection Program"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2020-04-24" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount
of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%
per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company applied
to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender and the U.S.
Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company
accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470: <i>Debt</i> (ASC 470),
and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the condensed consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zdJmBfjQSqhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_824_zF8wCZbz8sqg">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (the Original Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective
April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation
Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate
principal amount of Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC
470 and recorded a loss on extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20210630_zcI9jyvl89zh"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></span> and interest expense of $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_c20210401__20210630_zdDBSg77JXzd"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,647</ix:nonFraction></span> for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April and May
2021, pursuant to a Securities Purchase Agreement (the SPA), the Company sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zEo8x8D4RxPa"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,250,000</ix:nonFraction>
</span></span><span style="font-size: 10pt">aggregate principal amount of convertible promissory notes (the Notes) and warrants
to purchase shares of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated
maturity date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the
maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following
its Issue Date (the 270<sup>th</sup>&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued
interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Notes outstanding after the Trigger Date may be
converted into shares of the Company&#8217;s common stock at an initial conversion price of $2.87 per share; provided that a Note holder
may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company&#8217;s outstanding
common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment
from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes.
Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any
shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price,
such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes
shall be increased, as provided in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company completes an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise), each Note holder will be required to convert its Adjusted Note
Amount into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under
the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements
of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability to rely on Rule 144 for
sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from trading and/or fails to be quoted
or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American
within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock
underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement
to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and
sales of all or substantially all of the Company&#8217;s assets in the event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event of
Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay
such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by
(b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in
the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or
any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes include covenants, representations,
warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights
of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with the issuance of the Notes, the Company issued Warrants
to purchase in the aggregate 2,303,348 shares of its common stock at an initial exercise price of $8.00 per share. The Warrants may be
exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified
Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s
pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt
discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the
Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20210630_zLQhFeUgY766" title="Volatility Risk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.98</ix:nonFraction>%</span>, risk-free interest rate of
<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630_zTTyMnWBesig"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.86</ix:nonFraction>%</span>, a term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210401__20210630_zdBR3FIznx6b" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcp_c20210401__20210630_zVUrwzwUzpgj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">zero</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000,
which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest
rate method.&#160;The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the
three months ended June 30, 2021 was approximately $338,619.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. As of June 30, 2021, the Notes and accrued interest could
be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20210630_ze1tj2H1r0S8" title="Notes and Accured Interest could be converted into Common Stock"><ix:nonFraction name="modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,354,653</ix:nonFraction></span> shares of common stock at a conversion price of $2.87 per share.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_804_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3fT2NLfwrD1" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_827_zrIbQ6VC2YH6">STOCKHOLDERS&#146; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">During the three months ended June
30, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630_zEONyLqg5Yj2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of common stock to a service provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>2017 Equity Incentive Plan&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Board approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zrTxKqnMBzB1" title="Common Shares Reserved for Issuance under Equity Incentive Plan"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2017-10-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of common stock reserved for issuance. In January
2020, the Board approved an increase in the number of shares reserved for issuance by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zs8YHRuMHaHc"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares. Under the Plan, eligible
employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights,
restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative,
a committee designated by the Board.&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>Stock-Based Compensation
Expense</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. As of June 30, 2021, the unamortized compensation cost was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630_zpCqXHHc8Eoh"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,288,683</ix:nonFraction></span> related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxH_c20210401__20210630_zY4bYFgLShGk" title="::XDX::P1Y11M8D">1.94 years</span>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended June 30, 2021, the Company granted 5,508 shares to members of its board of directors (the Board) in accordance
with its Board compensation plan for non-employee directors. During the three months ended June 30, 2021, the Company granted
options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zg1c5pEi9Fv1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,321</ix:nonFraction></span> shares of its common stock to employees, directors and consultants. The options had 10-year terms,
and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2ewzSEiyrB3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,320</ix:nonFraction></span> options granted on June 30, 2020, in accordance with its Board compensation plan for non-employee directors, vested immediately.
During the three months ended June 30, 2021, the fair value of the options granted was $<span id="xdx_903_ecustom--FairValueofOptionGranted_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJDhrruAbBV1" title="fair Value of Options Granted"><ix:nonFraction name="modd:FairValueofOptionGranted" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">698,093</ix:nonFraction></span>, and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXdiNUaz4K22"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,918</ix:nonFraction></span> was recorded as
stock-based compensation expense in the condensed consolidated statement of operations.&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used
in the fair value calculations:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_z7jlNufFnNB3" style="display: none">Schedule of Fair Value Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:DisclosureStockBasedCompensationDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2020</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012021-06-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.81</ix:nonFraction>%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012021-06-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.87</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012020-06-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.31</ix:nonFraction>%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012020-06-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.37</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012021-06-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction>%</span>
                                         - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012021-06-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">366</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012020-06-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">123</ix:nonFraction>%</span>
                                         - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012020-06-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">128</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)"><ix:nonNumeric contextRef="From2021-04-012021-06-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
                                         - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa"><ix:nonNumeric contextRef="From2021-04-012021-06-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl"><ix:nonNumeric contextRef="From2020-04-012020-06-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
                                         - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe"><ix:nonNumeric contextRef="From2020-04-012020-06-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table></ix:nonNumeric>



<p id="xdx_8AE_zNTMtfaHyqji" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury
Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms
of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay
dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the EIP is presented below:</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zGHkWyRpu0S9" style="display: none">Schedule of Stock Option activity</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:DisclosureStockBasedCompensationDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" title="Shares Available for Grant, Beginning Balance" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">408,245</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" title="Number of Option, Beginning Balance" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,591,755</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" title="Weighted Average Exercise Price, Beginning Balance" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" title="Shares available for grant, Granted" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">182,321</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" title="Weighted Average Exercise Price, Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.23</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" title="Shares available for grant, Awards" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,508</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" title="Shares available for grant, Cancelled and Returned to the Plan" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,639</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" title="Number of Options, cancelled and returned to the Plan" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,639</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.87</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" title="Shares Available for Grant, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" title="Number of Option, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,751,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" title="Weighted Average Exercise Price, Ending Balance" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A6_zx3WXn833YCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the three months ended June 30, 2021 and 2020.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BE_zXSFOOU6AIe7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="modd:DisclosureStockBasedCompensationDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life<br /> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.66</ix:nonFraction></span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.90</ix:nonFraction></span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,751,437</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D" style="width: 8%; padding-bottom: 1pt; text-align: right">8.09</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" title="Options Exercisable" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,420,577</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" title="Weighted Average Exercise Price, Exercisable" style="width: 8%; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" title="Average Intrinsic Value, Exercisable" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,761,492</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A5_zP90vxl5TV5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic value per share is
calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading market over the exercise
price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the three months ended June 30, 2021
and 2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zAjAjm2kQUCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_82E_zVm2Wnp4JuBg">INCOME TAXES</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
for fiscal 2016 to fiscal 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of June 30,
2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmg12AlJhzaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE 7 &#8211; <span id="xdx_82A_zqwWgWQXTft2">RELATED
PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">In February
2021, the Company&#8217;s chief executive officer and an existing investor, who is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively.&#160;Effective April
30, 2021, the Related Party Holders entered into Revocation Agreements with the Company pursuant to which their collective $<span id="xdx_90D_ecustom--NotesCancelled_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zTGZuJroHhIk" title="Notes Cancelled"><ix:nonFraction name="modd:NotesCancelled" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></span>
aggregate principal amount of Original Notes and accrued interest of $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpWavPINNG35"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,091</ix:nonFraction>
</span></span><span style="font-size: 10pt">were replaced with Notes. <span style="background-color: white">At June 30, 2021,
the investor and executive officer held Notes in an aggregate principal amount of $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zHtwkZl74XA1"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,630</ix:nonFraction>
</span></span></span><span style="font-size: 10pt; background-color: white">and $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zTUw14m2hb6d"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,663</ix:nonFraction></span></span><span style="font-size: 10pt; background-color: white">,
respectively, with $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zIf2otZtXfSi"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,589</ix:nonFraction>
</span></span><span style="font-size: 10pt; background-color: white">and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zCq8kn5bjVS3"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,059</ix:nonFraction>
</span></span><span style="font-size: 10pt; background-color: white">of interest payable thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021, a member
of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zJCHYJM0yZo9"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-05-31_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction>
</span></span><span style="font-size: 10pt">aggregate principal amount of Notes. <span style="background-color: white">At
June 30, 2021, approximately $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zeG2zbPxxgw2"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-06-30_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction>
</span></span></span><span style="font-size: 10pt; background-color: white">of interest was payable by the Company thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zylavMPp90ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 8 &#8211;
<span id="xdx_827_zn3xkZCfqzbb">COMMITMENTS &amp; CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated financial statements
for the three months ended June&#160;30, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements,
and no claims for payment have been made under such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zt3BFuUIvZEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8211; <span id="xdx_821_z0q4d0zkLMue">SUBSEQUENT EVENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Board approved an increase in the number of shares reserved for issuance under the Plan by 4,000,000 shares, bringing
the total shares reserved for issuance to <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zScfyU9QtPo5"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-08-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span> shares.</span></p>

</ix:nonNumeric><p id="xdx_816_zIOMK0JzGeUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt"><span id="modularb006"></span>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p id="xdx_045_c20200401__20210331_zzrwVyPzHx93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-size: 10pt">To the Audit Committee and<br />
<br />
Stockholders of Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We have
audited the accompanying consolidated balance sheets of Modular Medical, Inc. (the &#8220;Company&#8221;) as of March 31, 2021
and 2020, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years then
ended, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of March 31, 2021 and 2020, and
the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally
accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Emphasis
of Matter &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The accompanying
consolidated financial statements have been prepared to assume the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company expects to continue to incur operating losses for the foreseeable future and incur
cash outflows from operations as it continues to invest in the development and subsequent commercialization of its product. The
Company expects that its research and development and general and administrative expenses will continue to increase, and, as a
result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described
in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">These consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on
the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the
Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.
Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Our audits
included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that
are material to the consolidated financial statements and (ii) involved especially challenging, subjective, or complex judgment.
The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken
as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit
matters or on the accounts or disclosures to which they relate.</span></p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0"><span style="font-size: 10pt"><i>Going
Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">As described
further in Note 1 to the financial statements, the Company has incurred losses since inception, and expects to continue to incur
operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development
and subsequent commercialization of its product. The Company expects that its research and development and general and administrative
expenses will continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve
profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date that these consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">We identified
management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern as a critical audit matter due to
inherent complexities and uncertainties related to the Company&#8217;s projections of operations. Auditing management&#8217;s
going concern assessment involved a high degree of auditor judgment and audit effort due to the impact of these assumptions on
the determination of the degree of doubt regarding the ability of the entity to continue as a going concern. The primary procedures
we performed to address this critical audit matter included:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    evaluated the reasonableness of key assumptions underlying management&#8217;s conclusion.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    evaluated that the disclosures included in the Form 10-K were complete and accurate and in accordance with accounting principles
    generally accepted in the United States of America.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We evaluated
        the impact of the Company&#8217;s existing financing arrangements on their ability to continue as a going concern.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"><i>Grants
of Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt">As discussed
in Note 5, during the year ended March 31, 2021, the Company granted 490,476 options to purchase shares of its common stock with
10-year terms and a grant-date fair value of $1,101,737 to employees, directors and consultants. Management is required to analyze
the fair value of each option granted and amortize it over its vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt">We identified
the grant of stock options as a&#160;critical&#160;audit&#160;matter. Management&#8217;s estimates regarding fair value of options
result in the application of a high degree of auditor judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><span style="font-size: 10pt">The primary
procedures we performed to address this&#160;critical&#160;audit&#160;matter included the following:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    gained an understanding of Company&#8217;s processes and controls in place for determining the fair value of each granted
    option.&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    evaluated the option price model the management selected to determine the fair value, and analyzed the underlying data used
    in the calculations. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    also recalculated the fair value of each option granted. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/&#160;Farber
    Hass Hurley LLP</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">We
    have served as the Company&#8217;s auditor since 2018.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chatsworth,
    California</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">June 29, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Modular
Medical, Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modularb007"></span>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zLuwwfeNOBfg" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49B_20210331_zJsknetPv7Cd" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_498_20200331_z7CjDOSb5Cvb" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zrzqEGjdDjt2" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">ASSETS</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zMPwF46GGM7h" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzxQb_zaTozqaAC46k" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Cash and cash equivalents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--PrepaidExpenseCurrent_i02I_maCzxQb_zSrEH8722Wne" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,853</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_i02I_maCzxQb_zOSRT2Tf79re" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_mtCzxQb_maCzI4V_zbOlcYP8O6nk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,089</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,186,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzBrL_zpMRFpm4IVKa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Property and equipment,&#160;net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzBrL_zryZZsVHcGSa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DepositsAssets_i02I_maCzBrL_zrmvtnb2AeWj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsNoncurrent_i02TI_mtCzBrL_maCzI4V_zLvsw7kIkdE4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL NON-CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Assets_i02TI_mtCzI4V_zuBF0cmvrh01" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,858,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzna8HPNs2c4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zTkgdSek77Rj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzPnu_z7niGuU3IjXb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzPnu_zr0zUsmrKdli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzPnu_zTph6Riok0L2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--UnsecuredDebtCurrent_i02I_maCzPnu_z25kXtNmVWs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maCzPnu_zOp1kxGVhed9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzPnu_maCzs7u_zIXSbOMbtVMh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">661,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzs7u_zGsGSdw9U7K3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Long-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,736</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzs7u_zqTpEA1HTKea" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Bonus payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Liabilities_i02TI_mtCzs7u_maCztDH_zQoI8dYSpqQh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_iI_zmJWRikcS7xj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">Commitments and Contingencies (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockholdersEquityAbstract_iB_zoZ2A0jzdLgc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_maCz5oc_z7ogGekcbRGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Preferred Stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331_z9BJIVBGq3L4"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200331_zlmFxHU2syvh"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;par value, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20210331_zTBi0OeRBQud"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20200331_zOyqD7GoacRg"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210331_zcnH0nSl3nP4"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210331_zBt30owpjWe1"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20200331_zybn0oRExgAi"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dn_c20200331_zAwTgXPSLsN7"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--CommonStockValue_i02I_maCz5oc_zRwXmcGQUNeh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 17.3pt; text-indent: -8.65pt">Common Stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210331_z4X7b7210PTb"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200331_zJnAAdxjedM5"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20210331_zlxlX5oNLqJ3"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20200331_zvYH68dbudFe"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20210331_zFRrCu0NBcGh"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20210331_zK01T81Gc3Q8"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,906,148</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20200331_zdrLOog7IUNb"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20200331_zLFmJ6EG8N92"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,870,261</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_i02I_maCz5oc_ztezYCWvxNVj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,652,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,505,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--CommonStockIssuable_i02NI_di_msCz5oc_zcVjMfktiwH" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Common stock issuable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz5oc_zOCxFQiAiBie" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquity_i02I_mtCz5oc_maCztDH_zjjQchjDfDIl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_iI_mtCztDH_z3ZtIBRvOg8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,858,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modularb008"></span>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zwlZnYMokX8g" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_490_20200401__20210331_zvuuGonH6Xf8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49B_20190401__20200331_zKMFsUZG7gjg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zpSQE3WkT4va" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzKWH_zSBR2Ipbscm8" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,034,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_zdEZO3y1sLyd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,253,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,313,870</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzKWH_msCzp4b_zg93iQNZLyq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,336,715</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,348,022</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_i01T_mtCzp4b_maCz4vx_zmdad6hJRyYd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,336,715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,348,022</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--InterestIncomeExpenseNet_i01_maCz4vx_zNm0Ezpc9LV2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InterestIncomeOther_i01_z57yYtxPkBX4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InterestExpense_i01N_di_msCz4vx_zNwqhHmWVhQk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zZ0u3YIw4ZPh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,376,376</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,319,273</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_z5ZThIgFWBd2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_i01T_mtCz4vx_z9RK9W8Ha5Md" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EarningsPerShareAbstract_iB_z7AECqWCCRH5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zoHgNNjr3dQ7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zdQmUr1tuPR1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_zwq5HPrBbcLl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,634,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,864,769</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modularb009"></span>Consolidated
Statements of Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_z5ZDLX5lYatj" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zRNmSu7NXLD8" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zybg0rUhPmN" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--CommonStockIssuableMember_zKtJNWCTwih5" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zlFCbvlt1xjc" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BB_zhGLfthITPUl" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Additional<br /> Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_430_c20190401__20200331_eus-gaap--StockholdersEquity_iS_zZKYrWvRhQy1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20190401__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNnvsVcuLQ3c" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,840,261</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,840</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,684,578</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,248,161</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,474,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20190401__20200331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkMP52N1uWKi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20190401__20200331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zjeuziWSkIM5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190401__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoWyKDjupCjb" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,800</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20190401__20200331_eus-gaap--ShareBasedCompensation_zMDQfBuQLYcd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20190401__20200331_eus-gaap--NetIncomeLoss_zF642jJfSPv1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20200401__20210331_eus-gaap--StockholdersEquity_iS_zOq31stEf0p1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlh6fcmPzSa7" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,870,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,505,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDVAgHPvMRni" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXnkIjKcdFy" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">962,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,914</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zSAzbma3F8yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z532Txk2PcQe" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,945</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20200401__20210331_eus-gaap--ShareBasedCompensation_zdF45w53Oehf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0726">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20200401__20210331_eus-gaap--NetIncomeLoss_zWga4JDVFgkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20200401__20210331_eus-gaap--StockholdersEquity_iE_zH9VTuTQKoH3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztrLChkzcsDf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,906,148</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,652,955</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Modular Medical,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modularb010"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zJe7U9lWWVc" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_499_20200401__20210331_zEHxvR9gP8I9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49E_20190401__20200331_zVtYiMeNZRtb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash Flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_zNnK1fHOZ964" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_z8BDAeWcEbk5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zcG7UsWN4YL1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i01_zufEbQLkvBZf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i01_zWs7a9dLG4N1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i01_z3QwLIyHYoah" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--IncreaseDecreaseInLeaseLiability_i01_zn1rV3LFrHX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Change in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0761">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AmortizationOfDebtDiscountPremium_i01_z3goiiZxNWr7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_zOdkCfLm5lEg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zVkoFcDrg1h1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_zQNsIKprMygg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other assets and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,391</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInSecurityDeposits_i02_zBs1XCJfhtMf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Security deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0775">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_zlTfdqcTu5B6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">86,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_maCzXv3_zjgDTRf90uz3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,908,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,094,839</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUWTku0UgMRc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_iN_di_zRH4M5k95JX1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzznH_maCzXv3_z7e5llJGpko9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">260,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zusB4eqLaIdl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maNCPBUz69e_zFoloTADCtI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from private placement, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz69e_z0JU917xMfLb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,210,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUz69e_zQtW2i18oGKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of PPP note payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzBRg_maCzXv3_zLA7ACprHNv" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,364,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCzEHg_zKJXmQgdoop6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,653,669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,431,634</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zIrwHzsqJfg1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Cash and cash equivalents, at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,768</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_z4wi5rPn29Fc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents, at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_iB_zuiLwv581jei" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_z6mmMsJUxsg2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>MODULAR MEDICAL,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modularb011"></span>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Note&#160;1 &#8211; <span id="xdx_82E_zMUTozRktbd4">THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:LiquidityPolicyTextBlock"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zymGf4t6LgG9" title="::XDX::3">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQzo91I1zBLh" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,591,755</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,177,945</ix:nonFraction></span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:ConsolidatedBalanceSheetDetailTextBlock"><p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE&#160;2 &#8211; <span id="xdx_829_zEATFVQb0qp3">CONSOLIDATED
BALANCE SHEET DETAIL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none; font-family: Arial, Helvetica, Sans-Serif">Schedule of
Property Plant And Equipment</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureConsolidatedBalanceSheetDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,693</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accured Expenses</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureConsolidatedBalanceSheetDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedWagesAndBonusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,563</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedWagesAndBonusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,160</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedPlacementFeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedOtherExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedOtherExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method.&#160;&#160;The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 4 &#8211; <span id="xdx_825_zi2Nz2cefmjg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#8220;effective date method&#8221;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;<span style="background-color: white">and paid a $100,000 security
deposit.</span> The <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_zC0Ttcd6sMx5"><ix:nonNumeric contextRef="AsOf2020-04-02" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">39</ix:nonNumeric></span></span><span style="font-size: 10pt">-month
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,400</ix:nonFraction></span></span><span style="font-size: 10pt; background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl"><ix:nonFraction name="modd:OperatingLeasesAnnualRentIncreasePercentange" contextRef="AsOf2020-04-02" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span></span><span style="font-size: 10pt; background-color: white">.&#160;</span><span style="font-size: 10pt">In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-04-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received"><ix:nonFraction name="modd:LeaseIncentiveReceived" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureLeasesDetailsAbstarct"><table cellspacing="0" cellpadding="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,432</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,028</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,692</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="modd:OperatingLeasesImputedInterest" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,297</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,855</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table></ix:nonNumeric>
<p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Rent expense
was $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,540</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,766</ix:nonFraction></span> for the years ended March&#160;31, 2021 and 2020, respectively.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii)&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetailsAbstract"><table cellspacing="0" cellpadding="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.28</ix:nonFraction>%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.71</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.77</ix:nonFraction>%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.37</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87</ix:nonFraction>%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">127</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86</ix:nonFraction>%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">103</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"><ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"><ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"><ix:nonNumeric contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"><ix:nonNumeric contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table></ix:nonNumeric>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" title="Shares available for grant, beginning" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,470,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,529,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.86</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,717,204</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,717,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">69,167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">69,167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">822,055</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,177,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">490,476</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,666</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">76,666</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">408,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,591,755</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life<br /> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.66</ix:nonFraction></span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.16</ix:nonFraction></span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,591,755</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonNumeric contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">8.25</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,228,738</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonNumeric contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">1.32</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,763,260</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_820_zIsr1RW0bfL9">STOCKHOLDERS&#8217;
EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">962,387</ix:nonFraction></span> shares of common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z2XCnSbkNPR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 7 &#8211; <span id="xdx_82B_zeLxB1QYD8T7">INCOME TAXES</span></b></span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7iCGckuioJk" style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font-size: 10pt"><span id="xdx_8B6_zkLl6W2dr03b">The income tax provision (benefit)</span>
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureIncomeTaxesDetailsAbstract_zbVBEAN7cKw1" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49A_20200401__20210331_ztSxkPwaaWR5" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_490_20190401__20200331_zhLLp8WLso9f" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zd2dOCWLZl2i" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalTaxExpenseBenefit_maCFSALz4R3_zhIpiEKpDuJ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCFSALz4R3_zA3pgAtPVAka" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_iT_mtCFSALz4R3_maITEBz8S7_zZMsFMMkNTr9" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_ztaZNPpd7GY8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDFSALzhVS_zoB8M39MpjV1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,931,390</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,180,434</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDFSALzhVS_z4BXs0FC0Hx9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">576,868</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">391,865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_mtDFSALzhVS_maITEBz8S7_zXlIPxK2RK27" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,508,258</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,572,299</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz8S7_zOCDceZhLZN5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,508,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,572,299</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz8S7_zd2Km15EqQb7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A1_zKsXvv4mOPz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of March&#160;31,
2021, the Company had net operating loss carryforwards (NOLs) of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zCb2U91pDzFh" title="Net operating loss carry-forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,954,000</ix:nonFraction></span> for federal income tax purposes and
$<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zq2a5tUTHKN8"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,019,000</ix:nonFraction></span> for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various
times from 2037 through 2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zn5lkCD7Ko9j" title="Research and development tax credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">535,000</ix:nonFraction></span>, which will begin expiring at various
times from 2038 through 2040, and state research and development credits of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaf2FE54j0J8"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,000</ix:nonFraction></span>, which do not have an expiration
date.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2QPCYm7wRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B9_zPiF9iXic74">A reconciliation
of income taxes provided at the federal statutory</span> rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as
follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zKHCyQBsNjhi" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_497_20200401__20210331_zhZ1R8N4N3u2" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49E_20190401__20200331_zByr8s5uhp62" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zMrYSIOdPoJj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left">Federal statutory rate</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">21</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td></tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z9Sg8wMY9tNi" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">State tax rate, net of federal benefit</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_z8cnsaHP9G1e" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Permanent differences</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction name="modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction name="modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2019-04-012020-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp_zWMUO54kfvPa" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Research and development tax credits</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">6</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_zTKF4a4Gwi9g" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Section 179 assets</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2019-04-012020-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zOvToIQp2qv" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Change in valuation allowance</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">34</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zmg7615yhEdd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Effective income tax rate</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2019-04-012020-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A1_zMZKqmc9Kta3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKlxfbzXdl0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BC_z9UCzdyF51Qb">Significant components of the Company&#8217;s
deferred tax assets and liabilities</span> were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureIncomeTaxesDetails3Abstract_zgaQQA7WvHOb" summary="xdx: Disclosure - INCOME TAXES (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_494_20210331_zFwEknJN9A71" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_495_20200331_zpYIhwrNwMEi" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzESI_zVsERk4fIaN4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,909,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,965,118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzESI_zuSZcDPf7mwg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzESI_zVusbhzB68dg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,039</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzESI_zaeHzNm7ytae" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,181</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzESI_zdZCqqLe3rZh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">646,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,716</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzESI_maDTANzJrK_z7nmZkOz2Kb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,012,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,567,484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzJrK_zyJTnNkQp2Fb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,012,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,567,484</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzJrK_zDuWqpNBID8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_zLDjVDnF8NIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the
available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2021 and 2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net
deferred tax assets at March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has
evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RoyaltyAgreementDisclosureTextBlock"><p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 8 &#8211; <span id="xdx_825_zCbrVhHYqJ95">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RetirementSavingsPlanDisclosureTextBlock"><p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 9 &#8211; <span id="xdx_822_zQx4uQmdvPXg">RETIREMENT SAVINGS
PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10 &#8211;
<span id="xdx_820_zkGXOVMGfxh7">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;11
&#8211; <span id="xdx_827_zfZkjWzcwctc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Consulting
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625<span style="color: red">&#160;</span>in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 47,062 shares of
common stock, were fully vested on the grant dates and have terms of 10 years.<b>&#160;</b>&#160;The most recent consulting agreement,
which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March 31, 2020,
the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated balance
sheet. The Company paid the $5,585 to the director during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
Company&#8217;s chief executive officer and an existing investor, which is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12 &#8211;
<span id="xdx_822_zye6Msj6Q1d7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#8217;s common stock at an initial
conversion price of $2.87 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares
of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#8217;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#8217;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 2,285,736 shares of its common stock
(Warrant Shares) at an initial exercise price of $8.00 per share. The Warrants may be exercised for a period of 5 years from the
Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of its Warrants shall be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
a member of the Board purchased $200,000 of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the Company&#8217;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.</span></p>

</ix:nonNumeric><p id="xdx_81B_zqsVc2a73tKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>






<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; text-indent: 0"><span style="font-size: 10pt"><b>Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="modular010.jpg" alt="(LOGO)" /></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>Common Stock</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 40%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 20%">&#160;</td>
    <td style="width: 40%">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>PRELIMINARY
PROSPECTUS</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 40%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 20%">&#160;</td>
    <td style="width: 40%">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>Sole Book-Running
Manager</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 18pt"><b>Oppenheimer&#160;&amp;&#160;Co.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">, 2021</span></p>







<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b><span id="modulara023"></span>PART II</b><br />
<br />
<b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other Expenses
    of Issuance and Distribution</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">The following
table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant
in connection with the sale of the common stock being registered. All amounts shown are estimates except for the SEC registration
fee and the FINRA filing fee:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">Amount&#160;to
    be<br />
    Paid</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left"><span style="font-size: 10pt">SEC Registration
    Fee</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><p style="margin: 0">3,198</p>


</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">FINRA Filing Fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Initial Nasdaq Listing
    Fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Printing and Engraving
    Fees and Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Legal Fees and Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Accounting Fees and Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Transfer Agent and Registrar
    Fees and Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Miscellaneous
    Fees and Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">*</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">To
                                            be provided by amendment.</span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Item 14. Indemnification of Officers
and Directors. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Second Amended
and Restated Articles of Incorporation and our Amended and Restated Bylaws provide that each person who was or is made a party
or is threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit
or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was one of
our directors or officers or is or was serving at our request as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, whether the basis of such action, suit or proceeding is alleged action
in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee,
shall be indemnified and held harmless by us to the fullest extent authorized by the Nevada Revised Statutes, or NRS, against
all expense, liability and loss (including attorneys&#8217; fees and amounts paid in settlement) reasonably incurred or suffered
by such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">NRS 78.7502
permits a corporation to indemnify any director or officer of the corporation against expenses (including attorneys&#8217; fees)
and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason
of the fact that such person is or was a director or officer of the corporation, if such person (i) is not liable pursuant to
NRS 78.138 and (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct
was unlawful. In a derivative action (i.e., one brought by or on behalf of the corporation), indemnification may be provided only
for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such
an action or the suit if such person (i) is not liable pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which
he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification
shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that
the court in which the action or suit was brought or some other court of competent jurisdiction determines that such person is
fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Second Amended
and Restated Articles of Incorporation provide that the liability of our directors and officers shall be eliminated or limited
to the fullest extent permitted by the NRS. NRS 78.138(7) provides that, subject to limited statutory exceptions and unless the
articles of incorporation or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual
liability, a director or officer is not individually liable to a corporation or its shareholders or creditors for any damages
as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that: (i) the act
or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (ii) the breach of those duties
involved intentional misconduct, fraud or a knowing violation of law.</span></p>

<!-- Field: Page; Sequence: 120; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The foregoing
discussion of our Second Amended and Restated Articles of Incorporation, Amended and Restated Bylaws and Nevada law is not intended
to be exhaustive and is qualified in its entirety by such Second Amended and Restated Articles of Incorporation, Amended and Restated
Bylaws, indemnification agreements, indemnity agreement, or law. <b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Nevada Revised
Statutes provide that a corporation may purchase and maintain insurance or make other<b> </b>financial arrangements on behalf
of any person who is or was a director, officer, employee or agent of<b> </b>the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or <b> </b>agent of another corporation, partnership, joint venture, trust
or other enterprise for any liability asserted against him and liability and expenses incurred by him in his capacity as a director,
officer, employee or agent, or arising out of his status as such, whether or not the corporation has the authority to indemnify
him against such liability and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have been
advised that in the opinion of the SEC, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to our directors, officers and other persons pursuant to the foregoing provisions, or otherwise, such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable. In the event a claim for indemnification against
such liabilities (other than payment of expenses incurred or paid by a director or officer in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or other person in connection with the securities being registered,
we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question of whether such indemnification is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In any underwriting
agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify,
under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act
of 1933, as amended, against certain liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0px"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Recent Sales
    of Unregistered Securities</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Set forth below
is information regarding shares of common stock, convertible notes and warrants issued, and options granted, by us within the
past three years that were not registered under the Securities Act. Also included is the consideration, if any, received by us
for such shares, convertible notes, warrants and options, and information relating to the section of the Securities Act, or rule
of the Securities and Exchange Commission, under which exemption from registration was claimed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Officer Purchases
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On October
28, 2021, we sold to two of our executive officers a total of 92,592 shares of our common stock at a purchase price of $2.70 per
share, which resulted in gross proceeds to us of $250,000.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Director
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On June 30,
2021, we issued 5,508 shares of our common stock to non-employee members of our board of directors for service as directors in
accordance with our Outside Director Compensation Plan (the Director Plan). On September 30, 2021, we issued 10,906 shares of
our common stock to non-employee members of our board of directors for service as directors in accordance with the Director Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between February
and May 2021, <span style="background-color: white">we issued </span>to accredited investors in a private placement (the 2021
Placement) $6,610,550 aggregate principal amount of our<span style="background-color: white"> 12% unsecured convertible promissory
notes, due 12 months from each respective issuance date, at par and warrants to purchase in the aggregate 2,285,736 shares of
our common stock at an exercise price of $8.00 per share, exercisable for a 5-year period, as provided in such warrants. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2020 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March
and December 2020, we sold to accredited investors in a private placement (the 2020 Placement) a total of 962,387 shares of our
common stock at a purchase price of $2.87 per share. The 2020 Placement resulted in gross proceeds to us of $2,762,054.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Other Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In 2019, we
issued 30,000 shares of our common stock for cash to a service provider, and, in 2021, we issued a total of 133,500 shares of
common stock to three service providers in exchange for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2018 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between November
2018 and March 2019, we sold to accredited investors in a private placement (the 2018 Placement) a total of 1,856,988 shares of
our common stock at a purchase price of $2.25 per share, resulting in gross proceeds to us of $4,142,666.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The above sales
of our securities were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation D
of the Securities Act. We made such determinations based upon representations by the purchasers of such securities including,
without limitation, that such purchasers were &#8220;accredited investors&#8221; as defined in the Securities Act.</span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0px"></td><td style="width: 72px; text-align: left"><span style="font-size: 10pt"><b>Item 16.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibits</span></b>.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Index to
Exhibits listing the exhibits required by Item 601 of Regulation S-K is located on the page immediately following the signature
page to this registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0px"></td><td style="width: 72px; text-align: left"><span style="font-size: 10pt"><b>Item 17.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Undertakings</span>.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The undersigned
registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 7.45pt 0 8.45pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
    include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the Securities Act);</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
    reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most
    recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
    set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
    (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low
    or high and of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
    to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum
    aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration
    Statement; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
    include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
    or any material change to such information in the Registration Statement; <i>provided</i>, <i>however</i>, that the information
    required to be included in a post-effective amendment by paragraphs (a)(1)(i), (a)(1) (ii) and (a)(1) (iii) above may be contained
    in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Exchange Act
    that are incorporated by reference in the Registration Statement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">That,
    for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
    time shall be deemed to be the initial bona-fide offering thereof.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
    at the termination of the offering.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">That,
    for the purpose of determining liability under the Securities Act to any purchaser:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as
    of the date the filed prospectus was deemed part of and included in the Registration Statement; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
    on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) (&#167;230.415(a)(1)(i), (vii), or
    (x)) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part
    of and included in this Registration Statement as of the earlier of the date such form of prospectus is first used after effectiveness
    or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B,
    for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a
    new effective date of this Registration Statement relating to the securities in this Registration Statement to which that
    prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
    thereof; provided, however, that no statement made in a registration statement or prospectus that is part of this Registration
    Statement or made in a document incorporated or deemed incorporated by reference into this Registration Statement or prospectus
    that is part of this Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective
    date, supersede, supplement or modify any statement that was made in this Registration Statement or prospectus that was part
    of this Registration Statement or made in any such document immediately prior to such effective date.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing
    of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable,
    each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated
    by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">That,
    for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
    of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
    pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser,
    if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
    will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24px"></td><td style="width: 24px; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24px"></td><td style="width: 24px; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">(ii)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned
    registrant or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant
of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0px; padding-top: 6pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; padding-top: 6pt"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">See the Exhibit
Index included immediately prior to the signature page to this registration statement, which is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    Statement Schedules.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">No financial
statement schedules are provided because the information called for is not required or is shown either in the financial statements
or notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0px"><span style="font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    17.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Undertakings</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">The undersigned
Registrant hereby undertakes that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">(a) For purposes
of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule
424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it
was declared effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-size: 10pt">(b) For the purpose
of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</span></p>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline">EXHIBIT
INDEX</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 92%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt"><span style="text-decoration: underline">No.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span style="text-decoration: underline">Description</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">1.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Form of Underwriting Agreement</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">2.1(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm">Reorganization
    and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other
    stockholders of Quasuras, Inc.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">2.2(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm">Addendum No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">3.1(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm">Second Amended and Restated Articles of
    Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">3.2(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041209000212/ex32amendedbylaws.htm">Amended Bylaws&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">4.1(5) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618000822/ex4_1.htm">2017 Equity Incentive Plan, as amended</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">5.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Opinion of Lucosky Brookman LLP</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.1(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041217000014/stockpurchaseagreementbearla.htm">Common Stock Purchase Agreement, dated
    as of April 5, 2017, by and among Bear Lake Recreation, Inc., Manchester Explorer, LP, a Delaware limited partnership, and
    certain persons named therein&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.2(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_2.htm">Form of Common Stock Purchase Agreement,
    dated as of July 24, 2017, by and between the Registrant and the purchaser named therein&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.3(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618001091/ex99_1.htm">Form
    of Common Stock Purchase Agreement dated as of November 19, 2018 among the Registrant and the Investors named
    therein</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.4(8) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm">Employment Agreement dated August 1, 2018,
    by and between the Registrant and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.5(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm">Intellectual Property Assignment Agreement
    dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.6(1) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm">Technology Royalty Agreement dated as of
    July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.7(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_7.htm">Service Agreement effective January 16,
    2019 between the Registrant and Liam Burns</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.8(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_8.htm">Standard Sublease Agreement, dated August
    21, 2017, between the Registrant and Western Education Corporation</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.9(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_9.htm">Lease between MCP Socal Industrial &#8211;
    Bernardo, LLC and the Registrant dated January 10, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.10(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_10.htm">Consulting Agreement between the Registrant
    and Liam Burns dated April 15, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.11(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_11.htm">Consulting Agreement between the Registrant
    and Liam Burns dated July 15, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.12(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_12.htm">Consulting Agreement between the Registrant
    and Liam Burns dated September 3, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.13(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_13.htm">Service Agreement effective December 31,
    2019 between the Registrant and Carmen Volkart</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.14(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_14.htm">Service Agreement effective January 23,
    2020 between the Registrant and William Febbo</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.15(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm">Form of Indemnification Agreement between
    the Registrant and each of its directors and officers used from January 23, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.16(9) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm">Form of Notice of Stock Option Grant and
    Stock Option Agreement under the Amended 2017 Equity Incentive Plan</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.17(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000268/ex10_17.htm">Form of Common Stock Purchase Agreement dated March 2020 by and between the Registrant and the Investors named therein</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.18(11) +</span>&#160;&#160;&#160;&#160;&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm">First Amendment to Employment Agreement
    between the Registrant and Paul DiPerna effective as of May 12, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.19(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000315/ex10_1.htm">U.S. Small Business Administration Paycheck
    Protection Program Note dated April 23, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.20(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000102/ex10_21.htm">Form of Promissory Note dated February 8, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.21(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm">Form
    of Convertible Promissory Note issued in the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.22(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm">Form
    of Common Stock Purchase Warrant issued in the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.23(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_23.htm">Form
    of Securities Purchase Agreement for the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.24(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm">Form of Registration Rights Agreement for the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.25(14) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/ex10_26.htm">Service Agreement effective May 18, 2021 between the Registrant and Ellen O&#8217;Connor Vos</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.26(15) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000475/ex10_27.htm">Employment Agreement between the Registrant and Ellen O&#8217;Connor Vos dated August 11, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">10.27(16)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm">Promissory Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></p>


</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">10.28(16)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_28.htm">Security Agreement dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></p>


</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">10.29(16)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_29.htm">Form of Common Stock Purchase Agreement between the Registrant and Investors dated October 28, 2021</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/modular_10k.htm">Sole Subsidiary of the Registrant (as disclosed in the Notes to Consolidated Financial Statements as of March 31, 2021 in the Registrant&#8217;s Annual Report on Form 10-K)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex23_1.htm">Consent
    of Farber Hass Hurley LLP</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">23.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Consent of Lucosky Brookman LLP (included in Exhibit 5.1)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed July 28, 2017, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed May 12, 2021, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed June 29, 2017, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Annual Report on Form 10-K/A for the year ended June 30, 2008, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Annual Report on Form 10-K filed June 29, 2018, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed April 5, 2017, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed November 20, 2018 and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(8)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Registration Statement on Form S-1, as amended, originally filed June 27, 2019, declared effective October 22, 2019
(Commission file No. 333-232377).</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(9)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(10)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Registration Statement on Form S-1, as amended, originally filed April 9, 2020, declared effective May 11, 2020 (Commission file
No. 333-237615).</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(11)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed May 27, 2020, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(12)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed May 12, 2020, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(13)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(14)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Annual Report on Form 10-K filed June 29, 2021, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(15)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed August 16, 2021, and incorporated herein by reference.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.3in; text-align: left"><span style="font-size: 10pt">(16)</span></td><td style="text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
Current Report on Form 8-K filed October 29, 2021, and incorporated herein by reference.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><span style="font-size: 10pt">*&#160;</span> <span style="font-size: 10pt">Filed herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><span style="font-size: 10pt">**&#160;</span> <span style="font-size: 10pt">To be filed by amendment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"><span style="font-size: 10pt">+</span> <span style="font-size: 10pt">Management contract, compensatory plan or arrangement.</span></p>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of San Diego, State of California, on November 2, 2021.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 47%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>MODULAR
    MEDICAL, INC.</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    </span><span style="font-size: 10pt">Ellen
                                         O&#8217;Connor Vos</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Ellen
                                         O&#8217;Connor Vos</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">Chief Executive
Officer (principal executive officer</span>)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>POWER OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ellen O&#8217;Connor
Vos, as his or her attorney-in-fact, with full power of substitution, in any and all capacities, to sign any and all amendments
to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering
covered by this Registration Statement under the Securities Act of 1933, and all post-effective amendments thereto, and to file
the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby
ratifying and confirming all that said attorney-in-fact or his substitute or substitutes may do or cause to be done by virtue
hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to
the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    </span><span style="font-size: 10pt"> <span style="font-family: Times New Roman, Times, Serif">Ellen O&#8217;Connor Vos</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Ellen
    O&#8217;Connor Vos</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(principal
    executive officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    </span><span style="font-size: 10pt">Paul DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">Chairman,
    President, Chief Financial Officer and (principal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Paul
    DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">financial
    officer and principal accounting officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:&#160;&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Liam Burns</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liam
    Burns</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    William J. Febbo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">William
    J. Febbo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Morgan C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Morgan
    C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">/s/
                                         Carmen Volkart</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Carmen
        Volkart</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">November
    2, 2021</span></td></tr>
</table>




    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>CONSENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We consent to the inclusion in this Registration Statement on Form S-1, as filed with the Securities and Exchange Commission, of our report dated June 29, 2021, with respect to the consolidated balance sheets of Modular Medical, Inc. as of March 31, 2021 and 2020 and the related consolidated statements of operations, stockholders&rsquo; equity/(deficit), and cash flows for the years then ended. Our report dated June 29, 2021, relating to those consolidated financial statements, includes an emphasis of matter paragraph relating to uncertainty as to Modular Medical, Inc.&rsquo;s ability to continue as a going concern. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Farber
Hass Hurley LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Chatsworth, California<BR>
November 2, 2021</FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>modular001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 9@#1 P$1  (1 0,1 ?_$ *0   (" P$!
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MRBF47$2I)YQR4<NJ4P(5PT2=(-_"K\TOC+ZE2+_>_H,XV[*S"\9Z5Z/1FN'
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M:]$A9'L7'@>^JM[&E"*D_P B>W>C)M+P$^]N?-JW[N:;!PZ\O%=;5 0M/NH
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F059J7E=7:)3,AG3ZO.0W]55LRY6E(I?1HGQX-?DW]4R^U2+9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>modular002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ E0"* P$1  (1 0,1 ?_$ +<   $% 0$!
M       #! 4&" $' @$!  ,! 0$               (#! $&!1   0," P(&
M#0D#"@<!     @$#!  %$1(&(1,Q(M(450=!43*3LU1TE#46-M8887&1<Z/3
MM-05@2,(H;%"4F*R,R5U%^&"DD-3@R0W$0 " 0$$!@D# P4  P       0(#
M$2$Q49&A$E(3!$%QL='A<M(S%6$R%($B!?#!\:(C@K(T_]H # ,!  (1 Q$
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MQN4E63ELM_I_@GIEGLEQN;YWB:Z^_$@#<WVW7&%>;9C.."]#<<B?NC<=0FR
M^Z1-BU%-I&F=*$Y/:>"MZ.BVZ[,Y&LFEHS=ND-QHQ.2X4ILHTF4)&X^L C$T
M473;0=]Q0+B*BJB89DQI:R*I4TD[%?%XOIV>O/J$'=/:%8B6M]%YSGB.R'2Y
MR("^;< GU \#4VR&4B B( [-FU=M=M9%T:*47]'TX_MM[;B*U7;M+-6TG[2T
MD>0T_%%122K^=N5#YP:8%P;EW]VBI_S;:[%NV\JYB%/9MC<[NG-6ZB7ZA/\
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M * * * * * * J_6;KF)H;1%TU+($7"AM818Y+@CLAQ<C+>S;@IJF;#@3%:
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MOC B!L,S&5$<)E5+CHO"F.%=A&;:O=_]Q)Q2=Q(S=8VZ-$."6G4<MM^GRH)
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MN8"Y=4VD;KIUB^'<[=&MLFYW I0L07M[&1K*C;2 .1M1) !-X18D9J1*O B
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MK7Z"CU%LT_Z,3ZZ1^(<K/4Q+8X$C4"1"EHO2^\CN-VYAA8TP;B*,@+:%* #
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1]3N.X_M\/]FM-W^I5?K/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>modular003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ S (& P$1  (1 0,1 ?_$ +T  0 " P$! 0
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M%6N.P@6/"K?$RL/;V7(Y6SGQ?GY\>9*5DT* JN\OZBV)_''OY'DZ M5 * 4
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MD )0A("4I2.   [ *-R1*#*H44!5=Y?U%L3^./?R/)T!:J 4 H!0"@% * 4
MH!0"@/G?5'<S\53&)87I2\GF2K=I1>P3\1K-S-VHI?I\N4H.+3W; ) %K <!
M:N9MHWI>=0;B_$>2DF8.^'FI3*DV<-AVIK2N,NTM6-SN,?*>?P/E%_\ 95UF
M-):HBHBT QR@CX+7JZB0;RM">TW/FJD@UKD6^B+4+)H7(4>T_)02:5O6[30A
MI7('D-_BH:@Y7<@T@D+<"2/(.)J2(.![,GB&A_F/$_@J25(BY.7=7PYFM5^R
M_P#NI)3D>EO<LK! (\G&WX:('-#6MR4V5DD_#6R0?6XXLPV/\(_%0&R@% 57
M9O\ 46^_XXS_ "/&4!:J 4 H!0"@% * 4 H!0% ZO-*Y6U9+06N0SN" &F@Z
MMIM96L]UP).E0X#Z256[1QIMRMZV.%_]EQG>_P 5T_<_OM^DQB]3\HK*1\7,
MPC4><G,#"Y5")I=2RMV-Z5'?85Z.CGMN-]NH-J2?(:MJU1'S*[OMQ7[? W>G
M:G.6E]MMUVF>U/+Q(YWJ5O67E]OPX&(@,*F9?(XO(LNSG5 G'MNGZMT1"0E6
MC7?1>X">PE0;2U0\GMN[^I6^W'I#;WH5RS5UJ_FMU+Z'C'/+/;/4S=,K'VR&
M,ANY?(YB=B\)%9EN):5Z$M[F\]PQKM(;1'/?"5J7^:GZ-+;6[;8^)V:GV4^E
M*/'$FYZ;[_LVM)=K7LY[5PGK9ZLS'9D#%C;SOKA_)OX6>SZ2T(\:6Q&,I/UQ
M <<;=:[Z5):OI[0%62;;:[JVX.UW5I\-VEK/,MWIF<G;A][!Y?7WEBVENJ1N
M+;;F31#1&GLO2HCT)3Q6T),-Y;"TA\-I46RMO@KEWM^3Y*QN^FQ7*LVJY=4$
MO4[;LG!4=G]3-V93;V$Y^+A2=RYX2Y,**F8XS']$C. +<>=]%4IHI+B6TH2A
MS5P)5VVW$I1]BVY]4HCF\<DJUPF1#<_;NM7:G=X*,<^"+)"W!$W?L;)2"P_"
M5HF09T7F*;=9?C%;+R$O,J2K@I/=6DCAQX5P_5*-K4L';J7MYG38G\32U570
M_;FG**7L'J*O;FQMJL[A@B/B7MO)F0\JT^7UN&%%2Z^V\P6T%M11=2-*UW\M
MCPKV_K'^;>OF58XJ5;WRTNN)PV4VK:_%<UU]3[H3J363WA.R,29M[/XE6*<S
M&(ES\4]$FK=ULLH3K0XXVB,MA] =22E!4GS+->/]5;&WN+YK%/+IQJJRCM^G
MNFZQQZ;W'U\)6%3BV9O3+8[:F#Q3.+9DEC:4?+Q'URU-<U3#;:%LN)##G+^E
M<+!7\0KU?K[]-^]=]BY=SU>*TNGB>?\ 35T6_;U=Z:\]2KX$K%ZJ)DY?"XU,
M*.P]EX$2>AJ3-2PZOTL]Y$-"V@F3R$@J=LM*APLDWX2[:B^^V?@<?MCAE-:]
MXLW=6W;?]I3R[)X]U"_5R.HH!0"@% * 4 H!0"@% 57>7]1;$_CCW\CR= 6J
M@% * 4 H!0"@% * 4 H#XKU665;J4D_D--@?\I56;T=+"M)R#J?(+<*Y2=-)
MUQ\LDK*7 0;=WB.WY:22#K3(:=X V5YZH@V!3B>PW\QI!EDE!S$Z,.:"KEI.
ME2^-@?,323+1:L?NUIU 2^#K'8H5I,PT2BLHV4A2?HGL-:DS!R/9=M/:OY$T
MD0<3F;OP;22?\7;\U9DWI.&9DW$ %]T-@]B>-_F%)+!P/9($_4@K\ZU\!\@J
M2-)R//NK2HJ4>SLO8542#5CT+7)2E *UG@$@$DT!:X>S,K)39[3&;5VE7>58
M^8#_ 'UI L^)VKBL: I#?.>'8\[91'Q>05HA,#LH!0"@*KLW^HM]_P <9_D>
M,H"U4 H!0"@% * 4 H!0"@(G<VV8.X8#<64Z]'7'?;EPY<=24NLR&3=MU&M+
MC9*3Y%H4D^4&I%5<L5[U#\&*--.J?TSYHAY'33%/8]#(R$YK))GMY9>;0MDS
M')C2.4'5A;2H]BUW- 9" GL2*U,.UJFF:?O3/.L]H=4TZZH\&FH[&OIQ.:+T
MDV_%DQY3$_))E1\G(RX>,G65/2T*;>;LM*DH;6EP_P"F$J\NJ]+'IB,K7;T;
M3\TG];&YZYG/3_2H\OV1"C(])\$&%H8G3X[Z,D[E\=+;=:YL*3(4M3OHX4TI
MLH67EZDNH7<&QX 6BE*V'\*T].#]N>-2W/4[I^:'U6?;3VDR<Z7P%/XJ2WF,
MBS+Q<US)N2$&(5RYCS996[)UQECBT2@):"$@'@!9-M6W0Z46EVQR;E\\:U(Z
MISFTWTP[B4V9L^/M7&2,>QD)>1;D2GYBG9OH_,#DE9<= ]'9CITJ<4I7$<+^
M:PJ75M5N24= ZW.[-D-&Z286' QL?'Y3)0Y>'<?7BLFVXPJ0PU)-W(Z0ZRXP
MMH]EG&E'@#?4+U$XB/LJWM2B)[LH\6+JS.=VKL;ET[WWQP++B-NXS%8?U3&2
MI49?-4^IQ1+CKDA2EO..*%KJ<6M2B1;MX6IN)7K2_AB.F M;3U3ZIF2!QG2O
M;<.(B#)=E93'QXCN-Q\*:M"FHL)](0XPT&D-%0*$A.MTK<MPU5;V[YU5NNQ>
M?'I7ARG MKTM-4AS'/CXOOH>1.F,%B&ZPO,9.4]Z$YC($R0N,MZ%$>TZVHYY
M 2J^A/?>2XO@+JJ;GKM:?S?$^,>&;PCR)9Z&HPMP62^K*<.\TL=)\8Q#Q<9O
M,Y1(Q>.=PP=#D9*WX+NFS3Q3' [FA.E;80KAQ)XWN\_Q'<W\Z4])KVU?*N!-
MM:(CY7*Y3BNRAM/2O!G%XK$*G9!S$8HQRU!>>0^EPQ%:V2MQYMQY&E8!^J6C
ML"?H\*T]QN_6\<?".WOQ<MF;;%;9I6#4>?3/I2(+9$CO,!T.RG91<<6X@NAH
M<M*C<-)Y2&^XCR:KJ\ZC6%@;S]O;G^RAOH!0"@% * 4 H!0"@% 57>7]1;$_
MCCW\CR= 6J@% * 4 H!0"@% * 4 H"N[KV5B]Q-)+Y+,ML'DR4=H\VH?E"C*
MF?(]R[-S6!?LZTJ5$78-RF$*4GC>^H"Y%K>6N-UIUMO*5N%G<1Y4C$)<6F,?
M^Y0VFX 40$J6/S3V<:].WIBIXM[7JH33#SR$I4KNN$)*T#B NW>37FNQ/;9.
MFIV,9%Q)XFWP'LH5HF8N6A);!+BFPI9;);/>(_.*>'=^ FD&(,7I3"'BJ.M0
M9OW2H@'Y;5)$'6SF0&M)6IPCR WM21I,QF3P*6P5>91N/FI(TF#N4G/  N:$
M'\AL!L?](%)+!J0KC<GCYR>-)$$MC-O9B?93$=0;)_U5]U-OEK:1ELM./Z?1
M['UB^7">QMDZ0/C4>)^85I(P63'X7%X].F''0T;6*P.\?C5VU8!V@6J@4 H!
M0"@*KLW^HM]_QQG^1XR@+50"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M[B\=YS]#@_=E /L;N+QWG/T.#]V4 ^QNXO'><_0X/W90#[&[B\=YS]#@_=E
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MMZI^(<'[$F>]J >K>J?B'!^Q)GO:@'JWJGXAP?L29[VH!ZMZI^(<'[$F>]J
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M2%((2X"PL]FH@I^>I!I7$N%)(N#<'L-9-GM * 4!5=F_U%OO^.,_R/&4!:J
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M1%$CLYA_).0H\C3RB4<XA&DJ2./<!U#C634DE'Q>XG .<]H2/+V#YZU U$Q
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MK:V(H7%94&FG19QMNZ>ZE8^DD<#5]Y9<SSGKQ[>9@WM]XY>/*D.QSCL;?U-
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MK7J</NX<NPKK/WL>?:>2-E[.DKC.2<%CGG(3BGX:W(C"RRZXH+6XT2@Z%*6
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M.8VE6FWFN.%4'0TPPT@(:;2V@=B4 ) ^04!E8"@/10"@% * 4!5=F_U%OO\
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MRZI^'L'[;F>Z: >LNJ?A[!^VYGNF@'K+JGX>P?MN9[IH!ZRZI^'L'[;F>Z:
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M![E[#MMPOM6/U9:&D^L_09=RA/[6'0G77F66RX\M+;:;:EK(2D7-A<FLE,Z
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M?7(CMQ[W@0(6^8V)WHMOD[=Q^3Q[R9[;S@F+YH7R.:7$MAX<@%#(2.^-(25
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MX=+SJZT<4*_MK,8W+JZ6YW,9N1*/+RC4N>F?(2%2FK.-H=Y#B$:RF^I!'%'
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MDDI)XI/ BG,9P>NS(C3[,=U]MM^02([2E)2MPI25*"$DW59(N;>2BJ&;: 4
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M8X3R#4J.G3@^*Y,D,]MO#9^,Q&RL<R&HS[<IBSCC2D/-$Z%I6TI"O*01>Q'
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ME1OIO14265N'MY<,B75;;SCPCZ*\<R;H!0"@% 57>7]1;$_CCW\CR= 6J@%
M* 4 H!0"@% * 6% 1^3P.)R:"B;$;>)%DND .)_X5CO)^0T)!4,ETSD:]>-G
M H_]B4"?F<0.'RH-!!0\QB9\&0XQD(ZF"DV"E \I8\A0Y8)/XZ%1#*QKJ H1
MG"VERVM [R#QN+BA&:G(&72V>0ZPA?8IQ:5K(XW[H&GC\M*E4%OV5FUD.1Y,
MQOE(%D!YP)5J'#AJ(-JJ,M%GE#+2'0,?+CM1R!=RQ==^$) .C\-9NDS!K1M7
M&*<YLT.Y!T\2N2HK1?X&^"1\U95LXB"1YV/AM!LN,QFTCNHNA  ^!/"NU"01
MS^Z8H6&X<=Z8K\]M.A ^-:O)\0J@UF;FI!X*;BMGR)NM?R*5P_Z:0#3ZI9<.
MJ2MR2H]O-45#YC6M)F3N::;;1I0@( _)2+#\ J04*<:0 5J2D<>*B!^.DA'3
M AY">3Z*P="?_6>NVW_ENDJ5\U1LJM)6+M):K^L)!6#_ .E'NT/E7?6?DM6&
MS:M)J'BL?#%HT=#1'Y8 *C\:CWC\M234'5:U >T H!0% QVY(FW]T[Q:R4'*
M_P#>Y5B5$=BXG)S67&?5$!C4EZ+'>:-G65I(U7!% 2OWE[=_8\Y_;^<_<J ?
M>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]O
MYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W
M?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W
M*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\
MY_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?
M>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]O
MYS]RH!]Y>W?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W
M?V/.?V_G/W*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH!]Y>W?V/.?V_G/W
M*@'WE[=_8\Y_;^<_<J ?>7MW]CSG]OYS]RH"*R.Y(FX-T[.:QL'*_P#995^5
M+=E8G)PF6V?5$]C4IZ5'9:%W7D) U7)- 7^@% * 4 H!0"@% * 4 H!:@,'&
M6W$*;<2%MK%E(4+@CRW!H"J9KIQB)8YF/4,:^+E7+0%-*O\ G-W2!_EM0%7G
M;-RV/*>;']*9(/U\4*7:WYS=@M/R:JJ(<#6.Q,NZ1RGBDZ5IX%0/F([4GXZT
M1F0VKB@=26N63Y4$H_%2#,F]O;T("RE.K'D!<7_OHD23JCX6 R>XRD'MN1<G
MY3>K DZT-I3V#Y*I#(J"!=?=2/*2+4!FPA^4D&&PY)![%(%D?I%61^&CN*K2
M79VGD'RDR928[?E;:',7;_Y%]T?\M8U&])-PL#BX:@XTPDO@6+Z^^X?C4JY^
M:I)4D=X38WO4*>T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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A"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>modular004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ KP"^ P$1  (1 0,1 ?_$ *H  0 #  ,!
M       $!08" P<! 0$  P$!                 0(#! 40  $# P($ @0(
M"@8)!0    (! P0 $042!B$Q$P<B%$%1<3)AD4(CLW46-H&AL5)B<C/4%5;1
M@G15-PCPDM)#4Y,DE1BBLG.#%Q$!  (! @()! (" P$       $"$1(#(3%!
M46%QP2(R$P2!0C,4D:&Q4O#A8I+_V@ , P$  A$#$0 _ /2)^%[@#D9;<5)W
ME(\IS!Q21TU$X.5<)YR?[W%8:.- )<TT%:@M861[ER)C$,?,16CE(WD'3AAI
MB@#CNEN,9\'VS: +NKJM=.-UTH%.NY^\GDP0(K_4%UW5+.$2(;G3;5IE&$9Z
M@M:U-#)4MPLCR^]0>QAJT#J1$*R:D3E?TT$#.9R'AX@2)(N.JZZ$>/'9'6ZZ
M\XMA !X)=>?%42U! >WIB@Q&/R;+4F4WDWO+Q8[+2J^KR"9&! 2CI4.B:%?D
MJ4$S<>?BX';\W-RVW#C0&2D/-MHBN*(I=41%5$O^&@LTY4"@4"@4"@4"@4"@
M4"@4"@4"@4"@SDS=,EC>,3"C#<. ZR9/S4%; [J%!3]5-2(2^LD^&L)W9B\5
MQP9S?S8:.MVA05NXL.&7Q#T$@8,STDR4D"=;!P"0A/2!-E<52Z6)./IH,[)V
M []DPVM&<B%CFP!IEV7')YYM5$T>?%4<!.LIGK DMIXT%9WBVIAG=A9;)R1=
M>R&-QIMQY)/O#P!+W-L#%LUNMU4A6@]&;(3 2!4(21%$D6Z*GP*E!]H% H%
MH% H% H% H.+SS3+1O/&+;3:*1N&J"(BG%555Y)011S.((E$9T<E1&R5$=!?
M"\J(VO/D:KX?7Z*#G_%,9TI#WFV>E%)0E.=0=+1#[R.+>PJGPT'P<MBC-0":
MP1BK:**.@JHKW[)+7^7\GU^B@^CD\<;)O#*9)EMSHN.(X*B+FI T*M[(6HD2
MWKH)-!1R?OK ^KI?TT>LI_)'=/@I/JA>5JN4"@4&/[P"A=L-S"7NE =1?8J6
MH.>RY#V.F3=KRBU'"7JP37Y<<^*6_5O6E^,9</Q9FEIVYZ.7<UM9NXH% H%
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MO.&(T$K[=YG^2\Y\4#][H'V[S/\ )><^*!^]T$6)W-E3'Y;$;:&;=>@.I'F
MB045MU6P=05O*_X;@EP]=!*^W>9_DO.?% _>Z"+D.YLK',@]-VAFV6G'FHX$
MHP5N[(<1IH>$I?>,T&@N(^Z,B]B94\MMY-EZ,0"WCG/*>8>0E1%)K3()NPWN
MNHTY4&@H% H% H% H,;OK-Q(U\=F\6DO".LN34<:?7K*>-$9ER900L*&V(H7
M4]Y414LM!<[=S\G)N3XLZ&D'(XYT&Y# .]<+.M"\V0N:6[^$[+X>:+Z.-!-S
M,\\?BI<X !Q8K1/*#ADV.D$U%<A!TDL*+R%:##8O>T-E5S4;#""95O'SMP2
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EUC8K3[<D6F!$GV20VS/F:@2<%'5>U5M/%>D8A;U"Q0*!0*#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>modular004a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular004a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!=@)P P$1  (1 0,1 ?_$ *\  0 " @,!
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M_P#\Q&JBWKK&6V-;Y/-R@3Y5DV5L=5STG>#*Z2DFRR>&=N4,=&MUUU&5,O\
MG2?6BY[$7E7E XY8S*9<ASW(4?EV5NBCIDGSW+G7J*>^Y4C2:Q6JUSKMDC5?
MY'?Q <X,ZR"+NQ5T<V346ZCS*&CF2BFW>5S32M1S973(B61M3D>UR+R\G*!A
MGRPM[K=_Z:%::*CA6C<RGRR5TM-&Y[6[Q855K.5RI:MU/*!G*1G=:+O91IW1
MDC?%-EU8_.UIWJ]',NMW#JCE7_-WEO\ '];R@8JR2?*.XU-53TD&429:YR+F
M+'24;ZE&,N-D:CXVWKEJLO+9S<H%^[@4#:')9H(\Q@S&#%2O@=2(J4\+76+N
M(K7R_58MO][S@:]I^[>3_DW(LU:Q[,SJLX93R5[)'MFW,U:^%\3'HMK6*SDN
MIR?_ *!G)8\E[L9CWNIH*-R9-%E])4R993/6-JR2NDC>YJHJ7+R-2^Y.:T#'
MY))2Q=XLZIZ*/+Z6FDR&666DRN=9X;Z/L:^7ZK&;Q&K9:GF GFR/+,O\*:*K
MHH6LKJZ/*7U-5):Y\K]]"K-XY>5S6J[D3S)R(!CLPD>E!AJZ1E/G#LW8SO=/
M67GPN8K7K3.<C71K@W_51B6HU/([S@=C-<ARV'NAWBDQF79A2-DI*AM'E\=E
M-2.:]$ED:W>375DCM5UE@&S\D3)DRR!,E6!<ML7#K2JU8;+5MNJSZOE [P
M                           ".J]VE]1W0 I?=HO4;T 2
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MR^F21*>EBA27_P N[8UE[UK$2T#[%E]!#3NIHJ:*.F?;?@:QK6+;Y;6HEG*
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MH,TA6>B>^2%++)'12QM<B^16K(UEY/VH!W0
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M32W4 P[N-)I;J 8=W&DTMU ,.[C2:6Z@&'=QI-+=0##NXTFENH!AW<:32W4
MP[N-)I;J 8=W&DTMU ,.[C2:6Z@&'=QI-+=0##NXTFENH!AW<:32W4 P[N-)
MI;J 8=W&DTMU <F0N:Y%65[OV.LL^A %5[M+ZCN@!2^[1>HWH D
M
M                   $=5[M+ZCN@!2^[1>HWH D
M
M        $=5[M+ZCN@!2^[1>HWH D    &.RO/J#,ZNOIJ6^KLOD2*9[FV,<
MYR6VQK_>1.5+><#(@
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M(:&LJ51T\\+7R*U+J*Y?+8AIN4Q)KPJ:I]<PRW.848>+533ZHEDB0C
M    !'5>[2^H[H 4ONT7J-Z )   #A41++!)$U[HG2-5J2,LO-54LO-MMY4
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M PD/I;;]8#"0^EMOU@<F4\3'7FVV_M<Y>E0%5[M+ZCN@!2^[1>HWH D
M                                                      -,>(_S
M?6>I#]VAC]6\15LZFTT?PU.WK5HKEF              WEW+^5,K_#LZ#:Z?
MD4=UA=1\17WF:)B$          $=5[M+ZCN@!2^[1>HWH D
M                                              -,^(_SA6>I#]VA
MC]6\15LZFTT?PU.WK5DKEF              WGW+^5,K_#LZ#:Z?D4=#"ZCX
MBOO,R3$(          (ZKW:7U'= "E]VB]1O0!(  X3R.CADD:V^YC5<C+4;
M:J);9:O(G_Z!B\BS_P#W2EJIEA:Q:5ZL5T,J3PR6,1]L<K4:COXK%Y.10/G=
MCO [/*'&;N&)BW5:R*H;.Y+R6W9$:UMQR=4#, ?+S>= %YO.@"\WG0!>;SH
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M!AJ;A,V4 86FX3-E /K8(&.O-C:UR>141$4#Y5>[2^H[H 4ONT7J-Z )
M              !JWQ;_ .8H/P[O\9F=<S*>CWM5H&75WO<HI2+T
M     !MWPL^5OYB7^PU>C9'S2R&N9_RPMY;*<                      T
MSXC_ #A6>I#]VAC]6\15LZFTT?PU.WK5DKEF              WGW,^5,K_#
MLZ#:Z?D4=UA=1\17WF9)B$          $=5[M+ZCN@!2^[1>HWH D
M           &K?%O_F*#\.[_ !F9US,I[OO:K0,NKO>Y12D7H
M  #;OA9\K?S$O]AJ]&R/FED-<S_EA;RV4X                     !ICQ'
M^;ZSU(?NT,?JWB*MG4VFC^&IV]:M%<LP    =>"NAFG= C7LD:V^B2,5MYMM
MEYMOE2TZ5X4TQ;Z+'*C&BJ;/3;^K@W-*1TKHDOJJ7T:Y&+=>L?\ &UB_WE0]
M3@566^CV?^^JUYCF*9FST^WV>NSUV)::KBJ$>K$>QT;KDC)&W7-=8BV*G[E/
M&)AS39;[7O#Q8KML]EZ8\.@    -Y=R_E3*_P[.@VNGY%'=874?$5]YFB8A
M         !'5>[2^H[H 4ONT7J-Z )    ZVQ;J6KYD7D2T#!=W<[KJ^LKZ6
MK2*]2+&K'Q,EB54?>M18YK'_ %;O(^RZ[S>0#.^0"+%TO%9I0!BZ7BLTH Q=
M+Q6:4 8NEXK-* ,72\5FE &+I>*S2@#%TO%9I0!BZ7BLTH Q=+Q6:4 8NEXK
M-* :P\6)8Y,WH58Y'(E.ZU46W^^9G7,RGN^]JM RZN][E'*1>@
M   -L^&$\$?=BZ][6KB)>15LYC5Z-D?-+(:YXCY86[%TO%9I0ME.8NEXK-*
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M-LC[[((U5S6)8B*B.<B*MJI;Y#GCXD5S'MLCUWNN!A31$^RV?5'L=PX.X
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M:K"DKI7.>J.57O\ JLN7?X;+5MM\P%H@=>@C=?WMK6KO4L2]:G\7)S@<P
M           -6^+?_,4'X=W^,S.N9E/=][5:!EU=[W**4B]
M ;=\+/E;^8E_L-7HV1\TLAKF?\L+>6RG                      -,>(_S
MA6>I#]VAC]6\15LZFTT?PU.WK5HKEF              WEW+^5,K_#L-KI^1
M1W6%U'Q%?>9HF(0          1U7NTOJ.Z %+[M%ZC>@"0"@MILZ<B-KLMS&
MJ<L,RSWGQ/9C%>FYEB1TUC+K;;+J(B<P%URM*I,MI$K+<6D,:5%MEN\N)?ML
MY/X@.R              !JWQ;_YB@_#N_P 9F=<S*>[[VJT#+J[WN44I%Z
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M4[>M6BN68             #>7<OY4RO\.PVNGY%'=874?$5]YFB8A
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MQ$1]U67DL3D6ZY4_<!+0Y9EV7QNCH:6*E8];SFPL:Q%7G6ZB =D
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M*O[ .R              !JWQ;_YB@_#N_P 9F=<S*>[[VJT#+J[WN44I%Z
M            V[X6?*W\Q+_8:O1LCYI9#7,_Y86\ME.
M     :8\1_G"L]2'[M#'ZMXBK9U-IH_AJ=O6K17+,             !O+N7\
MJ97^'8;73\BCNL+J/B*^\S1,0@          CJO=I?4=T *7W:+U&] $@%'[
MT?[=6]Y)<NS"IH:.!M(R2RM?*[?7GJEF[;/!'=99RWD55MY@+I3(U*>)&N:Y
MJ,;==&EC%2SRM1%6Q.;E D               U;XM_\ ,4'X=W^,S.N9E/=]
M[5:!EU=[W**4B]              ;=\+/E;^8E_L-7HV1\TLAKF?\L+>6RG
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M45/-S&DTK"KHP;*HFF;9]<6,MK&)37CVTS%461ZO2N)9*H
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MO+A!              >@? WY&_FY^E#-:MG;(6_)9>UL$K$L
M          \X^,7_ &%F/^G3_<M-3IF1&WK4W-YDJ63T8             !Z
M?\./D3(_PD?09'G<ZKI7G+Y<="QD5V          ".J]VE]1W0 I?=HO4;T
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M]#M8"RLZT>AVL!96=:/0[6 LK.M'H=K Y,2HO?75BM\]U%1?I4!5>[2^H[H
M4ONT7J-Z )                  !HWQ^^8<J_"/^]-#H_P5=*KY_P"*.AJ\
MMT$             !Z!\#?D9/Q<_2AFM6SMD+?DLO:V"5B6
M         ><?&+_L+,?].G^Y::G3,B-O6IN;S)4LGHP             #T_X
M<?(F1_A(^@R/.YU72O.7RXZ%C(KL          $=5[M+ZCN@!2^[1>HWH D
M                 &C?'[YARK\(_P"]-#H_P5=*KY_XHZ&KRW00
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MQV>     >@? WY&3\7/TH9K5L[9"WY++VM@E8E@
M'G'QB_["S'_3I_N6FITS(C;UJ;F\R5+)Z,              ]/\ AQ\B9'^$
MCZ#(\]G5=*\Y?+CH6,BNP          1U7NTOJ.Z %+[M%ZC>@"0
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M)M* PJ<63:4#SMXOMN^(&8-M5;(Z?E5;5_\ "TU.F9$;>M3<WF2IA/1@
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MM3<WF2I9/1@             'I_PX^1,C_"1]!D>=SJNE><OEQT+&178
M      (ZKW:7U'= "E]VB]1O0!(                  -&^/WS#E?X1_P!Z
M:'1_@JZ57S_Q1T-7EN@@             /0/@;\C?S<_2AFM6SMD+?DLO:V"
M5B6                      ><?&+_L+,?].G^Y::G3,B-O6IN;S)4LGHP
M            #T_X<?(F1_A(^@R/.YU72O.7RXZ%C(KL          $=5[M+
MZCN@!2^[1>HWH D   .$TT4$,DTKKD435?(Y?(C6I:JZ ,;D_>&',IEAPTU+
M*L+*J%LUS_,@E549(EQS[/)RM=8J 94            -&^/[FIWARJU43_Y'
M_>FAT?X*NE5\_P#%'0U=?9UDTEO8@VE]G632+"TOLZR:186E]G632+"TOLZR
M:186E]G632+"TOLZR:186E]G632+"TOLZR:186E]G632+"TOLZR:186E]G63
M2+"TOLZR:186O0/@8J+W&M1;?_KGZ4,UJV=LA;<EE[6PBL3
M         #SAXQ.:GB%F**J(N[I_N6FITR/_ (1MZU-SF9*EWV=9-)/L1B^S
MK)I%@7V=9-(L"^SK)I%@7V=9-(L"^SK)I%@7V=9-(L"^SK)I%@7V=9-(L"^S
MK)I%@7V=9-(L"^SK)I%@7V=9-(L'I_PWY>XF1_A(^@R//9U72O.7RXZ%D(KL
M          $=5[M+ZCN@!2^[1>HWH D   (JRECJZ2>EEMW<\;HGV>6Z]JM7
MI Q619%644Z5%;4,GEBIHZ*GW3%C:D,2JMYR.<_Z[E7ELY.0#- 0X.FZB:5
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MH#!TW432H#!TW4^E0.3*:!CD<UMCD\B\H"J]VE]1W0 I?=HO4;T 2
M                  "K5/>7.*2KJ:&:.FEJ;U+'321;S=QRU<BL;'-:MJJU
MJ7^2RU/,@'&I[R9Y#E<]5NZ7?9?4.IJN-=Y_GO1S48V!$5;JR->EEZ]R\G[0
M,G3YOF#^\]1E<U,R*D92MJ*>:_>D>JON.O-1+&IS<MH&8
M                     X3[[<OW"-6:ZN[1ZJC;WFO*B*M@%7B[RYW-,W+8
MVTKLP?534\=79)AG,IXDDD<C;U^\USMVJ7O+;^X"6'O+FDS,GJFQ0)39D]D+
MZ6UZSH]4=O'L<GU;L:MM7D\GG0#MY;F&=R9]4T%4ZFEIZ:%LDLL#)&.9)([_
M "XUO/>B_417+_\ G.!FP                 !'5>[2^H[H 4ONT7J-Z )
M                        !@*?N;10TDU+C*N6.:3$(Z21BO9.CTD29KT8
MCKZ.1.5RKR<@'U_<ZB5U-(RKJXI:9\LR2->Q5?--_'*]',<U7V<B*B<B<B =
MMN0QIG?^[XNH6?=[G<JYFZW=MMV[<M_BY?*!DP
M             (JRF2II9J=9'Q),QS%EB=<D;>2RUCO,J>90,-#W/HX:.FIH
MZRJ:M&ZVCG:Z-LD2*U6.:U6QHU4<B\MY%YP.=/W3H::O@K*6HJ(,/"RGC@:]
MJQ)$Q;5:B/:Y4OK_ !JBVN R-#EM-1.J7PWE?5S.J)WO6U5>Y$30UK41$Y@.
MT                  (ZKW:7U'= "E]VB]1O0!(
M
M        (ZKW:7U'= "E]VB]1O0!(
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MV_W55+4_8!D                                      ".J]VE]1W0
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M7X>33'V@&_E^'DTQ]H!OY?AY-,?: ;^7X>33'V@&_E^'DTQ]H!OY?AY-,?:
M;^7X>33'V@&_E^'DTQ]H!OY?AY-,?: ;^7X>33'V@&_E^'DTQ]H!OY?AY-,?
M: ;^7X>33'V@&_E^'DTQ]H!OY?AY-,?: ;^7X>33'V@&_E^'DTQ]H!OY?AY-
M,?: ;^7X>33'V@&_E^'DTQ]H!OY?AY-,?: ;^7X>33'V@&_E^'DTQ]H!OY?A
MY-,?: ;^7X>33'V@&_E^'DTQ]H!OY?AY-,?: ;^7X>33'V@&_E^'DTQ]H!OY
B?AY-,?: ;^7X>33'V@(ZB:1:>5%@>B*QW*JLL3D_8X#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>modular005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular005.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!#P'T P$1  (1 0,1 ?_$ +8  0 " P$! 0
M       #!0($!@$'" $! 0$! 0$!              $" P0%!A   @(! @,$
M!08* PP)! ,  0(  P01!2$2!C%!$P=187$B,H&1T4(C%*&Q4F)R@I(S%1;!
ML@CAHM)#4W.S)'24559CD],T1#4V%S>#5+1U)288$0$!  (! P,!!P0" @,
M     1$" R$Q$D%1$P1A<:$R4A0%\(&1%;%"P>'Q(C/_V@ , P$  A$#$0 _
M /U3 0$! 0$! 0$! 0$! 0$! 0$! 0$! U,G.<7?=<2OQLK0%@3HE8/8UC<>
MWN XG\,LC-V](P&VV6\<S*LN)[4K)IK'L"$-^TQC)X^[T;+MX.JHZ-^4MMBG
MYPT>5/",31N.+[V/:<NH=N/<0'T_,M&G']/YQ'1,6-G$RZ<JKQ*B>!*NC#1D
M8=JL.XB+&I<II%(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @("!X64=I$#PVU#M=1\H@RQ.1CCMM0?K"$R\.9B#_'U_M#Z9<&8R2^E
M_@L5O809#+.%(" @(" @(" @:^?DMCXS.BAK6(2E#V&QSRJ#ZM3Q]4LB;7$>
MX6(N+0*P>>QB7NM/Q.Y^)C[?P=D6DF$SNB*7=@JKQ+$Z 2*K+-^HY]*:VM ^
MO\(^37C)E<)J-WQ[" X-1/>>*_/&3#'- Q<A-PKX(Q6O, [&0G17]J$]OY.O
MJFIUZ.>W2Y6$C9 0$! 0$! 0$! 0$! 0$! K<KJ7IS$R&Q\K=</'R$X-3;D5
M(X/K5F!@8?S9TK_QG!_WFG_"@/YLZ5_XS@_[S3_A0,J.J.F<B]<>C=\*V]SR
MI4F14SL3W!0VI@6<! 0$! 0$! 0$! 0$! 0.0.Z;B?\ Q#_/.N(\WG6)W'//
M_B+/VC&(>5>'.S3VWV?M'Z8P>58G*R3VW.?UF^F,)FL3=<>VQC^L8,L2[GM8
M_.91YJ80T@-! 0$#8HW#-H_=W,!^23J/F,F&IM8M<3J3L7*K_P#J)_2LS=72
M<GNN:;Z;T%E3AT/>)ATERSA2 @0_?</[V</QD^]!!9X!8<_(Q(#<O;I[IEPG
ME,X32*0(QE8QR/NPM0Y 7G-((YPNH',5[=.,83,SAK9OO9^!6?A#V6?*M94?
MUY9V2]X]W7=,?;<877<>=A76@^LQ!.GS"2M*&[*OSF#VOS(.*U+\(^F9RN$@
M5.4:+H85H;GNM6(G(OOWMP2M>))/9(.FHQ[7V)*,H:6OC\EP/<2FA$W&-NL;
M&!:UN#C6M\5E2,WM909::WHGD4@(" @(" @(" @(" @('/\ F'N&9MO0G4.?
MA6FG,QMOR;,>Y?B2Q:F*N/6IXB!HCRI\O7V!]F;8L-L>_';'MO:FMLEA8A5[
M#>RFPVG7FYR>;7C ^5'^Q3Y:Z\-WW@#T>)C?]A \_P#\4^6W_&-X_P"LQO\
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M! 0$! 0$! 0-&L>-NUSGBN(BU5^I[/?<_L\DOHS.M;.3E48U?B7.$7N])/H
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MYSS$Z+PU[>/9,W29Z>S<YK)UF;G'1V0[)R>D@(" @(" @(" @(" @(" @("
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M!@"1ZB#"I*WI9K%K*DUMRV ?58@-H?7HP,#. @("!$N7C-D'&%JF]=2U6OO
M *3P]CK\\#-[JD>M'8*]I*UJ3Q8@%B!\@)@90$! 0$! 0$! 0$! 0$! 0$!
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MN/=B.U2+B8]%UJ-4:U-3L;38CJ78<CGDY>^ :SJ_+Z76['/+NN2_,FG*GAU
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M#Z;TJ7;;VM8:+8Y*_( # U=#_-NO^+\73U>+]UU_J3?_ %<?^_\ 7LZ.8=B
M@(" @(" @(" @(" @(" @("!A9339^\17_2 /XX3" [7MQ.IQT^;27-3QCT;
M9MX_\.GS",T\8R&!@CLQZ_V1&5\8R&'B#LHK_9'T1DQ'HQ\<=E2#]429,,A5
M6.Q%'R"%PR"J.P" @>,JL-& (/:# K<W8L6\%J0*;?5\)]H^B:FS&W'*YW(Q
M[<>TU6KRNO=_2)N5PLPCE1G5:4YAH"KJ593V>KYCQD65Y96U;LCC1E.A$I8Q
M!(((.A'$&$=AMN6,K$2WZ_PV#\X=LY68>G6YC9D:(" @(" @("!J;N2-IS2#
MH11;H1P/P&6=V.3\M^Y\BV?S#ZFV^I*S<N94H&BY +-II^6"&^>=[I*^+Q_6
M\FL]UZGFONK4M8-J1@GQV*[E%U]/NG3YYCXWHG\AMC\JIW+S*ZES%*5/7A(>
M!\!??_;8D_--3CCCO]=R;=NCO]LJRLGI/:LFHFS.QZJLBHLW%W"Z,I8_Y1&9
M=?7K.=[U]/BS>/6^JHZV\O\ 9^N]GLNQLI]OS\FAJ!FUJK'3L-=U;=O(W#N9
M3WS/:N\LL<1A]'>8VPWK1_#SETHJJ,G"N1TL(&G-X=QK=-?1Q]LQ8UEW_2_2
M.4'3<=['^LCC5ADA^0^FQA[I;U#@/7+(9=@S*JEF(55&I)X  2HX_I+KGIGJ
M/?\ <QA9B/EXS?=L>AO=+T5\6NJU^-7<GB.X"==^.ZR9>;BY]=]KBNP5T<:H
MP8:D:@Z\0="/D,Y/2K,RQ<'=J<MR%Q\T+B7,> %H8F@_K<S)[2LU.L8MQ<^Z
M;==LQMPI\*]"=/A=2 PU]LRVXO+\I]IR;2]@9M3^2@/],#;VKRQV3 L#I4QT
M[06 U_94?C@=:UF/@8;66\M.-CIJ=!P"CN B1+<3*M^XYO\ "_OGAG^)>/\
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MG/:._'<Q:3+H0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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9^'\#," RGLT)[9SV>C2]%C,MD! 0$#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>modular006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular006.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ F@"+ P$1  (1 0,1 ?_$ )8   (" P$
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M(_ZPV_)^'U^37F]';_?_ !<O\-=GU[_3E^S/[7<S7W^5>7:]0C(QMH;_ !I
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MV!6Y%B;T B\45F8H7.Z@$#Q#4&@4E))F2,3Z2(>TZ_LJ<!A,/+E:SR\B_P"
M48-8X?1\5'#2HLYVM(Q?7MY12R,+/'Z?TJX'T:V-]4+)MK]]+(\5WT['Z7'X
MA@<Y O:21R"/E1D86WU&)S?Y"#S6MR#R\OE_MK0,-7=QR$J;D,-][=E;H33(
M#CEM<KH"=J \RQR1L#?F)T<_>:D\D98\?D]-F(;6Q' ]U+!K+VA::7-PD8J,
ME<B!7^+0D_&UB@I2#92I!&,('TRK1$ L>)V/WTS3PH8Q(#J&=;\^VM I3DB6
M1C(C.;GD(.QW%13@BIS1,18@-X:J%1(XF)-R%!'W_*F0Z1$1J?3]4C?6WVT
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2_+\=_P .^]!0C^/\7]EH-__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>modular007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular007.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ C@"7 P$1  (1 0,1 ?_$ )0   $$ P$!
M      ,"! 4&  $(!PD!  ,! 0$!               ! @,$!080  (! P,!
M!04& P8%!0    $" P 1!"$2!3%!42(3!F%Q@3('D:&Q0B,4P5((8G*2HK)#
M,U.CLS0D9!5U%Q$! 0 " @,  P # 0        $1 B$#,1($05$383(4(O_:
M  P# 0 "$0,1 #\ ZIH#* 9<UF#"XK*RC_LQLP]]M/OK/MVQK5]<SM'CR BY
M8W8ZD]Y.MZ\/;;+V)Q2'/?0HW8]:FK@3&W6G#)+JRD4P'8 Z4!OVT -R;Z4
MVGC)UI QG4A2*J:Y5-L +Q>=*;B(HNEF?2]^Z^M7_,7LA1X3D"5"[#N-OF-.
M=:/Z0TRL#.Q3^O&0@O\ J"Q733J*?\U:[P(5-X:22E!;]:0+$8L103JZO=?-
M,H"L_4#(*<$(0?\ R)D0CO \9_TUQ?9M9JZ?EUSL\[0$WKRL1Z8,JU1FSC2I
MIY".E[TXJ4-AIIVTS8%L* R@$'K0 9%T)[ +TADXQ,"-#OD'ZK6Z_E'4@#OK
MJTUF&'9O1C&'5G9K@E=  02=/Q%:,0)6B@=E>_6VB]2.@O1[0YI:07C>,,&\
M+:%#UUO<$'II[ZK,I265!<K@ICE9X5"0N;&*^H/>/97/VZNKJWR9 ]]9N@0,
M-M!.K:]U\TPFE0I7U'D(AX].PR.Q^"@?QKA^V\2.SXYS:I8.MJ\YZ. I;:WH
M!LP%JF@W<FB*U#OK3RHJ_=3#1'?0&B!01$$?F92I;P W;X=OVU?7KFI[+P/C
M,^5RLV/M+1)$QC!#$7) N2.MJZ,_AS[)./$SX=CA(FF;4AA9E4=+;;ZUIAE[
MQ$^HES!EM,RS) FT*R(-K7%SK?4^ZLM]>6_7MP!EXTF-B).9B\<ORBP7:"-X
M!-[FVHIS@K<TSR_+DQI$NK%D96]FFX:@=:>_@^N7*!1]RK[JYG:(#X;4!U?7
MNOFFCUI4*/\ 4G3_ ..'ME_!:X/N=WQ?E3[BVE>>[P);F] -VTJ: FMVT*D(
M(O[J%-*+&J#&H!)^7VT%^1>+(?->- 3(T9(4"]@&&IK;I9]MX+BC>#EFCCDW
M9.2C",*QC1;$&Q8!B3IV"M9.7/M>#V18,>SDAC+H;22&Y7J +]E7EG-4'SN3
MD%HPH+J44QQ?*2W3QOJ?A66];Z:@'?\ MHVE8-:P2+J 50EV+7-]=*<O"IY-
M)G\N-]QLI1M%[.W4^VGOX/3RAX[V KG=6!+'OH-UA7NOFFCUI4*+]3& ;C#W
M-+^"UP?=^'=\7Y4V^O6O/=X;M>] -I&(M4U< 9KG2@V@Y[Z U<WZTPTQ(UZT
MP%*96E6",7F:Y6_0*/F8V[J)"M;3//'RJ<8;Q&P:8GK+V&_\*O3;%1MKF#9,
MWG30YD!W%&5K6^96-M:WERQNN!1.XG<[;1]CEA:R];+[*>$!3P2Y21*L5O+/
MSEQ9@2;'P[C1A4IFV-+H-X+$BQ&@"]MKWIS4Y49R\@0#&#>)K%UM:RBY'VGL
MK/:X;=6J-&@O63I*W&@.L:]U\RT:5#SWZI2;9N,3LM(?]->?]UYCN^'Q50#B
MPL*\[+T I7"CWT9$-996[M.^FL R:T GS%U[Z SS:8R4\UD).EA>]$%)CW1X
M?G-<39?C/>D5_ /CU-.W"*:.-*2X;Q32XDA:$ @]8VZ5KKL+I*>IR^*1XPT3
MZ7N 1?H+&M?Z,/Y4IN6XU02\HV@$ :C\/N[?;1_2%_*FF9ST)3R\.-F<=)I
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..4)#(QM-3;L^:WX4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>modular008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular008.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 9 "J P$1  (1 0,1 ?_$ )H   (" P$!
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M>^_N)S!:QV> Q^378(62"T[WMKX*_M[JMI2W&G6GFTN-+"VU:I4DW!HC*@*
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B!0% 4!0% 4!0%!XKIYT&O\F_*]%;$]/*B/: H"@* H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>modular009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular009.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!10*S P$1  (1 0,1 ?_$ ,T  0 " P$! 0$
M       $!0(#!@$(!PD! 0$! 0$! 0             " 0,$!080  $# @0!
M!P0*#@D$ 0(' 0(! P0 !1$2$P8A,5'1(E(4!T&1DM1AH3)"(U24%546<8&Q
MX6+2,U.3LW65-A=RHK(D-'0U5AASTU<(M$,WP8)C1&2$I"81  (! 0,(!P4&
M!P$  @(#   !$0(A,1)!46%Q@9&A _"QT2(R4A/!X4)BDG*"HK+",_'2XB,$
M%!530Y-S!6.#X__:  P# 0 "$0,1 #\ ^J: 4 H!0"@% * 4 H!0"@% * 4
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M)GM:4PYXL;XCA#9:=98M*N3 5Y77L[+JBCB&X329,,!R /LXTY7[;_\ R/\
M+2;SO%1]A_F*65XGWY;]=[<Y<K)MN5 DZ5OL^X&I##DV,A( R&YRO--97B$\
MNDR[EX8XUG*FI)WMNVFYJV[+;%MT6QI'-BEYE'BR7=2NOF\Z2\;JO[V[XVT+
M$$6-<4@_.=RN$P')+#+*GI VTRV<4W3-SRJX*"*8\57"MI6)U->&EI:VYW66
MY<VDQN%3/BJG9$2^,<3=M+==SFWV];9O;;*7FR:+A2XB&$>3'E(1,N"VX3AM
M$F51,%,N*8H2HM;3%5,K(\+6F$^*<Z+C*IIJ2?Q*5OA[N)RI[_\ $&5 WK<X
M"6IB'M"9,8;:?8D.N2VXC8O**D#[2,D@+[O*:$J^Y'#K<\<<NGF/*[OO1,^R
M,FFSHZ)YOIJ^*;=-2[>!U-YWE<F_#E-U66U.3YTB&Q*BVT4)PD60@+UD:13,
M6D/,2 F*HG"NG^13Z=>&;,4-YEG@Y\BI5J=$QGT+60=B;TF;@N"(SN&P7^WG
M%1\DMHO0YS!J2(FK$=>F%D7'!5-6R%>&5:K#?.BWM]EN>PF;EEME=FW1F<G=
M5!9^769WZQ63>.\9>#KC@W*VV5%XI'@1!)E4!..4GW6U<<5/==5.04KS\^S_
M !6\O,H=3XX5J2XML[<NW_(5.3EU);;,3XQJ2+[PM_\ M)MS]DL?J4KU?_L;
MJ_L_I/-_AY/M/\S(G@+_ /:3;O\ T7?_ )#E=.?>OLT?E1G+^+[=?YF<TUMA
M;9(O+V^=D.;O-Z:XZSN)EN+='%B/N?!MC&?,);*1Q)!TV&R3E4:\U"7ITTNR
MJZIY_FE6Z-$':MO&ZE:LBS1\-MFG3-IWWAX]8CVRVW8[K*NT".\\R+T\C*4T
M0.+FCNHZ#3PJU[E!=',@X8XUVJ;:3=LJ_P VFRS7VG*E)-I60[LV@XKQZV^W
MN&7LVR.&K7?KC(:!Y.5MQ8;JMN)AV#1"KA3B]9.GQ*BMK6L+7$[5-+E/%X<=
M">IRGP)I;WN=V\,88-? [KNSR;?<;3W3-P0U8EN+@B\&0!Q[["5UYM-/,JI2
M\',6+[D34OT:SGRG5RE4W;5R[-=5U.^4]1[_ .O\"-;MFW*WQ148T.]W)A@5
M555 :?4!3%>*\$K56ZN5RZG>Z/;42J</,YBS5^Q%/?O&2^P85SN#4RT#)MZR
M'$VNPP_=I@QXAH!E,FV^0;$,G.5-1K*&*(JJJ%7)5Q2JK_#,6)8G=BN;C?D1
MV='>=-T3&F%,X;'KS96=-NC?M]99V8MA8C"YNQX6B6:)N(P#L97T/!HV\RM\
MJCCUL,,1QS)VJHCG/ESDKM^S'6IZ6/C36GR?4SX?Q$?Q?;NS?@QN,;M(CR9J
M12U'HK)QFE35'+@TX[().KACUUKASFN[]NC\])Z.1.)_9J_*R9LW>%SW-<U"
MS=V:VU: ;CS7Y &4N3()H3'NX(;>BR@FA(ZX):GO1R]:O34I=53N=32V.V<W
MV;\\7'DY;BFFE7JE3[L_VKINF&5M[\5!3>ERVY&OECVZS9FVN]SKV6H<A]\4
M<%J.PDF#@+8>[-37BJ(@^6N%#Q4NK3"6J]O-;9=D9Z*UA:6=3JT:9OT%MLK?
M,C>.TKE*B'%CW:WO2+>_(8)9D%9#(HJ/L$!-$XR8F)BF=%3'#'AC3_)LY6)2
MDZ6]*OE:[+'MC(.7^YA=L1MG+EVK00? $KJYX76A^X2FY*/(Z;*BV8.(BON9
MM4S==U24\5S(@_8\M=^:DH7RT[L*CIU'&B^K[56_$YZ<6;;B_P#5CQ/M Q!0
M+9O+O#-PCCP%)\5K5;E(*>^=;16W%\N JO)7+DWU4:,5.QK$M3E/7+RLZ<WP
MJO*FJ7J?AW/@]"._H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MS2XA1=GMRSP+"L.HH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MJE .\[J^CH/RY[U2@'>=U?1T'Y<]ZI0#O.ZOHZ#\N>]4H!WG=7T=!^7/>J4
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MM ?SQVG=-H6V _&W P8W)IQ=)-$3(2%$$FW,Z8CQ3[7-2I2535%J+4]Q>%A
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M]</_ )KU 6M * 4 H#\EW!_KD_\ Z[G]I:]7+\)X^;XF5]=#F* 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * _7;'_HMO_P LS^K2O'5>SW47(FU)0H!0"@*Y
MW;EA><)QR P1DN)$H#Q6MD&'U5VW]&Q_T8TD'GU4VU]&1_T8TD#ZJ;:\EMCI
MCS-HE$V@1'MB;=<3!&GFO^E)?%/-GP]JMQL&+6QK.!=9R2X'E;-\LJ^QU<%P
M^W3$P7T>.Q'9!EAL6F6TR@V"((BB>1$2I!LH!0"@*J3_ !5;O\C._71* M:
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M- Z@&*XB0YT7*2+R*E +?9+1;B,X,-J.X:()N *(:B*JJ"I<N"*JX)0$V@%
M* 4 H!0"@*K;7^G/?YZX?_->H"UH!0"@% ?DNX/]<G_]=S^TM>KE^$\?-\3*
M^NAS% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?KMC_ -%M_P#EF?U:5XZK
MV>ZBY$VI*% * 4!3R[S*CW]("C&&*4(I(N.NJVXK@.B!)AE(<B(28KSJE513
M*>AT_BGC98NVSGS*W2UI57X8[;=%N2VF?W\[\\W&U-1V1=@O, )ZR/J;;KB-
MD1@TF5DD5>J)'F\JCA3#W,7VN%-37Y?9>2^;_<P?9XU4)V9/%9-]]IE;M[7.
M2[$!RVM(R_I9Y"2%1>N;;1D+6F7(X^."*?)FX\$S=:N4L34W-_KC\CX;.5'^
M14U39XDNJAO/YU&V[+<;AO$BVMLE&%M]]Q2PB$AYS 1Q(Q4,RHC7NBZJXIP3
MK**+QI4N+EGS:?9DOOL/36VE9:\V?0M.^[:H47<NKN.+:QNEN?%Z*+_=VD+7
M<10S:S9:A @DO(W@2Y>MFKI@\5CLX:^.;)G./JVTJ5WEOONZ/+F.DKD>@4 H
M!0"@*J3_ !5;O\C._71* M: 4 H#D8&\+E(D,Q'&&AD=\,'E1#R]S5XFFC'%
M?=D29>54ZI5TIH3PO/3;]K!BW1V:3SU<UK%HKA?9QX&]<]:9'8\1G7K=<9A0
M8\48<I(K1/SV<F!9L"D*T+I1BZF&0QQS*B8\V.CNTOS:-$V9S?6MK5G<:5K^
M;#;Y5I@G/[LGQT:<..P;1VGYQ0%<)MTGD(4(!%1-,B9TQ7BJ8U;Y?>JI62NF
ME?>;7LZ9)]=X*:GEHJJ^FE..GLMS<W=(8O*VN1$81\(RO.@W)4W$)&E=51;5
MH%5C$<FJN'6X9:YNGNU5+X?=N=O!G15O'30_BT_:W^'B1W]Z7&/;VI4F"RP[
MJN-2&$?4VT08^L)ZZMMY13,F<E;7*F/+5OEJ8G)^M4'-<]NG%&779Z;KWY">
M_>ILC;(W.WR(2235$ VE*X1C)3TT!LVRBJ68\$S<,/*E351%2779V_P.E/,F
MAU6;+;MT\+2)?-S3K7=K+;W7HJ',RC*%0+,X2F(+H(KHDG%>01=+DS((]:JH
MI55524PO??NU7RU9,<SF544TS$N_A=OTNZ$[2&QO.>Y&FN%*@)HDRAR,AZ<!
M77# VYB*[UB:0$QXM\O%!3C68;*7GXV39U;5EL-?-:=5UG#O1+V=[)8GK5WM
M&]R+Q:.]OJV9"Z;2/L9-)T07@8:;TH,/)P=+BGD7@CF41&E=,VOMO-Y/,=4Y
M8=ZRV+2^F:XNJYG84 H"JVG_  K9O\C&_4C0%K0"@.6ONYYD&ZG&"3#CZ0MD
MQ D"929ZGRC%(7 P7WO!L^/+@E=.53BWQJ^9Z-USMS<.?S73E2LFW+?W5ILT
MOO+NY]E\W9/MT]R.S;@D,M"I$^<A6EQ%I7R1 1ISD; O+[K!.1547*H53AN+
M?;2NNI<=N\[FNBY3TJ?Z'P/)>Z;BT5T%(33;<1MTXCZNJXKBL$(GJ-9&\G$^
M&!KC[%**$XTU4K8ZFO89S.:Z<5GAIJ>U4JJ[[V?(:I.^D9EW6/W9DOFT#)5[
MRB*F0P'-(3370;+4Q0^MP$N'#CE-$TSI2WMK?9,:4;5S8J=/EIG3X55=FR3G
M,;EOER-8X-P;9C"Y.5P05V0J,JK:JGP!HW\.KGNFDP#./'%*NGE3S%3GC7;&
M31-N;217_D1RG79>U?99BRY9PV++)8;IO3EL"'EN,*UA(=(#EW$5-I,K9$@H
MFM&ZRJG:^U7.A35&B>*7M.O-JPTIS'>BW54_85\/>DQZ; !8HN6XT%FY7)I4
M1IN2\J=W01(\Z"ZBBON5X.#UN?HN7,Y,RTQ-2V79+4U$G+UG"RYVLURJ6N_+
M%-LQ:1IV]Y\:_P!QM[:QWQBM&3$5H6R>4@ 2ZY=Z%P<<53K1Q#D34Y\Y=&*E
M/YDOQ8>EJU0;S><Z:FK+*6]U+JS]2>M.Q=%9[O,G2I;<F [;^[Z>1F0K).+G
M154E5AU\,.'#CC4NE89F;6N"[3I36W5#46)\:LST%I4'04 H"JVG_"UF_P C
M&_5#0%K0"@% * 4!R,#>%RD2&HAL-#([X8/*B'E[FKQ--&.*^[(DR\JIU2KI
M30GA>>FW[6#%NCLTGGJYK6+17"^SCP-ZYZTSVW;KFR+B3)2(3QJC^K:V@-)<
M/20E$I)*X:*BJ*#^3#B28*M34HY;J^69R3Y=>WX79FNBN>:J97BB,L>;4]4=
MY6W8L]M;EGW,'4:G6Z[NI&%X2@H33;+J\C+Y([,XEY%3!>"]6KY]&!.^QWY[
M[M7M5QR_Q^<ZXM3E3"R:[7?['?DO[1+=F6F%+>04=D,-.N(&*"A&"$N7%57#
M%:GF4JFII9&=^6VZ4W?!+J"Q0"@% * JMM?Z<]_GKA_\UZ@+6@% * 4!Q5UV
M>V_<I+ZRE177%<RH"<,W'#E]FNE/,:4'*KE)N2+]26OC9>@G36^LS/00^I+7
MQLO03IIZS'H(?4EKXV7H)TT]9CT$/J2U\;+T$Z:>LQZ"'U):^-EZ"=-/68]!
M#ZDM?&R]!.FGK,>@A]26OC9>@G33UF/00^I+7QLO03IIZS'H(?4EKXV7H)TT
M]9CT$/J2U\;+T$Z:>LQZ"'U):^-EZ"=-/68]!#ZDM?&R]!.FGK,>@A]26OC9
M>@G33UF/00^I+7QLO03IIZS'H(?4EKXV7H)TT]9CT$/J2U\;+T$Z:>LQZ"'U
M):^-EZ"=-/68]!#ZDM?&R]!.FGK,>@A]26OC9>@G33UF/00^I+7QLO03IIZS
M'H([&$2184>,B9T9:;!"Y,<H(F.%<FY.J4*#=WO\#V_O4-'>_P #V_O4 [W^
M![?WJ =[_ ]O[U .]_@>W]Z@'>_P/;^]0#O?X'M_>H!WO\#V_O4 [W^![?WJ
M =[_  /;^]0#O?X'M_>H!WO\#V_O4 [W^![?WJ =[_ ]O[U :#;:.<S/5"U8
M[3C "BIE47R;,E7ACBBL#A]N@-_>_P #V_O4 [W^![?WJ =[_ ]O[U .]_@>
MW]Z@'>_P/;^]0#O?X'M_>H!WO\#V_O4 [W^![?WJ =[_  /;^]0#O?X'M_>H
M!WO\#V_O4 [W^![?WJ =[_ ]O[U .]_@>W]Z@'>_P/;^]0&B"VU;X,> RA$U
M#:!ALC5%)1:% 12P1$QP2@-_>_P/;^]0#O?X'M_>H!WO\#V_O4 [W^![?WJ
M=[_ ]O[U 8@^VWFR-(&95(LN"8DO*JX)RK0PR[W^![?WJ&CO?X'M_>H!WO\
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MF^F>-&]17TN..KL>84 H#["V)_!&WOV;#_4!7R^9XGK/T?(_;IU(O*@ZB@%
M* K)G^)/[7W$H#30"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@)2^]_HC_9
M2@/* 4 H!0"@% * 4 H!0"@% * 4!DGY,OLI]Q: QH!0"@% * 4 H#6Y'8<<
M;=<; W65563(44@4D45457DQ1<.%.G3<8;*&B@% * UM1V&<^BV+>H2N.9!0
M<QERDN'*J\],D=,_68;*&B@,G/RA?97[M 8T H!0"@% * 4 H!0"@% * 4 H
M#Y-WW_&^X?VE,_7G7U.7X5J/SG/_ '*M;*.K.0H!0"@% * 4 H!0"@% * 4
MH#["V)_!&WOV;#_4!7R^9XGK/T?(_;IU(O*@ZB@% * KY;A)()$0?)RB*^1.
M=* TZQ\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z*
M :Q\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z* :Q
M\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z* :Q\P^B/10#6/F'T1Z* :Q\P^
MB/10#6/F'T1Z* DJ9=7@GN1\B<R>Q0'FH7,GHIT4 U"YD]%.B@&H7,GHIT4
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MJIAB2-O.&"&6&)&B9B7BJJJULY.G2VXR+9Z=+"RK#10"@% * 4 H!0"@% *
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M5>;5:H=W\>UEU0T4 H!0'R;OO^-]P_M*9^O.OJ<OPK4?G.?^Y5K91U9R% *
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M]- -$^<?2'IH!HGSCZ0]- -$^<?2'IH!HGSCZ0]- -$^<?2'IH!HGSCZ0]-
M-$^<?2'IH!HGSCZ0]- -$^<?2'IH!HGSCZ0]- -$^<?2'IH"2H%U>*>Y'RIS
M)[- >:9<Z>DG30#3+G3TDZ: :9<Z>DG30#3+G3TDZ: :9<Z>DG30#3+G3TDZ
M: :9<Z>DG30#3+G3TDZ: :9<Z>DG30#3+G3TDZ: :9<Z>DG30#3+G3TDZ: :
M9<Z>DG30#3+G3TDZ: R0%TUY.5/*GL^S0&.F7.GI)TT TRYT]).F@&F7.GI)
MTT TRYT]).F@&F7.GI)TT TRYT]).F@&F7.GI)TT TRYT]).F@&F7.GI)TT
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MV-GV)DU%3:M\4"5LQ<!5%D47*8*0$G,HJJ+Y*^;7XF??Y*BA:D7-2=!0"@%
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M5@77(<2 ""JY\35@!1,$5<>L710ZJ:=[^^OT/>KB'*I;T_I?ZDM^[=8KSO\
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MA@ODHK5*#L<=.EI84-/DW??\;[A_:4S]>=?4Y?A6H_.<_P#<JULHZLY$JU&
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M<XHTI)@?'J$./EQJJ7#GI=4OU,FI2HZ?#_*C9 VC:X,MJ4P3B.-*!"BJ&"J
M/-IC@*<O>35?9^WCE'=4+I90OT+B:[:IZ7U5==3&V]KLV1'B24[+>?004G$;
M 0; S<%ML6Q'JH;QKB:D7'W7)2FRE4YNQ+J7\0[:F\[;WN>GL([FRFS;>CK=
M[@D(U(HL-"8TXQJ>H)MKHYSR%[D7B,4[/!*Q*$EFCA$=2MOTVN3M;TS/WIGK
M>C18B/)\.;5(>M[KDR6AP$<13#N[9R%>(S=UW09%W*9N*2M@0MXX=7A6.E.=
M-&'9$=)FTU5-1HJQ;9GW69+#I($1(<&/$1TWDCM@TCSF7.: *#F+((#BN''
M43V*Z5UXJFWE(HIPJ$;ZDH4 H!0"@% * 4 H!0"@% 2E][_1'^RE 5&ZGYT?
M;EP>@F\W+;9)6G(K7>'Q7M-,Y'M0T3B@Y"QYEJ:KUFQ4SJQ*>$FJYY\-4:X<
M<3AG]P[WBVIV19GI]U:;-WN\N]VN0PZ1]V)4%Z+#AL25:!W+E5MA")<1Q7EI
M4VE,9+-/>Y?XK:\RA2U'>)24Y;_TU\)5&>UPG\*F;2WQN^[7>W19MM*,T['
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M,XX&8$3V9M<N.*%[GC[%0N;*>BF>NS79O9=7^.DZ;?%5AZK5G5NY'*5W/**
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MUF8;@HXAKI$F545.LF&%4FL=+R*?S2K,L4V7D0\#7Q./RPXS=ZVX[RI+% *
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M*F52Y,*Q*-\[<^LV7[-E_66 B("@BB"(I@(IP1$3R)6MR8E%B/:&B@% * 4
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M1// _K"ZA\,K;9-X>6JIOJG9PNXWF.ZF-O'W7'6UAHH!0"@% * 4 H!0"@%
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MSY>&;"MK[V*?COVQ.JY79C*>[ACX+MDQKO=Y.M5GMUJCE'@,Z+)$A$.8CXB
MMIQ-27W+8I6U5-WZ>+=3XMF4TI7:."27!(GN?E"^ROW:PHQH#C7W]Z#$W##B
MP)P2D><>M=R1V"X#C1D'P<87GCRNB&;(C[0MYN7A4*<"SJJW/&-O\L:<QK\;
MS.FS-.!+\Q67$/$P[= ;1+BKSD1X'.Z%:0-'R(D:6X$X0951I055@KP//[W+
M55S;$3@47X<4.?FOB.)O+:4-^>W/AE1HNF<MT".WXMK<]K=Y?<8AMHY]9&V6
M8$EMUW45,"=<>C/-,9,%9)ELW,/RB9N6U&-^7"HUPYF,LQDPO0CBDURTOBQ<
M+/9,VRM)=;(:W<DFZ.[A[UUR;&,DDXA!B*N:G=QB<!9XCDU4U</=\4J:/VU/
MBG;X:;\E^*ZS>75XW'AR;ZO9AOMF<D'+L[*WG#MLF9.FW*ZG+? G;/ G2X\I
M&N\YURR9%ST140X? *PBIBBHO!$CEV4T)VV*=?IU+;WVIMBR8*KM=35EKC5C
M7Z4\DVWED5LWJW:[2_;VIS10)C\I+7+G ]).*C1($64^3SP/$X2KE4G30545
M4NKBERU4F[>ZT\TNJF,E]-&7*T[7,N(E-734MB5+G/8ZXLM[KN5RM(ULW<WM
M.YQRD&M\?<<<BO&:N"!.Y2P'!P%1L#4D$,X]7APK(A4)/PU*7G2YE[UTWK[N
M@V9=;B].%F[EVRK+G[QSVY8?C0PX!VV<DIY93)N.6V+%:8.. ]=@V+C,=)M"
M5>LZTYFY, 7E3>5&)3X<3G5W-J^*S/-THSF3A<>+"HU]_8_AV:H+J=%\06G+
MS(CS)$AI\'/F^& V\28R.@@=V)P$17'&5-4[P1!FPQP2I4X;;Y6[%5.CPX=.
MVZWXK+L+WX:8T^+$4[H>+L=S;R0$DO C<KYW9EK;LF=PW"8<E/H;CJD"9?@H
MK:"N/Y1$3+2J;4O_ #4?;5.]R_-KMM,IB%/GVX<2V+NVV3FA6,D[2@^).3;S
M^XIT^0^Q(F)=!)FVQ$)IQKX!9#45^4V8 8X K1Y\53,.&*UUL56C _JQ*-N&
M<ZTVLB6Z7GQK=A<QG4Y[=R/T.H+% ?)N^_XWW#^TIGZ\Z^IR_"M1^<Y_[E6M
MF#=DW#:T8N8,MYP)LA;0V)#@*Y^3UHV+A@AX\-0,%Q]FMQ*8V>[7HOOS&8*D
ML6:'V.+XNMNNSHGRY.^UCS#?C.1H\4&2EMI$:C TVXJHRJ-"VV@"2DON1XJN
M-0G2FG-L\;'^E<,YTJ7,<IKX<T6=Y?KJZ*SU+AOB +LLHIDCY TDTHP.@+CA
MK* 6SRDVCBD_G3#K)CPPI@I\&S<L'NL'J<R7S+[+XL[T5ZLSMSFJ(.^H0/VI
MNW2"%ELGI,)^ +Z@#F"JZ8/-&H^YX'Y/(M*G0U+=BLF=>7:Q0N92X2<N7$3,
MQD?V41[<&YF9L>W1%!B1%/OS:&3#8 I-B>HZZXJ!ET\.#A8<</*N-50TV\DT
M\8?&S<<Z<2A++%7"4]BMT$B SO>(J_-\1V0TQG:SL1PEQU155TQS@+K3@KE5
M5XJF'L5+=,2^.B5EULZ4KF3%.?);;W7DU(SBW7?3V>YQHSCS$QT&C,(+3D9Q
MT0T@;1O25E50>" @^SAC6X:5"UN^VURWGOIG82JZW-2T*ZRQ84LUU41I)KDO
M>T2"[MV38]2X703D#(=C..W'3>-%<%M<5R"1BN84#E5?+48:*HAV4Q=O4G55
M\RF95M<WJW,XS=,D%6V_NZ+8-((RC:U)QC7[JT1@3BY7&N\*VKK:FJ*F7.F/
M&K>&IK3$:;96NVTY4NNBEYDW-EUB3U60C>^[OYZ2<5R!(61"C&#\=((B8,/
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M0>_-EYEH!H/?FR\RT!)5MSJ]5?<CY%YDH#S3<[*^9: :;G97S+0#3<[*^9:
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M8<BX*G"@#CK32(KAB"$2 *DJ)B1+@*)CY57@E 9T H!0"@)2^]_HC_92@/*
M4 H!0"@% 1F+E;Y @4>4R\+I.-MJVX)(1M*HN"."KBH$*H2>3#C1>R=EENJU
M;T9VQMS:["30T4 H!0"@% * R3\F7V4^XM 8T H!0"@% * TO2XC+K#+SS;;
MTDE",V9().$(J:B"*N)*@BI8)Y$HNG3:8[#-EYEYM'&3%QM<40P5"1<%P7BG
M,J4!G0T4 H!0"@% * R<_*%]E?NT!C0"@% * 4!IE2XD1E7Y3S<=A%$5==)
M%%,D$4S$J)B1$B)[-9HS@1Y<20KJ1WFWE8<5E]&R0LCB(BJ!X*N4D0D7!:W)
M/3-UF:.F<W4-% * 4 H!0"@/DW??\;[A_:4S]>=?4Y?A6H_.<_\ <JULHZLY
M"@% * 4!G'COR'@8CMD\^XJ"VTV*D9$O(@BF*JM8%F/"9=$!,@(0-50"5%1%
M4>5$7V,:2;#,:TP4 H!0"@% * ^PMB?P1M[]FP_U 5\OF>)ZS]'R/VZ=2+RH
M.HH!0"@*R9_B3^U]Q* TT!6[CM!WBQR[:#_=CDAE%_ BR*BHJ+@!M'Y/>F*\
MRI4U*8T-/<Y-3OTIK>H*B)L^Y!'M;<NY@^Y;9!2$/3D.:HDJ?!N%+E3'5%.)
M)BY[M&R3W&!7*F=#6_IUY[)BQK.T]W3=*RR5UQ\+HDRSV>UZL<8]GEN2FFD8
M>;97.X1@N2-)CDCH9N!YE3'%<G'!,H<5459:*4MV&WAIO-K[RK7GJG?-G'1<
MB9(\-[._":CF#"N-O29>OW<<RRGRQ!_E_*-"B"A8X\/)2CNNA^14K<Z6]^'C
MO5]Y5)_$V]^*S9BX$=CPW1K=L_< S&A*>\R^ZVVPX+A*PZ+@(X:ODVN41R(H
M-#SEF7BKE=Q;6]ZK7Z^%UHYO?>Q+<Z'^GCH+>Y;=N3]S?D1)L=F).!INX1WX
MB27"%E2PTG%< 0Q$N1QMP47BB<N*BQZ)Q;;/Y5ITW0JMUX<.RW^9Z-%\U,3P
MR@C"E0IYQI<65)"0XPD5 ;<T\^!OBKCB.ODKF+CO#-E'JIA4.CN*GRSQHPV9
ML^LK%WJJO-_/B]VHD+X>0#)Y)"QY#,I+?WL'(PD3W<$RJCI$2H8N#@B(2=7C
MRX\.SJ[V+YZJOJIP\'WI_B<XBE)9*53NJQ<;F>?4%._7J2DIH$NP&"*W&RN]
M<A+^\.:BZ^GERM=4<@JJ<:CE]U+16JMU3JWN8;T(VM3/V73OI5/LF"- \,V8
MFY2OBRP>>*.]&$B;?1UL7B,E$%&2C.3%S%1)E5S<<R>2,'<JI\U*IW4TT_IG
M(7B[ZJ\M3JWU5/VQEN+A=G6_ZNPK$TJQ8L0FC,H:G$(R;+,9"4<VS;)P\251
M+'CY:Z\RK%7BUV:TU&R?8<Z*<-&'+9;J:?L**T>%;-NW3(OG?U?5UIUAAQU9
MAS6FW45,O>7);C;F"JJXFRJ\G'A7/#W*J?,HZNR7$34V]!;<U*KRY^FS4EEM
M-<#PUN,-AUAB= B@Y@!=U@DTV31-Y'$1GO"H#A**%GS$BKBN7C7156I_-,9/
M@=F:VBZV^\BM3*T7N_XU;G<5WY\A=GLB*Y=I5R=>$GGAD)&/234CG) &U<:<
M5542005,4PY:Y8>XZ?,HG[U=7Z_P[ND]]5.Y.8V4+]'$HK#X3,V<K7HR(B-V
MYW5RA$?(D5'$<7N[DB7)-A7.1W!20N'!,*[*KO3HC\W#O79U><G3*C3/Y>/=
MOS-V'Z%4%B@% * E+[W^B/\ 92@/* 4 H!0"@% <>UX>-L/JY&GFPV\W*26R
MV"(AOR1(!D!UO@W! LI<N; >3"N>#N.G)Z>#5X9>W#.'/:K75BI517BR^ICU
M^*%LQ1.:RZ(L-D;5^K-E^;M2.>+I.Y(4;N45O,(CE9CZC^FBY<Q==<34B\N%
M=ZZ\4:.UO<IA:#E11AZ:$O8=!4%B@% * 4 H#)/R9?93[BT!C0"@% * 4 H"
MGW#MJ)?%BI),@&*1N-D'!P7%'!MQL_>&V6!"N"\:F&G*</"TM$NESPAJYIP[
M+&=JAW2GN37MF;TU9;:<^GAN\5RL,]^X,/O6<?A7SAIW@BUE>(HKJ._W754L
MCR93SAU>%70\-4_)33]-+IW6S&=*TRM8E'S55?54JM]D3I=AW%8:* 4 H!0"
M@% 9.?E"^ROW: QH!0"@% * U28[$F.[&? 76'@)MULT0A(#3 A)%Y45%J*Z
M931M-33E'Y[:O!R+;K^U>0EMOR6[6MM5YT)FNI&"HZYG;FMMY77"5TQ)M34U
M5=1%P5*K4KF+SJ-2BE):EAR81/>I?D<\:NV+94*XZ#PZV86SMM-V/O34EIIU
MUQA(\?NK33;A9A: %<?<5![;CAF2\2):NJN4EF4'.FF&]+]G3J5AT]26* 4
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MYGB>L_1\C]NG4B\J#J* 4 H"LF?XD_M?<2@-- * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * E+[W^B/]E* \H!0"@% * 4 H!0"@% * 4 H!0&2?DR^RGW%
MH#&@% * 4 H!0"@% * 4 H!0"@% * R<_*%]E?NT!C0"@% * 4 H!0"@% *
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M]["V[_F26&QJ=!-;A2O/5NQ)*[0W;=8=W6%"@% * 4 H!0&3GY0OLK]V@,:
M4 H!0"@*W<A7(;%-6V&;5P5M4C.M@CIB:K@A(!(0EARX*E9;-/VJ=V)3P%D-
M_+5OAQQ.4N.Y=\Q+?/,H9-2XKT:,3PP)-P8P425R0Q'BD$A\#7(F"'BWFZWN
M5K,5DI7UU6:%0H4W0ZIBK3:D[$5-L-W4TVYWC:;^FUTZ+)5K[2VO2G[=%?EL
M]VE.LMG(CXXZ;A"BF&/ERKPKIS$E4TK5)%#;I3=Y)J2Q0"@% * 4!\F[[_C?
M</[2F?KSKZG+\*U'YSG_ +E6ME'5G(4 H!0"@-\%V,U+:<E,))CHOPK*D09A
M7@N!"J*BIRI[/*BIPHE-ET\!,6G87:Q;&&U*Y!E.%-9E#$SA(B:9MBX@$\3;
MKR.XFBJ0D"::)@BKP(JXT55.JF58[]%_9;.?4CU5T<O!4T^\KKM%^>^.[FMR
ME'O"U6>V7A8]HD]YA$T#@*K[4DP4DX@XXPB-9T\J I(G:6MY553F<CZ7D<^B
MFEK"[(SI]125U. H!0"@% * ^PMB?P1M[]FP_P!0%?+YGB>L_1\C]NG4B\J#
MJ* 4 H"LF?XD_M?<2@-- * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * E+[W
M^B/]E* \H!0"@% * 4 H!0"@% * 4 H!0&2?DR^RGW%H#&@% * 4 H!0"@%
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MT U'.TOG6@&HYVE\ZT U'.TOG6@&HYVE\ZT!DXXXCA(A+ABOEH#'4<[2^=:
M:CG:7SK0#4<[2^=: :CG:7SK0#4<[2^=: :CG:7SK0#4<[2^=: :CG:7SK0#
M4<[2^=: :CG:7SK0#4<[2^=: :CG:7SK0#4<[2^=: :CG:7SK0'S'O/>>\(^
M\+['CWVX,L,W"4VTTW*?$  7B01$4-$1$3@B)7T:**<*L/@\[G5JMVN]Y2F^
MO6]_]PW/Y9(_'J_3IS(Y>OS/,]X^O6]_]PW/Y9(_'IZ=.9#U^9YGO'UZWO\
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ME* \H!0"@% * 4 H!0"@% * 4 H!0&2?DR^RGW%H#&@% * 4 H!0"@% * 4
MH!0"@% * R<_*%]E?NT!C0"@% * 4 H!0"@% * 4 H!0"@/DW??\;[A_:4S]
M>=?4Y?A6H_.<_P#<JULHZLY"@% * 4 H!0"@% * 4 H!0"@/L+8G\$;>_9L/
4]0%?+YGB>L_1\C]NG4B\J#J?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>modular010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular010.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ /0"  P$1  (1 0,1 ?_$ *4   (# 0$! 0
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MD.E_<ZUL7ZZ@+JU.!9V?5=]/<#)RY,]5^HF(S&XV>6=7HAKM2>T(@:^D2;^
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M*88W/> W-,I7AK23DES^VZ'+:Q6X27448\F7_3Z\-VP$0R3T:KI]5,OV[@9
M-H"P_K6D,)YTU;DZVU;Y3KJZ-MLN$:KV;1%56E3!4A,'' KYHZ6X3G-\M4R5
MC]^*T16W^4ZV+S[2&X@(6NC7!=$)*])>W$3' /;J*1VL$CVDM=I6U^5'5_\
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M]*(91X]7R7/0R'-_>M+BO0K#;&\$J4)W>8"HHG*TY0JG>+*</\RE6:?]G(_
M;HYE?%8,9B<2F.B(B(B)HB<$1*7K:OVA"1U_A7QS+,I9@\PHU]DA:Y1AV,"R
MQ'D*XOK95X:=Q.;PV$YL&KIQ([Z)5(':W ?R-.P'YJ;>6XS^ ]/&ID!VZQG"
MCH] 8XN/)Y(UT'Q!W\?>JN.HEEH=)QQ_Y*3Z&..HKS=2L,CAVV'TAO86RS2+
M"P1@I0Y/A<4E=913X..\"3A[W=541<;AM7!W..M62 "$T&E6MIL=NQG/XENL
MH%%MMRMS[LB"AF;2.QW6T!T4-2T+:XHKI53WF2$N=B6N&/353:P1R@-R(42%
MB&,M]692MV]M%8MS$]K12\,HY3NYU./O+M2K'3O-N,?Y$=5 HMA;QCALKUU*
MZ'CMJRS.<DCWULI4>TA#8MS7,,!9\PPKSC@("CXU)4\7;PJ F=%$TLPU5JI&
M,22.U8TI1>\P-;-T[B6>==D=<GN1K2=U=5&T5MYQ!=<-2(M-K GJJEZ5HM]^
M8N#<JNI[<Z)MV(-)SH*^W,O>)W,9G2V6T,@9)VR/-MY2 )"$TBH;;9H2=NYI
M +7TUR=FF<<]#[UV%U83S5'N5_@"JN"8ZJKJJVV)JJ_\ U3=?VN_W'O5MO\
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#5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>modd-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSaKGKbPtzpN2SekhtWp7fekqvycjn18uWiHn7QD20YQF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:modd="http://modular-medical.com/20210630" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" id="CompanyAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Leases" id="Leases">
	  <link:definition>00000008 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNote" id="PppNote">
	  <link:definition>00000009 - Disclosure - PPP NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" id="ConvertiblePromissoryNotes">
	  <link:definition>00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" id="StockholdersEquityDeficitStock-basedCompensation">
	  <link:definition>00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CommitmentsContingencies" id="CommitmentsContingencies">
	  <link:definition>00000014 - Disclosure - COMMITMENTS &amp; CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEvent" id="SubsequentEvent">
	  <link:definition>00000015 - Disclosure - SUBSEQUENT EVENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" id="ConsolidatedBalanceSheetDetail">
	  <link:definition>00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000017 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000018 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RoyaltyAgreement" id="RoyaltyAgreement">
	  <link:definition>00000020 - Disclosure - ROYALTY AGREEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RetirementSavingsPlan" id="RetirementSavingsPlan">
	  <link:definition>00000021 - Disclosure - RETIREMENT SAVINGS PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="CompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000025 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" id="StockholdersEquityDeficitStock-basedCompensationTables">
	  <link:definition>00000026 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" id="ConsolidatedBalanceSheetDetailTables">
	  <link:definition>00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000029 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000031 - Disclosure - LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" id="PppNoteDetailsNarrative">
	  <link:definition>00000033 - Disclosure - PPP NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" id="ConvertiblePromissoryNotesDetailsNarrative">
	  <link:definition>00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" id="StockholdersEquityDeficitStock-basedCompensationDetails">
	  <link:definition>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" id="StockholdersEquityDeficitStock-basedCompensationDetails2">
	  <link:definition>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" id="StockholdersEquityDeficitStock-basedCompensationDetails3">
	  <link:definition>00000037 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" id="StockholdersEquityDeficitStock-basedCompensationDetailsNarrative">
	  <link:definition>00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
	  <link:definition>00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" id="ConsolidatedBalanceSheetDetailDetails">
	  <link:definition>00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" id="ConsolidatedBalanceSheetDetailDetails2">
	  <link:definition>00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" id="Stock-basedCompensationDetails">
	  <link:definition>00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" id="Stock-basedCompensationDetails2">
	  <link:definition>00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" id="Stock-basedCompensationDetails3">
	  <link:definition>00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000047 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000048 - Disclosure - INCOME TAXES (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
	  <link:definition>00000049 - Disclosure - INCOME TAXES (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="modd_CommonStockIssuableMember" name="CommonStockIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CEOAndInvestorMember" name="CEOAndInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables1Member" name="NotesPayableOtherPayables1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables2Member" name="NotesPayableOtherPayables2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_MemberOfBoardMember" name="MemberOfBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedWagesAndBonusMember" name="AccruedWagesAndBonusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedPlacementFeesMember" name="AccruedPlacementFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedInterestMember" name="AccruedInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedOtherExpensesMember" name="AccruedOtherExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CommonStockIssuable" name="CommonStockIssuable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationShares" name="ShareBasedCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_GainOnPPPNoteForgiveness" name="GainOnPPPNoteForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosurePppNoteAbstract" name="DisclosurePppNoteAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PPPNotesPayableTextBlock" name="PPPNotesPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" name="DisclosureConsolidatedBalanceSheetDetailAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ConsolidatedBalanceSheetDetailTextBlock" name="ConsolidatedBalanceSheetDetailTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureRoyaltyAgreementAbstract" name="DisclosureRoyaltyAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RoyaltyAgreementDisclosureTextBlock" name="RoyaltyAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureRetirementSavingsPlanAbstract" name="DisclosureRetirementSavingsPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RetirementSavingsPlanDisclosureTextBlock" name="RetirementSavingsPlanDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureLeaseDetailsAbstract" name="DisclosureLeaseDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureLeasesDetailsAbstarct" name="DisclosureLeasesDetailsAbstarct" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetailsAbstract" name="DisclosureStockBasedCompensationDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails2Abstract" name="DisclosureStockBasedCompensationDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails3Abstract" name="DisclosureStockBasedCompensationDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" name="DisclosureConsolidatedBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" name="DisclosureConsolidatedBalanceSheetDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetailsAbstract" name="DisclosureIncomeTaxesDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetails2Abstract" name="DisclosureIncomeTaxesDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetails3Abstract" name="DisclosureIncomeTaxesDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_OperatingLeasesImputedInterest" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_OperatingLeasesAnnualRentIncreasePercentange" name="OperatingLeasesAnnualRentIncreasePercentange" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LeaseIncentiveReceived" name="LeaseIncentiveReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CashPaidforLeaseLiabilities" name="CashPaidforLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" name="NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_FairValueofOptionGranted" name="FairValueofOptionGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesCancelled" name="NotesCancelled" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>modd-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20210630.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20210630.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsContingencies" xlink:href="modd-20210630.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20210630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20210630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20210630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20210630.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20210630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20210630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20210630.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:href="modd-20210630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20210630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20210630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20210630.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20210630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS &amp; CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000017 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000020 - Disclosure - ROYALTY AGREEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000021 - Disclosure - RETIREMENT SAVINGS PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:title="00000026 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000031 - Disclosure - LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000032 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000037 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000048 - Disclosure - INCOME TAXES (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000049 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>modd-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20210630.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20210630.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsContingencies" xlink:href="modd-20210630.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20210630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20210630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20210630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20210630.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20210630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20210630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20210630.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:href="modd-20210630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20210630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20210630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20210630.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20210630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_moddCommonStockIssuableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationShares" xlink:label="loc_moddShareBasedCompensationShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddShareBasedCompensationShares_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS &amp; CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000017 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000020 - Disclosure - ROYALTY AGREEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000021 - Disclosure - RETIREMENT SAVINGS PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:title="00000026 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000031 - Disclosure - LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000032 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000037 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesCancelled" xlink:label="loc_moddNotesCancelled_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_moddNotesCancelled_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedWagesAndBonusMember" xlink:label="loc_moddAccruedWagesAndBonusMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedWagesAndBonusMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedPlacementFeesMember" xlink:label="loc_moddAccruedPlacementFeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedPlacementFeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedInterestMember" xlink:label="loc_moddAccruedInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedOtherExpensesMember" xlink:label="loc_moddAccruedOtherExpensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedOtherExpensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000048 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000049 - Disclosure - INCOME TAXES (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>modd-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CommonStockIssuableMember" xlink:label="modd_CommonStockIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuableMember" xlink:to="modd_CommonStockIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CEOAndInvestorMember" xlink:label="modd_CEOAndInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CEOAndInvestorMember" xlink:to="modd_CEOAndInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CEOAndInvestorMember_lbl" xml:lang="en-US">C E O And Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="modd_NotesPayableOtherPayables1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables1Member" xlink:to="modd_NotesPayableOtherPayables1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables1Member_lbl" xml:lang="en-US">Notes Payable Other Payables 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="modd_NotesPayableOtherPayables2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables2Member" xlink:to="modd_NotesPayableOtherPayables2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables2Member_lbl" xml:lang="en-US">Notes Payable Other Payables 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_MemberOfBoardMember" xlink:label="modd_MemberOfBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MemberOfBoardMember" xlink:to="modd_MemberOfBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_MemberOfBoardMember_lbl" xml:lang="en-US">Member Of Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedWagesAndBonusMember" xlink:label="modd_AccruedWagesAndBonusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedWagesAndBonusMember" xlink:to="modd_AccruedWagesAndBonusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedWagesAndBonusMember_lbl" xml:lang="en-US">Accured Wages and Bonus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedPlacementFeesMember" xlink:label="modd_AccruedPlacementFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedPlacementFeesMember" xlink:to="modd_AccruedPlacementFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedPlacementFeesMember_lbl" xml:lang="en-US">Accured Placement Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedInterestMember" xlink:label="modd_AccruedInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterestMember" xlink:to="modd_AccruedInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedInterestMember_lbl" xml:lang="en-US">Accured Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedOtherExpensesMember" xlink:label="modd_AccruedOtherExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedOtherExpensesMember" xlink:to="modd_AccruedOtherExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedOtherExpensesMember_lbl" xml:lang="en-US">Accrued Other Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment,&#160;net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="us-gaap_UnsecuredDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl" xml:lang="en-US">PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES&#8217;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Bonus payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001&#160;par value, 5,000,000 shares authorized, none issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001&#160;par value, 50,000,000 shares authorized, 18,906,148 shares and 17,870,261 shares issued and outstanding as of March 31, 2021 and 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CommonStockIssuable" xlink:label="modd_CommonStockIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuable" xlink:to="modd_CommonStockIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_CommonStockIssuable_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Shares used in computing net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Warrants issued with convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationShares" xlink:label="modd_ShareBasedCompensationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationShares" xlink:to="modd_ShareBasedCompensationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationShares_lbl" xml:lang="en-US">Stock-based compensation, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Placement of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Private placement of common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="modd_GainOnPPPNoteForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GainOnPPPNoteForgiveness_lbl" xml:lang="en-US">Gain on PPP note forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="modd_IncreaseDecreaseInLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseInLeaseLiability" xlink:to="modd_IncreaseDecreaseInLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Change in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xml:lang="en-US">Fair value of detachable warrants issued with convertible notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Amortization of lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosurePppNoteAbstract" xlink:label="modd_DisclosurePppNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosurePppNoteAbstract" xlink:to="modd_DisclosurePppNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosurePppNoteAbstract_lbl" xml:lang="en-US">Ppp Note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_PPPNotesPayableTextBlock" xlink:label="modd_PPPNotesPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNotesPayableTextBlock_lbl" xml:lang="en-US">PPP NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS &amp; CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheet Detail</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:label="modd_ConsolidatedBalanceSheetDetailTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:to="modd_ConsolidatedBalanceSheetDetailTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConsolidatedBalanceSheetDetailTextBlock_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_2_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="modd_DisclosureRoyaltyAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureRoyaltyAgreementAbstract" xlink:to="modd_DisclosureRoyaltyAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureRoyaltyAgreementAbstract_lbl" xml:lang="en-US">Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureTextBlock" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureRetirementSavingsPlanAbstract" xlink:label="modd_DisclosureRetirementSavingsPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureRetirementSavingsPlanAbstract" xlink:to="modd_DisclosureRetirementSavingsPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureRetirementSavingsPlanAbstract_lbl" xml:lang="en-US">Retirement Savings Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RetirementSavingsPlanDisclosureTextBlock" xlink:label="modd_RetirementSavingsPlanDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RetirementSavingsPlanDisclosureTextBlock" xlink:to="modd_RetirementSavingsPlanDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RetirementSavingsPlanDisclosureTextBlock_lbl" xml:lang="en-US">RETIREMENT SAVINGS PLAN</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_2_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_LiquidityPolicyTextBlock" xlink:label="modd_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityPolicyTextBlock" xlink:to="modd_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per-Share Amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum payments under the facility operating lease, net of the lease incentive</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureLeaseDetailsAbstract" xlink:label="modd_DisclosureLeaseDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeaseDetailsAbstract" xlink:to="modd_DisclosureLeaseDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureLeaseDetailsAbstract_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureLeasesDetailsAbstarct" xlink:label="modd_DisclosureLeasesDetailsAbstarct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstarct" xlink:to="modd_DisclosureLeasesDetailsAbstarct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureLeasesDetailsAbstarct_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Option, Range</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property Plant And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accured Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_2_lbl" xml:lang="en-US">assumptions were used in the fair-value method calculations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2_lbl" xml:lang="en-US">stock option activity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails2Abstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_2_lbl" xml:lang="en-US">summarizes the range of outstanding and exercisable options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails3Abstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">The income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetailsAbstract" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetailsAbstract" xlink:to="modd_DisclosureIncomeTaxesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">A reconciliation of income taxes provided at the federal statutory</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetails2Abstract" xlink:label="modd_DisclosureIncomeTaxesDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetails2Abstract" xlink:to="modd_DisclosureIncomeTaxesDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetails2Abstract_lbl" xml:lang="en-US">INCOME TAXES (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Significant components of the Company&#8217;s deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetails3Abstract" xlink:label="modd_DisclosureIncomeTaxesDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetails3Abstract" xlink:to="modd_DisclosureIncomeTaxesDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetails3Abstract_lbl" xml:lang="en-US">INCOME TAXES (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_OperatingLeasesImputedInterest" xlink:label="modd_OperatingLeasesImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeasesImputedInterest" xlink:to="modd_OperatingLeasesImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeasesImputedInterest_lbl" xml:lang="en-US">Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Monthly Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:label="modd_OperatingLeasesAnnualRentIncreasePercentange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:to="modd_OperatingLeasesAnnualRentIncreasePercentange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeasesAnnualRentIncreasePercentange_lbl" xml:lang="en-US">Operating Lease Annual Rent Increase Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_LeaseIncentiveReceived" xlink:label="modd_LeaseIncentiveReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LeaseIncentiveReceived" xlink:to="modd_LeaseIncentiveReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LeaseIncentiveReceived_lbl" xml:lang="en-US">Lease Incentive Received</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="modd_CashPaidforLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidforLeaseLiabilities" xlink:to="modd_CashPaidforLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashPaidforLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnsecuredDebtCurrent_2_lbl" xml:lang="en-US">Unsecured Loan Received under Paycheck Protection Program</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Volatility Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:to="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_lbl" xml:lang="en-US">Notes and Accured Interest could be converted into Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares Available for Grant, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Option, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xml:lang="en-US">Shares available for grant, Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant, Cancelled and Returned to the Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, cancelled and returned to the Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options cancelled and returned to the Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Shares Available for Grant, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Option, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price, Maximum Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Option Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Average Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Shares Reserved for Issuance under Equity Incentive Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_FairValueofOptionGranted" xlink:label="modd_FairValueofOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValueofOptionGranted" xlink:to="modd_FairValueofOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FairValueofOptionGranted_lbl" xml:lang="en-US">fair Value of Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesCancelled" xlink:label="modd_NotesCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesCancelled" xlink:to="modd_NotesCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesCancelled_lbl" xml:lang="en-US">Notes Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="us-gaap_InterimPeriodCostsNotAllocableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableTable" xlink:to="us-gaap_InterimPeriodCostsNotAllocableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterimPeriodCostsNotAllocableTable_lbl" xml:lang="en-US">Interim Period, Costs Not Allocable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="us-gaap_InterimPeriodCostsNotAllocableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:to="us-gaap_InterimPeriodCostsNotAllocableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterimPeriodCostsNotAllocableLineItems_lbl" xml:lang="en-US">Interim Period, Costs Not Allocable [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3_lbl" xml:lang="en-US">Expected Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current portion:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred portion:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Section 179 assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_lbl" xml:lang="en-US">Reserves, accruals &amp; other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_2_lbl" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuable" xlink:to="modd_CommonStockIssuable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockIssuable_2_lbl" xml:lang="en-US">CommonStockIssuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeaseDetailsAbstract" xlink:to="modd_DisclosureLeaseDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureLeaseDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureLeaseDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstarct" xlink:to="modd_DisclosureLeasesDetailsAbstarct_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureLeasesDetailsAbstarct_2_lbl" xml:lang="en-US">DisclosureLeasesDetailsAbstarct</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureConsolidatedBalanceSheetDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetailsAbstract" xlink:to="modd_DisclosureIncomeTaxesDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureIncomeTaxesDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>modd-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20210630.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20210630.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsContingencies" xlink:href="modd-20210630.xsd#CommitmentsContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20210630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20210630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20210630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20210630.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20210630.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20210630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20210630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20210630.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20210630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20210630.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20210630.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:href="modd-20210630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20210630.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20210630.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20210630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20210630.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20210630.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20210630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CommonStockIssuable" xlink:label="loc_moddCommonStockIssuable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_moddCommonStockIssuable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_moddCommonStockIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationShares" xlink:label="loc_moddShareBasedCompensationShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddShareBasedCompensationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="loc_moddGainOnPPPNoteForgiveness" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddGainOnPPPNoteForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="loc_moddIncreaseDecreaseInLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddIncreaseDecreaseInLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInSecurityDeposits" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInSecurityDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_PPPNotesPayableTextBlock" xlink:label="loc_moddPPPNotesPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_moddPPPNotesPayableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsContingencies" xlink:title="00000014 - Disclosure - COMMITMENTS &amp; CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:label="loc_moddConsolidatedBalanceSheetDetailTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddConsolidatedBalanceSheetDetailTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000017 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000018 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000020 - Disclosure - ROYALTY AGREEMENT">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="loc_moddDisclosureRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="loc_moddRoyaltyAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureRoyaltyAgreementAbstract" xlink:to="loc_moddRoyaltyAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000021 - Disclosure - RETIREMENT SAVINGS PLAN">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureRetirementSavingsPlanAbstract" xlink:label="loc_moddDisclosureRetirementSavingsPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RetirementSavingsPlanDisclosureTextBlock" xlink:label="loc_moddRetirementSavingsPlanDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureRetirementSavingsPlanAbstract" xlink:to="loc_moddRetirementSavingsPlanDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_LiquidityPolicyTextBlock" xlink:label="loc_moddLiquidityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_moddRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000025 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureLeaseDetailsAbstract" xlink:label="loc_moddDisclosureLeaseDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddDisclosureLeaseDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureLeasesDetailsAbstarct" xlink:label="loc_moddDisclosureLeasesDetailsAbstarct" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddDisclosureLeasesDetailsAbstarct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables" xlink:title="00000026 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetailsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails3Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddDisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddDisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails2Abstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails3Abstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetailsAbstract" xlink:label="loc_moddDisclosureIncomeTaxesDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetails2Abstract" xlink:label="loc_moddDisclosureIncomeTaxesDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureIncomeTaxesDetails3Abstract" xlink:label="loc_moddDisclosureIncomeTaxesDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetails3Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000031 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_OperatingLeasesImputedInterest" xlink:label="loc_moddOperatingLeasesImputedInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddOperatingLeasesImputedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000032 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:label="loc_moddOperatingLeasesAnnualRentIncreasePercentange" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddOperatingLeasesAnnualRentIncreasePercentange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_LeaseIncentiveReceived" xlink:label="loc_moddLeaseIncentiveReceived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddLeaseIncentiveReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="loc_moddCashPaidforLeaseLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddCashPaidforLeaseLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PPP NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000037 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_NotesCancelled" xlink:label="loc_moddNotesCancelled" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_moddNotesCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventDetailsNarrative" xlink:title="00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedWagesAndBonusMember" xlink:label="loc_moddAccruedWagesAndBonusMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedWagesAndBonusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedPlacementFeesMember" xlink:label="loc_moddAccruedPlacementFeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedPlacementFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedInterestMember" xlink:label="loc_moddAccruedInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_AccruedOtherExpensesMember" xlink:label="loc_moddAccruedOtherExpensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedOtherExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000046 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000047 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000048 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20210630.xsd#modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_moddEffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddEffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000049 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000050 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>modular_s1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:modd="http://modular-medical.com/20210630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="modd-20210630.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-02</instant>
        </period>
    </context>
    <context id="From2020-04-012020-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2017-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CEOAndInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-08-11_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedWagesAndBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedWagesAndBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedPlacementFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedPlacementFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2021-06-30">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2021-06-30">false</dei:AmendmentFlag>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-04-01to2021-06-30"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012021-06-30_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012021-06-30_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-01to2021-06-30">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-04-01to2021-06-30">P1Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:CommonStockIssuable
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0726"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0731"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0800"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-04-012021-03-31_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-04-012021-03-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedPlacementFeesMember"
      id="xdx2ixbrl0891"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedInterestMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl1085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-04-01to2021-06-30">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2021-06-30">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-04-01to2021-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-04-01to2021-06-30">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2021-06-30">16772 W. Bernardo Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-01to2021-06-30">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-04-01to2021-06-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2021-06-30">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-04-01to2021-06-30">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-04-01to2021-06-30">800-3500</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2021-04-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-04-01to2021-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-04-01to2021-06-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-04-01to2021-06-30">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3380968</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">80830</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">178158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4632</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2466</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3466430</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1649089</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">294384</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">181499</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200124</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">575883</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">599082</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4042313</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">462615</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">169284</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">511990</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">130142</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125500</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4369440</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2133453</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">5474187</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3296965</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">149614</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">184355</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">5623801</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3523320</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">18971656</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">18971656</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">18906148</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">18906148</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">18972</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">18906</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">19181641</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">14652955</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-20782101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-15947010</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-1581488</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4042313</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">1788131</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">970815</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">1585456</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">903397</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">3373587</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1874212</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-3373587</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1874212</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">368823</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">55</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">508877</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">18954340</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">18334482</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18906148</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14652955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">172140</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">172200</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <modd:ShareBasedCompensationShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5508</modd:ShareBasedCompensationShares>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">655914</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">655920</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18971656</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18972</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19181641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20782101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-1581488</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">17870261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">17870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10505592</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8569034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">729897</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">730</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2041898</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1118634</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">344716</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">344716</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18600158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18600</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12892206</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10443191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">2467615</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-368780</modd:GainOnPPPNoteForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">655920</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">344716</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">24649</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">24986</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">266910</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-18625</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">19593</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-30099</modd:IncreaseDecreaseInLeaseLiability>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">121204</modd:IncreaseDecreaseInLeaseLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">338619</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">2</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-575</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-451</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-13478</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">402723</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-117607</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-2204621</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1507548</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">20076</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">12934</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-20076</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-12934</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1170808</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">4137200</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">368780</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">4137200</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1539588</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">1912503</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">19106</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3380968</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">3141240</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_znsMCbFUIpT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_820_zch3DXJAL2Ji"&gt;THE COMPANY AND
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#x201c;basal&#x201d; delivery allowing a small amount
of insulin to be in the blood at all times and a &#x201c;bolus&#x201d; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zP0bhh1ad0t3" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_z5DYXfoSdPNd"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going Concern&lt;/i&gt;, requires
management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&#160;If
management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going
concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the
plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue as a going
concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity must include
a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s ability
to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal
conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2) management&#x2019;s
evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet its obligations,
and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#x2019;s
ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#x2019;s
plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional capital,
through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such
additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such
capital will be offered on terms and conditions acceptable to the Company.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS50JxFyrXhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUd2jEQDs2k8"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
fiscal year ends on March 31 of each calendar year.&#160;Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal&#160;2022&#160;refers
to the fiscal year ending&#160;March&#160;31, 2022). The condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Quasuras, Inc. All significant intercompany transactions and balances have been eliminated
in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying
condensed consolidated financial statements of the Company have been prepared without audit.&#160;The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC). The information in this report should be read in conjunction with the Company&#x2019;s consolidated
financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#x2019;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zdNMeBvdrMG6" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zNULOOVfYZqf"&gt;Use
of Estimates&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBVaERNbaRdg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zqYed8dss7ce"&gt;Reportable Segment&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one
business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zl1DVRRsI7Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zVYmUBbNPvGh"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5Sl9CpZTL39" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zap7DK35VZr2"&gt;General and Administrative&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJ9zWZdhZf4f" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zIOaCa9WuI56"&gt;Concentration
of Credit Risk&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&#160;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/&gt;

&lt;p id="xdx_84C_ecustom--RisksAndUncertaintiesPolicyTextBlock_zRkpppeZuZsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zOzaeijQf4M4"&gt;Risks
and Uncertainties&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQcKX7Pvqo0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zz1LxsPhAfo9"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk3RqqL1ocJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zIKvhxIuoTA8"&gt;Property &amp;amp; Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zi3kilqgb5D1" title="::XDX::3"&gt;three&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zRnszKAR0bbd" title="::XDX::5"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zykOpbp9ZKu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zaNJq3OZWuDa"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 inputs to the valuation
methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 inputs to the valuation
methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 inputs to the valuation
methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to
their short-term nature, the carrying values of cash equivalents, accounts payable, accrued expenses and notes payable approximate
fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfdYFZHKMHQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zcLqvdLJqyx4"&gt;Per-Share Amounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For
the three months ended June 30, 2021 and 2020, outstanding options to purchase &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_za1mTS6um7Bg"&gt;3,751,437&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z7oZc56jjaCa"&gt;3,407,587&lt;/span&gt; shares of common stock
were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyEVxFlqxohh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zrkQy9CE9Mm4"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRRfC5iABdsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zpXgx0O2bWK3"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30,
2021 and 2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeacMZKZELzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zl7WyuBQNj6l"&gt;Recently
Adopted Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In August 2020, the FASB issued ASU
No. 2020-06, &lt;i&gt;Debt&lt;/i&gt;&#160;&lt;i&gt;with Conversion and Other Options&lt;/i&gt;&#160;&lt;i&gt;(Subtopic 470-20) and Derivatives and Hedging-Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/i&gt;(ASU
2020-06)&lt;i&gt;.&lt;/i&gt;&#160;ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models required
under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no
separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for
equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU
2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective April 1, 2021, and the
impact of the adoption was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zP0bhh1ad0t3" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_z5DYXfoSdPNd"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going Concern&lt;/i&gt;, requires
management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about
the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&#160;If
management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going
concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the
plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue as a going
concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity must include
a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s ability
to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal
conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2) management&#x2019;s
evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet its obligations,
and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#x2019;s
ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#x2019;s
plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional capital,
through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such
additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such
capital will be offered on terms and conditions acceptable to the Company.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</modd:LiquidityPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS50JxFyrXhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUd2jEQDs2k8"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
fiscal year ends on March 31 of each calendar year.&#160;Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal&#160;2022&#160;refers
to the fiscal year ending&#160;March&#160;31, 2022). The condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Quasuras, Inc. All significant intercompany transactions and balances have been eliminated
in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying
condensed consolidated financial statements of the Company have been prepared without audit.&#160;The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC). The information in this report should be read in conjunction with the Company&#x2019;s consolidated
financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#x2019;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zdNMeBvdrMG6" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zNULOOVfYZqf"&gt;Use
of Estimates&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBVaERNbaRdg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zqYed8dss7ce"&gt;Reportable Segment&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one
business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zl1DVRRsI7Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zVYmUBbNPvGh"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5Sl9CpZTL39" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zap7DK35VZr2"&gt;General and Administrative&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJ9zWZdhZf4f" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zIOaCa9WuI56"&gt;Concentration
of Credit Risk&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&#160;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84C_ecustom--RisksAndUncertaintiesPolicyTextBlock_zRkpppeZuZsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zOzaeijQf4M4"&gt;Risks
and Uncertainties&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQcKX7Pvqo0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zz1LxsPhAfo9"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk3RqqL1ocJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zIKvhxIuoTA8"&gt;Property &amp;amp; Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zi3kilqgb5D1" title="::XDX::3"&gt;three&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zRnszKAR0bbd" title="::XDX::5"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zykOpbp9ZKu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zaNJq3OZWuDa"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 inputs to the valuation
methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 inputs to the valuation
methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 inputs to the valuation
methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to
their short-term nature, the carrying values of cash equivalents, accounts payable, accrued expenses and notes payable approximate
fair value.&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfdYFZHKMHQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zcLqvdLJqyx4"&gt;Per-Share Amounts&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For
the three months ended June 30, 2021 and 2020, outstanding options to purchase &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_za1mTS6um7Bg"&gt;3,751,437&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z7oZc56jjaCa"&gt;3,407,587&lt;/span&gt; shares of common stock
were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">3751437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">3407587</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyEVxFlqxohh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zrkQy9CE9Mm4"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRRfC5iABdsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zpXgx0O2bWK3"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30,
2021 and 2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeacMZKZELzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zl7WyuBQNj6l"&gt;Recently
Adopted Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In August 2020, the FASB issued ASU
No. 2020-06, &lt;i&gt;Debt&lt;/i&gt;&#160;&lt;i&gt;with Conversion and Other Options&lt;/i&gt;&#160;&lt;i&gt;(Subtopic 470-20) and Derivatives and Hedging-Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/i&gt;(ASU
2020-06)&lt;i&gt;.&lt;/i&gt;&#160;ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models required
under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no
separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for
equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU
2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective April 1, 2021, and the
impact of the adoption was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_807_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zt1Ic83YlFs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_822_zYSTuApIomm7"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April
1, 2019, the Company adopted ASU No. 2016-02,&#160;&lt;i&gt;Leases&#160;&lt;/i&gt;(ASC 842),&lt;i&gt;&#160;&lt;/i&gt;and related ASUs, as amended, using
the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the
&#x201c;effective date method&#x201d;). In January 2020, the Company executed a lease for a new, larger corporate facility in San
Diego, California&#160;&lt;span style="background-color: white"&gt;and paid a $100,000 security deposit.&lt;/span&gt;&#160;The &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_z6KyHj6Qz5Mb"&gt;39&lt;/span&gt;-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $&lt;span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent"&gt;12,400&lt;/span&gt;&lt;span style="background-color: white"&gt;&#160;with
annual rent increases of approximately &lt;span id="xdx_904_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zoQzdrxSonPi" title="Operating Lease Annual Rent Increase Percentage"&gt;3%&lt;/span&gt;.&#160;&lt;/span&gt;In addition to the minimum lease payments, the Company is responsible for
property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility
lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated
the Company&#x2019;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized
on a straight line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
obtained a right-of-use asset of $&lt;span id="xdx_902_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z0wwJgEA7pe7"&gt;270,950&lt;/span&gt; in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $&lt;span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zaCDSyZC1nP2" title="Lease Incentive Received"&gt;139,000&lt;/span&gt;, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z5HZ4L20eB9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdEpQCkJFzYj"&gt;Future minimum
payments under the facility operating lease, as of June 30, 2021, are listed in the table below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeaseDetailsAbstract_zKN0EWmy5i8a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210630_zVOlOCGmZcXa" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;lease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_z3t0HyaeYl44" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;115,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_zK62Imh2n4Gl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zshoydplaCTl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zSMq2d3uIwD3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(34,038&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zSrCqh8htHu2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zDDLLBqGohk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
paid for amounts included in the measurement of lease liabilities was $&lt;span id="xdx_908_ecustom--CashPaidforLeaseLiabilities_iI_c20210630_zacg8xjxCiNg" title="Cash paid for amounts included in the measurement of lease liabilities"&gt;48,085&lt;/span&gt;. Rent expense was $&lt;span id="xdx_90F_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_zagodc8eUrO3"&gt;26,884&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_zGqzwmCOJlQk"&gt;26,885&lt;/span&gt; for the three
months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-04-02">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-04-30"
      decimals="0"
      unitRef="USD">12400</us-gaap:LeaseAndRentalExpense>
    <modd:OperatingLeasesAnnualRentIncreasePercentange contextRef="AsOf2020-04-02" decimals="INF" unitRef="Pure">0.03</modd:OperatingLeasesAnnualRentIncreasePercentange>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <modd:LeaseIncentiveReceived contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">139000</modd:LeaseIncentiveReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z5HZ4L20eB9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdEpQCkJFzYj"&gt;Future minimum
payments under the facility operating lease, as of June 30, 2021, are listed in the table below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <modd:DisclosureLeaseDetailsAbstract contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeaseDetailsAbstract_zKN0EWmy5i8a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210630_zVOlOCGmZcXa" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;lease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_z3t0HyaeYl44" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;115,074&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_zK62Imh2n4Gl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zshoydplaCTl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zSMq2d3uIwD3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(34,038&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zSrCqh8htHu2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureLeaseDetailsAbstract>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">115074</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">158028</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">40692</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <modd:OperatingLeasesImputedInterest contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-34038</modd:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">279756</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <modd:CashPaidforLeaseLiabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">48085</modd:CashPaidforLeaseLiabilities>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">26884</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">26885</us-gaap:LeaseAndRentalExpense>
    <modd:PPPNotesPayableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80A_ecustom--PPPNotesPayableTextBlock_zjuXw9H2hdxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_821_zzrX3ReFL8S9"&gt;PPP NOTE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April 24,
2020, the Company received a $&lt;span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zN9wm3m1F9Si" title="Unsecured Loan Received under Paycheck Protection Program"&gt;368,780&lt;/span&gt; unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount
of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%
per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company applied
to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender and the U.S.
Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company
accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470: &lt;i&gt;Debt&lt;/i&gt; (ASC 470),
and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the condensed consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:PPPNotesPayableTextBlock>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2020-04-24" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zdJmBfjQSqhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_824_zF8wCZbz8sqg"&gt;CONVERTIBLE PROMISSORY NOTES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (the Original Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective
April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation
Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate
principal amount of Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC
470 and recorded a loss on extinguishment of $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20210630_zcI9jyvl89zh"&gt;1,321,450&lt;/span&gt; and interest expense of $&lt;span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_c20210401__20210630_zdDBSg77JXzd"&gt;70,647&lt;/span&gt; for unamortized debt issuance costs as of April 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In April and May
2021, pursuant to a Securities Purchase Agreement (the SPA), the Company sold to investors $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zEo8x8D4RxPa"&gt;4,250,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;aggregate principal amount of convertible promissory notes (the Notes) and warrants
to purchase shares of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated
maturity date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the
maximum amount permitted by law. Each Note may be prepaid at the Company&#x2019;s option during the first 270 calendar days following
its Issue Date (the 270&lt;sup&gt;th&lt;/sup&gt;&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued
interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Notes outstanding after the Trigger Date may be
converted into shares of the Company&#x2019;s common stock at an initial conversion price of $2.87 per share; provided that a Note holder
may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company&#x2019;s outstanding
common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment
from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes.
Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any
shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price,
such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes
shall be increased, as provided in the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the Company completes an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise), each Note holder will be required to convert its Adjusted Note
Amount into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under
the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements
of the Company&#x2019;s consolidated financial statements filed with the SEC, (vi) a holder&#x2019;s inability to rely on Rule 144 for
sales of shares underlying the Notes, (vii) the Company&#x2019;s common stock is suspended or halted from trading and/or fails to be quoted
or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American
within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock
underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement
to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and
sales of all or substantially all of the Company&#x2019;s assets in the event the Company is not the survivor of such transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon an Event of
Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay
such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by
(b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in
the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or
any lesser outstanding amounts due under such holder&#x2019;s Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes include covenants, representations,
warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights
of participation and first refusal and exchange rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection with the issuance of the Notes, the Company issued Warrants
to purchase in the aggregate 2,303,348 shares of its common stock at an initial exercise price of $8.00 per share. The Warrants may be
exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified
Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder&#x2019;s Note(s) in whole or in part, such holder&#x2019;s
pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt
discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the
Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20210630_zLQhFeUgY766" title="Volatility Risk"&gt;88.98%&lt;/span&gt;, risk-free interest rate of
&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630_zTTyMnWBesig"&gt;0.86%&lt;/span&gt;, a term of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210401__20210630_zdBR3FIznx6b" title="::XDX::P5Y9M"&gt;5.75&lt;/span&gt; years and a dividend yield of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcp_c20210401__20210630_zVUrwzwUzpgj"&gt;zero&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection with
the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000,
which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest
rate method.&#160;The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the
three months ended June 30, 2021 was approximately $338,619.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. As of June 30, 2021, the Notes and accrued interest could
be converted into &lt;span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20210630_ze1tj2H1r0S8" title="Notes and Accured Interest could be converted into Common Stock"&gt;2,354,653&lt;/span&gt; shares of common stock at a conversion price of $2.87 per share.&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">70647</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      unitRef="USD">4250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.8898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">2354653</modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_804_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3fT2NLfwrD1" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_827_zrIbQ6VC2YH6"&gt;STOCKHOLDERS&#x92; EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;During the three months ended June
30, 2021, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630_zEONyLqg5Yj2"&gt;60,000&lt;/span&gt; shares of common stock to a service provider.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2017 Equity Incentive Plan&#160;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In October 2017,
the Board approved the 2017 Equity Incentive Plan (the Plan) with &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zrTxKqnMBzB1" title="Common Shares Reserved for Issuance under Equity Incentive Plan"&gt;3,000,000&lt;/span&gt; shares of common stock reserved for issuance. In January
2020, the Board approved an increase in the number of shares reserved for issuance by &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zs8YHRuMHaHc"&gt;1,000,000&lt;/span&gt; shares. Under the Plan, eligible
employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights,
restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative,
a committee designated by the Board.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock-Based Compensation
Expense&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. As of June 30, 2021, the unamortized compensation cost was $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630_zpCqXHHc8Eoh"&gt;2,288,683&lt;/span&gt; related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxH_c20210401__20210630_zY4bYFgLShGk" title="::XDX::P1Y11M8D"&gt;1.94 years&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the three months ended June 30, 2021, the Company granted 5,508 shares to members of its board of directors (the Board) in accordance
with its Board compensation plan for non-employee directors. During the three months ended June 30, 2021, the Company granted
options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zg1c5pEi9Fv1"&gt;182,321&lt;/span&gt; shares of its common stock to employees, directors and consultants. The options had 10-year terms,
and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2ewzSEiyrB3"&gt;47,320&lt;/span&gt; options granted on June 30, 2020, in accordance with its Board compensation plan for non-employee directors, vested immediately.
During the three months ended June 30, 2021, the fair value of the options granted was $&lt;span id="xdx_903_ecustom--FairValueofOptionGranted_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJDhrruAbBV1" title="fair Value of Options Granted"&gt;698,093&lt;/span&gt;, and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXdiNUaz4K22"&gt;300,918&lt;/span&gt; was recorded as
stock-based compensation expense in the condensed consolidated statement of operations.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following assumptions were used
in the fair value calculations:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_z7jlNufFnNB3" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Three
    Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June
    30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June
    30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates"&gt;0.81%&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e"&gt;0.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj"&gt;0.31%&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl"&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility"&gt;89%&lt;/span&gt;
                                         - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8"&gt;366&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9"&gt;123%&lt;/span&gt;
                                         - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi"&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AE_zNTMtfaHyqji" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury
Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms
of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay
dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A summary
of stock option activity under the EIP is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B2_zGHkWyRpu0S9" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance"&gt;408,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance"&gt;3,591,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted"&gt;(182,321&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted"&gt;182,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted"&gt;4.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards"&gt;(5,508&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan"&gt;22,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan"&gt;(22,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan"&gt;2.87&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance"&gt;243,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance"&gt;3,751,437&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zx3WXn833YCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;There were no
stock options exercised during the three months ended June 30, 2021 and 2020.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zXSFOOU6AIe7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value"&gt;0.66&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;3,751,437&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D"&gt;8.09&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable"&gt;2,420,577&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;1.47&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable"&gt;10,761,492&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zP90vxl5TV5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The intrinsic value per share is
calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading market over the exercise
price of the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the three months ended June 30, 2021
and 2020, there were no such tax benefits associated with the exercise of stock options.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-10-31" decimals="INF" unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-01-31" decimals="INF" unitRef="Shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2288683</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">182321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">47320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <modd:FairValueofOptionGranted
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">698093</modd:FairValueofOptionGranted>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">300918</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following assumptions were used
in the fair value calculations:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_z7jlNufFnNB3" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetailsAbstract contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Three
    Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June
    30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;June
    30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates"&gt;0.81%&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e"&gt;0.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj"&gt;0.31%&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl"&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility"&gt;89%&lt;/span&gt;
                                         - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8"&gt;366&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9"&gt;123%&lt;/span&gt;
                                         - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi"&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012021-06-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012021-06-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012020-06-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012020-06-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012021-06-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012021-06-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012020-06-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012020-06-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012021-06-30_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012021-06-30_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012020-06-30_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012020-06-30_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A summary
of stock option activity under the EIP is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B2_zGHkWyRpu0S9" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails2Abstract contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance"&gt;408,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance"&gt;3,591,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted"&gt;(182,321&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted"&gt;182,321&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted"&gt;4.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards"&gt;(5,508&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan"&gt;22,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan"&gt;(22,639&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan"&gt;2.87&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance"&gt;243,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance"&gt;3,751,437&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">408245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3591755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-182321</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">182321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-5508</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">22639</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">22639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">243055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3751437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zXSFOOU6AIe7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails3Abstract contextRef="From2021-04-01to2021-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value"&gt;0.66&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value"&gt;5.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;3,751,437&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D"&gt;8.09&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable"&gt;2,420,577&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;1.47&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable"&gt;10,761,492&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3751437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2420577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">10761492</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zAjAjm2kQUCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_82E_zVm2Wnp4JuBg"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
for fiscal 2016 to fiscal 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of June 30,
2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmg12AlJhzaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82A_zqwWgWQXTft2"&gt;RELATED
PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;2021 Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In February
2021, the Company&#x2019;s chief executive officer and an existing investor, who is represented by a member of the Company&#x2019;s board
of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively.&#160;Effective April
30, 2021, the Related Party Holders entered into Revocation Agreements with the Company pursuant to which their collective $&lt;span id="xdx_90D_ecustom--NotesCancelled_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zTGZuJroHhIk" title="Notes Cancelled"&gt;1,100,000&lt;/span&gt;
aggregate principal amount of Original Notes and accrued interest of $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpWavPINNG35"&gt;50,091
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;were replaced with Notes. &lt;span style="background-color: white"&gt;At June 30, 2021,
the investor and executive officer held Notes in an aggregate principal amount of $&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zHtwkZl74XA1"&gt;1,026,630
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;and $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zTUw14m2hb6d"&gt;102,663&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;,
respectively, with $&lt;span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zIf2otZtXfSi"&gt;20,589
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;and $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zCq8kn5bjVS3"&gt;2,059
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;of interest payable thereon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In May 2021, a member
of the Board purchased $&lt;span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zJCHYJM0yZo9"&gt;200,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;aggregate principal amount of Notes. &lt;span style="background-color: white"&gt;At
June 30, 2021, approximately $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zeG2zbPxxgw2"&gt;4,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;of interest was payable by the Company thereon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <modd:NotesCancelled
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember"
      decimals="INF"
      unitRef="Shares">1100000</modd:NotesCancelled>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember"
      decimals="0"
      unitRef="USD">50091</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">1026630</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">102663</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">20589</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-06-30_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">2059</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-05-31_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-06-30_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zylavMPp90ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 8 &#x2013;
&lt;span id="xdx_827_zn3xkZCfqzbb"&gt;COMMITMENTS &amp;amp; CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&#x2019;s consolidated financial statements
for the three months ended June&#160;30, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements,
and no claims for payment have been made under such agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-04-01to2021-06-30">&lt;p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zt3BFuUIvZEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_821_z0q4d0zkLMue"&gt;SUBSEQUENT EVENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 11, 2021, the Board approved an increase in the number of shares reserved for issuance under the Plan by 4,000,000 shares, bringing
the total shares reserved for issuance to &lt;span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zScfyU9QtPo5"&gt;8,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-08-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">178158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">63853</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2466</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">306</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1649089</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3186293</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">301308</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200124</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">270950</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">599082</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">672258</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3858551</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">169284</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">367019</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">202160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125500</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">92214</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2133453</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3296965</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">661393</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">184355</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">178736</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">140000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3523320</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">980129</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">18906148</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">18906148</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">17870261</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">17870261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">18906</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">17870</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">14652955</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">10505592</us-gaap:AdditionalPaidInCapital>
    <modd:CommonStockIssuable contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-923994</modd:CommonStockIssuable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-15947010</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-8569034</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3858551</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4083303</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">3034152</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">3253412</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">2313870</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7336715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">5348022</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7336715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5348022</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">130</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">28749</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">39791</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7376376</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5319273</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">18634686</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">17864769</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">17840261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">17840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9684578</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">19800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3248161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">6474057</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">30</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19770</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-19800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">17870261</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">17870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10505592</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8569034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">962387</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">962</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2708914</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">73500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">74</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">210871</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">210945</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18906148</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14652955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">111015</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">35431</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">68880</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">70826</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">38905</modd:IncreaseDecreaseInLeaseLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">12253</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1004</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-25600</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">48391</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-92500</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-86747</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">530250</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-5908662</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-4094839</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">109669</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">260789</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-109669</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-260789</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2210000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">368780</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4364662</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1653669</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-3431634</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">6553768</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note&#160;1 &#x2013; &lt;span id="xdx_82E_zMUTozRktbd4"&gt;THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#x201c;basal&#x201d; delivery allowing a small amount
of insulin to be in the blood at all times and a &#x201c;bolus&#x201d; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zDQdXEmUbbvb"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going&#160;&lt;/i&gt;Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2)
management&#x2019;s evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet
its obligations, and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zgcZE7UT1anf"&gt;Basis of
Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#x2019;s fiscal year ends on March 31 of each calendar
year.&lt;b&gt;&#160;&lt;/b&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zkVTFpwCYJTh"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zYSzqPmtkea"&gt;Reportable Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business
segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zhvjzB3hriT2"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvwI2K5ZXTqd"&gt;Risks and
Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z90kSs4OLyka"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUcEsPUJ4DLc"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zymGf4t6LgG9" title="::XDX::3"&gt;three&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQzo91I1zBLh" title="::XDX::5"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z3q4LBjYHSv1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zIfOdHenFOg9"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zGAah61b4eJa"&gt;General and
Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zNRpWSNYg7F3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;



&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNciwlCAEoM4"&gt;Per-Share
Amounts&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"&gt;3,591,755&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"&gt;3,177,945&lt;/span&gt; outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zszo70i8EdZa"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6I11cISyor1"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zDQdXEmUbbvb"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going&#160;&lt;/i&gt;Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2)
management&#x2019;s evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet
its obligations, and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:LiquidityPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zgcZE7UT1anf"&gt;Basis of
Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#x2019;s fiscal year ends on March 31 of each calendar
year.&lt;b&gt;&#160;&lt;/b&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-04-012021-03-31">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zkVTFpwCYJTh"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zYSzqPmtkea"&gt;Reportable Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business
segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zhvjzB3hriT2"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvwI2K5ZXTqd"&gt;Risks and
Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z90kSs4OLyka"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUcEsPUJ4DLc"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zymGf4t6LgG9" title="::XDX::3"&gt;three&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQzo91I1zBLh" title="::XDX::5"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-04-012021-03-31">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z3q4LBjYHSv1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-04-012021-03-31">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zIfOdHenFOg9"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zGAah61b4eJa"&gt;General and
Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zNRpWSNYg7F3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;



</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNciwlCAEoM4"&gt;Per-Share
Amounts&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"&gt;3,591,755&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"&gt;3,177,945&lt;/span&gt; outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">3591755</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">3177945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zszo70i8EdZa"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6I11cISyor1"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <modd:ConsolidatedBalanceSheetDetailTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;2 &#x2013; &lt;span id="xdx_829_zEATFVQb0qp3"&gt;CONSOLIDATED
BALANCE SHEET DETAIL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zHWRXpwdOD49" style="display: none; font-family: Arial, Helvetica, Sans-Serif"&gt;Schedule of
Property Plant And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;353,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 17.3pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(51,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;301,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"/&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"&gt;&lt;span id="xdx_8B4_zcJkXV60NCF2" style="display: none"&gt;Schedule of Accured Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:ConsolidatedBalanceSheetDetailTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zHWRXpwdOD49" style="display: none; font-family: Arial, Helvetica, Sans-Serif"&gt;Schedule of
Property Plant And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <modd:DisclosureConsolidatedBalanceSheetDetailsAbstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;353,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 17.3pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(51,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;301,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureConsolidatedBalanceSheetDetailsAbstract>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">56476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">49724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">52383</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">51882</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">202993</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">112198</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">451049</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">353001</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">152091</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">51693</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"&gt;&lt;span id="xdx_8B4_zcJkXV60NCF2" style="display: none"&gt;Schedule of Accured Expenses&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <modd:DisclosureConsolidatedBalanceSheetDetails2Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureConsolidatedBalanceSheetDetails2Abstract>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedWagesAndBonusMember"
      decimals="0"
      unitRef="USD">372563</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedWagesAndBonusMember"
      decimals="0"
      unitRef="USD">198160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedPlacementFeesMember"
      decimals="0"
      unitRef="USD">88800</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedInterestMember"
      decimals="0"
      unitRef="USD">27538</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedOtherExpensesMember"
      decimals="0"
      unitRef="USD">11047</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedOtherExpensesMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">202160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_82D_zcREI3129Eqe"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;PPP Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Convertible
Promissory Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#x2019;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#x2019;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#x201c;Change of Control&#x201d;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#x2019;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#x2019;s assets, or the exclusive license of all or substantially
all of the Company&#x2019;s material intellectual property; or (iv) the dissolution and winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method.&#160;&#160;The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_825_zi2Nz2cefmjg"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#x201c;effective date method&#x201d;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;&lt;span style="background-color: white"&gt;and paid a $100,000 security
deposit.&lt;/span&gt; The &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_zC0Ttcd6sMx5"&gt;39&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;-month
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $&lt;span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6"&gt;12,400&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;&#160;with
annual rent increases of approximately &lt;span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl"&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;.&#160;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#x2019;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
obtained a right-of-use asset of $&lt;span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg"&gt;270,950&lt;/span&gt; in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $&lt;span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received"&gt;139,000&lt;/span&gt;, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4ymE4sowwz9"&gt;Future minimum
payments under the facility operating lease, net of the lease incentive&lt;/span&gt;, as of March 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
    Fiscal Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 87%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;153,432&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;158,028&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,692&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Imputed
    interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(42,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value
    of lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;309,855&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rent expense
was $&lt;span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1"&gt;107,540&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg"&gt;35,766&lt;/span&gt; for the years ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-04-02">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-04-30"
      decimals="0"
      unitRef="USD">12400</us-gaap:LeaseAndRentalExpense>
    <modd:OperatingLeasesAnnualRentIncreasePercentange contextRef="AsOf2020-04-02" decimals="INF" unitRef="Pure">0.03</modd:OperatingLeasesAnnualRentIncreasePercentange>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-04-01to2021-06-30"
      decimals="0"
      unitRef="USD">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <modd:LeaseIncentiveReceived contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">139000</modd:LeaseIncentiveReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4ymE4sowwz9"&gt;Future minimum
payments under the facility operating lease, net of the lease incentive&lt;/span&gt;, as of March 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <modd:DisclosureLeasesDetailsAbstarct contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
    Fiscal Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 87%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;153,432&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;158,028&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,692&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Imputed
    interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(42,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value
    of lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;309,855&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureLeasesDetailsAbstarct>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">153432</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">158028</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">40692</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <modd:OperatingLeasesImputedInterest contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-42297</modd:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">309855</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">107540</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">35766</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 5 &#x2013;
&lt;span id="xdx_82A_zCTmmfmICWHf"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Equity Compensation
Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In October 2017,
the Company&#x2019;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The exercise
or purchase price of a stock option shall be calculated as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(iii)&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of other grants, such price as determined by the Board.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following &lt;span id="xdx_8B5_zlf1rY5Degjc"&gt;assumptions were used
in the fair-value method calculations&lt;/span&gt;:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"&gt;0.28%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"&gt;0.77%&lt;/span&gt;
    - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"&gt;2.37%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"&gt;87%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"&gt;86%&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"&gt;103%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of &lt;span id="xdx_8BD_zo1WcKMoXVka"&gt;stock option activity
&lt;/span&gt;under the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning"&gt;1,470,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"&gt;1,529,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"&gt;0.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right"&gt;(1,717,204&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"&gt;1,717,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"&gt;69,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right"&gt;(69,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"&gt;822,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"&gt;3,177,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right"&gt;(490,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"&gt;490,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"&gt;76,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right"&gt;(76,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;408,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,591,755&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;There were no
stock options exercised during the years ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table &lt;span id="xdx_8BD_z7khsmxDY1Ib"&gt;summarizes the range of outstanding and exercisable options&lt;/span&gt; as of March 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"&gt;0.66&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;3,591,755&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;2,228,738&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1.32&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8,763,260&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading
market over the exercise price of the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following &lt;span id="xdx_8B5_zlf1rY5Degjc"&gt;assumptions were used
in the fair-value method calculations&lt;/span&gt;:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetailsAbstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"&gt;0.28%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"&gt;0.77%&lt;/span&gt;
    - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"&gt;2.37%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"&gt;87%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"&gt;86%&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"&gt;103%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-04-012020-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-04-012020-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-012020-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-012020-03-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of &lt;span id="xdx_8BD_zo1WcKMoXVka"&gt;stock option activity
&lt;/span&gt;under the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails2Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning"&gt;1,470,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"&gt;1,529,908&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"&gt;0.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right"&gt;(1,717,204&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"&gt;1,717,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"&gt;69,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right"&gt;(69,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"&gt;822,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"&gt;3,177,945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right"&gt;(490,476&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"&gt;490,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"&gt;76,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right"&gt;(76,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;408,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,591,755&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31" decimals="INF" unitRef="Shares">1470092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1529908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">-1717204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1717204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">69167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-69167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">822055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3177945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">-490476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">490476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">76666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-76666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">408245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3591755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table &lt;span id="xdx_8BD_z7khsmxDY1Ib"&gt;summarizes the range of outstanding and exercisable options&lt;/span&gt; as of March 31, 2021:&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails3Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"&gt;0.66&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"&gt;3.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;3,591,755&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;2,228,738&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1.32&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8,763,260&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">3591755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember">P8Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2228738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember">P1Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">8763260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_820_zIsr1RW0bfL9"&gt;STOCKHOLDERS&#x2019;
EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Private Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi"&gt;962,387&lt;/span&gt; shares of common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;


</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">962387</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z2XCnSbkNPR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82B_zeLxB1QYD8T7"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7iCGckuioJk" style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zkLl6W2dr03b"&gt;The income tax provision (benefit)&lt;/span&gt;
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureIncomeTaxesDetailsAbstract_zbVBEAN7cKw1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200401__20210331_ztSxkPwaaWR5" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_490_20190401__20200331_zhLLp8WLso9f" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zd2dOCWLZl2i" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentFederalTaxExpenseBenefit_maCFSALz4R3_zhIpiEKpDuJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCFSALz4R3_zA3pgAtPVAka" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_iT_mtCFSALz4R3_maITEBz8S7_zZMsFMMkNTr9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_ztaZNPpd7GY8" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDFSALzhVS_zoB8M39MpjV1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,180,434&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDFSALzhVS_z4BXs0FC0Hx9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(576,868&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(391,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_mtDFSALzhVS_maITEBz8S7_zXlIPxK2RK27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,508,258&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,572,299&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz8S7_zOCDceZhLZN5" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,508,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,572,299&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz8S7_zd2Km15EqQb7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zKsXvv4mOPz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March&#160;31,
2021, the Company had net operating loss carryforwards (NOLs) of approximately $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zCb2U91pDzFh" title="Net operating loss carry-forwards"&gt;13,954,000&lt;/span&gt; for federal income tax purposes and
$&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zq2a5tUTHKN8"&gt;14,019,000&lt;/span&gt; for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various
times from 2037 through 2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
also had federal research and development tax credit carryforwards of approximately $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zn5lkCD7Ko9j" title="Research and development tax credit carryforwards"&gt;535,000&lt;/span&gt;, which will begin expiring at various
times from 2038 through 2040, and state research and development credits of approximately $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaf2FE54j0J8"&gt;141,000&lt;/span&gt;, which do not have an expiration
date.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2QPCYm7wRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B9_zPiF9iXic74"&gt;A reconciliation
of income taxes provided at the federal statutory&lt;/span&gt; rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as
follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zKHCyQBsNjhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"/&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_497_20200401__20210331_zhZ1R8N4N3u2" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20190401__20200331_zByr8s5uhp62" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zMrYSIOdPoJj" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; width: 74%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z9Sg8wMY9tNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_z8cnsaHP9G1e" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp_zWMUO54kfvPa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_zTKF4a4Gwi9g" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zOvToIQp2qv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;34&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;31&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zmg7615yhEdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zMZKqmc9Kta3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKlxfbzXdl0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BC_z9UCzdyF51Qb"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities&lt;/span&gt; were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureIncomeTaxesDetails3Abstract_zgaQQA7WvHOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_494_20210331_zFwEknJN9A71" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_495_20200331_zpYIhwrNwMEi" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzESI_zVsERk4fIaN4" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;3,909,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,965,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzESI_zuSZcDPf7mwg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;554,892&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;364,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzESI_zVusbhzB68dg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,039&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzESI_zaeHzNm7ytae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserves, accruals &amp;amp; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzESI_zdZCqqLe3rZh" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;646,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;237,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzESI_maDTANzJrK_z7nmZkOz2Kb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,012,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,567,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzJrK_zyJTnNkQp2Fb" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,012,705&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,567,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzJrK_zDuWqpNBID8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zLDjVDnF8NIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Based on the
available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2021 and 2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net
deferred tax assets at March 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Management has
evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated
financial statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7iCGckuioJk" style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zkLl6W2dr03b"&gt;The income tax provision (benefit)&lt;/span&gt;
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <modd:DisclosureIncomeTaxesDetailsAbstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureIncomeTaxesDetailsAbstract_zbVBEAN7cKw1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200401__20210331_ztSxkPwaaWR5" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_490_20190401__20200331_zhLLp8WLso9f" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zd2dOCWLZl2i" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentFederalTaxExpenseBenefit_maCFSALz4R3_zhIpiEKpDuJ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCFSALz4R3_zA3pgAtPVAka" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_iT_mtCFSALz4R3_maITEBz8S7_zZMsFMMkNTr9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_ztaZNPpd7GY8" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDFSALzhVS_zoB8M39MpjV1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,180,434&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDFSALzhVS_z4BXs0FC0Hx9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(576,868&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(391,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_mtDFSALzhVS_maITEBz8S7_zXlIPxK2RK27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,508,258&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,572,299&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz8S7_zOCDceZhLZN5" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,508,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,572,299&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz8S7_zd2Km15EqQb7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureIncomeTaxesDetailsAbstract>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1931390</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1180434</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-576868</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-391865</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-2508258</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1572299</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2508258</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1572299</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">13954000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">14019000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">535000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">141000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2QPCYm7wRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B9_zPiF9iXic74"&gt;A reconciliation
of income taxes provided at the federal statutory&lt;/span&gt; rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as
follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <modd:DisclosureIncomeTaxesDetails2Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zKHCyQBsNjhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"/&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_497_20200401__20210331_zhZ1R8N4N3u2" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20190401__20200331_zByr8s5uhp62" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zMrYSIOdPoJj" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; width: 74%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z9Sg8wMY9tNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_z8cnsaHP9G1e" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp_zWMUO54kfvPa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_zTKF4a4Gwi9g" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zOvToIQp2qv" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;34&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right"&gt;31&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zmg7615yhEdd" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureIncomeTaxesDetails2Abstract>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">0</modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">0.31</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKlxfbzXdl0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BC_z9UCzdyF51Qb"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities&lt;/span&gt; were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <modd:DisclosureIncomeTaxesDetails3Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureIncomeTaxesDetails3Abstract_zgaQQA7WvHOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_494_20210331_zFwEknJN9A71" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_495_20200331_zpYIhwrNwMEi" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzESI_zVsERk4fIaN4" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;3,909,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,965,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzESI_zuSZcDPf7mwg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;554,892&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;364,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzESI_zVusbhzB68dg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,039&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzESI_zaeHzNm7ytae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserves, accruals &amp;amp; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzESI_zdZCqqLe3rZh" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;646,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;237,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzESI_maDTANzJrK_z7nmZkOz2Kb4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,012,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,567,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzJrK_zyJTnNkQp2Fb" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,012,705&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,567,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzJrK_zDuWqpNBID8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureIncomeTaxesDetails3Abstract>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3909434</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1965118</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">554892</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">364989</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-18039</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6842</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">79878</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">7181</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">646296</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">237716</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5012705</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2567484</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5012705</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2567484</us-gaap:DeferredTaxAssetsValuationAllowance>
    <modd:RoyaltyAgreementDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_825_zCbrVhHYqJ95"&gt;ROYALTY AGREEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#x2019;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</modd:RoyaltyAgreementDisclosureTextBlock>
    <modd:RetirementSavingsPlanDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span id="xdx_822_zQx4uQmdvPXg"&gt;RETIREMENT SAVINGS
PLAN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:RetirementSavingsPlanDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 10 &#x2013;
&lt;span id="xdx_820_zkGXOVMGfxh7"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#x2019;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;11
&#x2013; &lt;span id="xdx_827_zfZkjWzcwctc"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Consulting
Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625&lt;span style="color: red"&gt;&#160;&lt;/span&gt;in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 47,062 shares of
common stock, were fully vested on the grant dates and have terms of 10 years.&lt;b&gt;&#160;&lt;/b&gt;&#160;The most recent consulting agreement,
which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March 31, 2020,
the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated balance
sheet. The Company paid the $5,585 to the director during fiscal 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;2021 Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s chief executive officer and an existing investor, which is represented by a member of the Company&#x2019;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 12 &#x2013;
&lt;span id="xdx_822_zye6Msj6Q1d7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Convertible
Promissory Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#x2019;s option during the first 270 calendar days following its Issue Date (the 270&lt;sup&gt;th&lt;/sup&gt;&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#x2019;s common stock at an initial
conversion price of $2.87 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#x2019;s outstanding common stock. The conversion price and number of shares
of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#x2019;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#x2019;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#x2019;s consolidated financial statements filed with the SEC, (vi) a holder&#x2019;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#x2019;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#x2019;s assets in the
event the Company is not the survivor of such transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#x2019;s Note.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 2,285,736 shares of its common stock
(Warrant Shares) at an initial exercise price of $8.00 per share. The Warrants may be exercised for a period of 5 years from the
Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#x2019;s Note(s) in whole or in part, such holder&#x2019;s pro-rata number of its Warrants shall be cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In May 2021,
a member of the Board purchased $200,000 of the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;PPP Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As a result
of the Company&#x2019;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138320000680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16772 W. Bernardo Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138241317928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,380,968<span></span>
</td>
<td class="nump">$ 1,468,465<span></span>
</td>
<td class="nump">$ 3,122,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">80,830<span></span>
</td>
<td class="nump">178,158<span></span>
</td>
<td class="nump">63,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,632<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">3,466,430<span></span>
</td>
<td class="nump">1,649,089<span></span>
</td>
<td class="nump">3,186,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment,&#160;net</a></td>
<td class="nump">294,384<span></span>
</td>
<td class="nump">298,958<span></span>
</td>
<td class="nump">301,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">181,499<span></span>
</td>
<td class="nump">200,124<span></span>
</td>
<td class="nump">270,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Security deposit</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">575,883<span></span>
</td>
<td class="nump">599,082<span></span>
</td>
<td class="nump">672,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">4,042,313<span></span>
</td>
<td class="nump">2,248,171<span></span>
</td>
<td class="nump">3,858,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">462,615<span></span>
</td>
<td class="nump">169,284<span></span>
</td>
<td class="nump">367,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">511,990<span></span>
</td>
<td class="nump">499,948<span></span>
</td>
<td class="nump">202,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="nump">130,142<span></span>
</td>
<td class="nump">125,500<span></span>
</td>
<td class="nump">92,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">4,369,440<span></span>
</td>
<td class="nump">2,133,453<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">5,474,187<span></span>
</td>
<td class="nump">3,296,965<span></span>
</td>
<td class="nump">661,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES&#8217;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">149,614<span></span>
</td>
<td class="nump">184,355<span></span>
</td>
<td class="nump">178,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Bonus payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">5,623,801<span></span>
</td>
<td class="nump">3,523,320<span></span>
</td>
<td class="nump">980,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001&#160;par value, 5,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001&#160;par value, 50,000,000 shares authorized, 18,906,148 shares and 17,870,261 shares issued and outstanding as of March 31, 2021 and 2020, respectively</a></td>
<td class="nump">18,972<span></span>
</td>
<td class="nump">18,906<span></span>
</td>
<td class="nump">17,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">19,181,641<span></span>
</td>
<td class="nump">14,652,955<span></span>
</td>
<td class="nump">10,505,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Common stock issuable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(20,782,101)<span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="num">(1,581,488)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="nump">4,042,313<span></span>
</td>
<td class="nump">2,248,171<span></span>
</td>
<td class="nump">3,858,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CommonStockIssuable', window );">Common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="num">(1,581,488)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 4,042,313<span></span>
</td>
<td class="nump">$ 2,248,171<span></span>
</td>
<td class="nump">$ 3,858,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CommonStockIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CommonStockIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138325029400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">18,971,656<span></span>
</td>
<td class="nump">18,906,148<span></span>
</td>
<td class="nump">17,870,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">18,971,656<span></span>
</td>
<td class="nump">18,906,148<span></span>
</td>
<td class="nump">17,870,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138321034664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,788,131<span></span>
</td>
<td class="nump">$ 970,815<span></span>
</td>
<td class="nump">$ 4,083,303<span></span>
</td>
<td class="nump">$ 3,034,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,585,456<span></span>
</td>
<td class="nump">903,397<span></span>
</td>
<td class="nump">3,253,412<span></span>
</td>
<td class="nump">2,313,870<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,373,587<span></span>
</td>
<td class="nump">1,874,212<span></span>
</td>
<td class="nump">7,336,715<span></span>
</td>
<td class="nump">5,348,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,373,587)<span></span>
</td>
<td class="num">(1,874,212)<span></span>
</td>
<td class="num">(7,336,715)<span></span>
</td>
<td class="num">(5,348,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Other income</a></td>
<td class="nump">368,823<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(508,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,791)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(1,321,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,835,091)<span></span>
</td>
<td class="num">$ (1,874,157)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
<td class="num">$ (5,320,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">18,954,340<span></span>
</td>
<td class="nump">18,334,482<span></span>
</td>
<td class="nump">18,634,686<span></span>
</td>
<td class="nump">17,864,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 28,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,376,376)<span></span>
</td>
<td class="num">(5,319,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138323282008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock Issuable</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 17,840<span></span>
</td>
<td class="nump">$ 9,684,578<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="num">$ (3,248,161)<span></span>
</td>
<td class="nump">$ 6,474,057<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Mar. 31, 2019</a></td>
<td class="nump">17,840,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">19,770<span></span>
</td>
<td class="num">(19,800)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, Shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">801,244<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">801,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,320,873)<span></span>
</td>
<td class="num">(5,320,873)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 17,870<span></span>
</td>
<td class="nump">10,505,592<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Mar. 31, 2020</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">344,716<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">344,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,874,157)<span></span>
</td>
<td class="num">(1,874,157)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 18,600<span></span>
</td>
<td class="nump">12,892,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,443,191)<span></span>
</td>
<td class="nump">2,467,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Jun. 30, 2020</a></td>
<td class="nump">18,600,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 730<span></span>
</td>
<td class="nump">2,041,898<span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,118,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement of common stock, Shares</a></td>
<td class="nump">729,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 17,870<span></span>
</td>
<td class="nump">10,505,592<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Mar. 31, 2020</a></td>
<td class="nump">17,870,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">210,871<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, Shares</a></td>
<td class="nump">73,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 18,906<span></span>
</td>
<td class="nump">14,652,955<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Mar. 31, 2021</a></td>
<td class="nump">18,906,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">2,708,914<span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement of common stock, Shares</a></td>
<td class="nump">962,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">172,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">172,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, Shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">655,914<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">655,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationShares', window );">Stock-based compensation, Shares</a></td>
<td class="nump">5,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,835,091)<span></span>
</td>
<td class="num">(4,835,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 18,972<span></span>
</td>
<td class="nump">$ 19,181,641<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (20,782,101)<span></span>
</td>
<td class="num">$ (1,581,488)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Jun. 30, 2021</a></td>
<td class="nump">18,971,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237604264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,835,091)<span></span>
</td>
<td class="num">$ (1,874,157)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
<td class="num">$ (5,320,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_GainOnPPPNoteForgiveness', window );">Gain on PPP note forgiveness</a></td>
<td class="num">(368,780)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">655,920<span></span>
</td>
<td class="nump">344,716<span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
<td class="nump">801,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">24,649<span></span>
</td>
<td class="nump">24,986<span></span>
</td>
<td class="nump">111,015<span></span>
</td>
<td class="nump">35,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares for services</a></td>
<td class="nump">266,910<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use asset</a></td>
<td class="nump">18,625<span></span>
</td>
<td class="num">(19,593)<span></span>
</td>
<td class="num">(70,826)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_IncreaseDecreaseInLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(30,099)<span></span>
</td>
<td class="nump">121,204<span></span>
</td>
<td class="nump">38,905<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt issuance costs</a></td>
<td class="nump">338,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,253<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets and prepaid expenses</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">13,478<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
<td class="num">(48,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">402,723<span></span>
</td>
<td class="num">(117,607)<span></span>
</td>
<td class="num">(86,747)<span></span>
</td>
<td class="nump">530,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,204,621)<span></span>
</td>
<td class="num">(1,507,548)<span></span>
</td>
<td class="num">(5,908,662)<span></span>
</td>
<td class="num">(4,094,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(20,076)<span></span>
</td>
<td class="num">(12,934)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
<td class="num">(260,789)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,076)<span></span>
</td>
<td class="num">(12,934)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
<td class="num">(260,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,170,808<span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">4,137,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,210,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,137,200<span></span>
</td>
<td class="nump">1,539,588<span></span>
</td>
<td class="nump">4,364,662<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">1,912,503<span></span>
</td>
<td class="nump">19,106<span></span>
</td>
<td class="num">(1,653,669)<span></span>
</td>
<td class="num">(3,431,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of year</a></td>
<td class="nump">1,468,465<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
<td class="nump">6,553,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of year</a></td>
<td class="nump">3,380,968<span></span>
</td>
<td class="nump">3,141,240<span></span>
</td>
<td class="nump">1,468,465<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of detachable warrants issued with convertible notes</a></td>
<td class="nump">3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use asset</a></td>
<td class="num">$ (18,625)<span></span>
</td>
<td class="nump">$ 19,593<span></span>
</td>
<td class="nump">70,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GainOnPPPNoteForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GainOnPPPNoteForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138320923832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_znsMCbFUIpT2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 1 &#8211; <span id="xdx_820_zch3DXJAL2Ji">THE COMPANY AND
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;&#160;</span></p>

<p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zP0bhh1ad0t3" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_864_z5DYXfoSdPNd">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going Concern</i>, requires
management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.&#160;If
management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going
concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the
plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going
concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include
a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability
to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal
conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s
evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations,
and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#8217;s
plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital,
through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such
additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such
capital will be offered on terms and conditions acceptable to the Company.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS50JxFyrXhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUd2jEQDs2k8">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year.&#160;Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal&#160;2022&#160;refers
to the fiscal year ending&#160;March&#160;31, 2022). The condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Quasuras, Inc. All significant intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit.&#160;The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC). The information in this report should be read in conjunction with the Company&#8217;s consolidated
financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zdNMeBvdrMG6" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zNULOOVfYZqf">Use
of Estimates</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

<p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBVaERNbaRdg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_863_zqYed8dss7ce">Reportable Segment</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The Company operates in one
business segment and uses one measurement of profitability for its business.</span></p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zl1DVRRsI7Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_862_zVYmUBbNPvGh">Research and Development</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.&#160;</span></p>

<p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5Sl9CpZTL39" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_861_zap7DK35VZr2">General and Administrative</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJ9zWZdhZf4f" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zIOaCa9WuI56">Concentration
of Credit Risk</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&#160;&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/>

<p id="xdx_84C_ecustom--RisksAndUncertaintiesPolicyTextBlock_zRkpppeZuZsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zOzaeijQf4M4">Risks
and Uncertainties</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQcKX7Pvqo0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zz1LxsPhAfo9">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&#160;&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk3RqqL1ocJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86E_zIKvhxIuoTA8">Property &amp; Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zi3kilqgb5D1" title="::XDX::3">three</span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zRnszKAR0bbd" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zykOpbp9ZKu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86A_zaNJq3OZWuDa">Fair Value of Financial
Instruments</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs to the valuation
methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs to the valuation
methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs to the valuation
methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable, accrued expenses and notes payable approximate
fair value.</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfdYFZHKMHQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zcLqvdLJqyx4">Per-Share Amounts</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For
the three months ended June 30, 2021 and 2020, outstanding options to purchase <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_za1mTS6um7Bg">3,751,437</span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z7oZc56jjaCa">3,407,587</span> shares of common stock
were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyEVxFlqxohh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zrkQy9CE9Mm4">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b>&#160;</b></span></p>

<p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRRfC5iABdsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_860_zpXgx0O2bWK3">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30,
2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeacMZKZELzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zl7WyuBQNj6l">Recently
Adopted Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In August 2020, the FASB issued ASU
No. 2020-06, <i>Debt</i>&#160;<i>with Conversion and Other Options</i>&#160;<i>(Subtopic 470-20) and Derivatives and Hedging-Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </i>(ASU
2020-06)<i>.</i>&#160;ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models required
under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no
separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for
equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU
2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective April 1, 2021, and the
impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Note&#160;1 &#8211; <span id="xdx_82E_zMUTozRktbd4">THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;</span></p>

<p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zymGf4t6LgG9" title="::XDX::3">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQzo91I1zBLh" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>



<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7">3,591,755</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl">3,177,945</span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138234796056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zt1Ic83YlFs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 2 &#8211; <span id="xdx_822_zYSTuApIomm7">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
1, 2019, the Company adopted ASU No. 2016-02,&#160;<i>Leases&#160;</i>(ASC 842),<i>&#160;</i>and related ASUs, as amended, using
the alternative transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the
&#8220;effective date method&#8221;). In January 2020, the Company executed a lease for a new, larger corporate facility in San
Diego, California&#160;<span style="background-color: white">and paid a $100,000 security deposit.</span>&#160;The <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_z6KyHj6Qz5Mb">39</span>-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent">12,400</span><span style="background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_904_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zoQzdrxSonPi" title="Operating Lease Annual Rent Increase Percentage">3%</span>.&#160;</span>In addition to the minimum lease payments, the Company is responsible for
property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability for the facility
lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which approximated
the Company&#8217;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense is recognized
on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_902_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z0wwJgEA7pe7">270,950</span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zaCDSyZC1nP2" title="Lease Incentive Received">139,000</span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z5HZ4L20eB9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B8_zdEpQCkJFzYj">Future minimum
payments under the facility operating lease, as of June 30, 2021, are listed in the table below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeaseDetailsAbstract_zKN0EWmy5i8a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_zVOlOCGmZcXa" style="white-space: nowrap; font-weight: bold; text-align: center">Operating</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">lease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_z3t0HyaeYl44" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">115,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_zK62Imh2n4Gl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,028</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zshoydplaCTl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zSMq2d3uIwD3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(34,038</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zSrCqh8htHu2" style="vertical-align: bottom; background-color: White">
    <td>Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,756</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zDDLLBqGohk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_908_ecustom--CashPaidforLeaseLiabilities_iI_c20210630_zacg8xjxCiNg" title="Cash paid for amounts included in the measurement of lease liabilities">48,085</span>. Rent expense was $<span id="xdx_90F_eus-gaap--LeaseAndRentalExpense_c20210401__20210630_zagodc8eUrO3">26,884</span> and $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_zGqzwmCOJlQk">26,885</span> for the three
months ended June 30, 2021 and 2020, respectively.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/>

<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 4 &#8211; <span id="xdx_825_zi2Nz2cefmjg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#8220;effective date method&#8221;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;<span style="background-color: white">and paid a $100,000 security
deposit.</span> The <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402_zC0Ttcd6sMx5">39</span></span><span style="font-size: 10pt">-month
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6">12,400</span></span><span style="font-size: 10pt; background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl">3%</span></span><span style="font-size: 10pt; background-color: white">.&#160;</span><span style="font-size: 10pt">In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg">270,950</span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received">139,000</span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">153,432</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">158,028</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">40,692</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(42,297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">309,855</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Rent expense
was $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1">107,540</span> and $<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg">35,766</span> for the years ended March&#160;31, 2021 and 2020, respectively.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236537032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PPPNotesPayableTextBlock', window );">PPP NOTE</a></td>
<td class="text"><p id="xdx_80A_ecustom--PPPNotesPayableTextBlock_zjuXw9H2hdxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_zzrX3ReFL8S9">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zN9wm3m1F9Si" title="Unsecured Loan Received under Paycheck Protection Program">368,780</span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount
of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%
per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company applied
to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender and the U.S.
Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in full. The Company
accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470: <i>Debt</i> (ASC 470),
and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the condensed consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138235084792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE PROMISSORY NOTES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zdJmBfjQSqhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_824_zF8wCZbz8sqg">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (the Original Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective
April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation
Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate
principal amount of Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC
470 and recorded a loss on extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20210630_zcI9jyvl89zh">1,321,450</span> and interest expense of $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_c20210401__20210630_zdDBSg77JXzd">70,647</span> for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April and May
2021, pursuant to a Securities Purchase Agreement (the SPA), the Company sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zEo8x8D4RxPa">4,250,000
</span></span><span style="font-size: 10pt">aggregate principal amount of convertible promissory notes (the Notes) and warrants
to purchase shares of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated
maturity date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the
maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following
its Issue Date (the 270<sup>th</sup>&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued
interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Notes outstanding after the Trigger Date may be
converted into shares of the Company&#8217;s common stock at an initial conversion price of $2.87 per share; provided that a Note holder
may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company&#8217;s outstanding
common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment
from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes.
Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any
shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price,
such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes
shall be increased, as provided in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company completes an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise), each Note holder will be required to convert its Adjusted Note
Amount into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under
the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements
of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability to rely on Rule 144 for
sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from trading and/or fails to be quoted
or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American
within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock
underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement
to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and
sales of all or substantially all of the Company&#8217;s assets in the event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event of
Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay
such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by
(b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in
the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or
any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes include covenants, representations,
warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights
of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with the issuance of the Notes, the Company issued Warrants
to purchase in the aggregate 2,303,348 shares of its common stock at an initial exercise price of $8.00 per share. The Warrants may be
exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified
Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s
pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt
discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the
Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20210630_zLQhFeUgY766" title="Volatility Risk">88.98%</span>, risk-free interest rate of
<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630_zTTyMnWBesig">0.86%</span>, a term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210401__20210630_zdBR3FIznx6b" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcp_c20210401__20210630_zVUrwzwUzpgj">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000,
which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest
rate method.&#160;The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the
three months ended June 30, 2021 was approximately $338,619.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. As of June 30, 2021, the Notes and accrued interest could
be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20210630_ze1tj2H1r0S8" title="Notes and Accured Interest could be converted into Common Stock">2,354,653</span> shares of common stock at a conversion price of $2.87 per share.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method.&#160;&#160;The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138234994360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_804_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3fT2NLfwrD1" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_827_zrIbQ6VC2YH6">STOCKHOLDERS&#146; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">During the three months ended June
30, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630_zEONyLqg5Yj2">60,000</span> shares of common stock to a service provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>2017 Equity Incentive Plan&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Board approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zrTxKqnMBzB1" title="Common Shares Reserved for Issuance under Equity Incentive Plan">3,000,000</span> shares of common stock reserved for issuance. In January
2020, the Board approved an increase in the number of shares reserved for issuance by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zs8YHRuMHaHc">1,000,000</span> shares. Under the Plan, eligible
employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights,
restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative,
a committee designated by the Board.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>Stock-Based Compensation
Expense</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. As of June 30, 2021, the unamortized compensation cost was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630_zpCqXHHc8Eoh">2,288,683</span> related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxH_c20210401__20210630_zY4bYFgLShGk" title="::XDX::P1Y11M8D">1.94 years</span>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended June 30, 2021, the Company granted 5,508 shares to members of its board of directors (the Board) in accordance
with its Board compensation plan for non-employee directors. During the three months ended June 30, 2021, the Company granted
options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zg1c5pEi9Fv1">182,321</span> shares of its common stock to employees, directors and consultants. The options had 10-year terms,
and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2ewzSEiyrB3">47,320</span> options granted on June 30, 2020, in accordance with its Board compensation plan for non-employee directors, vested immediately.
During the three months ended June 30, 2021, the fair value of the options granted was $<span id="xdx_903_ecustom--FairValueofOptionGranted_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJDhrruAbBV1" title="fair Value of Options Granted">698,093</span>, and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXdiNUaz4K22">300,918</span> was recorded as
stock-based compensation expense in the condensed consolidated statement of operations.&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used
in the fair value calculations:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_z7jlNufFnNB3" style="display: none">Schedule of Fair Value Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2020</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates">0.81%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e">0.87</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj">0.31%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl">0.37</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility">89%</span>
                                         - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8">366</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9">123%</span>
                                         - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi">128</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)">5.0</span>
                                         - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl">5.0</span>
                                         - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p id="xdx_8AE_zNTMtfaHyqji" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury
Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms
of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay
dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the EIP is presented below:</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zGHkWyRpu0S9" style="display: none">Schedule of Stock Option activity</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance">408,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance">3,591,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">1.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted">(182,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted">182,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">4.23</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards">(5,508</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan">22,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan">(22,639</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan">2.87</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance">243,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance">3,751,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zx3WXn833YCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the three months ended June 30, 2021 and 2020.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BE_zXSFOOU6AIe7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value">0.66</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value">5.90</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,751,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D">8.09</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right">1.86</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable">2,420,577</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.47</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable">10,761,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A5_zP90vxl5TV5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic value per share is
calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading market over the exercise
price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the three months ended June 30, 2021
and 2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii)&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">1,470,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">1,529,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">0.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right">(1,717,204</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">1,717,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">2.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">69,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right">(69,167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">822,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">3,177,945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">1.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right">(490,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">490,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">76,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right">(76,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">408,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">3,591,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">1.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">0.66</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">3.16</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">3,591,755</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.75</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">2,228,738</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.32</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138341378744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zAjAjm2kQUCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_82E_zVm2Wnp4JuBg">INCOME TAXES</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
for fiscal 2016 to fiscal 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of June 30,
2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--IncomeTaxDisclosureTextBlock_z2XCnSbkNPR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 7 &#8211; <span id="xdx_82B_zeLxB1QYD8T7">INCOME TAXES</span></b></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7iCGckuioJk" style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font-size: 10pt"><span id="xdx_8B6_zkLl6W2dr03b">The income tax provision (benefit)</span>
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureIncomeTaxesDetailsAbstract_zbVBEAN7cKw1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200401__20210331_ztSxkPwaaWR5" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_490_20190401__20200331_zhLLp8WLso9f" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zd2dOCWLZl2i" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalTaxExpenseBenefit_maCFSALz4R3_zhIpiEKpDuJ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCFSALz4R3_zA3pgAtPVAka" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_iT_mtCFSALz4R3_maITEBz8S7_zZMsFMMkNTr9" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_ztaZNPpd7GY8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDFSALzhVS_zoB8M39MpjV1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,180,434</td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDFSALzhVS_z4BXs0FC0Hx9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(391,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_mtDFSALzhVS_maITEBz8S7_zXlIPxK2RK27" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,572,299</td><td style="text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz8S7_zOCDceZhLZN5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,572,299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz8S7_zd2Km15EqQb7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_zKsXvv4mOPz2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of March&#160;31,
2021, the Company had net operating loss carryforwards (NOLs) of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zCb2U91pDzFh" title="Net operating loss carry-forwards">13,954,000</span> for federal income tax purposes and
$<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zq2a5tUTHKN8">14,019,000</span> for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various
times from 2037 through 2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zn5lkCD7Ko9j" title="Research and development tax credit carryforwards">535,000</span>, which will begin expiring at various
times from 2038 through 2040, and state research and development credits of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zaf2FE54j0J8">141,000</span>, which do not have an expiration
date.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2QPCYm7wRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B9_zPiF9iXic74">A reconciliation
of income taxes provided at the federal statutory</span> rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as
follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zKHCyQBsNjhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_497_20200401__20210331_zhZ1R8N4N3u2" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20190401__20200331_zByr8s5uhp62" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zMrYSIOdPoJj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left">Federal statutory rate</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(21</td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(21</td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td></tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z9Sg8wMY9tNi" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">State tax rate, net of federal benefit</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(7</td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(7</td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_z8cnsaHP9G1e" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Permanent differences</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp_zWMUO54kfvPa" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Research and development tax credits</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(6</td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(3</td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_zTKF4a4Gwi9g" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Section 179 assets</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zOvToIQp2qv" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Change in valuation allowance</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right">34</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right">31</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zmg7615yhEdd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Effective income tax rate</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td></tr>
</table>

<p id="xdx_8A1_zMZKqmc9Kta3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKlxfbzXdl0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BC_z9UCzdyF51Qb">Significant components of the Company&#8217;s
deferred tax assets and liabilities</span> were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureIncomeTaxesDetails3Abstract_zgaQQA7WvHOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_494_20210331_zFwEknJN9A71" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_495_20200331_zpYIhwrNwMEi" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzESI_zVsERk4fIaN4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,965,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzESI_zuSZcDPf7mwg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,989</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzESI_zVusbhzB68dg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,842</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzESI_zaeHzNm7ytae" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,181</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzESI_zdZCqqLe3rZh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">237,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzESI_maDTANzJrK_z7nmZkOz2Kb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,567,484</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzJrK_zyJTnNkQp2Fb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,567,484</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzJrK_zDuWqpNBID8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zLDjVDnF8NIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the
available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2021 and 2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net
deferred tax assets at March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has
evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated
financial statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138235157048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmg12AlJhzaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>NOTE 7 &#8211; <span id="xdx_82A_zqwWgWQXTft2">RELATED
PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">In February
2021, the Company&#8217;s chief executive officer and an existing investor, who is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively.&#160;Effective April
30, 2021, the Related Party Holders entered into Revocation Agreements with the Company pursuant to which their collective $<span id="xdx_90D_ecustom--NotesCancelled_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zTGZuJroHhIk" title="Notes Cancelled">1,100,000</span>
aggregate principal amount of Original Notes and accrued interest of $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpWavPINNG35">50,091
</span></span><span style="font-size: 10pt">were replaced with Notes. <span style="background-color: white">At June 30, 2021,
the investor and executive officer held Notes in an aggregate principal amount of $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zHtwkZl74XA1">1,026,630
</span></span></span><span style="font-size: 10pt; background-color: white">and $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zTUw14m2hb6d">102,663</span></span><span style="font-size: 10pt; background-color: white">,
respectively, with $<span id="xdx_909_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zIf2otZtXfSi">20,589
</span></span><span style="font-size: 10pt; background-color: white">and $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zCq8kn5bjVS3">2,059
</span></span><span style="font-size: 10pt; background-color: white">of interest payable thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021, a member
of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zJCHYJM0yZo9">200,000
</span></span><span style="font-size: 10pt">aggregate principal amount of Notes. <span style="background-color: white">At
June 30, 2021, approximately $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zeG2zbPxxgw2">4,000
</span></span></span><span style="font-size: 10pt; background-color: white">of interest was payable by the Company thereon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;11
&#8211; <span id="xdx_827_zfZkjWzcwctc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Consulting
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625<span style="color: red">&#160;</span>in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 47,062 shares of
common stock, were fully vested on the grant dates and have terms of 10 years.<b>&#160;</b>&#160;The most recent consulting agreement,
which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March 31, 2020,
the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated balance
sheet. The Company paid the $5,585 to the director during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
Company&#8217;s chief executive officer and an existing investor, which is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236922808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS &amp; CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS &amp; CONTINGENCIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zylavMPp90ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 8 &#8211;
<span id="xdx_827_zn3xkZCfqzbb">COMMITMENTS &amp; CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated financial statements
for the three months ended June&#160;30, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements,
and no claims for payment have been made under such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/>&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10 &#8211;
<span id="xdx_820_zkGXOVMGfxh7">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138327213704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zt3BFuUIvZEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8211; <span id="xdx_821_z0q4d0zkLMue">SUBSEQUENT EVENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Board approved an increase in the number of shares reserved for issuance under the Plan by 4,000,000 shares, bringing
the total shares reserved for issuance to <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zScfyU9QtPo5">8,000,000</span> shares.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12 &#8211;
<span id="xdx_822_zye6Msj6Q1d7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#8217;s common stock at an initial
conversion price of $2.87 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares
of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#8217;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#8217;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 2,285,736 shares of its common stock
(Warrant Shares) at an initial exercise price of $8.00 per share. The Warrants may be exercised for a period of 5 years from the
Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of its Warrants shall be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
a member of the Board purchased $200,000 of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the Company&#8217;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138233942616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract', window );"><strong>Consolidated Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ConsolidatedBalanceSheetDetailTextBlock', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE&#160;2 &#8211; <span id="xdx_829_zEATFVQb0qp3">CONSOLIDATED
BALANCE SHEET DETAIL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none; font-family: Arial, Helvetica, Sans-Serif">Schedule of
Property Plant And Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,882</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,001</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"/>

<p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accured Expenses</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ConsolidatedBalanceSheetDetailTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ConsolidatedBalanceSheetDetailTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138327213704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zdJmBfjQSqhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_824_zF8wCZbz8sqg">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (the Original Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Effective
April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original Note and the Company (the Revocation
Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550 aggregate
principal amount of Notes (as defined below). The Company accounted for the replacement of the Original Notes in accordance with ASC
470 and recorded a loss on extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20210630_zcI9jyvl89zh">1,321,450</span> and interest expense of $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_c20210401__20210630_zdDBSg77JXzd">70,647</span> for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April and May
2021, pursuant to a Securities Purchase Agreement (the SPA), the Company sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zEo8x8D4RxPa">4,250,000
</span></span><span style="font-size: 10pt">aggregate principal amount of convertible promissory notes (the Notes) and warrants
to purchase shares of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated
maturity date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the
maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following
its Issue Date (the 270<sup>th</sup>&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued
interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Notes outstanding after the Trigger Date may be
converted into shares of the Company&#8217;s common stock at an initial conversion price of $2.87 per share; provided that a Note holder
may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the Company&#8217;s outstanding
common stock. The conversion price and number of shares of Company common stock issuable upon conversion of the Notes are subject to adjustment
from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate events, as provided in the Notes.
Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company sells, issues or grants any
shares of its common stock or other securities to acquire shares of common stock at a price per share less than the then conversion price,
such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable upon conversion of the Notes
shall be increased, as provided in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company completes an offering of its common stock or other securities
in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise), each Note holder will be required to convert its Adjusted Note
Amount into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements under
the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material restatements
of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability to rely on Rule 144 for
sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from trading and/or fails to be quoted
or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American
within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common stock
underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement
to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and
sales of all or substantially all of the Company&#8217;s assets in the event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event of
Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required to pay
such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied by
(b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder, in
the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay all or
any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes include covenants, representations,
warranties, other payment obligations and agreements by the Company including, without limitation, most-favored nation rights, rights
of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with the issuance of the Notes, the Company issued Warrants
to purchase in the aggregate 2,303,348 shares of its common stock at an initial exercise price of $8.00 per share. The Warrants may be
exercised for a period of five years from the Trigger Date, provided that, if prior to the Trigger Date, the Company (i) completes a Qualified
Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s
pro-rata number of Warrants shall be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt
discount, which is being amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the
Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20210630_zLQhFeUgY766" title="Volatility Risk">88.98%</span>, risk-free interest rate of
<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630_zTTyMnWBesig">0.86%</span>, a term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20210401__20210630_zdBR3FIznx6b" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcp_c20210401__20210630_zVUrwzwUzpgj">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs of $116,000,
which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes using the effective interest
rate method.&#160;The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during the
three months ended June 30, 2021 was approximately $338,619.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The $6,610,550 aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. As of June 30, 2021, the Notes and accrued interest could
be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20210630_ze1tj2H1r0S8" title="Notes and Accured Interest could be converted into Common Stock">2,354,653</span> shares of common stock at a conversion price of $2.87 per share.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method.&#160;&#160;The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236542168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_804_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3fT2NLfwrD1" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_827_zrIbQ6VC2YH6">STOCKHOLDERS&#146; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">During the three months ended June
30, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630_zEONyLqg5Yj2">60,000</span> shares of common stock to a service provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b>2017 Equity Incentive Plan&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Board approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zrTxKqnMBzB1" title="Common Shares Reserved for Issuance under Equity Incentive Plan">3,000,000</span> shares of common stock reserved for issuance. In January
2020, the Board approved an increase in the number of shares reserved for issuance by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zs8YHRuMHaHc">1,000,000</span> shares. Under the Plan, eligible
employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights,
restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative,
a committee designated by the Board.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b>Stock-Based Compensation
Expense</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. As of June 30, 2021, the unamortized compensation cost was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20210630_zpCqXHHc8Eoh">2,288,683</span> related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtxH_c20210401__20210630_zY4bYFgLShGk" title="::XDX::P1Y11M8D">1.94 years</span>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended June 30, 2021, the Company granted 5,508 shares to members of its board of directors (the Board) in accordance
with its Board compensation plan for non-employee directors. During the three months ended June 30, 2021, the Company granted
options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zg1c5pEi9Fv1">182,321</span> shares of its common stock to employees, directors and consultants. The options had 10-year terms,
and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2ewzSEiyrB3">47,320</span> options granted on June 30, 2020, in accordance with its Board compensation plan for non-employee directors, vested immediately.
During the three months ended June 30, 2021, the fair value of the options granted was $<span id="xdx_903_ecustom--FairValueofOptionGranted_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJDhrruAbBV1" title="fair Value of Options Granted">698,093</span>, and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXdiNUaz4K22">300,918</span> was recorded as
stock-based compensation expense in the condensed consolidated statement of operations.&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used
in the fair value calculations:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_z7jlNufFnNB3" style="display: none">Schedule of Fair Value Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2020</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates">0.81%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e">0.87</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj">0.31%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl">0.37</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility">89%</span>
                                         - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8">366</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9">123%</span>
                                         - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi">128</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)">5.0</span>
                                         - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl">5.0</span>
                                         - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p id="xdx_8AE_zNTMtfaHyqji" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury
Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms
of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay
dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the EIP is presented below:</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zGHkWyRpu0S9" style="display: none">Schedule of Stock Option activity</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance">408,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance">3,591,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">1.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted">(182,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted">182,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">4.23</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards">(5,508</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan">22,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan">(22,639</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan">2.87</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance">243,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance">3,751,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zx3WXn833YCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the three months ended June 30, 2021 and 2020.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BE_zXSFOOU6AIe7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value">0.66</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value">5.90</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,751,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D">8.09</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right">1.86</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable">2,420,577</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.47</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable">10,761,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A5_zP90vxl5TV5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic value per share is
calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading market over the exercise
price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the three months ended June 30, 2021
and 2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii)&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">1,470,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">1,529,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">0.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right">(1,717,204</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">1,717,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">2.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">69,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right">(69,167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">822,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">3,177,945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">1.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right">(490,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">490,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">76,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right">(76,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">408,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">3,591,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">1.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">0.66</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">3.16</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">3,591,755</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.75</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">2,228,738</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.32</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138324475176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_820_zIsr1RW0bfL9">STOCKHOLDERS&#8217;
EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi">962,387</span> shares of common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138235018088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ROYALTY AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureRoyaltyAgreementAbstract', window );"><strong>Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RoyaltyAgreementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 8 &#8211; <span id="xdx_825_zCbrVhHYqJ95">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureRoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureRoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138235020600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT SAVINGS PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureRetirementSavingsPlanAbstract', window );"><strong>Retirement Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RetirementSavingsPlanDisclosureTextBlock', window );">RETIREMENT SAVINGS PLAN</a></td>
<td class="text"><p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 9 &#8211; <span id="xdx_822_zQx4uQmdvPXg">RETIREMENT SAVINGS
PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureRetirementSavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureRetirementSavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RetirementSavingsPlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RetirementSavingsPlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236922808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zylavMPp90ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 8 &#8211;
<span id="xdx_827_zn3xkZCfqzbb">COMMITMENTS &amp; CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated financial statements
for the three months ended June&#160;30, 2021 and 2020 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements,
and no claims for payment have been made under such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/>&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10 &#8211;
<span id="xdx_820_zkGXOVMGfxh7">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236772328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zt3BFuUIvZEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8211; <span id="xdx_821_z0q4d0zkLMue">SUBSEQUENT EVENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Board approved an increase in the number of shares reserved for issuance under the Plan by 4,000,000 shares, bringing
the total shares reserved for issuance to <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zScfyU9QtPo5">8,000,000</span> shares.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12 &#8211;
<span id="xdx_822_zye6Msj6Q1d7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#8217;s common stock at an initial
conversion price of $2.87 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares
of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#8217;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#8217;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 2,285,736 shares of its common stock
(Warrant Shares) at an initial exercise price of $8.00 per share. The Warrants may be exercised for a period of 5 years from the
Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of its Warrants shall be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
a member of the Board purchased $200,000 of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the Company&#8217;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237531944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84F_ecustom--LiquidityPolicyTextBlock_zP0bhh1ad0t3" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_864_z5DYXfoSdPNd">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going Concern</i>, requires
management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about
the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.&#160;If
management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going
concern, management must consider if there are plans that are probable to be implemented, and whether it is probable that the
plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going
concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include
a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability
to continue as a going concern within one year after the date that the financial statements are issued including: 1) the principal
conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s
evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations,
and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#8217;s
plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional capital,
through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such
additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such
capital will be offered on terms and conditions acceptable to the Company.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
<td class="text"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zS50JxFyrXhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUd2jEQDs2k8">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year.&#160;Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal&#160;2022&#160;refers
to the fiscal year ending&#160;March&#160;31, 2022). The condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Quasuras, Inc. All significant intercompany transactions and balances have been eliminated
in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit.&#160;The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC). The information in this report should be read in conjunction with the Company&#8217;s consolidated
financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended June 30, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zdNMeBvdrMG6" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zNULOOVfYZqf">Use
of Estimates</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBVaERNbaRdg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_863_zqYed8dss7ce">Reportable Segment</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The Company operates in one
business segment and uses one measurement of profitability for its business.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zl1DVRRsI7Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_862_zVYmUBbNPvGh">Research and Development</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p id="xdx_847_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z5Sl9CpZTL39" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt"><b><span id="xdx_861_zap7DK35VZr2">General and Administrative</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJ9zWZdhZf4f" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zIOaCa9WuI56">Concentration
of Credit Risk</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&#160;&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_84C_ecustom--RisksAndUncertaintiesPolicyTextBlock_zRkpppeZuZsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zOzaeijQf4M4">Risks
and Uncertainties</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by
the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQcKX7Pvqo0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zz1LxsPhAfo9">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&#160;&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk3RqqL1ocJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86E_zIKvhxIuoTA8">Property &amp; Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zi3kilqgb5D1" title="::XDX::3">three</span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zRnszKAR0bbd" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zymGf4t6LgG9" title="::XDX::3">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQzo91I1zBLh" title="::XDX::5">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zykOpbp9ZKu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_86A_zaNJq3OZWuDa">Fair Value of Financial
Instruments</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1 inputs to the valuation
methodology are quoted prices for identical assets or liabilities in active markets.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2 inputs to the valuation
methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: 10pt Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3 inputs to the valuation
methodology are unobservable and significant to the fair value measurement.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable, accrued expenses and notes payable approximate
fair value.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per-Share Amounts</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zfdYFZHKMHQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zcLqvdLJqyx4">Per-Share Amounts</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. For
the three months ended June 30, 2021 and 2020, outstanding options to purchase <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_za1mTS6um7Bg">3,751,437</span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z7oZc56jjaCa">3,407,587</span> shares of common stock
were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7">3,591,755</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl">3,177,945</span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyEVxFlqxohh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt"><b><span id="xdx_860_zrkQy9CE9Mm4">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b>&#160;</b></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zRRfC5iABdsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_860_zpXgx0O2bWK3">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended June 30,
2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeacMZKZELzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zl7WyuBQNj6l">Recently
Adopted Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In August 2020, the FASB issued ASU
No. 2020-06, <i>Debt</i>&#160;<i>with Conversion and Other Options</i>&#160;<i>(Subtopic 470-20) and Derivatives and Hedging-Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </i>(ASU
2020-06)<i>.</i>&#160;ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models required
under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no
separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for
equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU
2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective April 1, 2021, and the
impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236462248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future minimum payments under the facility operating lease, net of the lease incentive</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_z5HZ4L20eB9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B8_zdEpQCkJFzYj">Future minimum
payments under the facility operating lease, as of June 30, 2021, are listed in the table below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureLeaseDetailsAbstract', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeaseDetailsAbstract_zKN0EWmy5i8a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20210630_zVOlOCGmZcXa" style="white-space: nowrap; font-weight: bold; text-align: center">Operating</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">lease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_z3t0HyaeYl44" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">115,074</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_zK62Imh2n4Gl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,028</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zshoydplaCTl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zSMq2d3uIwD3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(34,038</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zSrCqh8htHu2" style="vertical-align: bottom; background-color: White">
    <td>Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,756</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureLeasesDetailsAbstarct', window );">LEASES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">153,432</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">158,028</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">40,692</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(42,297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">309,855</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureLeaseDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureLeaseDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureLeasesDetailsAbstarct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureLeasesDetailsAbstarct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138321055320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used
in the fair value calculations:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_z7jlNufFnNB3" style="display: none">Schedule of Fair Value Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetailsAbstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2020</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates">0.81%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e">0.87</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj">0.31%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl">0.37</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility">89%</span>
                                         - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8">366</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9">123%</span>
                                         - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi">128</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)">5.0</span>
                                         - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl">5.0</span>
                                         - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the EIP is presented below:</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zGHkWyRpu0S9" style="display: none">Schedule of Stock Option activity</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails2Abstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance">408,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance">3,591,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">1.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted">(182,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted">182,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">4.23</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards">(5,508</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan">22,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan">(22,639</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan">2.87</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance">243,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance">3,751,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">1,470,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">1,529,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">0.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right">(1,717,204</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">1,717,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">2.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">69,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right">(69,167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">822,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">3,177,945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">1.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right">(490,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">490,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">76,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right">(76,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">408,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">3,591,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">1.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Outstanding and Exercisable Option, Range</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BE_zXSFOOU6AIe7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails3Abstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value">0.66</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value">5.90</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,751,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D">8.09</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right">1.86</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable">2,420,577</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.47</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable">10,761,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">0.66</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">3.16</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">3,591,755</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.75</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">2,228,738</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.32</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236546776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract', window );"><strong>Consolidated Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant And Equipment</a></td>
<td class="text"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none; font-family: Arial, Helvetica, Sans-Serif">Schedule of
Property Plant And Equipment</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailsAbstract', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,882</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,001</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accured Expenses</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accured Expenses</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetails2Abstract', window );">CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138240891304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">assumptions were used in the fair-value method calculations</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zAyLWLepm4Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used
in the fair value calculations:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_z7jlNufFnNB3" style="display: none">Schedule of Fair Value Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"/></p>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetailsAbstract', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zxrRgWd6BzUb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Three
    Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2021</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>June
    30, 2020</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_zvow1z0hgIAd" title="Risk-free interest rates">0.81%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zY70amRqaE2e">0.87</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zqBRbw1M9qdj">0.31%</span>
                                         - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zGfDgTnU5kJl">0.37</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_z31c7caqgaw" title="Volatility">89%</span>
                                         - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_zbZHdR1vo0r8">366</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zgqs6O7SMYp9">123%</span>
                                         - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zo3hpdihgQoi">128</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MinimumMember_ze5z8Wl6D3Wf" title="Expected life (years)">5.0</span>
                                         - <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20210630__srt--RangeAxis__srt--MaximumMember_z5Aa3pxlVgMa">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MinimumMember_zQN3aw0xwnBl">5.0</span>
                                         - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20200630__srt--RangeAxis__srt--MaximumMember_zXmAngH4wDWe">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">stock option activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfwUgamWD4R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the EIP is presented below:</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zGHkWyRpu0S9" style="display: none">Schedule of Stock Option activity</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails2Abstract', window );">STOCK-BASED COMPENSATION (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zZy2yIQAt3K7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYYQZrkpA8W6" style="width: 8%; text-align: right" title="Shares Available for Grant, Beginning Balance">408,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQt4DRmZac68" style="width: 8%; text-align: right" title="Number of Option, Beginning Balance">3,591,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z92vUsHrOnv1" style="width: 8%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">1.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3nz1ODKX6Bf" style="text-align: right" title="Shares available for grant, Granted">(182,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsxPpdMyUIib" style="text-align: right" title="Number of Options, Granted">182,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zER4DbhYwNX4" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">4.23</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkzagfWuEk8l" style="text-align: right" title="Shares available for grant, Awards">(5,508</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlgAFFwUoXo4" style="border-bottom: Black 1pt solid; text-align: right" title="Shares available for grant, Cancelled and Returned to the Plan">22,639</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvnujAyvF0g3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, cancelled and returned to the Plan">(22,639</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhstKCucqCKf" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Options cancelled and returned to the Plan">2.87</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxc640WqIq2e" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Available for Grant, Ending Balance">243,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRq06jnYCHpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Option, Ending Balance">3,751,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztqqciivWwNd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">1,470,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">1,529,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">0.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331_zhVimLFm7xQl" style="text-align: right">(1,717,204</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">1,717,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">2.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">69,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zeH2x0trOYz4" style="border-bottom: Black 1pt solid; text-align: right">(69,167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">822,055</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">3,177,945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">1.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331_z7hdBZH2v8Mh" style="text-align: right">(490,476</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">490,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">76,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUkHIR01DRo7" style="border-bottom: Black 1pt solid; text-align: right">(76,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">408,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">3,591,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">1.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">summarizes the range of outstanding and exercisable options</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zrFp4f3YWjN" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BE_zXSFOOU6AIe7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails3Abstract', window );">STOCK-BASED COMPENSATION (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zaU0ikxZ5mtj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zlXo36smGYKi" title="Exercise Price, Minimum Value">0.66</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z8SHKepjKIu9" title="Exercise Price, Maximum Value">5.90</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRg31dhWE8C" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,751,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zqoxG7nDxOX5" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Remaining Contractual Life, Option Outstanding::XDX::P8Y1M2D">8.09</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyHK2ImqSW63" style="width: 8%; padding-bottom: 1pt; text-align: right">1.86</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMhieyiwL1B9" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Options Exercisable">2,420,577</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXFqrViGrQx3" style="width: 8%; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Exercisable">1.47</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHGRQaRRDw6" style="border-bottom: Black 1pt solid; width: 8%; text-align: right" title="Average Intrinsic Value, Exercisable">10,761,492</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">0.66</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">3.16</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">3,591,755</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkKNOoQ6ejkl" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.75</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">2,228,738</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSUifzAqoSk2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1.32</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138240810184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">The income tax provision (benefit)</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z7iCGckuioJk" style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font-size: 10pt"><span id="xdx_8B6_zkLl6W2dr03b">The income tax provision (benefit)</span>
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetailsAbstract', window );">INCOME TAXES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureIncomeTaxesDetailsAbstract_zbVBEAN7cKw1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200401__20210331_ztSxkPwaaWR5" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_490_20190401__20200331_zhLLp8WLso9f" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zd2dOCWLZl2i" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalTaxExpenseBenefit_maCFSALz4R3_zhIpiEKpDuJ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCFSALz4R3_zA3pgAtPVAka" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_iT_mtCFSALz4R3_maITEBz8S7_zZMsFMMkNTr9" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_ztaZNPpd7GY8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDFSALzhVS_zoB8M39MpjV1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,180,434</td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDFSALzhVS_z4BXs0FC0Hx9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(391,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_mtDFSALzhVS_maITEBz8S7_zXlIPxK2RK27" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,572,299</td><td style="text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz8S7_zOCDceZhLZN5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,572,299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz8S7_zd2Km15EqQb7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">A reconciliation of income taxes provided at the federal statutory</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2QPCYm7wRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B9_zPiF9iXic74">A reconciliation
of income taxes provided at the federal statutory</span> rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as
follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetails2Abstract', window );">INCOME TAXES (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zKHCyQBsNjhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_497_20200401__20210331_zhZ1R8N4N3u2" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20190401__20200331_zByr8s5uhp62" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zMrYSIOdPoJj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left">Federal statutory rate</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(21</td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td><td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 8%; text-align: right">(21</td><td style="white-space: nowrap; width: 1%; text-align: left">)%</td></tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z9Sg8wMY9tNi" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">State tax rate, net of federal benefit</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(7</td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(7</td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_z8cnsaHP9G1e" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Permanent differences</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp_zWMUO54kfvPa" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Research and development tax credits</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(6</td><td style="white-space: nowrap; text-align: left">)%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">(3</td><td style="white-space: nowrap; text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_zTKF4a4Gwi9g" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Section 179 assets</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zOvToIQp2qv" style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">Change in valuation allowance</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right">34</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: right">31</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zmg7615yhEdd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left">Effective income tax rate</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td><td style="white-space: nowrap; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; text-align: right">&#8212;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant components of the Company&#8217;s deferred tax assets and liabilities</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKlxfbzXdl0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BC_z9UCzdyF51Qb">Significant components of the Company&#8217;s
deferred tax assets and liabilities</span> were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetails3Abstract', window );">INCOME TAXES (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureIncomeTaxesDetails3Abstract_zgaQQA7WvHOb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_494_20210331_zFwEknJN9A71" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_495_20200331_zpYIhwrNwMEi" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzESI_zVsERk4fIaN4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,965,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzESI_zuSZcDPf7mwg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,989</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzESI_zVusbhzB68dg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,842</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzESI_zaeHzNm7ytae" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,181</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzESI_zdZCqqLe3rZh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">237,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzESI_maDTANzJrK_z7nmZkOz2Kb4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,567,484</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzJrK_zyJTnNkQp2Fb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,567,484</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzJrK_zDuWqpNBID8j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138235081128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,751,437<span></span>
</td>
<td class="nump">3,407,587<span></span>
</td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138240833640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">$ 115,074<span></span>
</td>
<td class="nump">$ 153,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">158,028<span></span>
</td>
<td class="nump">158,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">40,692<span></span>
</td>
<td class="nump">40,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_OperatingLeasesImputedInterest', window );">Imputed interest</a></td>
<td class="num">(34,038)<span></span>
</td>
<td class="num">(42,297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 279,756<span></span>
</td>
<td class="nump">$ 309,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237162936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Monthly Rent</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 26,884<span></span>
</td>
<td class="nump">$ 26,885<span></span>
</td>
<td class="nump">$ 107,540<span></span>
</td>
<td class="nump">$ 35,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_OperatingLeasesAnnualRentIncreasePercentange', window );">Operating Lease Annual Rent Increase Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LeaseIncentiveReceived', window );">Lease Incentive Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CashPaidforLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashPaidforLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashPaidforLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LeaseIncentiveReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LeaseIncentiveReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeasesAnnualRentIncreasePercentange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeasesAnnualRentIncreasePercentange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138236971816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PPP NOTE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Unsecured Loan Received under Paycheck Protection Program</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237133912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">$ 70,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility Risk</a></td>
<td class="nump">88.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock', window );">Notes and Accured Interest could be converted into Common Stock</a></td>
<td class="nump">2,354,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138241121992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">366.00%<span></span>
</td>
<td class="nump">128.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237590984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Beginning Balance</a></td>
<td class="nump">408,245<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
<td class="nump">1,470,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490,476)<span></span>
</td>
<td class="num">(1,717,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, cancelled and returned to the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,666)<span></span>
</td>
<td class="num">(69,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,245<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Beginning Balance</a></td>
<td class="nump">408,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Beginning Balance</a></td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
<td class="nump">1,529,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant', window );">Shares available for grant, Granted</a></td>
<td class="num">(182,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">182,321<span></span>
</td>
<td class="nump">490,476<span></span>
</td>
<td class="nump">1,717,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Granted</a></td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards', window );">Shares available for grant, Awards</a></td>
<td class="num">(5,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant', window );">Shares available for grant, Cancelled and Returned to the Plan</a></td>
<td class="nump">22,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, cancelled and returned to the Plan</a></td>
<td class="num">(22,639)<span></span>
</td>
<td class="nump">76,666<span></span>
</td>
<td class="nump">69,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options cancelled and returned to the Plan</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Ending Balance</a></td>
<td class="nump">243,055<span></span>
</td>
<td class="nump">408,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Ending Balance</a></td>
<td class="nump">3,751,437<span></span>
</td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237492712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,245<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
<td class="nump">1,470,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">3,751,437<span></span>
</td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
<td class="nump">1,529,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Option Outstanding</a></td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">2,420,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Average Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 10,761,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price, Maximum Value</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price, Maximum Value</a></td>
<td class="nump">$ 5.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237145080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Shares Reserved for Issuance under Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 2,288,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490,476)<span></span>
</td>
<td class="num">(1,717,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 655,920<span></span>
</td>
<td class="nump">$ 344,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,227,578<span></span>
</td>
<td class="nump">$ 801,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">182,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,476<span></span>
</td>
<td class="nump">1,717,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_FairValueofOptionGranted', window );">fair Value of Options Granted</a></td>
<td class="nump">$ 698,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 300,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">47,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,897<span></span>
</td>
<td class="nump">962,387<span></span>
</td>
<td class="nump">962,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">182,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_FairValueofOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_FairValueofOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138241113736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_NotesCancelled', window );">Notes Cancelled</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">$ 50,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">20,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,026,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">102,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember', window );">Member Of Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NotesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NotesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138234967000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138241085768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 451,049<span></span>
</td>
<td class="nump">$ 353,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(152,091)<span></span>
</td>
<td class="num">(51,693)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">139,197<span></span>
</td>
<td class="nump">139,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">56,476<span></span>
</td>
<td class="nump">49,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">52,383<span></span>
</td>
<td class="nump">51,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 202,993<span></span>
</td>
<td class="nump">$ 112,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138241121864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 511,990<span></span>
</td>
<td class="nump">$ 499,948<span></span>
</td>
<td class="nump">$ 202,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember', window );">Accured Wages and Bonus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,563<span></span>
</td>
<td class="nump">198,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember', window );">Accured Placement Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember', window );">Accured Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember', window );">Accrued Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,047<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterimPeriodCostsNotAllocableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterimPeriodCostsNotAllocableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138320994504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">366.00%<span></span>
</td>
<td class="nump">128.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138321033224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Beginning Balance</a></td>
<td class="nump">408,245<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
<td class="nump">1,470,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490,476)<span></span>
</td>
<td class="num">(1,717,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,666<span></span>
</td>
<td class="nump">69,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,245<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Beginning Balance</a></td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
<td class="nump">1,529,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">182,321<span></span>
</td>
<td class="nump">490,476<span></span>
</td>
<td class="nump">1,717,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="nump">22,639<span></span>
</td>
<td class="num">(76,666)<span></span>
</td>
<td class="num">(69,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Option, Ending Balance</a></td>
<td class="nump">3,751,437<span></span>
</td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237632280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">408,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822,055<span></span>
</td>
<td class="nump">1,470,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">3,591,755<span></span>
</td>
<td class="nump">3,751,437<span></span>
</td>
<td class="nump">3,177,945<span></span>
</td>
<td class="nump">1,529,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">2,228,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 8,763,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237260472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,897<span></span>
</td>
<td class="nump">962,387<span></span>
</td>
<td class="nump">962,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237322840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,931,390)<span></span>
</td>
<td class="num">(1,180,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(576,868)<span></span>
</td>
<td class="num">(391,865)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(2,508,258)<span></span>
</td>
<td class="num">(1,572,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">2,508,258<span></span>
</td>
<td class="nump">1,572,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138237554984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Section 179 assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138323244104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 3) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,909,434<span></span>
</td>
<td class="nump">$ 1,965,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">554,892<span></span>
</td>
<td class="nump">364,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(18,039)<span></span>
</td>
<td class="nump">6,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Reserves, accruals &amp; other</a></td>
<td class="num">(79,878)<span></span>
</td>
<td class="num">(7,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development tax credits</a></td>
<td class="nump">646,296<span></span>
</td>
<td class="nump">237,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">5,012,705<span></span>
</td>
<td class="nump">2,567,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(5,012,705)<span></span>
</td>
<td class="num">(2,567,484)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140138240969960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 13,954,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">535,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">14,019,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 141,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_
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MJCI<*AFHM 3 _44"B^GZI/R4N/W6//P/4$L#!!0    ( )&"8E.T< "S"0,
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M^08?X&NUF0:''O[]<K451BV$.W##&F[X8;BK([MI^&X=WF 8>D$_V"-K%.+
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M*J5%3M]::\$4CPBF6 ?3P,-J@0U@2J$?(/49L\'0#*;V6QBR91G E/JN[_>
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MP[C <"@7F&$7%Z/88NQ-X;?.2Q 2YX??J%N86[?<UE4J9=:;V=7Y@X"#_:Z
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MZK_+OOG;Y-'!]^IG+IA.DA78#,15,N%KL"R8^M?.<IT2\!8*?"65HR5W+/$
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MZQ\\&]ROT-8G'0OK,<#F8$%Z>;/?U0:HOE@;8/8[V@#5%VL#S'Y'&Z#ZHFV
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MTQC=9V<"BU?>(,9E\>'3[,A0"UZEM[593,7I2S9CDEL:JVEB@+DAA.,:"!]
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M[/ED[096U>Z:NE 6+[WN=8U_2[BF!3B_5,KN!K1!]T?GZB]02P,$%     @
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M_8N/$9AV]+0;IW1H][5R-#S"LJ)IC<8'T'VIR.I^XQ-T\W_V&U!+ P04
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M.#T]'>,Z.'T)(R58569Z@Y/DNFI+UJ ]\SGV!03#$7-<&@GF:"0^1Q>"/+0
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MBS<'9^'+BR&NIP4_*;DI.O<<)9EK_1$?KI,W!P$R)%,9ETA!P.5!7L@T14+
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MC30%>FAS(T'K.3J:=3S*RE'DC0<S?NBN1SP"L.E*T,-A'@TA;8]0@,DH](8
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MQ Z>& M(90MPVP9-8UBC4Y60<L%A2HGI@TYO%_O\K3;/BA%6QPCA;1M_$!V
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M/1T>:J+BOB@#%BG^V;=66_4_5$3"D/88B: 7!2$0F/6..^I3]Q&5(H_H)@^
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M1.$E.B(-K!#<X!/6:!#P-BA@E8> 1,,TD.C8]EF6/K.)K+\<J@)P<8L/K?X
M(422J5P56 0VI9NU@39>'9,BA>^Y0#^ 8H^,J\H26Q59J&5.(=/=Z[LFM(8
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MUC3JG!P%H.M)K 52I>_^I2([2WZ;V\<+M5.P]RNE:"LX!^US./H+4$L#!!0
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MYK(1A .IX<=$/,C+@AM&5%P60UB=C#0Y[K #Y%S.5FY;0F@;CTVO7D&7B[3
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M/EJ ]TL#)\,7VB#^BOONOU!+ P04    " "1@F)3Z'N]C[46   K6P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6SM/&ESVSB6W_$K4)ZM+KN*MB4Y
MCI/N)%6*8J<]TSDV3GIJ:FL_0"0DH4,2:H+T,;]^WWLX"%H4[5S=N[WYDE@2
M\?#P[@M\<J6KCV8E9<VOB[PT3W=6=;W^\?#0I"M9"'.@U[*$7Q:Z*D0-'ZOE
MH5E74F2TJ,@/)Z/1P\-"J'+GV1/Z[FWU[(ENZER5\FW%35,4HKIY+G-]]71G
MO.._>*>6JQJ_.'SV9"V6\D+6']9O*_AT&*!DJI"E4;KDE5P\W9F.?YQ-1KB
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M(&_MK_ N0.[L)3O@%=[H]D5T4;IQ.4LMN@^*,W2D7RN=T_VR:"3Z@&[H5Z@
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MMNQZA:^680,[@\A9_/8[.V+L&EJ4+BZUS]DTF5Z#<B5QBM%TQOPKN125?2N
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M73"*6X2:@-]G62:K@5J@OH0Z_1=02P,$%     @ D8)B4[GMA\>6 P  \ @
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK5;;;N,V$'WW5PS4HD@
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M_R)(.?TH,B-?>T;;F[*?]8QU4H4*%+NFUDJ(>5VJMB!UHUTYG[95[&UY^RU
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MV49WUXSB'J FX/MEELEJH!:H__Y<_P]02P,$%     @ D8)B4Z9E-&^@!
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M5=$,9D-,.@7R&8;O$$1ZS E;<\)><PZAT:5X+W6WXG\"E35"",8W6YL #TR
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MX80FB,&T:YS:)X'MI( :<4=@Q3>>4;J4>TH?TL8P[!I6.B.(8")2"2R__L(
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MHB)J0#>WJ,V$ITMU39BD7%PZU' A;IZ$2@/Q?I:F?#N1"Q1WV?9W4$L#!!0
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M> XO4_[J='B9].MG;"=Q)?RF&C[TY0:.[(I(FGFZF D_\PB_CN\OHV5())W
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MJMR/)'*5.!7CGLX"S)-.&*I'TE7+:I)\X5HF7/M?Y^ /) E)]P1#N4+^.A-
MSO&XGNVC?EF/&YE0X]V9;IR8;%O51C,_T\U,N'G&X2I1;9X>+<NNU9R"HT6L
M0U&R+N6Q?8['Y*@\DLNZ3 X5B927I'-\3BG>&%W@,SF4*^*\S^D4?VIU@?*A
M?I'R I9X!<,%W#'*O;/,.Y0H4KVP>8>B1,JKTEGFU4[J8:6P#I-#'2+U=YGG
MIOCJ/X<FYPM@'K41NH=[I'SI1P("7"B@=5-7##QIBY*)9.NXLY@QJ?J4>+A2
MK21RO4 ]7S"UM72BFY6L.>W\!5!+ P04    " "1@F)3JVU[)58"  !6!@
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M 2.:<'U%JSS6JQDH6G!!TP(L3Y#&67XG[X40&P#L[@'8!<"N"G *@%,5X!8
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MZ[(N\2P?S_*-H',]L(RID../7L[D2 M,!<CW4TK%QT;-0.60W/H+4$L#!!0
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M5TK>\UA1UQ8-0;>Z<%M0(<M _;@!G !3 ^3[%:7BJ:$FJ/Z[,/P/4$L#!!0
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MV)=8QP++'1<T+X6E!WE:''[Q4QF($P&IQRR 2@%4%P@N"+BE@%L7\"X(>*6
MIR-SH*+C,,8"#WJ,[@%3:*E-#70PM;2DGQ9JW>>"R7]3*2<&\\_3^(_;T7 ^
M&8-X>C^;/,R'G^^F#^#G,1$XS3A '\ M^ G8@&\P([QG"VE6"=O+TL3H8 )=
M,.&">UJ(#0>3(B&)03YNEX>H18$M^5:DT0OI$6K5^/NNZ #7N0'(0=#D4+OX
M/692'%X4'U\O[K2P<:LE=+4^]X*^Z6K%B1!IL09#+D<<?/U30L"=(#G_I\6
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MD0]L^1<4"OF:WX0EPORB94'K6&B2"\G2 JPD2.-L\T]7A2$J .(= ) "0'8
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MLQFHFB'1>(VJ=$.Z-LN])>71&;I?:(!0@UP*2;-(27N&[O)T#+PNH#8"M8Q
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MG?-050<OYE2QD6QE&O&<2=76S3)1HQVX-E#W"\;D=J,=5'\6>G\ 4$L#!!0
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MAA1K4M7"0E5C0I/6):W]]EG.0)\&=C/C5V;<R3SC;).;PJ_N'0H]824@25Y
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M52XWS5256\#U C6?,"8/';U!7<!-_@%02P,$%     @ D8)B4\C?MXD\ P
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M[Z+;&-P^%,5,M<75O&;Y\'1_^,^$C_\ 4$L#!!0    ( )&"8E,X@V\FQ $
M  T>   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNPD 4A>&M
M("\@PWV8A BHTM!&V8!%AH=BL.69*+#[(%*0@U*D07,J:VSY^J\^6^/9:VR;
MO.L.:;OKT^BX;P]I7FUS[I]#2*MMW#?IH>OCX7QEW0W[)I^7PR;TS>JCV<2@
MX_$D#+]G5(O9[YFCMU,?_S.Q6Z]WJ_C2K3[W\9#_&!R^NN$C;6/,U>BM&38Q
MSZMP;*^G4[@<Y.$\N1HMW^?5L'R7*I0.4@C2\D$&058^R"'(RP?5$%27#YI
MT*1\T",$/98/>H*@I_)!4PB:E@^2,<HX)DBZP9I :T&NA<!K0;"%0&Q!LH7
M;$&TA4!M0;:%P&U!N(5 ;D&ZA<!N0;R%0&]%O95 ;T6]E4!OO?G8)M!;46\E
MT%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\C
MT-MN-DL(]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(]';4VPGT=M3;
M"?1VU-L)]';4VPGT]IO-;@*]'?5V KT=]78"O1WU=@*]'?5V KT=]78"O6O4
MN[ZGWBF?VIBN/3]K?/X]J<[G>^/U\9?ESTE\7]07G /\_5U\ U!+ P04
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "1@F)3OYZL..P    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "1@F)3
MF5R<(Q &  "<)P  $P              @ '* 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( )&"8E-]VC'*P0,  $(-   8              "
M@0L(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "1@F)3
MW@AC]0D'  !W'@  &               @($"#   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ D8)B4[1P +,) P  )PL  !@
M     ("!01,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M )&"8E,;8S4$M@0  -T1   8              " @8 6  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " "1@F)3KE7NI D'  ")*@  &
M            @(%L&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ D8)B4].CRC7B!P  *B,  !@              ("!JR(  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )&"8E,4<A(@8A@  *==
M   8              " @<,J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " "1@F)3182D!E@%  #T#   &               @(%;0P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ D8)B4RHZ>WG)
M @  "P8  !@              ("!Z4@  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( )&"8E,'57TM[1(  .,V   9              "
M@>A+  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ D8)B
M4ZY"SI8D#   RR4  !D              ("!#%\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " "1@F)3%3Y<(.H&  #G$0  &0
M        @(%G:P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( )&"8E/B Q>Y> 0  -8+   9              " @8AR  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ D8)B4\C]]T9!!0  7!$
M !D              ("!-W<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " "1@F)37#6NOW(+  #/'0  &0              @(&O?
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )&"8E-]I7YF
M8P,  #4'   9              " @5B(  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ D8)B4PZI38[K$@  Q38  !D
M ("!\HL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "1
M@F)3XRCBD2,,  !U)0  &0              @($4GP  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )&"8E.\T"$!6P(  !H%   9
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M970R,RYX;6Q02P$"% ,4    " "1@F)3Z'N]C[46   K6P  &0
M    @(&RQ@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M )&"8E.^I1)I"0,  )\(   9              " @9[=  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ D8)B4Q/IE3G,!0  D!(  !D
M             ("!WN   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " "1@F)3N>V'QY8#  #P"   &0              @('AY@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )&"8E-XC,H9J@4
M  D2   9              " @:[J  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ D8)B4Z9E-&^@!   O0P  !D              ("!
MC_   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "1@F)3
M&M#XA1$#  #W"   &0              @(%F]0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( )&"8E,Q>3]!< (  *P&   9
M      " @:[X  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ D8)B4P&AJ"MS P  YPH  !D              ("!5?L  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "1@F)3/;?7DSP"  #8!0
M&0              @('__@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( )&"8E,N/AM(P0,  (@+   9              " @7(! 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ D8)B4QKA>29<
M P  >PX  !D              ("!:@4! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " "1@F)3JOQ#+ZL$  !:$P  &0
M@(']" $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )&"
M8E-D'RP5' 0  -<.   9              " @=\- 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ D8)B4^*[U[A.!0  <18  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( )&"8E.8$VR.IP,  &D0   9
M  " @2 D 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MD8)B4[;NX3=L!   CQ(  !D              ("!_B<! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " "1@F)3.99% 1($  !L$0  &0
M            @(&A+ $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( )&"8E.4/^LUT0(  #@(   9              " @>HP 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ D8)B4\ )L'K^ @
MS@D  !D              ("!\C,! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " "1@F)31A6^" 4#  #,"0  &0              @($G
M-P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )&"8E/(
MW[>)/ ,  &@)   9              " @6,Z 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ D8)B4QWT#PR% @  U@8  !D
M     ("!UCT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M" "1@F)3U"M%D1$#   P$0  #0              @ &20 $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( )&"8E.7BKL<P    !,"   +              "
M <Y# 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )&"8E,NJWD.1 0  !TA   /
M              "  ;=$ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "1
M@F)3.(-O)L0!   -'@  &@              @ $H20$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "1@F)3@(3XG< !    '@  $P
M            @ $D2P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .@ Z
+ ,T/   530$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>294</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PPP NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNote</Role>
      <ShortName>PPP NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - COMMITMENTS &amp; CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CommitmentsContingencies</Role>
      <ShortName>COMMITMENTS &amp; CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - ROYALTY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RoyaltyAgreement</Role>
      <ShortName>ROYALTY AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - RETIREMENT SAVINGS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RetirementSavingsPlan</Role>
      <ShortName>RETIREMENT SAVINGS PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - PPP NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNoteDetailsNarrative</Role>
      <ShortName>PPP NOTE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PppNote</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/SubsequentEvent</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - INCOME TAXES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails3</Role>
      <ShortName>INCOME TAXES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="modular_s1.htm">modular_s1.htm</File>
    <File>ex23_1.htm</File>
    <File>modd-20210630.xsd</File>
    <File>modd-20210630_cal.xml</File>
    <File>modd-20210630_def.xml</File>
    <File>modd-20210630_lab.xml</File>
    <File>modd-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>modular001.jpg</File>
    <File>modular002.jpg</File>
    <File>modular003.jpg</File>
    <File>modular004.jpg</File>
    <File>modular004a.jpg</File>
    <File>modular005.jpg</File>
    <File>modular006.jpg</File>
    <File>modular007.jpg</File>
    <File>modular008.jpg</File>
    <File>modular009.jpg</File>
    <File>modular010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "modular_s1.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "modd-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "modd-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "modular_s1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20210630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20210630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 353,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 81,
    "http://modular-medical.com/20210630": 3,
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 86
   },
   "keyCustom": 31,
   "keyStandard": 263,
   "memberCustom": 9,
   "memberStandard": 15,
   "nsprefix": "modd",
   "nsuri": "http://modular-medical.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotes",
     "shortName": "CONVERTIBLE PROMISSORY NOTES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INCOME TAXES",
     "role": "http://modular-medical.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://modular-medical.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - COMMITMENTS & CONTINGENCIES",
     "role": "http://modular-medical.com/role/CommitmentsContingencies",
     "shortName": "COMMITMENTS & CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://modular-medical.com/role/SubsequentEvent",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:ConsolidatedBalanceSheetDetailTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:ConsolidatedBalanceSheetDetailTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - NOTES PAYABLE",
     "role": "http://modular-medical.com/role/NotesPayable",
     "shortName": "NOTES PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://modular-medical.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://modular-medical.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://modular-medical.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - ROYALTY AGREEMENT",
     "role": "http://modular-medical.com/role/RoyaltyAgreement",
     "shortName": "ROYALTY AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RetirementSavingsPlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - RETIREMENT SAVINGS PLAN",
     "role": "http://modular-medical.com/role/RetirementSavingsPlan",
     "shortName": "RETIREMENT SAVINGS PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RetirementSavingsPlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://modular-medical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://modular-medical.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - LEASES (Tables)",
     "role": "http://modular-medical.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Tables)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://modular-medical.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://modular-medical.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeaseDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - LEASES (Details)",
     "role": "http://modular-medical.com/role/LeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeaseDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-04-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - LEASES (Details Narrative)",
     "role": "http://modular-medical.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-04-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - PPP NOTE (Details Narrative)",
     "role": "http://modular-medical.com/role/PppNoteDetailsNarrative",
     "shortName": "PPP NOTE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PPPNotesPayableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-04-24",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
     "shortName": "CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-012021-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails3Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30_custom_CEOAndInvestorMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "modd:NotesCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30_custom_CEOAndInvestorMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "modd:NotesCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SUBSEQUENT EVENT (Details Narrative)",
     "role": "http://modular-medical.com/role/SubsequentEventDetailsNarrative",
     "shortName": "SUBSEQUENT EVENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-08-11_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailsAbstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailsAbstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetails2Abstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31_custom_AccruedWagesAndBonusMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetailsAbstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31_srt_MinimumMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 2)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails2",
     "shortName": "STOCK-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2019-04-012020-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - STOCK-BASED COMPENSATION (Details 3)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails3",
     "shortName": "STOCK-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails3Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31_us-gaap_StockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://modular-medical.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetailsAbstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - INCOME TAXES (Details)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetailsAbstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails2Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - INCOME TAXES (Details 2)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails2",
     "shortName": "INCOME TAXES (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails2Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails3Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - INCOME TAXES (Details 3)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails3",
     "shortName": "INCOME TAXES (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails3Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2019-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2019-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_DomesticCountryMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_DomesticCountryMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "modd:GainOnPPPNoteForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - LEASES",
     "role": "http://modular-medical.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - PPP NOTE",
     "role": "http://modular-medical.com/role/PppNote",
     "shortName": "PPP NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 24,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r358",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "modd_AccruedInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Interest [Member]"
       }
      }
     },
     "localname": "AccruedInterestMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedOtherExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Other Expenses [Member]"
       }
      }
     },
     "localname": "AccruedOtherExpensesMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedPlacementFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Placement Fees [Member]"
       }
      }
     },
     "localname": "AccruedPlacementFeesMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedWagesAndBonusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Wages and Bonus [Member]"
       }
      }
     },
     "localname": "AccruedWagesAndBonusMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CEOAndInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C E O And Investor [Member]"
       }
      }
     },
     "localname": "CEOAndInvestorMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CashPaidforLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidforLeaseLiabilities",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockIssuable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockIssuable",
        "negatedLabel": "Common stock issuable"
       }
      }
     },
     "localname": "CommonStockIssuable",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable"
       }
      }
     },
     "localname": "CommonStockIssuableMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ConsolidatedBalanceSheetDetailTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetDetailTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheet Detail"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetailAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetails2Abstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureConsolidatedBalanceSheetDetailsAbstract",
        "verboseLabel": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetailsAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details 2)"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetails2Abstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details 3)"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetails3Abstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureIncomeTaxesDetailsAbstract",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetailsAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureLeaseDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLeaseDetailsAbstract",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "DisclosureLeaseDetailsAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureLeasesDetailsAbstarct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLeasesDetailsAbstarct",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "DisclosureLeasesDetailsAbstarct",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosurePppNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ppp Note"
       }
      }
     },
     "localname": "DisclosurePppNoteAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureRetirementSavingsPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Savings Plan"
       }
      }
     },
     "localname": "DisclosureRetirementSavingsPlanAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureRoyaltyAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement"
       }
      }
     },
     "localname": "DisclosureRoyaltyAgreementAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)",
        "verboseLabel": "STOCK-BASED COMPENSATION (Details 2)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails2Abstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)",
        "verboseLabel": "STOCK-BASED COMPENSATION (Details 3)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails3Abstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetailsAbstract",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "pureItemType"
    },
    "modd_FairValueofOptionGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "fair Value of Options Granted"
       }
      }
     },
     "localname": "FairValueofOptionGranted",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_GainOnPPPNoteForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on PPP note forgiveness"
       }
      }
     },
     "localname": "GainOnPPPNoteForgiveness",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LeaseIncentiveReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Incentive Received"
       }
      }
     },
     "localname": "LeaseIncentiveReceived",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_MemberOfBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member Of Board [Member]"
       }
      }
     },
     "localname": "MemberOfBoardMember",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and Accured Interest could be converted into Common Stock"
       }
      }
     },
     "localname": "NotesAndAccuredInterestCouldBeConvertedIntoCommonStock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_NotesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Cancelled"
       }
      }
     },
     "localname": "NotesCancelled",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_NotesPayableOtherPayables1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 1 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables1Member",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesPayableOtherPayables2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 2 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables2Member",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_OperatingLeasesAnnualRentIncreasePercentange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Annual Rent Increase Percentage"
       }
      }
     },
     "localname": "OperatingLeasesAnnualRentIncreasePercentange",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "modd_OperatingLeasesImputedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest"
       }
      }
     },
     "localname": "OperatingLeasesImputedInterest",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PPPNotesPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP NOTE"
       }
      }
     },
     "localname": "PPPNotesPayableTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/PppNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RetirementSavingsPlanDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RETIREMENT SAVINGS PLAN"
       }
      }
     },
     "localname": "RetirementSavingsPlanDisclosureTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RetirementSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RoyaltyAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROYALTY AGREEMENT"
       }
      }
     },
     "localname": "RoyaltyAgreementDisclosureTextBlock",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/RoyaltyAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant, Cancelled and Returned to the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant, Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationShares",
     "nsuri": "http://modular-medical.com/20210630",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r146",
      "r164",
      "r182",
      "r183",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r335",
      "r336",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r146",
      "r164",
      "r182",
      "r183",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r335",
      "r336",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r146",
      "r164",
      "r179",
      "r182",
      "r183",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r335",
      "r336",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r146",
      "r164",
      "r179",
      "r182",
      "r183",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r335",
      "r336",
      "r346",
      "r347"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r50",
      "r51",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r203",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r200",
      "r201",
      "r202",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r58",
      "r65",
      "r155",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r56",
      "r65",
      "r155",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r72",
      "r106",
      "r114",
      "r118",
      "r122",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r239",
      "r241",
      "r252",
      "r280",
      "r282",
      "r308",
      "r322"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r43",
      "r72",
      "r122",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r239",
      "r241",
      "r252",
      "r280",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r72",
      "r122",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r239",
      "r241",
      "r252",
      "r280"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r27",
      "r67"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of year",
        "periodStartLabel": "Cash and cash equivalents, at beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r133",
      "r313",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS &amp; CONTINGENCIES",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CommitmentsAndContingencies",
      "http://modular-medical.com/role/CommitmentsContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Shares Reserved for Issuance under Equity Incentive Plan",
        "verboseLabel": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable",
        "negatedLabel": "Common stock issuable"
       }
      }
     },
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.001\u00a0par value, 50,000,000 shares authorized, 18,906,148 shares and 17,870,261 shares issued and outstanding as of March 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r97",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r19",
      "r310",
      "r324",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r18",
      "r309",
      "r321",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r225",
      "r232"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r225",
      "r232"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE PROMISSORY NOTES",
        "verboseLabel": "NOTES PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotes",
      "http://modular-medical.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r226",
      "r232"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred portion:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r226",
      "r232"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "negatedLabel": "Reserves, accruals &amp; other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "verboseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r46",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Per-Share Amounts"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r74",
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r211",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Section 179 assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r94",
      "r123",
      "r176",
      "r177",
      "r200",
      "r201",
      "r202",
      "r228",
      "r229",
      "r248",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r337",
      "r338",
      "r339",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r65",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on debt extinguishment",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r106",
      "r113",
      "r116",
      "r117",
      "r119",
      "r307",
      "r314",
      "r318",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r212",
      "r214",
      "r220",
      "r230",
      "r234",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r75",
      "r87",
      "r88",
      "r105",
      "r210",
      "r231",
      "r235",
      "r334"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r208",
      "r209",
      "r214",
      "r215",
      "r219",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Security deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r104",
      "r260",
      "r262",
      "r317"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Other income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r312",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Interim Period, Costs Not Allocable [Line Items]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Table]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Shares for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Monthly Rent"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r72",
      "r115",
      "r122",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r240",
      "r241",
      "r242",
      "r252",
      "r280",
      "r281"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r72",
      "r122",
      "r252",
      "r282",
      "r311",
      "r327"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r72",
      "r122",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r240",
      "r241",
      "r242",
      "r252",
      "r280",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LIABILITIES\u2019"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r48",
      "r52",
      "r55",
      "r66",
      "r72",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85",
      "r87",
      "r88",
      "r89",
      "r106",
      "r113",
      "r116",
      "r117",
      "r119",
      "r122",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r249",
      "r252",
      "r315",
      "r332"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r19",
      "r310",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r106",
      "r113",
      "r116",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of lease right-of-use asset",
        "negatedLabel": "Amortization of lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r76",
      "r103",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Bonus payable"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.001\u00a0par value, 5,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from private placement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from issuance of PPP note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r129",
      "r282",
      "r319",
      "r328"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment,\u00a0net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r129",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r181",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r181",
      "r274",
      "r277",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r275",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r207",
      "r293",
      "r348"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r177",
      "r203",
      "r282",
      "r326",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r123",
      "r200",
      "r201",
      "r202",
      "r228",
      "r229",
      "r248",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accured Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Schedule of Fair Value Assumptions",
        "verboseLabel": "assumptions were used in the fair-value method calculations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "The income tax provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Significant components of the Company\u2019s deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "A reconciliation of income taxes provided at the federal statutory"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Future minimum payments under the facility operating lease, net of the lease incentive"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r185",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Option activity",
        "verboseLabel": "stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Schedule of Outstanding and Exercisable Option, Range",
        "verboseLabel": "summarizes the range of outstanding and exercisable options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Reportable Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Exercise Price, Maximum Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Volatility Risk"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares Available for Grant, Ending Balance",
        "periodStartLabel": "Shares Available for Grant, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Options, cancelled and returned to the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted Average Exercise Price, Options cancelled and returned to the Plan",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Options, Granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r187",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Option, Ending Balance",
        "periodStartLabel": "Number of Option, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Options Granted",
        "verboseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r194",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Life (years)",
        "verboseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Average Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life, Option Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r178",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensation",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r32",
      "r331"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r50",
      "r51",
      "r52",
      "r77",
      "r78",
      "r79",
      "r81",
      "r86",
      "r88",
      "r94",
      "r123",
      "r176",
      "r177",
      "r200",
      "r201",
      "r202",
      "r228",
      "r229",
      "r248",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r337",
      "r338",
      "r339",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r94",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Warrants issued with convertible notes",
        "verboseLabel": "Fair value of detachable warrants issued with convertible notes"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Shares issued for services, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Private placement of common stock, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r176",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Placement of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r72",
      "r121",
      "r122",
      "r252",
      "r282"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r259",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r259",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r259",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r259",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENT",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEvent",
      "http://modular-medical.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebtCurrent": {
     "auth_ref": [
      "r18",
      "r309",
      "r323"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.",
        "label": "PPP note payable",
        "verboseLabel": "Unsecured Loan Received under Paycheck Protection Program"
       }
      }
     },
     "localname": "UnsecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/PppNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r95",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r351": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r352": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r353": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r358": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r359": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r361": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r362": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r363": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r364": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r365": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r366": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r367": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001019056-21-000561-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-21-000561-xbrl.zip
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MBASZ]/3'KJG%:A?/\^)E.N"YJ>7 )E(LV2]F5GA)CR@SUN4&(BDZ)XG,2?P
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MI^GJP8>AT 484$PF!T)33<8DO'PV&\&MZULH[(=2YALIW4X.D*9:)5L\^<Q
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M:(^0,:EESD6_(:G0;8#<QZA4H.-C @XE$+6N^!G1_%[*(D9\AL "*&BZC_\
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M2JF>X!ZRJ7;W*+0=C$/@M$/D^@^K@N3550\]\#WZBANRE.E_]TX-^TJ*5!=
MDL5G?6(L+7OA!K:W GX(,$"/P+F!Z":D!>H4%7K!AU0,1FZHAC-_-WQU#6AO
MK' "NCL!^6D&/?I(*M[>$#2&!.?X]RV(@QX,OH%@"";PP7?_ 9SK3RJ;LN%R
M52U=-(U058;T2B.3M;C^B+;C)'K4"\=14HL22U-_LO%7=39;$*NB"#,&5>[U
M=]MJ(#A= ;2^B"]'!&A[5O.F,E&($]-'TG'1%UVW3>6:&"D6V]3F] U!A//
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M3$4<XW12=4ZX.]=$R+ X]T976U10GLKO=W>A*%%H9P=2!A^)N(_BV\C;8('
MQ%U?4[_P0$1LWS'G$ 7N/]'G3$S9S"YKAN:)1;F82]A$N@8.MV^I)2.'E[M'
M#HU+I;'#*/?&G:^*P>GU!+@' ].C4]Y[0"* *#V \H0K)I"" *)49VUBAP49
MFI>*)4>HAL0.>S8]N.A/K2=:L"V(%>8V5A8;+,(,*,9#4U>4CZ4H<"376TT@
MD,>%(LM.]\A?]1S4.?97+I=K+8\@9AW1S\X?]@/ Q$R[AG[(CMW1'NP.BN)V
MA18.E$6D;$W))S^QDB>1K-T ($7^G ZJ8G%[TI^%2>GA.#X'-@GH,L1/ME45
M5]N3[CE(E!Y3XY,\*H99JTPIH<_IH"H\MB?Q69CH&AM;@]UU[7O7(Y2--&:$
M1.PC;M1$W%U92&0_=ZD ;A)1,U6//C+?=LP/=ESE/NG(>Z=1;<'$YOTHB6!&
M7ELMGM 3Y3BEVFD3C6 3G_4TG@8Q!HR"&(O(7VGVD(_NAO2Z148T@7P?^UI=
M;E$^36$>D/4$!^0IRS0)-F!O&M3LVN=2#>:#5I._7CI1M?2VY0E?9[Z,%.UO
M">'FX9Q'_423NGUIAMQ"-G0::8M;^TE(W'B3VN]N$%,W QZ3O*K+RG:]>GA[
MXZV)<3A?W4-,7WBY00!L?-$AV:PX%D[54ZMZ7$7>0JJ% A)N2N,EC_K>DP X
M7Z%'AB%.VK)&V<N?_'E)'X<&FAY21;AEW.0L^O=%T*=7R'">9ZANSF9(6W6H
M,PUS#82L[#76=A]=!_B. A47G[H9(E<Y!9ANB<910$;.TZO"84#%J4[]Z12#
M('#]!\(I$&1O^\_->V=U49R]GP!+$!UD--<F2"AD3#:-GXU^0]*2#NIE73Y#
MRGA"5['Y=WQ"]_B$KM9)2,<G=//-VLPSM(J.F4MY0O<@0X/K5\GZ88 #VW?(
M'M(+!4PM>RIER0=%#9^*,#^TF%\6VS^ ^S"CSS(^ F0_ .N)F#8N!@/D\J[[
MJ0F YRA^8GIH:@GN30.:'-3Q)XB6C>,V6/^R>8ZQ0F'D3_Q\A%"&#H<6(-3E
MY=7G(F1,W"7B?UH*%BZ$<$7;;7E '(X@EDT3EH#N^@JP)IKO!J(I<&FA#LW0
MM9X6+HI&J&'C%4Y].,)8#B58(JCE"\@E8J_&2=D+K*/H[J]9U;X0S3_ZN\H_
M^GM=_.COZGCT=SSZ.Q[]'8_^CD=_QZ._QK'L>/1W $=_#3[YTZODH@&E;U+;
MDEP%7+DQWV,%W+$"[E@!ET/] ZF 4Z MGE4%7,-/X+X"3(-$40AI590 Z4?K
M<!'=I-1$ ?>#2U5R?]U1P!*H=/BY-O6G;ST3Z<M'7-.PR<X57/REQDXA&@+*
M,_+YQLT*;:^J KO286R4".M#L0--TVE,XF*3I+8F<C0UP6=ORZ?J;5\6@N<B
ME(7HH7-63_G;"=L>U\=(V '&1DFV/A0[T'0B,97,AP<$'NR 7O*"7!^[DZA,
M7:6*9H#4*,E61B"-$XCH^W< 8?K.2[!<I_ST;(2B<Z_\'*(WN3E$O_6[;6LX
M^OFG=Y<7;S\:UN]?.N-O/[*(MF,JS2:*O88351-084!@1N/[]!"6D 9T(99)
M,BH^DB8O+/&@%:0D%1M%FTRE79G.?DE)FH8-R6O:7K6R4@,4,^C3%'5^8I.@
MF[(CY)TXQ;C4ED<1[4)W*6!%>3.,YFIRG.0H#F40T#6[J0SV:'F^738+M<YD
M(K#.H1\93Q)/NB:;*LIDXJ^3S.NM69@UU7<1E!V,0^"T0V)T/ZPR^B-+'O?
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M4+2L:,[Z<_J#YGJ03_X+4$L#!!0    ( )&"8E,4A& *840  &H&!  5
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M1RWJ;%/6 +;9GU7(@2"* 9RP:\O%.T3Q- )-TS(N7^BCGM<;R1D0N8@K;JC
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MY)7"!!V]>BI@62;'*61;HU)\59++'0?7V+S@(BY"TE$VN7&?971I@+AI,GD
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MB8>=HL7D/P$>%)\NEYB&#%NS;H,2WV+:ZG'"PXN!3G5,D7Z\ZGCCY6YU>'D
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M2=HMK6<2L$T_M9@@',^B._[*85S9@/5D*+MQI"5A6G7@T]!'T4OSZ:TH+0C
M*%5C'*0^S0WQR%IV65+8 ;U^7Q41"QDW\["ZF#>?O\IY=';]?96SZ^PW_FIM
M_>"77O*IWC?IQ_YFRJ%V)F&A6BD34'?<&S\IB4M%)<!<.]5D+"AY(S-22SZ%
MVS[''&5]2R,DPJ8WB>T\0"J9MH9)YDBO1"+(D)\M<&:$&!)EXD\.^UY\T?+9
M@4BDO%L7A5/.228A C6F<4S<K;^Q'$\2L2AO;IA89"J7#TV4,Y0YN#,DB?$C
M$;P$G[8M:8J=DU-%'D*.#=F."RKWJ*2CZ(:=AU-%4B DVKL]+Y2 X-:Y)O3-
MWV"!0*_@Q:B9DB]OHYHBHO;8N3-5YH:<=T,$U%(YG^:7E\)&O_DJ/EM"'7_%
M**"A 1%DC0L.U6\U-+_X*.4(N+C0:3'N;3I9W4:4\3>+R8OOL24_OO/I@M G
MQY;EDFH.8\P"")K&NO"89&N+M&?O3YTB6^$XQBR>%86K ,@DZ?:]U6\6I1;;
M&0B4]/C&<::]0MXGC8R=HJJG 36 :(I.I.>@A&_8^0%&C+AB82YICYW1JK<Z
M"QENR!$L_VAB-02^H+P+=F*I&FXU#T;-@VYFDH*U7I5"BKXLM5&-KL&"K95=
MO-)Z956\@Z%G0CK]*2Z>AB2;RPRM[N6=FR0E;LR$?(E_4]&[RW1'SQ"MQ:TK
MX&&2915Y*]6%6.B/GNI9C_\&$:,!R3L#*WB\<_TO@D(3/U1)UN%C]N)!#<S)
M.3"LE8I3TNML-Y@M5'(1"J%#.\W^ZO]%05)'>^G/B>U[MN.2(XJ7/F=T1OTG
MATW2F]TG-G%&WN'&5M\.G:>D^JQ2%YOYFC''&7"5:!+VAAQV?A%RZLUF,_Y@
M[!U#RGDB'BF=N+R]N#GVJ46CV/L0!(RR $9<]VWLC*(-8</1J.H,&7='O.48
M:6.G'"VJ!SC*VM7;4+>$46X[B>R\57_CT]#YCT(QI)VP3T!:U X >(:L%W'J
MDF>3-/$\<XZ3.>:;TH%K.;($;LUAL ]36E2%2@ ;HAS'[V'/^?W0Z9H!T6>K
M8IA5:F6!&/V1L ^ 6E21JC!C[CP$;@4#AW(F;DGRY\@[?DI=X%ZHNV$?1+7E
M9D !-,1"9+4SV1;SZ\5^Y(4S2C9.M)%$#]1=L8^]6K0!8" -$7Q13^/[X7T[
MICF863OY/3QH?_3SLC:W"EJ8FJT(+]SS18P_995YV(JA!ZJK?-K Z$=O^*JC
M*X5.Z=2IJF/ L5Y=8JNB#";L(AO3EYS-Y#ZX;=.(9('4T1_8>.CU7]K2)QUX
M#;$IC$V@J96>78+'0"_D4NUH4Q,CLX4[\IY(H'NJ664L])(N]0D;@)DA0F?&
M)]U;]>T_(X<2Q@K3U' W<RTO9#:))R#&SPF(A:TS!E3(C44M3Y"87YGKL]DD
MP-&KPS; U:6Q"&9MZJ*/7.=K]PI83E][JF5!D8X%59[F$^]/7E  F)FRH%#?
M)F05E[)[.;:94>>)8<%,HTT4BPFP/U2XC<4U3Y!4_NU.'<0,%// 9T:,A@YS
M8N3),=).X!RH3@E4@(V!4N0I6>J0L[@'5'Z-10H;D5\9*H8(#\YO'<LJ7,"-
M!?IJ$[ ^<IW?BW%^F4_"_^!^R9/E<M\EN=>0#TV)U45O%*C"M/&@-G3_506G
M,U6./ILDE.[8?(BO+^EJ1:$[5!U,"N9I(7,FE5O:T :-6YQ7)L7[P,S5HA%F
MW/%\J8VW1VGH)G?"&!*+:+M-_O7RZY&W]NG&*GO(659,\)31H;K4QA/D\ LO
M]>%JRI;4]VQ&[$M0RUL=-E7QA4M H <^!%3H#:8WUBA!ORH,1FG &50/NFHL
M'J@OU,:K"G7U9@5>5K7.UJ7!I,K&+$\5/(PR0<5,BP6QV1SASU=L_<#12WHJ
M]@7?W^N@\.'8F2/L_9LXO'*SXNGC8ENH,$VZ*2WFV9Q2%/Q"G^7M8H7<;"RZ
MFZX7SH/GK%DS+TQ3G_BRY;N.G0VT'56I^+'WNO?RU!;[Q_*?P]Y@^G'6GWSN
M]2>WO<6GCQ_[\\^]Z5UO,?HP&=V-!OW)LM<?#*:?)LO1Y$-O-AV/!J/A K-*
MQ90^6%YJ-5_*:R37VF89[*?K=#M@N2^%-]1;YIJ&1UW.3V'A14.XNLFT;,F4
M^8;Q\4=#8%:B!+EZ1ZW*F=]+((G5'#L8;Z($UNVGO'4;#_L+7$N5D*LV.?EV
MF+8CH66Z'A.V0R4O@ (F.Z K\NPL%TANFH$1,&=>S+9;?K1:/C'>YR?&;#;K
M3:;+8:6I(;AE^?*!E!:)UO,.DO9U7OY,BZ/LSYQE2LS;BYMC*:X"JV,%EK-@
MFM)FDCEFC%\G"'RZBVDOU>-W;_-Z/)A.?AW.EZ.;\; WFT\_CA:+*=N]<M5&
M-?O[JY+I<JLT_Z+VN+4VLC0!C+^P [+)EPNC4"1#RK4Y<T?XF&C\B]?WPBHP
M1S/J77Y&+9;3P;_^.1W?#N>+O_[EIZMW/_[2&_[[TVCYN??-[9"Y@Z/EWWI_
MM3;;7Y*FKV_8%NLV]B&'DT5_.9I.,"<>]/%0HUX)Y55[CA_7]#)%O ]Y\>H9
MJ#\2\M2$O25:$1]SYFHFP%0^#:_RTW T83-JV%OV_QMW(3M0KK.:23L9$=S4
M6M?DO9!G$$! HFAG)Y:Y.7'Y59V91</=DEIL,;/YZ()Y=)V?1_/AN+]DZ].L
M/V<KV'+>9VO4@"]2J+-*Q)1Z:JE[XK[J5TZ=UG33&@1Y]D$%67@!4!LG<V8D
M?V+220I(,/^-APV))SQQ>/==T67[^'&T_#B<+!?I/I(Y<?QD83C!/E;(<,9S
MTK+,Z2Q_FL-@/R&L)!4P9W7'09ZVE01=\A:Q/G3F3.-%=!^0/R,VZO I>QWJ
M:/9^7W //]TLF#O(9F]O^"O[/VJM^F,.('7JA3U0_;\<51!'3]P%NW:]0BAY
MWT[%NSD3)ON.PXWE\EN%BT="PEO^G*];/G]^* E8+J;CT6V\*;WIC_N3P;"W
M^.=PN.S=#I?]T;B9B+R<=G"@'CI,O:]YR[ZI"N>#>YL1W=>3T_'#WUHPF3.M
M2B\$'DVB0M)*'-YG+MWG_LVXVA'6)<Q_"?,#P_QU)/1B'A% 3P(*R1.7\/XE
MO-^1\'[7YVCI,YS'T[.0PB$^J+M,T I7;(Y$P/<D6FNBQA"=F)*ZB)BSG9S[
M.\ME##Y0<ESF)3N;K@J))//IY_YX^;G7_S ?#C]6#6PH_; \=6#/2]RQ3E\K
M_Q78'.!=03W-\+%4,LAZ51J &#0%2.C0F-R%]>1X#P$OH%<^#PKI'_/A<C2/
M)T!OT?]U-/G _*QQO]J>3ST;R@B%3PEY[UKG1=FG-"8'N+LA,P0BEZ-IHHF/
M.7-%$L4OGS&%3(WL>1:_07,YS3*;X\MI5MF.[^33K"Z[8+DSB/*)7T@MR1^%
MH4[VRUG8UW46UN'IIGN357JC]:J07U+]1FOOF_VG4)]@/^/+K8+M]=CY,W)6
M3KB+\=^IMM/BYN=X\U/.L7 _C:&Y-U;@!--U;@H#I)H. .V/_1A[DS=\]3 T
M1/"? C)=#X/0V5BAK#IJOAWV,^U-"K(<$T,$MB /G(<YV?+R,]H3%=@=^V'V
M)L6KA: A4I\SEAD1O.#B+7DBKA^_II&6'4I(%\L<U!G[K?4F):Z!GB'R7A"7
M#?KP@7B$6BY_#VNU<3R'<QDZ3R0E/="8]M7&PWYCO5D[< K&AB@* \5FO-(8
MA;D3_#%@GJ43\K_)HF223MAOJ3<I<@!:I\I5= [!/L'C<Y\8 32T'"]T(-,W
M#M&#NF*_;]Z8!Z6#G"F3LKQR.M18 [MC/V'>Z$350= 0J0L?/0,+'CX"]DOF
M3<I>%T=#Q']G.32N.9OA>>0Q3J/-B^Z*90_LCOY^>9.2UX+0$+$/+>K%Y^:$
MQIF/X,FN[(C^WGB3H@;"9HB09]3Q:5)6>DYLUPJ"^,PCQN+P*/LM"6SJ;+-Y
MVF4F7G<D]$?%F[7UU8 U1"_X@1@EC\Q/9 YC4IU!,QX''P'],?!F'3,]( V1
M_X1\R83[J>^QOR9O% ::>J _$OJ#X$WJ0U5@#=&+[)V=M&+$P ]T7$#H .@O
MA3=M%31@-$3XARH]8&F+>Z"_$=ZD>%5 F9-KFE257?*+KH)DED*YA:2 <>^;
MI!-J6DH7*QDO[$?"A,$]P2ADB'YT/&<3;>9<L.[^8MF=3X^?Z$A$!#D/J6?X
M+E1$KA7)AJ+C+S-GG#RYP6^^RS3V..N]O!-VKHE<.A ."IBW_D013%Y!AG)&
M)U!@Q5[89]#:$A,Q?A[IGKIU:F7K8Z&<2@W5:HU87#MY;?:P)/2#(-K$D96
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M;4C3N]\R4'--T&(G>= *D);RTHRS!,/6>E9B>]P$+<J@QK:,%T,<46%B\J>
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M2A6UKB;ZL7D)+8<*58F*<\)]C]_=D6>T*+J=C6 5?!J2ZI(C3I7C(FANAM!
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M2:S@58Z\&?5MDD2C=3+\]$?"MIO5Q5L5-:VTBO0W_'^\_BW[R?\'4$L#!!0
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M.?4I?0>:[&@2';#4C.,C$N>:[ET)K/L^*I>]\!GZ_/Z5AJYI+39L9T.*I\^
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M?F"QOV!KV'U.X1BGN_1BF9L^#F,XH 3F[,>:P4J1ZO!&O;J<I.\V<Y5*L<=
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M#X<*@$N%@T>%<]<#Z/C+-BX>#@X.X#^ @! 7#Q^'B!CGW^'_:<'YVT! 2 G
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M/W:D42W6( <!R:2BNXIL"7E6%P@WD7W>X4&_#NCX3]KR3[17AP2_-#Q9V"@
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M0!W\O> >4C978"/A^K$DP>Q_I=)RVW;O1YT;Q16\F522U]6BU]X_0K[<<>K
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MH,-'B OE"9FO,)''6VW#=^!??$EBNH^#@:4_>)Y<$5/'/04V^!C6(!)X[@#
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M[G5'!T_&[0O:2[3EWG2O6GH(\5E\J+LSH'F4_8 /)ESI;%=\JHU(V21[FIV
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M_HPQ):6GM/.37G(<OW+N[0VPW;JOTQ]LHC0]ML%QN]M3NHF=;OF/R*,ATI9
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MWKQ]8\Q9_MM_S+&6(D3]]'-66Z7!%U!9T054TDS"03M-=TI&>8_]$$33^FU
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MKGK61A0>&XMO!A)Q'7B4D;%=.E73YE+-::XV%K,3;?(VS-_!(AX;%M(?_L(
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M2W_HK;$YH__-HTAOYOX#4$L#!!0    ( )&"8E/I ^3[DA\   0A   .
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MLCSY1+V2 ]93QAFO'-)7(B+XA5S-ILOPG"W8-C*CHSYM$Y*:T/G6;.^E*(E
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MY 01,!!H AM)8./A?3V>(VGJZM5V6*S_9?S9IW=/Q6EQV)O4%T3S"!=$E;.
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MV^7>;MI6 !..5P-]55P31A 6B@54G9U)/7-BA_W*#"U3K0)28RN4;/9VNTN
M [(*R294"_HLQ Z1IJD7B5,0N@<S#K&G$Y*EP>&("<&J\LX49IE5#FV]'OS.
MG9>2&KTX>]3KU(.['<=*%#BFXU4OL#XG)UZTX<G.S$'$QT#:H.+N+*:IGEG
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MQ*A*E[%-SK=G3%_0%^E\ZLMT+O\ZG;E4]ZKJ<!5"E!PD5L6K"Z^:"%T&_):
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MWX;P?>&MWE&>//>+SU4^^?SV'_B<1K39C#(EDH,:'EJH$.DG5RSGF]YC,M%
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MEIH@GNQ!=*[75=?S'X]B2=^;@UEXNV#D_%R;[T>1R,3>P/Q)#B>1F$KGDCO
M-LM)Z<#$J#.DW*8E95A7/>C=PDLZ9L0;-4QL29_VJ^GVPYA]:9QT#-.AGHXO
M<\T-D'P#EMA!T@^Y^%U:/#U7%;5$4D8N'YA2.3-=R%%C8:9\?($PA^8,?]WS
M=]/6?;5Q#,AX-X4%\7GW3S[PIX;N]&[DDP$[/-A;QP_8Y&FJH(,FZ%9>(C:U
M:Z:MI+XE1HTU:LY \JSZO5HSEN=79W#L,H]H98N _!QZY%1T6%8>-++74;PC
M_YMBE^ .S5.*VKHWD_!.RP\#*$M</: 72]0'_+^#]@Z0" FTFAU.>Y?QW::
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MJ<R?"<^W&-H"$D'O.FP%:$6M['0-Q\ R]4##-YI\%@:>0!6!%Y??0G:\(/G
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MX5=_:X0(P\WWF<X(:(J+956:YE.<0I(I&7/_&]!?XLA-]L=_.);':U;F9H7
M.2Z>$3);W<@L#=M^GZ^Z3Z8?$^SN\//_J5.?0HH@S_%$O9>YT[6GA.M/#^$X
M(1%CBJ&F%RGMDOPF VC%T)3P6)I?/H9O=/4QRW-OU03#)'0JK48+HC[0)J34
M:CO$W:C!;%5 29Q2?WSZ$,2=6&'&**:Q);D[0/LZVE=3<DE9&>70N.%7B9RI
M+KF2W76;JIVHLA:/<-505WUQ^>7S3>T9RY'(HCQZ'T59I6Y:C(H1::1<EA7
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MV)G))7@=+6>QX]NS4-ZP708L>ZOUA?5Y. #K"^##7%BFRZT):CHEX^TI[F*
M;B,?FT-O"7W4#%K@$[EL\ZZ'5.FL6,>F09-,+PULIH6'T[:W+S]TY\5A^4P9
MFZ5]QB,V0ND$=O/=CPZZKBY3ND(WQ;5B#8S][8PVY4T?D1&5L0W(6'""G-9:
MZ39A\9K(9GA2(/^%QH]>@7R'1#J\R B':LB,;7F\/MT8;Y /2<#C(EW.?M=A
MUO!/EDYHEJ/61WS$68+%U:^\[4(IY@*[:YRG0J-<YD)V3G4X A+=J6C W(__
M2W WY,(*BKH*_WP5K]!9<?[L#5E(./^Y!<UUIYK4CN]GBGLRWM\SCK,A^%B%
M:+@]:(GVA>YNB,;'OU/,AZJE:75;?36]($U'?(GIWJT$]J6_I02IAT(C?TZ6
MG98%)-KTBXJ/3%GVF7/(;3571F09BLMW*[>7MH S(GA+"MQJ1&*!DHK!# $?
MC@NZ*<C5-3\\R<7/V2X<]GT0OVJ) 9!B>BOP& #@QY+>_D?X4^0[5&.A!VK%
MHY_57Z[<EC5'O0!B2J[=!-W2A-X!5(W/N1D05\370I2WV:T')M9:B&IULUDE
M7'&W9Q-TK#(F/HS^6,[_7;8<AT5U:;LD/B#DZI\B),98DV V=/@#8T 6K;3_
MRW=E\31D)$.=0>Z2DZ,?:LD*&Z>$R)5/%92^I-F:3Q>A=,-SH/0+H5M!9O_G
MGMA@WZ/]48:)Q\'//N#3MAJ>ROHI:\)6S;7B1^P5?&YT=5/-)A3FG:"QD3YJ
M5>^WNG-G.6FOX9]T;^3X0M=95"PPDQ+^V*7?&H8F).C7RMCHI:>"Q.1OQ_/F
M!L%[9UJN32[[CAFJM?OAD#O P=2,=_NBBY"85QJ/5G_HX6?0SY*PCD]A\ON0
MBXO(>OUZ9'+K-[>=EW/.LC67X65W #IQ" =/ Q+</5N9X3@[:&4Y&R^[Z#!'
MEOQ3W44+?^/>PIL$4"O3?*Y)6[MSZU7@I/IN.0M1%I;<+_\S_,,GF&O%E02T
ML4E0][XLYMW*PDEK1Y"B#U/=8%43S"P[CE1M$^AE)\(&Z5D(HLN0M A_SULE
M5?-KL>H5!B>]@'G%SCYQ0HO5]A:4.53O#%4;F/\[:+C/+T<W@WKK2*[ >Q;O
M?-Y/LR58S.9(EL5O5@YI?IEO3.T=%;Q-USBZ<6K>E?'"PRL2Z\A.LE@B\;#H
M_J0B[JN2BNN K4C2U3!EM15WM3O _0>LM3!E=?7Y=][+QM@7TN,3[BL5:.[[
M5F5ME3_"(Q<[IU&%U]2]*UK.LJ=4.F?A-I7&4Q[78V_L=8TFKA"M'_PTI*+)
MOOA3R-1-X @3_<C]F=>#9:2FE'S[F64:D]TN'"H18"40NZ8"[?Q94@A>F8<^
M_<37U?B(2?\PB1TI-?DRJ 87$+7-^#NW;,NJ$LBJ"$*8,&C^(,PZW6QK&_S+
M?A02PJ;QGNKEGX[7ZEVU 7(/T"+7!WR08KDRNJ_-N66VRA2,%(S>7Q*II/X'
MY&W3/NFI__RFH-%A\XPA^B^NAQ9_!77X\TT;UMI><TD!3-Z\V5W9H4^B?M_7
MUZE#;CI#C,4J]NW_4+M7:=^OV#C3*>GAWV7<[CM;8O!(<F*@FV3.6E(#',IL
MO&*I&F,<K!!H= ?X(/'U);M;PFL+-1Q)U5WDGHT,N*HXDL2@8IS(]4P_80?2
M1Y[0_-&_(*WJ%-?-GEXF*6XYA#;%Z3#I=U3QX]6JJPT9R^$O_.(M/T-N,^8J
M82&.3G,&^W$*^GV3:H&Y>:IQ,]6#9,E_/-*8Z[75IX1P[4KX#Z>:?]G)R">T
M@VA4)'HB_$+?82VN&8ZO3/<VB.O:A\4U3 ,Y-)OM<6RI[GDH08XI9=Z_HA%W
MLU&)Z'7OH5UW;6DS.ZRMO&R@KX79E$'^PM^(;EA .T](GZ*CT<G>4'D/U:I=
MP1P"EVP2UD\:CS5VGT=_IHJ(&9#I/3ARY3(7_[B\0'ZM,#")-]*\ ):@+YD2
MSY4*7(B:3Z'KA/SXE&](Y0^2C_DHD$(LZGPTUML/%G$[:YN:];)VZ9[GX:UR
MD3BJ:XNQC->;I/M\T"1A*..%RUQ?,WY]&:3X;]EH6=2Q37&[:J]VK8> )A8P
M8$>OG80KW&S_*5'FC/#7Z:@_I%,.<KG>Z&+\PX)>"M:^/JH/K+*9$8P!3/9^
MA9=G>2)>G3G.@S+]U=)&Y%*S$(H_$@,"3,8?AQ5WNMUVEQ"G(C:C"RT#K$T=
MLQ?*H>&.]N8%7*]I&ZZ:2]]LS0H=C+IT!E+J[0HK/9Z9VH/@(/HD/]NV!EH=
M3HVO3T+)XV)Y?VH<8CMA*]D70@=_9QXM1AG*#>\5^SU(>. 6E:8]YGRL;C;5
M&ON-^Z+C6^G2OZX>X>/3\Y:\UJ(NHGX,^>6/L&\T7YKMSS%PEUCQDN0?C%[;
M6#3@?YG(*.],57*PBW%"S<00[!,TLLUKZGRB$I&)M(TI(/-SW-E&^E\L.7;R
M[(,WY*<31C&8#F35R?2XK%[55H+/8[$*T3]Z_2N/R./T8%J^#_$9,RPL.KW.
MZP6*W$N+(T;-7[*-!$5+/<,-^L$<Z\M'94Q]U 1A-[)<&S-\4P5=><X;C45W
M_3:U!Y\ZVM#UXG24UW1E6*60,RAQ:Z]"!.(:ENAU?EVLWUE6<UD\D]%)Q4U@
M\-5_0G@\'*Q&H_R9]KU%IPSK8^:NWD;J$4N.OG;XL%SF7PF0;3=47^E,+3VJ
MY!"Y>1JIL6%%'^Z&L)>-O?G0+'5B7H[(GET.<(G.D<$RQ/>=8($K2>1@!O;;
M%T-=*87X+&?"#=F[\M^>YNTI>A>AP>D66!TKW<I*6;4)X9.Z2MW),ZQ@JX-M
MV#>+M1[.D+(<6Y3*0_"9CR-CZR,H1Q>B_"H\U%RG.#:9S<%3YYF6K]/2H9&)
ME(.#!\@*U'@C7'=F)JH1&API,YFC 517KZR9BLB;<A9>7=O_ A1IY<J;W'5!
M-*RV\MKTI=-)?0XC_[TSU$<75\.4>,GO7Q#ME?!(I-26G<U-<X'91H=01="H
M:[U1;RIN=6S)%'%L2Q-K @9-;,6X//S";%,S/#A4IG<<JV1DO$"&-0%UQ,#E
M[)WPV '7K.OQ&CQ,G#N9TM4$8<Y[BKXC6T,VUDC-0>T7@8.=5YUH2ZUZG)W:
M:W&@C!"47D8Y(CH$XK-)]^*O+#K=:(VUV\,?C_A(,P%.+Q+)!<9\#\3LHD]0
MX5UA*O+BB+DSDAP<^]43;R/_\D%G3_?=FNR05X6:,D!-A8/)$'*Y"B)2CMY
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MAW0<<M(<" (" M(\SO/,/,__[?/9V3??G=F=?;$[NS=S-\L K9XV5!L $0#
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MBKCHDY'&;4$!P/%J=F1KPJI%;9RM1)S_._?RN@K-3S(OT,-)S"/"8^^<G(V
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M8AQ-K AG;UM,+//AL[NP"]'AV;\JR".4P;)KG0)?'\\/>H GU-)@4^W-KNK
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M(T!'G4 & # P@$$@X'\!A3 Q@!E!,- ?_.L$=*Q#.  0&,P AH(A$ CS_Z@
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MY#UG[_V<O5][WG-R-W.W!'BLJ:JA"L"Z!P#8_OD [O8 ),I>-LY^ "P #@
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ML,@%6TM^S%"MM[0;Q"+AUR ;20'X*G!&0S",IS=WBUM/*5 /1D6%#Y3=X:>
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M.\@ .78=N+RS,T# 7BN BOJ^Y*^W&NV%.03Z+S+ (6QQ"*?,:&68SJ1!_?[
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M?5GS;3I+/]W'B"(L"[=OZ-3HPY?IS[5]D0-=N!)35C4I.;&);XPGDSLL18N
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M2HUHAS:EG)P&.%V]^,IN-'9UNT9-#T[9-9/G4XG15ZW9JK;<+"N;*D!68_I
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M4%>U GJ#(GG/_4ZPZXE##??[M<^VHNKQ[C5<#46M9>L7\*]^VWI&RXLK%!=
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M%X60$((E>-#@,(,%=Y( @SLSZ #!=7"7A)#@[NXP, ,,/L@@(;@'EX'@$"!
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M1&^2;6Q:XF^9(+X*(8V.1K!H4=:G#L(S[&]\KC]1NE57SJCLYPA-.U$;8$<
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M]D(6IJ+0-9$^K0J!E+MPQDQ>?%:E'/B,JR)8!+:;ZW6?P5&7B*>M <GR,G8
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MU3@\GFBA*/%FRNFD_I)(97Q\(HKP=VT^!*QIQJ&O=>/:5[\T>547)Y>BLCW
M%):T'P>9D&V%P^'>I90S4EQQDT35'5N&%1&5W1R_<?B69<QY7/GX+49^G?@>
M1PTTQCTP32+<S!%@!E:*H'#9/E?TJ,ZZY5,,_5%;VY,@T+SK:'Z^12G_R</Q
MUT&O>[-=O:@U\J/72ENY)][&R0AA,&Y?QSZ6^L?VIIG/3O8W#45GCL;[1 J(
MU$ZZ%I+<)@^WLV9F$N6_RC--'?1VMCNS(&'HG-3D/JT))\-G(5J@)7AXV;[.
M/DI*BR+(AK+<'6103VE[[85WKIEIAUE[];;V*@2TG9@K>ZVY1)6CQ:I5T+"_
M/1RZ45$HP&K]3:MEZ2I PK#8>W]JK^FTVVH?FRH:T3YS#_>*NN\7 7:MT?)7
M$<_.N8RV\7<YY:,9!$WZ?=W_ ^;!N#E'?@1[M?K4"Y02)8!_IRV<B@JDDY2L
MZ][CH3:0&CTTL[*]U*WF'!C6> #)1CQ=:2E9WNQC$<A=1_<*YNMX@;UB1,JR
MGC 5D\I!G1#N>^5S K/#"+6$PH=GI38DI<YO^1 :%%%;:G>YD8^!H3++UJ$5
M @&B%O9'6VE^8/X,G6[Y36<T8C\$XC,[@%W^LD2VJ:HU&G#Q2,^#'A?__7@/
MK-Y%&1EQBN(L@X8L<  :TK5<^]HS3TF7<R>PG_8JZA)V1URP@5*KQP\(9F-X
M13A%MN@*BG*=2_/.:-IHHOJE9<CKN57M$L@8U; 7R]M';AJ3G[(/ T6,HLZ"
M)9M5 C\=IG(4OU<FTY#&V+.8LXG[K.*#5N"N )Z7\I\D?/P-I/3S12R7R*;M
M9B":2C'UL.QKXY3>LC=D+#V)9(SB*=(OIV5VH;NAW)*QS*&;K1[O=65C]LW\
MD; =UACW2J7O*>'_Q/S5;2_,?^(*90IS$^=#JYIX\IAMG)K/:&P'Z4Q)%&WS
M!F3 J^9=P!/5:OZJR+U"$ET4@X>$_37I=:R3+RA[_]H@5SRH [.*4B!-OK8"
MTY3T1O2E.S".IIM:$F22]0<XZCMJV#1J!V7>U-0*A?,I^Z>E[71?+'R T!ZY
M%WZ P_A.,<<+0=[&Z.FXF?KWQ\08MW3:^:AL-D.2:9]=XYL79"J[R,WBK1A;
M:."'G$:>%IVKKDN]]$7O%*QNX7>D*:4^ '/.J5C8)0.R=UFM&$0_6+%2=6 3
M,JC*08%8YU^RH>';I2ZX0BKDL+=ZU_)1S8,4O0I.UY_FPF4S1D[LIA-:#:0R
M0'ZS<[5\&8OE*LZ!-[&LKNL.-<Y,O$;50TU TPKV=U[2#H?: +;Z0H@"A#+.
MIDT_X5X/7Z46MBW:_GC3L;7S@[[MN>V5EY:U-E_'ZA= >;;))A.D>_3JY%1(
M-H;]%M+!F'..G^ 7&]*+*2DKQM]FD%C_\=605F-HDIQXU<VSRAA<<>&2X^QC
M5J[7! ,H[TYEO*L=%PVIA%'''X_O7/;'FGY5A#TTE7\Q:K7F[D.7F:;:YW.M
M)QQ (V:P[*(Y 9')LC1(\9EOT-?K+5?;@AVVI[?1L;2$9:97^?0.YXP6!JRD
M-Z!=;P=V(CO1?>JO@WEL!@FXA!GA<ZG:P-93Y=1,C< 1X)8$7%)E%)D\TI(U
M@[E[M ^_Z;)<$QJA,-S</QHN,!/D]-O/+1!]ZTX[GC8[8&?;U'WG06N@XJC2
M(ILUW6=%NG?R6^U<)W6C/?BF3CG!\Q/?.S/*@2Y&-2D(->CJ#RG;.<NXT=WK
M;\>41E=M"J[), C@8"7XK>2TXSUS1@6?3H;1J"(@/T^_CH?6.*\/3P:/J%I6
MP$9KUM>=U!28KGI7=;>F@4VTXQ]MF+:-PG^JC^Q8"8SM\YK,'#<0RM=_PDV1
M!?N;@G3]],4*")@[:,18&*J"35Y#7T&>P6#(+^Y-/GIKIJ:$[U=^L0X98CJ4
MWK!EMQ[(.N<QT(/TWBWG'AWDN(]R"SJ<'D3>J][!1GBN=85+L5$9/.-=<1,;
MTVWTT?+M%[/)LED4E[UJJ"G;P)OR4#JV\KU>8M/+<-F<X&=MAB^S *@]6#1T
MR8A$W?CGX7N:TE_!:Y1ICK%">\*\ 56K,6FMX@^KCRH=4UYI=(V$]!<)%DDH
MH?QV/B4,/FBQ?YH-SQCD&Q(KBX0#M>)^?7Z<XL'^Z\(HTU @F2%7KS#'V]3@
M\0_)+[!]X_'ZI;.!7$#_LUA1A)-WBM]U5,9A7M0)%O*9A7:/+L5@'UGT=5B7
MQ"_U13BY0S@][)W'!W..S%&&%A&L=8+%)MBZX5H/UFI<<GG/H+@5<UL825^A
M%P-!8;TD^:U<QP^VL41:SV]HVS!+P5C13EWEX4YHGY/8CVKF[@HN06HIQWFU
M0[6<XM5PV593WYUF#D*L"J)?J+&KW=,BH\KU>%BW37PONF[/50*-47<M8[/>
M=51VPLC2/H_E"?O6%'9XS$^(6#5F)D590PT%J/1[!%TYFU$72CM\'\8#[0W5
M^FF?GAY?82@Q3 Y^]!9>;M+OAL=66"1&52G7;$F)L[9'D:$U=V0.V+3W)AR3
M[C^U.43N:O 4E,1\O4&XD7[?,HO)!(Y:G4GR.U=016\4PK/G7"I]OX @F #_
M$H^3GP>K5*5O[J4VE7YU/=@?UKG+EES,D..OJJJN!40DMK%K =,GW)'>VRB:
MI;YY3,F32.FP (,-[6&!(TMM/;2^X9*E_\3ZRDR'\*NO+JIO0[C+ O'N9B7-
M1$7'Q!F.F&R=),N1N6\D10M5_\9)^SHC<M'"[S)Y8/ B..%24Y8G0KU""B,<
MJX%N'O75;#R23(G>4#6)]H==@2Q$/GKG>,>9Q,3?22+<6'W?_B$V,T;@E2W
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M\%N5]Z5JC,KY;#=@#XAA-3(/Z*@+$OEFM=: 4#]#S1\!VI 5*=4&(8B"KB&
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M6'"M%0G^"\9Y?RQH@G^2;R,$0"/]UJWF@UX[UO>*^.YEK-"#ZH]ZBN8@78V
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MV73)%UQ(N?;B/;Z.J/%%&(J'YMNQ*9Z^E2>T"<U:ST[#E1LF)_1$EG@@4-5
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M#V11V!]SU&O6X_L.BD($-LW#^IB$+DS5&-:O=#$$F*?S,,QSU?)WZV,#><^
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M.4KHNDY^TE(DTHD]HY*D>[0JT*T17*%_#=ID*&XM&Y>=L4=:G@;2AR!)\C$
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MF\/:.G1*G]*.@0QRQHJ!8#F[KWU(#;!I/-4M!3]AS[6V;7)UCZELNX5[ECY
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M 8\L3=#WBPIQR 7:G)C]@?+C4;5/8J6\_!C^6W:M, ^J3@I>7<NA\9Y)6K=
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M"IB@;"5[B0WOEAI3F%\^P)1'HHH;.3MI-P=K6>_G4>R9%9]@LO;;9O+G9=I
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M?XK=2,)!&\[21PUPKB':@4.:8]1XV"I-T4-/.OD :V"2)=JMSB5T63VP9>G
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M/5](T43-S_I"?>7#8!XZ8> %2J%R_ "N9#RJW.4#:X;WL[\'G9MQ!+_*HX=
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M*A%S5R+F0P&OVHDTNT6: #3\E9X1F,CA-:(\\UG 7POSFJL.O7AI61.@L_]
M!&'/:TD00]@H#*SVJMDH3N#E?/';KT_J3,6^WWX14JQMO[*U[27%VO9,U1[@
M"3O%3!J#760C!+UN5M[7FP!AF6Z['='K"'ED[G-4?]4>S9(.JGN;U<IKCJ'J
M"<S:1JB^YD72$WAA&V&H@]5\8_K++)VOH_G,1*/(ZC+P S?IWKBAP:XLC&#
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M1O:;] 0JM#3U#T=R=:41A,*'Z:0M)VT)>)L'7# -8"ANY#MG#UX+U6L']:I
M(G-UX'\76-.(++=6<I!7_?*N#A/'U\$_G:G-L3"?XKR3H-E*QYCBM6@&8)6X
MR--75R[BLK.UM;7IS&C S]X434E3&AD3>Z7O; P<[R-CVU:K^>7B_/;LU+FY
M/;H]NYGJ&DY[I#=G)U^NSV_/SVY65XXN3IVS_Y[\?G3QVYES<OGY\_G-S?GE
MQ4*.OZ;&_]65K2!JIG%46ETY+9^4X9SM;!^\*KJ=R>@>&<F^6KN/E]>?';X*
M1=N#__#MH++[3?@BV-P\C3UR46#!Q3</F5=ENU+]]HU^VMVJ?/OG.OK][+]_
M[>[<M[;A<2"VHC@B$1]XCM*LKD7#V."JO7P:YTU<UIS(10T87GAHOV_MP\UF
ME21A_LA\.V>_L^/PR[/?SF]NKX]NX8"LKM!!_WQV<>M\N3@]NW9N?S]S\I/E
M')W<.I<?G>K!UM9+2("G,<\4L:-@ <(0/O?@3/VZ!AN$OW=<W]>_3SQ22P$P
MVH,7AZ';D3 @_1.J5+^DR>2/OQ,)6*9NJ#>0^8G6T'Y)_1ZMYE'%Y0DS&HMX
M#IW:]JCG$E7U'L93=1C/R#K2,CI*+^#8##Z427:9?/I_.]&VNS>%0SGHO6L?
M/E^>?OET=.U\/CL]/SGZ5'+.+T[*XQS7U,>_DFGM-8B2 1L]_O/&W+O1C\*5
M_K!^]N!Z*0\'5]")&TYB5LYQI2,[PD/KW7<"V.14.J S)O#6#5B[@8OTCL[D
MAR6+>*4L8JLZ/H<8B\KZ.<1V@4.@&R?IQ*S&D\]&^>Q.8G\(PSC>;>WL'7\Y
MC_Y]\&2&T8B3MIO^NA; 3*7PT'^;"@1TP7,@HGZ.\N@XUSY<B#O7=\?D*,]@
M &J;:K!+BH#-YE<[(ZVFGC,R:"C3IZCMJ5/4UOYV]6VOZ>Q/Z6[AE-ZZ#^?*
MD^O1"0 *QY#GP/-Y5X\K=_]\.O^ZM3,U@3YD &L?]O?@EEIE^V!G#N)\*%^>
MFT0GSL3#B1,GQJ1TYR_+^8TBWI;=(XR&Q'FG)]=W9<-M!V'W<(Q1!3;OI'$E
M33<*_J'?BZK$% [T% [LW+;O*@E ">KR@& O(]]-?.<\\C/0R0(W?/F].PE=
M*<VI<U#:.7SVEAMG;=QY^;I\4^;QG+4[8=R%@_?BFU5DD2/VJ4]EGY=C0N]K
MGYMA,?QV>IB]$G*_("&/?#\14JI_/@61J Z6C@<'!]5_IU\J_]P^77OME8X#
M7K[VH;J[MU=SOI:=8Y%$P$9BYS0)[L00,=GO-U_<E3\>M/(G\.-E<AO?1X/7
M??NOK__\^;7C!P>M::][_NJU#S<PTM- -.,AZUSJ<U^>#9H-R?'+Y HL$I">
M0PRADW_B3^W=C_\Y_;/^<H;0X &N?3B!786'1<$P*ZAOXJ>#)GX5PPC"_Q=T
MAMM_?]]T=KMG[2^)YTU[)PMO7_MP4*O6]E["J_M2)P8I]2@1[O#%O6S]43DX
M^_?O=^[6%!;7?M_:A_7]G?V-2:F#\C>N6G$D'K,Y*N(XC7>C__YK?PJC[GTE
M6!F5RN;63J7R^F@!=!-%VZ75%3BI888&KO-/T(&%\46)8L&I"$4'Y^M$-.&2
M8ZXL* ^+-C472(NGL;I2\%W^[__LUZI[[Z7326 F00<T9_$@O QS6<$$0L!.
MN3%@:@NG BW*6M<_G(6AB)Q+M;(G<13%R>K*?V*YT*,^:06BX9SIO5]=8;36
M9*$'W:>YK:Z0ZC;=W(9IC]IH/G 8<V7 43)T@0=.8LG)6?S"#A5X.8:S8'U=
MQ=*=D1Q]H?EWG[2!F1F6CJXJMPF/0AW5D2*Y@X,[B&DO;IK$/$3)5\SW\N).
M(.3J2AH?+FI>R:-2[\<(VSTWVJN&NX.)B/,@I7_%$IA(GJ'Z*?-B^;U;<L[D
MW^6^;3-YK',8Z2?W/A%@AN:C^"R !0:I=!=QM+R.^2".DSC^#B]R/GVZ6JB1
M5BO5? !?X]AWCNY$E GG)L[2UD(-%4=73P*_B?)1#^3B7TYE?W^K7ZC/<Z3K
M>UNUC7P(6P<[F]O;?8K'E**:<V,>YW=NE$_R#U!F0\J6:[GA0NW&YR!*_[%(
MYI.X"^ E)W$+_OXHDB2 =_T6QG=P8DFUNHH[(BXY5^43YBJ6[Y[F4/^PN[OK
MW+:"Q)R6A9HP/#@?P)]Q\KW$<OCB3_X7I&-U;\C,UD&9WW!V#VJ;NWL[ REV
M41*!?N1TH,%ZQ7S3!<<)E&%1 @Y:QG&$V66=Q/5P8K@G;@.>3'4*HM$0'CEJ
M?#>EG+2T%4CCW*'(EM0EHV\D4>^HTTGBAZ!M@OMZ:;RXW4;%!]<"?X?+.J"U
MP8A=6-0TIA7M9/4P\%Y-SMYS1C'JC>=@4T9=)BH!1J4IB:D+-**9R$0B_-45
M(#,BO(]QTG; +,75K)/W$+_'6AG7\47H=O&7A-S,093%&3S+E7!?)TMDAGF4
M<!_6"3G;U1TG@^5)>LMQCCS:.TRV+CE>2\"YA2M65QK ..)['%<]?B@_$AG^
M"M<@]Y)K'^+>2.]"96P_9Q3XW^ATK/.&M6OP+Q=!P1;HK27GB>ID;1, .AG<
MB+<7E[Q_^W9KZ_6-H3MH[9Q3V#A2&D)X=\]-JRNX[X/9FO+#:SH5;A)B_6W.
M&H?<AI,@PN9L7I[*XE'.@C\ZI]Z7X4@%@G4=8.#IIMEJH%?86I^WEXAY(&5Z
M4Z1,IY<P5U?>"F4NGKB:!G'X;X\XIE1_O#6@_+@RNOS84KL'JN7;G=F4'_?.
M&K][#YOW=X9*(CQ57TB*K36%#ERX64^$^WVS+F [X%HWO'>[LK@<NP.60Q4V
MYJ:5;4KUFEK/,:WP)<D'2QT?Y(@>N'Q:V=6JKBY2IU6P%[1O+6=ZN",?,_6$
M4^^J0PBW?G?N6X+2=DD%M,IQZ/B'\' PECQ85P0F@ ./QS[!H,_ 3YTHCC8'
M?"';;@@_P('LQ&#YP)$'2P(&VRTYK ?!P<1I-%=7FDE\3R$%^KX,TQ1T6'W1
M"")2I"0>> P,URKOAPV0OJZ^UY>-O$ -$%>@=X3Z2F10ZFH]6J<X6'UE$#$O
MK-;JFS7-G4P!/#"T\F**EA_97?%$3^;3;.A/2)4\A#[*>Z*8F:)W]HG>E'PB
M/!">C:*DI\YI<9PH3W>8]&22U0IYAA]QE4Y@U9IQTAV<3/9'.TV.C[_>5;:>
MGF#8FU?):$&T19YZ^:#LRL+HUCY<]'!O^GI8!MT$._\PX[S]\6Z[Z15"/ 3%
MO,<[E[V;?5#8;'K#<2:#2$@Y>+/WPDZW\GNS5O_/TZN5K,T^K,=Q*$!>)YGH
MW][">&@;AN03OJYS.:LRC2=3UEE1'Y@"716K5O7S?Z/'G_"#AR345C]__.\_
M?WW\_6 JU:J/T]? <3V)SGXDI_#8GD-+[^W1)#%'B;7UU96BNAZP-FDIZBU7
M.L"Q/63844R6>"999X;% ',='9)PI23EV6&<-[*!\65A%]].J$U(K!',+D86
M>1=(TE@B-_("-P3+W_.P AFOEJI2#$,J,:*#%?T -X)K__;6W8WUVL;Z\8;6
M@8MF_9@6=^_1J!:/QL.MF=L536WPN:CN7N_Y__EZ5OG/5(2L/A<--Y2##D;?
MJ$C]&>M4Y Z%%R]*FI8?<M+$/?W"YSM0!KQS N?)5)TC/_RN/<+>U!W$=O#4
M'#I9IX.J*-IYF"?MAEX6*G\>, <;7,WY*,1B9A$^.JN7R<@<$8:8D5=LJ-'>
M<T06 W^D'H?^>%9Q*TC%)JX,3"F*[Q.W4UQSY"^CY/AMD(:Z!+[AG+E>RZ$B
M9OS-DG<<S;TV =^"$M2KJCYO!@-1)>PTE6%_/UW1!GK CW]=JZW-:Z_&3DBZ
M4CD+/'H%\MZ;@(28ELTF:%GH,+U4(8(!%UV!(!>_R*SS8;VZ 6N3=3[T(4!,
M=W?[Y=]44$26-/B2-'C41EW:<(T!A-4G$8G&MJ9.8[,BIZG#GH 4@MT#,RF+
M?)1$<7+H),WZ>JVR7:IM[9?@WXUI^'WWMI\&S,/] AQJ&%!R?JJ4*Y4J/"=Q
M[MPP4P*B@Z#FB,O,NUDSN_G(3DXP]*U7 "G43V]:@QCDFBZ,\Z<AZS2;P1$N
ML!G=_LC1;6V7=BJ54@4SJY^YG8^LT:RX_9+*%H7*MDK5@_UR=6>AR6<0ELN,
MRID'6SQ%F]>\?!G!M(9;*=?ZT,[_RF0:-+I/]G2SECN-D.0T1W5.!9UH99GT
M8ZU;Z?1*U--1U>*V"'"ARYE&E*AT#T::2*33<N_8<1I3?RDTVCI9XK5<2>FX
M7GR'V4;P%PP\C%-,)L*B6$KR+3MG,(DVQ<V )8A0%5SI9"-X$)H=E$6MO1\P
M,/S*)6U0.TD+24L-(0;D6.WLK<?#<ZQ,<J^*0$N'LK:$7U[,",^4*;2VB!1Z
MU;.'/*SMZNY@UWAI5+ZXTX*_F0"XFAFNSKP6A@T$7$#-/(25'V<G(=,),+:'
MQWJK1+T5::7M=M%3$4B9P6OR.@DJ <"WXM,P-P@>DH5$;'RO[& !9$G]QFU#
M(E]B.$$&[2 $59@\9RY%!^3;(,:M121&[7VUXC8\LAX&4W>EJCR('*&8FZ97
M4_G19@>*XQIW":5I :$Q(^[AP0.W_<>+_HV[8;V.@=N>+#P\</4N,W#Y6&42
M;A-Q "[52>A?:1WH2'A"2C?IXBY3(0DA;/>4/V&$+UQ=Z0DQ LL(0TKX@7/?
MR!)*&,Q3@>]; ;Q8@7?#20R[/"XC9H>/FI^,SQ/,:NH"^VRMKN3C"BC5$)0N
M-P(13I%*'6'<7W>'Q!8IKY FTR]3>]_.K[16@I*,S5JZK%;D?6M*#K*PGIH-
MZ09^85PE6GC-C45_2?A;2Q=^+%&XMDP4'CM1>([<:0AHY@QL/S6F]X[V] F_
ME[V/#,P@*PTB#MKCJ0Q4A5TG$6& &A+P0A!CR+?23&+",Z9/4%*$P',?^9IW
M<N:N7W:^"OH(KY."&9<LZ&F#68Y=LS!YFZS XM)EK/0>-05=5T9\"8:YNA*A
M0(CA'0$.7'PO7%+/NOT30:X;=8M@SO?(IMD^HGM1L\.Z3_7:#G*Z-+7MC!FD
M-S\+Z&7ZSHFGTR=B6'TY_M?9R>WJRNTEMI.Z^G2&W7)*SND1-L>ZN/S/V>?C
ML^L9]T:;8$)3K%-[YLI=79]].O]\?G%T_:=S=7UY<P7+^&6ZC<1&#G*JJS':
M\?4DP@_:34<FWJ]K[=@'E3^I5*KEOSK--9"BZ:]KZY\N?[O<6'/>O5S"PB(N
MVXVRB$&3M*,XL^Y$]?*VR9/D/L@\+$?79MSJRCAAW$G_5FXYV($X2PH^B5(>
M1#-1-1U&FX6@F6QQ%F2/+GL6#10?4A(D4!I88Z"&^&S)D_!&!R;\L$D)G;"6
MF%@J4M(__L[B-+_R\O;DW\?ZZ]S=*+OM>ASJ8JC/EZ>G95WZ=!DYSR&#TNH*
M2CIV?X6N3%6ROD:8,&[<7BIQ[L%,^^E9[[;_SBD,53YR"[N=3AAP;3^5J?:-
M0*W9A2M]]V_$I.P$J1LZGR=8O8L8K$V9)63I>K#?H'LV0>N+V)#&5](P%.#^
M?4#6*WZ6P*82+H1Q;..>TW&E-1MXM 9NLWZH2D!F!%OE\AGZH&#0CI"R2)2G
MT"WTXCC%M2D[YWP[KBO:U?8<M4JKIUCOV@\B/JT>4X(W\NCQ!ER6>JC<]I',
MV@QF8I17>D_D\PVYQY0,!%,2//=SO2#LY0AM"#H/M&9P.C;Y-\N\*J&CY!Z-
M(O0.D[M(Y8X7K\)D:S>(N,>;LL>, 8.Y['4!].[Z.#0^;DVJ/&<32&/,Q)'8
MA(=N?H,_SGJH?M[ Q'61H"63NZ2==;Q!';=K]3T3S@U^KP[?1DGYL9"3!&@#
MHKG&M/M-_V%%G!8A=Q>I ]>+C:,.X)"#][__<_#^6\]S7X+>9J9]3:9-N%%O
M+6UOY:_FB<PX%4O $SV&Q9QDH?I6<S.9U?]2Y .Z?.:1ZYO<T^IU=N5O(O[.
M@H0V4LY^3V91O_M#9O\^*U@RS\29*6?+/#G1<=*E>R:2V!76TQ, &Z6\S6 5
M)\_67N[H<W;T-DX13G-!-_)UIYP^099>#<UTF5ZNWPN6WQ;RU,:@A_%H=E@^
MW\2CVN\9%:7N38(..B+Q?4K#''/Q9IH@NL!$,U:NYZ+1QD)2R(NPVZ]8<K$P
MZ3Q?=+*@ 8_P TE>-+8V/&."R-Z:H&=MW8N>IY<_1(-.SM2RGU^$]RW:!KV4
M:%RTG7M]*N!3U+XD]H3P)2,]..N<&,-C$ \=$4GJ-O9#$?22XRSX!KUQCF-5
MPKQ!#^%H!(Z<(P](UQ["!7&\9E-U34O_=FNM=J^\-:8C8=SS-88&-TWMDA+6
M"O4HY+U.A"<PS(".:N#MKLYETRG].B226<JIT4L9/U.YVFWU5;O7ZP*V*J(X
M1>1@MN7JRMY>N<@W"CF*LTOU6X3L[;&&-D;FX?AU15D'?W4CNT1#AX6<X6D1
M3B.)VT N4H>?!F;;E^ (2#F<//K,EA)E)@)U;54<W^W*W@(0W1XCC]EAU[<1
ME5%SVJ8%HJ QDI#.HSLAV;"$Y>^/L$=W<7B'42VG!6+/\44S$;0?22"_%X[Y
M-7S@?'2]-$YD:>@Y=ZI;_3GIRVWI;U\4Y/#(8X0>(\(S5@40=D)M?L@HRFWG
M;,!IS']M].?BPB4=5Q)D2=91F12N+_[.7*]+^,D>7$H_]YW.LG,$@TF$R@5R
M;8&!D?@$,X@)ZME+**$X) X")L22.";D\JLK:'QQC-D787"G\WT,#R\<:+@J
MH",/IQ3/).YC/<[2::4P >V64'37/PQ*+5@01*VI;^:T6\;>Q%BK>1S'WS>O
M,^:?G]T(V&?RNCO#[K_T@NXK?GK9 26V)>!-B:)6M]U1)'L2#V(ZKVQEYT.J
MMST*&J;]V64AL\C9U54)Q?5XI,IKBTN8>FN\!H:Z:WFHVUXN+.KJ6['=UUWH
MM2QW&]478U[-K6^/CC^=.9<?G9/+B]NSB]L;%JB+V;UAAMVMEK JUG /MO$(
M@!F6(%[P_ZC"&K=2J8YTW)M")>?FR^?/1]=_FCUTIQ4&WQT4B1Z>9%==,/B%
MP2M;&RG^?L=C^O'L^OSBMRFNZ00+.<&)K59>Q:)OC9J4HF'GX_G%T<7)^=$G
MK%L\6MSEKU9G%2N<Q?)OCYK4]?G-'\['HY/;R^N;!5[TK=>TZ#LC:1[X-U+Z
MQ>7MF7-]]MO1]2FP'.?CY?57^''ST^7E'_C[S>W1[=EGU!@6=V>V7M5QV!TU
MJ2\WI*F!C#TY.SM=Y'6OO:9UWQLU*1 !?YS=X@G $O;/EQ?.V;^_G-_^Z1Q=
MG,()^42E[#>WER=__'[YZ?3LVOE\='M[ML@L:^M5L:S]49,Z/?_/^>D9;,;5
MY:?SDVFJG&]ZW0]&3>KDZ.K\]NC3^?\[0E"'Y;)/9=FK(X.OI^>?OBSJ@F_M
MO*:E'FG/?CZZ./J-U!R,,E;WWM\XI^<W)U]N;F#]B?_#!9_^O#F_0<F<FPDG
MEQ>GY[?ZFNNSFR^?;NF2RZNS:SHMBRP==E_3'HZTG(^_W)Q?G-TL\()OOR9]
MJ3K2:LX/S>(N^>ZK6O*1EO+)V?7MT?D%:Z/(77X_O[HIZ*=71]>@L=Y>'UW<
M@$&]V QH;_LU;<Y(N^WF[.3+-=H+EU\OP"R K2&'N]JRX[.+LX_G)#7X>]JV
M>9^AO9U7L?8C;;?3LYN3Z_,K$L6XZ*RQLK6VN = C6QO]U5LPDC[[,L%6,5?
MX0@LM.]Z;_\U<9V1QMFGL]^ T!?>%;'_FGA];:1M=O9?4/ 7V2?ZNM9[I('V
M]?>SZS/GS\LOP-HOT  #T7D)GYQ??+R\_KS@?HG7M1<C#2U8_+/_.K>7EAV\
MV%&"CYNO*4!0&VEXH8[OG)_;Q(]A'+ !_OWE_!J, % W;2C1Q=N1\_/!6]+7
MAF<&N2!%W*BYI6-K-+XH3E=7W"QMQ0E<X&/*=1P1VIMJ24U)V#;Z<TQ8QVWW
M.W]53(F63JRRO%U,K\8^+8_BE,78=@,&  ]J8!J^KJO(+Q$(AL9CA1=UW$3!
M1Z<X@ A1J&0'WAO4@S!(N]@EIL2U&#  /87(A@-TI<[;1NQGE^]#S-(2S8?'
M;T^8(0/Q8^X!@#!J3C?.#(2TG1_8"QGMQ%'8+:8O-TS?D7JWY-2SE*Y1%4N.
M%R1>UL;.X)[*CH=EL]&CI8*/#E)\7^C>-[*04J7AA3&.J8 F]_CRPV]>EB0"
M^U;00%W*K\9^!I@$N4Q='\7:B7Y5\CDL899*I#?<[B]1@+![-]2_X="QSAO3
MY^">2?2UCR<0:!'KAYI,?O=Q%OH*&+R(K4A%#;&$<R*Y"3250:1) (1%Q[6O
ME.$12')N*:-:+<%K=:\EZCM!6&Y^J7C">R9:7EVY@LD0(U"+H4 O"Y?!Z[#6
MJ8VDBJS&C'_0<-NP%XJD\4EM.%94OX-)_KR6<5V*Y([6#.'G</;JJ, 1=[D]
M5%QR"IB5:EA#B@KT#HU:RH&37%U1BS'O_,:90;B/\>+/.1;N)1',>>3#1B9=
MY]1-W1\S^_,932&^1%A@",<7U^H^D 8W%D^<0I0%ENRR; .M!W@Z7L)+BAG.
MGBN!;6?82BAM)7'6; %Q]A$L@<G&=242L/;1N7.3((:O9)PE('-*6#>'G;#P
ME 28X$O-KC(X8%UIQH(RWTV\5HE18<.4VMOHB[B&$N7)G1N$E/1JRR26:FKL
M?*W2'N ;;!E#CRGG)-/S8+YXT*OIT?EJ-$4D$M?TT<E!?0=+2&J?@_J(@4\M
MKI1:(?@J#,0=@ZK6M1X1"A;FYAVFFDR5AE(WC$AP1W/59,QJJL'XO,W,Q4Y!
M K2<U15+:%!#LHX@^H;IW"'E!:RO:>9#Y$'CA$U/_$W0E4 ATF/&>CIZV#VJ
M0(J"A"6'PBYNN(#5B-N!1PI3FZIL)?)4@FS617.X2&7GAIN1A:#$])/) -+D
M/B ]U*.@8H5>TYXEY=99JEP/:SG;5#2$9;$J5"J=[U%\'PJ_:;BP?G<I7SW:
MS,%+R"I3(TLS.!D@86E+(J_O::BEZ@F0##5#C^$N5S4ZP96(B##TI[BQJF54
M@(28 ZCV5:!FD=J7E(D&*U(=/Z-%<5=7\*"*E/:[H:I2G?RHLK;M"^F!P-+J
M'I4_\M%*@Q0;I@RH;=6EK?A*]?4-]J""_;R(80;7HNDFC($-"L\]_+P9QO%W
M?.F-;L=2>(@(I5!*:I_.2<LM>;%8DU!S@2.".H[G @M3/?%(4_<#TJ<1=CH)
M\"ROKB@BQ_F*!S0_I)FO%'T,14&?3U<</\KJ%\3&4QC-J(X8D.8I"UZZMO)T
M"&.N]*32=X5+[0Z$GE:%^W97":S7AXMQG^GL4/D_ UB/7WI51JCX1L)ZK^GI
MF&.W<_/&@(1$Q"=I=<7T'!HT4B0XH%)F\-:3B44*Y(/ZX82%1%Q5&Z21P+=C
M'[@XM)M.]BJIV 8)WLB<"T:&HU"FN7@0B8?J0Q%D7G>AQ$,'*BN(3.(9?&\:
M(*?-ZZ1UZTD&65#XSVZ"<HE'O[J"J/ :69R;RL'CPF[9^1B'87RO&[(:;&\M
M]H:L6HF6S!:'RJDPT&Q56A*;(*;&/Z(J-VK&F".FFW91TJCT( Z$9"D&RVZ@
M_WMPTIT<)IUVLC!H6'\<]:!:X%&E>]OOG4M>UD,\7:K1W7OG/]B7 P[&FZOL
MLQ=++]-[Y[;;@=7X%(.Z2J]\[URX;<'+"2<6%BDH%+KI.ZGMW[)*\*E5@OTT
M=^C4%6+R@R8V-5.U+KJ8:Y^ RZ<A5YF GU!G2-\&ONG1I$K)^)#F'FF0ASU%
M8W.#Q0@^D N1NFJ@AHGZ8(B>;8G.0^ -Q/\&F2J/J5C$ZJA+'??AHWN(P_::
M/F2K=.,,) PJ7ZLKR$8#G]J'XGE -R_R\B[)$')T45<&'[1#E#AEYYBO"S3H
MBC, <Z5DO0+TNT0T,C3)X-SY/'1X9) (:P8%&[1WT!(,"/@-9'#>"V8\K?9S
MO_%P&D@O8]<37G@$HKHK ^YA]=&(D9,X4AA1>-&U4D[ADDM2\I&=Z]<9?7N
MMXC%[QC"BFT-941R7P5<"19=JD_U(,E81B@5 63K*D=\T9/@L.E&$!G20)<
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M1)P,NVY5D2OXF>H539^4=*=G6@ILE$K\H@$,&[M=I^22<\-4XT%1=ZO-N-%
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MOP8\U$=BRO7]5I;XV'.-)+GI8*G?BW>A'A$T0.4@>E1-V'Y$IHBN@*>&4X_
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MX/B/373LV#4!7TQJ,:\M%?+;J9J0_/ #X[LEI>BZ3@3K2<[I).Y@XC=*B;:
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M4<6[G(Z%&BJ,A4IB47T$P>E+@S1H,3A791)ERJGA!5AFC=ZI0(:QW^2]8)T
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MG*46*&\B..13\+21KMGK%B!-6+4+G"R^KGQOW/C$XF@EZV2S!UY5X?=UH%=
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MD$&0D?3T56 D29N#K97=B@I]_N3OY(=-?MC7;8L\34^/7Z3'ST^NM46 *VG
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MUABBSY*+<W%!AAI>D8KU6%1T$G Y]*LU'PYL'7VLJSMRY)/PSX@G>57'THV
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M6&_R7%%WO%ZT>W6C:)!(7%"6LJ(QB^A5_6H&-/@R>,CE>9U<() GYQ$PR3P
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MH,YR0,DI59%]8Y@;P"4+X/8F+->G80.VUO[PX/K%=XNN+=]I3%RB2?^;*I9
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M/15=[^9DP,D1#TB3<PJT;UGW.#Q=.*)K1I J&A//_%#5EUK:%S";L">E_'+
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MRW;A*!N"EN]A2%F8)B_R 3G#&3Z=-Z,M+HR59U$?)8,@I?25DK:A<>F /3"
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MG?ZR84O,"8.U\,H7="7T#:S==/LPV3[3[M<?('A+,.@'E'D>'N.1 ,9?77.
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M[R9]][7H.Q>.<VR'(JD&/%1WW)"@D4/O,E_&7E7F#PB7#@R*JQ@97DR,#/?
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M/2<D@ *1G"4.DDW4?/@%*4<8%)"]E<]9"CAN#E_;:^!K#P!?.V[@:\\)OO9
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M#^K'CR$_06E;+/7%EC[%'C7UB[@3ZF"QO+>=695$MO[=FD8NB'?UR$L;PPW
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M8)+FS$1^2[V^5N_ZCA/,32$V5/$5H:HH:=">!->=9QT<P2N'J+22UXUQZ9S
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M0)BH-.\6/I$D$*%]R#E4$JR]V-UIS,PI0"F."K*E+IV-% =@L5SEO96$BQM
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MMW=<S.=GL#ZF/CM'ADZAZAJ,9=,T7_ST/6^!![*)[K /'ORYC4YK%K0QSC1
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M@3E=P@T \=DP3&=\/ 8.ITB0HYLW:U]97TD_G!07!6+%O5>F;?:'2NM&AWI
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MVA6NML/Q7E+%X6H[#/(<:+CH^K,+*B,:09##OZ1;^UJK)&\+&KC,4. $8K*
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MQXJ=SWW5.4X.F1FQCLD>!223S,W(V=FE0EC"I3 KZXV:J:*)Q+C0VA3N-._
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MD49/&C2.I@,OF,X+J3A!>\DT^1(")9V.HL1<UV[9QW&AL]3'_,,MFW'?##U
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M#6Q1>_J4%2Z"#A ,MK;$K52S,$*7>Z]E%4)9G62&>] TLV'%[V4+M!RN!6G
MDGG97' 9LR*(Z\4M[=;JQ.9CR.>ZQD'W\L;L0:XMM[JU?&>WYB3?N$T,R)83
M3IBH]ZH62V/W'Z\_DEO&7!( IQ=<_D/::@E64M>)NDZXJRMEVJ>OA..ID+5;
M,,LY^N"@ZRX2++]&(A,Q:;<& G+F^ASM5ADYR29 ^U>0@=JVNV+!NZA/;Q3.
M0SY05T-%!(!F .KT&3 _2U#!=DL 0\-DFJ2#"*4$>%M%$:71/%L-B?=MCQX
MY"X9]DB.=A!KI[(X&IL,*H.%RI$P\M]< EZ0+"];E9?;4]*3BL=C/UT#4?#0
M9^C.'MJ60-X"Z#I&>+WH'_J]XP/<\$7OE7]\W/^.^'"?8(.?AMF<-)]!V)5
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MB=."5C>D\#]IA_8.?Q2T6K^+P65%IKXV/ H,3Y$Z&'Y&ZGN.FF[!3>-[BZ1
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MYNV86*&6S.O>TV^O9-M]68J/C=4I[S@=E$@&*RJ!4UMP2T<I?3H3%JIU=H,
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M.CN_??SE\TL-P:,X$Z:>22$K/\W.^[>O7Z)/+F#4EK?,?0RG!,PEH;5%HA0
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MZ9-SB(T?)+^>9660(4>&)R1^'5>W:C4I$%R"M[K=*&/R-F_[@%XJCCL- 9^
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MF>7V%!YB[:LI.H"X[ *,E*R)='='WKVJ^JXL@'?EC?OGI7=*KHF$?K!%0M\
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M"=$(YL$E3V!8XM=K[N0D0[,"(Z)(<QJM"#YWU\>RXYH,_/E^ENO?CNV:QF=
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M@ ->?6]Y/7QSG&<LAQ7*"N49'/4T@MD[>0;P %US]^Q:P&KK:F8"BH[HU!1
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MQG0XSDB&K@;'G8DBQO!D&BQ!BD"^,,*9D117QHJ87,:\4\,E24KK@.OXT&G
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M:FH>&0=69-K0.^S4IJ23FS> &[2%6YR'9 P2N^ ^ -@F(5;\1ZZ2B+# TAD
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MG Z+-#/ :/)$9CA>&$AYZ5'KLS2X4-+3SC!R1"$U#T8*Z3A3TMH77O-M"*H
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M;OKN4N"4^3MJOLVH[B6#[7B?ZZ&H>*-$ZQZ1K2+UD!1P3J0T*$4-G=J^8(1
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MNIS3N8#H_(D<2K+TU56%KDU(['SIF>9+9K=/-R&0A&=D(/>F?8"X0/A(#'F
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MR+O. +$O?P<+)"&BG$^\NA$!+$QP]6=TLE[(H#!7C>W^AZM /PU4-<>5CB%
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M.@>BW2(C=J[0G(5GYUN10AH=6_X&,V5L4Y*6E5TSD$U"@AK$8A'M&L"KQRK
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ML!7> UMAOV$K? BVPB=?.C_R((:_L<?@N<49'* %[]=P[OSH7!G5H:UPM,%
MOPY>"W?&>7+)[I:3\%2C(H7MD!$%</H)LPR)\LB'5-]5.@K1I4KM3C4I)5?=
MDT3F'%'0H9-I#&PR%_,>+#'T$)X3;<RS)-IXN-),FM@C<$C.DG3^X@J?/IGE
M\;=AZOWRV\(JX8]A?'6KQ?RQO&KD5N[BT=\L+R+YXD;0%/6M,%=_TC?4>$O$
M%L#JP,U=?C4F;);BV4-/PJ1F'DQ(0T_ L)F &RT69Y6("%,U#>"TA>G3BR",
MT(::U8&AS4F1%RGO.0&ZLKQ_Z*GC5;&0[,W,+3;4=TVXQI*P(S#?$<0:P]]
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M\AO8;VNZA3]1H>6NO[,#?EEW]T:EEDY/M:=^@>??HG*PW;EAE?'/=];E5;J
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M1E&2"4M0"<%<JF)!_#I,DZW^+:'Q]$2@-62&F!6?3I!; 597L)R7#)0J-0)
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MNCM>B;_U*(DGL-00>:Y=WD_OY9O6$?U2I%F!!!W$W%%YDOZZ7QDSM_1":V
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M_P _J_L"?5WZ>%V2("V DEO!I=""GT*K+ET",;.:;O( KKTN!K7\P3_>F>I
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MT]:3=E^]KIZ^Q!0(CE0WZNYQ8XWSWV>YJ!((S3HZ)'WE3:VH/^L="\>L,R2
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M"X6"'W@ 5(IU6Z#$_^I?+BQMT%%MX4+70,B+AP=ELT$(J$[^: O_ *^HLU7
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MI+-B)KM,O>3.E):E5IPP&H;A21^_A#MR@"OJ3L4LO0(+&1A.&_A/I5G4ZWW
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M>+R!S56:=XZ>)VIUWT_;):K[>%9)_ELE=_L])X^^QUM?&X[]_JU!8+<#VZ?
M/;*:1P,'BE#($;9+$HM"=W,62U9,)^;G86Z+.N9X4]<"UO5U4LF)J9RRO*\C
MC$2+GB^L;#9L.&91I_\MFWCJ<T.M&QVL @,A=/O0N:W()_>9NSC+P"(09J&M
MFBT=7*.4)#M\G]MTB,V#X>8<8Y(HY9;1_.+WBZT9>NLCKX0,.!F#WE?RAR]\
M7(-ZCXJ&TX#A"U>VWC4&74IF5W8S>U9H9TZ*Z1T0>NB2T]@^MROIYL(O;H5/
M(:PK+>^P4155X9O; V%Q1/?'Z2:)N=)OZW:^@9?E7*E#R-*CV-YZ^%K_?GU5
M2K=:F[1L<$-;MF4B02EV(V9GL7F.@K8"^-8?!T]EEE%T9RAGN?GDY 6U025U
MB"W,I:4!K6+[7H1;DD]JHV;IV^OC:=:Z&<1I2W'ES 'M#*TC!WUR'6]K^]!U
M7 QV#"/(Q2>H'7WY57NY5ZWD7:*^7<T=M^G'BYZM]U1#XV&/;;N7(L%U<[E+
MJ?E92[OIP%T!D#$D*2EB,K-JO]]Y68&3)QZ31.#';C3L@>YGTT"BM5&CI_1_
M=9QO#[EM*/QLF^3/N$\:0J$[G2#+&7F5.]OS9U%,C7)O<6ME!+?$3&*^PV??
M>&OMMQ@#_Y$S8EK:0'^G@(Y -,"(J9"UKEH8E<Y:M9$FY:];OT]4Z6690&X$
M/6%.*K>7TCPW ?(=(W/TF]N8)@)]7I)B.K%XMXL_LXO<*O<71Y9V2LJ(J>3B
M_;&BLJ"5M98=-L9V:S=3(CGSV'[9?-:=&1GP?4O5],?\?:616*,.&HG=%_+5
M,^'TO')?%4YO*A="^?)'J7I;OOPJY NWY1_EVW*INHLWL5N["<.+C \OB![$
M"B?RC:>!8>L$0PA#Z@^O.JK9)^H1].3IP2-N^+WK%$;='V>UT>OO^^*ME?GA
MM+?L/K@:V(TV1/RLIM!C^T=[1>>;?\=B)?H-QNXSED0ILWC;MS]0%5CQSM88
MX!1S$<:PK&Z!Y)821<!R;FO=/N4WKCGRO6)=/62OS'9RXT)IP@8Q^*[_:!LD
MY.XV9X/LN<YF+B\& R1>]K.W/K:I92;GL_Q3VH=LJO5Q_<-PTI7?_=+I-OU.
MXX;(:?DR?UG8&R*KHX@_&YC@1D/7-0>8C9?.S4:K7O')JI@<TNM)/8FH Y>%
MJY.[43JGUT:M_DE7-JS<3^WW%F(E?.]"DVR>6"!CXV!W)+]'D5:L*]U6U# :
M:JQ=9A'4T<.G%V8D,2O%$3G,3B&(@F4B-M<[.J_/#:."K)%KR;^MM")MN8PQ
M2! &NS,Z%MD]"=:M.R(V-@##W9V>W-2W'?"? ?L8]-HIB)84925#;N+-5Y(H
M\HH#&N?%M/S7!7T' JF$(732=SHO3O[JI9%=IP$9E3C*/G+@[1O>LM41&0N2
M\[#@CPE;1^<^?G3>E(2+VD)CB>M:,DP18B@PWQ#S"77[/O*VZI67OIF]'.9B
M$H.+N8IZ[#!"?<@[+[\;=]%2#H>0VXP]<2:R+-WSH'5<W1IGA:>4G)C*KBU&
M'<Z-]JZB;?H!9)\$ *S+FQK\!X(@ST1$0;H6#JD?3^>J&30Z@%&!BY^R=7]3
M_5G,Q9DN2?FZP38"$0#D\1!LQ!]T;\_;-6$6@6/<W%<6<W)"3$G+5*KN@@-B
M95BNL^!7CC!9:\_V=FTW86Q/F<OV\D0(VS;,^\!A&S6C6ANIWSJ#E*'*B9.8
M&LN&>,"GL3A![0MUO668,$,+G3A($^]7+8IT3:$#K @+58X4>7D6FB1663*]
M^ "K/U2!7?ZFI-5N2A'E1(*8&VN+:^Y9]^ZQ[N+BK+M4&Q4>3J^^REHG=;:,
M8V*U;,I9+%PGOX_,O-_TM,&5^/=*/0)$)2N)N?1^%O'&F/AJUR4G93&1C&D.
M<0SS(B-Q@=UELKNUFWFQ66]R,J F#'4J=>BD)X*MU4&O1__E_;EL4CR$QH7^
M#)=,I_1P7W]Y3)3D32GS_NUA!Y>.Y0QL?4OE]W.GN&P?59;8(L4?V-:T;L27
ME@F2V,N],S77MUKNZUUGK$W#[U^*U;XVJL4?RS39FL8TP@*4H;$,NEM_MJNI
MA08S]F@4.QKYLZ;&VUU";%G7B@.;W KU3Z&(O++UIF[;NC;^/"TT+UW]3GV7
MAT;B]'$3S7;DS+$">#9[@LVI:MC",^R>]IOJJXTV%J*_L+UC7HFND67Z[<F\
MD@GP;WXP2X3!URM<7>Q=K<2,)(EI97XGH%#,G@G(*12RA2N*F+N@I.?E+JP&
M!)?2XYDQ#.-EC.9P??,TE]X:'5 K38RGW>!0Y $?OKG:>.0Y Y*5_8#D!0<D
MI_8#DM_-@.1*\>X\?R-<E(KE0OX<!B1?%B+,1TZY\Y$O*[>EJG!;$0J5RV+I
MLEHJPD_5RGFYF+\E_V!)^/ESH7I+?G%1NKRMCGW@X]UE_JY8)D_'-:QX#8R4
MBM;+09=\H1%9HNM.0^T!YMC@_ACK4&RW5).UP_3&$=..^429<,#PHZTR3SF?
M\P85%UU[$ Q9<NE&DRB!9I^U30'5A*S7((K^+=GG28>H).3</5<[S0:"6IO>
M2FUD.A>%^NE=N7>;6()(W?N-@.* H(2UHU(@_RMXV(Q@2$BU4:.M%']^RY\G
MOAE$5)V5" )?7.4O'X3\9?'PH'IW<9&_>1 JIT*U_/6R?$H(Y?)6R!<*E;M+
M+'._(LA>P-H2AC*[BL-KUU/F;2-\_KKPD<AWH4"U@4_$3(!F@PW+[EDVBG7#
M)/MY5C45?JHT^E9=MP4YE\L2C8!(8M .D)2$$YVL?:X^ZL(-!O4!144!/W'K
M?4%HJQI1],A1"$\DF'MX4!\X!LPZXXUI",;3!/B$)"4$P-F.H/9ZMO5JP$N=
M(?F#G!%>VCK!G#[19+ 46",2J\.T%6[B@+5M#?I$'3%!) D.'<! 'KH>J(1$
M5(?!0!14H:AWU!=0@?C9P?;XR!_\="SD'5R[J_Z& 0ZP5-OJ  1\ZPDV,;C(
M:5 UZML6[HB(RK;@ S+NR[<#^!.N)^BO#=J,&VY!I10+FI4%7?[('FV=6&M$
M%R-LKZ7;N"5GT&B+@=5A#B(A^Q%Y$7X=WC;2O^G# Q>&Y(KQC+B^"$$.\D]B
M4+8-IV_9@#5"@SF183 ,M(0Z%JZ(U67#K$7\'"SE&+SAL0L8^#ZY9Z*9D$6A
MT7@?[Q>W?GC ]X[G)L @>H/ %%01CJ[I380JV=_-@"@:<J)^E( 4T>Z@TT(T
M]9"QJC>(-8B'+'%XYANHR<HY)4GQW?^73\> !71H,Z!6$)ST.?)I D3$<\3-
M&<A. #%.:?B'V.G_#;,F'X,X/#  !S2"ZAT+B_F/" &W "D1F/ 7HZ%S]"#$
MT<"J<HNBKJ9#U:SH?Y_VM'@F/PU41"N"WB T?7VYT>PQK6?RBV>"CH;I##H$
MUWJ#;@_NDZBT-G HIVW9?;( 07_><-,B&F47Z+Y')3--6(:=V(2AP'*$876,
M+EI.JF;U^"<)DMKD>?)7]5DU.J@_P_<(.0*]LRT<:7I/QPL5>KK5 S\.^&TT
M0LDZL=G&6:O#SPT?(_^V-61I?;W1-JV.U1H"E[1>@'S]RTU\[/" ?X%-5M7)
M01@OT,ANA_P5Y!@OE@#& M"-;0U:;?)I8'^&.; &#LKZA/1O7774#OY,Y+ZF
M=\B"MF\[A.J[P,$I5SD\(!#BGR [J.N<-=4[EJ4!#X&'^XB3V&+1_8S5&3@3
MG_'=85=7Z8M"JS-H6)B-V!M0)/$>.SQ ^>)]D3_< ?B2_<"(7 <8-GF87G+;
M:+6/A9,A7P).!>_CMQ %F^1B^P2:C-F2KY%?Z0V&)'U@(PS&8&(C#V7B@=]P
MG1R(;, !P4>T.O=0\$P'?X";!C(A"SKJ\S-AG_C[KM7'NC_-;]4#T3[J_6/*
M!/S_&Y^^C?,)S@T" G+ (>JBPRE*<?+4FZDQ[8W:Z$JJM]NRJDE]907=%9^-
MHL".::SI9&V4*C[\;%I5[>I2^_#%W6A,^B?Y_]2ML027=<V%PP//'!"JH!X1
M3N$()Q;YC_#Q-%\]^22$/"'<]<#5(WS,5^\^"9?6,8C+Y)&<PM_P?WP2&0X9
M7[Y:\#JQ81JZ;?[WC_%%Y-A/"(R<DK!U9-! ">"SAL4)W6%;8_@?7: *&2,&
MHK78E)$3P(#OR2 RW]-:U%;+UD$; $9$2,E6#4*PSJ ."F ?'%,042>47B=*
M(:4KLA2Y*K1&,O\23D+'8\!^& /3J>+5PH,TZ$&09^(<85T8@AZ@-OM,]T#P
MX,?A7V$>,3P1U4\9W96; 5@8P'^)T4:P(>S@$8X&TFRA@QT>L).)@F\C78)4
M+I0%H^F[D5Y'-=E.\)]$"J+\8IRZRR*ENB8BX^-72I@6D>W>TPQ.AP=TO1>#
ML'0B*(T6A6+XS>/9.6^=!H&%[]8%@7LI4]8G!S ME#Y$#4&&2F^? \I5*3Q(
MNEO 8XJ^S5$8$ZVX,] (&%0/3SA.4\\LTZU#\8FH>X3?]RE$*$ 1PY: #:&)
MC2 ^.S%9F7"F3_A&SR:_,WK FI;%^J7I6102GT*NZ_" \21VH8@/KD.%%J+V
MVZ 3A.Z8P(EJ@);)[V_Z[KHZE$>0MX@Z">@/:Q'1#\2CA.V-4R#15_H$OCUD
MH?-)IZ$.EB =LH](<(S?PEG(C(!NVXV^$]@T^9G@V<#V-<'MX#QJM+$1=2W0
MXW5D4,U!?V!3W8V^A=%\ J0F45J9D\+GM%"I6L:^Y2 UT= _I^9QHP3N !WV
M_7"S!#""L$MMT.@'-7WW;$ 6\!1L6K4;-%G1]QF*0RW=U"&B@YJR1LP7 [(D
M0.]T>Y)3[CL&*"S-0!XN<@<$4<G[(IP3G^=6%=$V39VJM/1;?3^MD%VP4Z '
M X"#J-MH@S(+)VP:?89C>$Z@*<-N#+J H43#CD#Y##*S2)_ 8FF6YLR7YD*9
MR[T RQC;&!=VB%3]!52.#EB^8)X)@QZS=6><F0),=1.N".KV"(P[:$]0(PV9
M@-I!/N9[$/0SL@8A!QQ6Y;C>%!'6=0:]'A@QL'5&'AX%X-V!PD9(M ZR"YQ/
M QN9)0(2G%7D%B9WY:D()J?"KCLO"_@7W92;.B-2@-0!)YI-<&>;^)QG2B/.
M$J7%_8WHWP+[KKN*1>PPFSD1=+M+K\?'0M5&0^_UN8[C@_WQ5'N)F(8@U;_,
M#'<F]^'.!<.=Z7VX<]WA3LQ4X>BZ#@-56M(^W27]P>/7GJI@8G,>IJY3M97P
M<NKM=ZBF01_6D3_RP(;HZ;O<:1YP C4'8"-9]B,R?,:9:-$!_DQ5&>!%A-T&
M77XNZV>\F+_-EF<RRF21 (W\5FT,N6;A,4O8@1.0,801=M&[JC;ZE@VZJ'>&
M.:*'<%APBC4'H!7XU1K=K\^(Z,#5J=W"W9/HWX7M4L>47Y'AZC :14S50"J
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M!V\*[0L\^#:_XVXAKYRE35,0O2;706<]CZ-0OJ_ZGVT;A!J(D3ED01;H6V8
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MZUFTU?4S#98='C!9(@8]$^@JT6#N!\QD=W.X>'"5^R4^.I_0@4B;2;))B.C
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M<J1 3(_8G40!)LH?+(R/B: ^(E0([([0.\8^P"IZ@X\C6-B0-N0@!GF.-=[
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M ^&HC6#O2K!W2;$TF\>;>360!8\KUD"\E/2_]]9#*92V$VDI6[P*ZU<FZSZ
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MP#W,IB<OV7E.L>><SKC/9_:9&)XJ\[MU@C]$X$'"VXO.@"\9NB@8OIA$EX^
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M7"DJE,:%#$3 Z(EP1%&L@X2=3&=$Q9 @[F3<)WV!,@,NRB/)8/RT^<L<4'A
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M(9W=VL!,)*WW3%5]'T$5ZR%R&P  =$U>:\[*Y7(2]YK#$:!KYBB:P=2:8AE
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M&;F<GY^[^<N.,*[#O/!E\S\;;^LI\-^0PYS.R^5<44ZEY]>4Q#[%N3[SWW2
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M8\L'&5Q9(&;!T^0-74\\R1H,N#WV'5!TIN'(M#9H:L,1?5B XZY@O9;&[%N
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MF+. %:)C\ $]9,GMBW### 1P["E^:=[^'ICH@'$]\)-)+B@ZB;;@02IDAC6
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M_! >V)6S#823H.HRSK<;P[O<Z?#S#[->O-D&N772&#X^U3-?\K]^W/Y6P6;
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M&I1SZH;CE]G&L)QZN+%SEV>#!R74&YA^",'\-\0QER+)D6[*^WOA^(27BZ#
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M\U=]<<$>L?X6 YFAQIVQ!</(QH-),6*;^WOCIS3>0@&L2U-W_?F\_3X("E$
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MC![YS=:JIF4:RJ-FN;94T519NL9NPFW>^[L&,L3L@2P1XRX&4J7E\-=6*]?
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M[0)S\3?N[]FN/T,S:E@S#6FF3SQ6M[Q+L2X?R.FQ13"KW6O8'!"3[<]&XHW
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M_*3V+WNMU7 1!&D99(2)8 @CFBJ4/9R[_3NJ[S6H\\*1Q2%%[('GZ<J$%M3
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M6I)*Z6)V(83MK1:/**LQ)AGQ6_/)8>3K^%^-6ZT]K#R9C<<9&<4_UO]:XL3
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MI1,W5 H,VHYL;8F9(6)=?':UQ4?Q3W:<?Z:KC3 75;*]AXIS];WR*">C-U@
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M15S\L?=#Z=O5R5VW^'R=!$S58JV)Y?OAE796UGYJK6*.N.((#.2O'*& @OD
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M/%E0 T978ZHVJKYRXZ'T?'%7=NK+=)Q/*BF8Z3W07>+*,, 'W9:FMWEM+X?
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MX2I1_P\TT&NIZ*"2;[3\,Y#],R#60+-!IS+%CQE_V0)USEY*=#)[:]C7IU<
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M<IK-N(]VNH(SAJC/==TX"DCW?O& +\EFXY$"XT0X/*J-GAG,$Z."Y\%:,F%
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MS-!AT 4K(-M5#?)#2P4G!C-D_HP-&68+$#YMX]W!J(UB2P@Q+[QF/X @X$U
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M?=DA=HC3FHH3O' OY1W @?!7(5T@(I//9TA,_0!.L:..SPRFDC'?.@51^EN
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M66^Y/CY.B('.5)7G\:GR9U_U>7Y\,*OOGL*F=L9N9^RVP=AMM+4+.JF@TRP
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MA@N.A5ESOM<0GMU+M0'KC9N+T2QI%",2+N_)+%$/$[?X1,09C$T^BE8()DB
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M,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ D8)B4Q2$8 IA1   :@8$ !4
M             ( !73D  &UO9&0M,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( )&"8E,8<"=T;C0  +R: P 5              "  ?%]  !M;V1D+3(P
M,C$P-C,P7W!R92YX;6Q02P$"% ,4    " "1@F)31^RKO20:  #>&@  #@
M            @ &2L@  ;6]D=6QA<C P,2YJ<&=02P$"% ,4    " "1@F)3
M7Q($9= :  "9'0  #@              @ 'BS   ;6]D=6QA<C P,BYJ<&=0
M2P$"% ,4    " "1@F)3/$4WE>)F  !C<@  #@              @ '>YP
M;6]D=6QA<C P,RYJ<&=02P$"% ,4    " "1@F)3Z0/D^Y(?   $(0  #@
M            @ 'L3@$ ;6]D=6QA<C P-"YJ<&=02P$"% ,4    " "1@F)3
M[-KC$DLK   T2   #P              @ &J;@$ ;6]D=6QA<C P-&$N:G!G
M4$L! A0#%     @ D8)B4YPGMDYL0@  PT8   X              ( !(IH!
M &UO9'5L87(P,#4N:G!G4$L! A0#%     @ D8)B4ZRL4#4&%0  *A4   X
M             ( !NMP! &UO9'5L87(P,#8N:G!G4$L! A0#%     @ D8)B
M4^!J_'EZ%   GQ0   X              ( ![/$! &UO9'5L87(P,#<N:G!G
M4$L! A0#%     @ D8)B4ZF;'8QY#@  Y@X   X              ( !D@8"
M &UO9'5L87(P,#@N:G!G4$L! A0#%     @ D8)B4U45(P9/PP  %.$   X
M             ( !-Q4" &UO9'5L87(P,#DN:G!G4$L! A0#%     @ D8)B
M4P=A$8[8#P  +Q    X              ( !LM@" &UO9'5L87(P,3 N:G!G
M4$L! A0#%     @ D8)B4VAUC9T'A , WW$;  X              ( !MN@"
E &UO9'5L87)?<S$N:'1M4$L%!@     2 !( 5 0  .EL!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
